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TANDEM REACTION SEQUENCES ON A ZIRCONOCENE TEMPLATE 
By Józef Stec 
 
The novel research work described in this thesis covers three areas of organozirconium 
chemistry. 
The first area concerns the synthesis of rigid core structures containing the cis-
bicyclo[3.3.0]oct-2-ene skeleton. Zirconocene mediated co-cyclisation of 1,6-enynes 
provides unsaturated 5-membered zirconacycles which are homologated to 6-membered 
zirconacycles by insertion of 1,1-dihalo-1-lithio species (dihalogenocarbenoids). Further 
rearrangement to a novel zirconium-alkenylidene complex driven by acetylides 
provided a powerful method for a rapid construction of novel bicyclic compounds with 
the potential for functionalization at multiple sites. Such obtained analogues provided 
an attractive template for structure-activity studies with respect to investigating the 
biological function of the human orphan nuclear receptors: LRH-1 and SF-1. Equivalent 
tandem insertion of 1,1-dihalo-1-lithio species and lithium acetylides into saturated 
zirconacycles resulted in the synthesis of novel bicyclo[3.3.0]octanes, though in many 
cases limited by a -H elimination process. 
In the second area is presented research work relating to acyclic organozirconocene 
systems. Insertion of allenyl and propargyl carbenoids into organochlorozirconocenes 
and bisalkyl/-alkynyl zirconocenes led to 1,2-zirconate rearrangement with expulsion of 
the corresponding leaving group. Lewis acid promoted insertion of aldehydes and 
ketones into the resulting allenyl/propargyl zirconocene intermediate gave after 
hydrolysis a series of propargylic alcohols. Insertion of carbenoids derived from chiral 
propargyl tosylates into organochlorozirconocenes and further 1,2-metallate 
rearrangement gave the final alcohols as enantiomerically enriched products. 
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The third area was an attempted total synthesis of the natural product mucosin, whose 
structure contains a bicyclo[4.3.0]nonane unit with four contiguous stereocentres. 
Zirconocene mediated co-cyclisation of the appropriate precursor provided four possible 
diastereoisomers. It was proved that thermodynamic equilibration of the zirconacycle 
gives the desired bicyclic product as a major isomer. Although the target molecule was 
not realised, thorough work on Zr-based total synthesis of mucosin has been achieved 
and a viable route for successful completion of the synthesis has also been proposed. 
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Chapter 1. Introduction 
1.1. Overview 
At the outset, the aim of the PhD research project was to develop highly convergent, 
zirconocene-mediated, synthetic routes to rigid core structures for use in pharmaceutical 
discovery, which have the potential to be implemented in high throughput automated 
synthesis facilities. This involved optimisation of reaction conditions and substrate-
scoping studies for the existing method for one-pot three-component coupling on a 
zirconocene template, originally discovered by previous members of the Whitby group. 
Application of this method with optimised conditions to a wide range of enynes resulted 
in synthesis of a series of novel compounds containing the rigid cis-bicyclo[3.3.0]oct-2-
ene skeleton. Such analogues were used for structure-activity studies with respect to 
investigating the biological function of the human orphan nuclear receptors: Liver 
Receptor Homolog-1 (LRH-1) and Steroidogenic Factor-1 (SF-1). 
The aim was also to explore novel methodology for synthetically attractive carbon-
carbon bond forming reactions by using stoichiometric zirconium chemistry. Discussed 
in this thesis are examples of current methodology for further elaboration of cyclic and 
acyclic zirconocene systems via carbenoid insertion and a novel 1,3-Zr alkenylidene 
rearrangement.  
Chapter 1 presents a brief description of biological background for a part of this project 
before the subject of zirconacycle formation and carbenoid insertion into 
organozirconium bonds is explained. The subsequent chapters then describe the results 
obtained. Firstly, the insertion of dihalogenocarbenoids into unsaturated and saturated 
zirconacycles and subsequent rearrangement to a novel zirconium-alkenylidene 
complex are discussed. Elaboration of acyclic zirconocene complexes through allenyl 
and propargyl carbenoids insertion with the potential for asymmetric synthesis is 
presented. Finally, attempted first total synthesis of the natural product mucosin based 
on zirconocene mediated co-cyclisation of the appropriate triene is described. 
 
1.2. Orphan Nuclear Receptors (ONRs) 
The nuclear hormone (NRs) superfamily in mammals comprises a highly conserved 
group of 49 receptors which act as transcription factors to regulate genetic networks 
involved in cell growth and differentiation and metabolism.1 Most are ligand regulated 
responding to dietary or endocrine signals such as steroid hormones, retinoids, vitamin 
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D, fatty acids and thyroid hormone. NRs are attractive targets for drug discovery2,3 and 
small molecules that regulate them comprise around 13% of current FDA-approved 
drugs.4 Originally around half of the NRs had no known natural ligands and were 
termed Orphan Nuclear Receptors (ONRs).5 Since most have a ligand binding pocket 
they provide great potential as novel targets for pharmaceuticals.6 A key step is to find 
natural or synthetic regulatory ligands to probe their biology7,8,9-a process termed 
‘reverse endocrinology’.10  Several have been ‘adopted’ (or deorphanized) recently, for 
example NR1H4 (FXR) by bile acids11 and peroxisome proliferators-activated receptor 
family (PPAR’s, NR1C’s.),12 leading to great advances in understanding and 
application. We have a particular interest in the Liver Receptor Homolog-1 (LRH-1, 
NR5A2)13 and Steroidogenic Factor-1 (SF-1, NR5A1),14  members of the subfamily V 
nuclear receptors (NR5A). 
 
1.2.1. Structural features of NRs 
NRs typically have a conserved domain structure (Figure 1.1) that includes the N-
terminus A/B domain [often containing a ligand-independent activation function-1 (AF-
1)]; also N-terminus, highly conserved DNA-binding domain (DBD or C domain), 
which is composed of two zinc fingers; the C-terminus ligand-binding domain (LBD or 
E domain), which contains an equally conserved ligand-dependent activation function-2 
(AF-2) motif that mediates coactivator interaction; and the D domain, which serves as a 
flexible hinge between the DBD and LBD.13,15 
 
 
 
 
 
Figure 1.1 Canonical structure of generic nuclear receptor (NR). 
 
The DBD is responsible for DNA response element recognition and dimerization, and 
the conserved LBD is involved in many overlapping functions including ligand binding, 
nuclear localization, dimerization, silencing and transactivation.15 When bound by 
hormone (or other small lipophilic ligands, including metabolites and certain synthetic 
ligands), these receptors function as ligand-dependent transcription factors by binding to 
unique response elements in the promoter of specific target genes.13,16 
A/B D E 
Hinge 
Ligand 
binding 
domain 
C 
AF1 AF2 
DNA 
binding 
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1.2.2. Structural features of the NR5 subfamily in the NRs superfamily  
Members of the NR5 family are orphan receptors that belong to one of the four 
subclasses of the Ftz-F1 subfamily (named for their homology with Drosophila fushi 
tarazu factor-1, the first cloned member of this group). Steroidogenic factor-1 (SF-1, 
NR5A1) and its closest homolog, liver receptor-homolog-1 (LRH-1, NR5A2) are the 
only human proteins that belong to this class.17  These and other NR5A subfamily 
members are unique in the NR superfamily; however, because they contain a distinctive 
26-amino acid motif, called the Fushi Tarazu-Factor1 domain (A box). The A box is 
located just C-terminal to the conserved zinc finger DNA-binding domain and contact 
the upstream motif in the binding site, thereby it is thought to be a key protein-protein 
interaction module (Figure 1.2).18,19 
 
 
 
 
 
Figure 1.2 Specific structure of NR5A subfamily members. 
 
Although SF-1 and LRH-1 are derived from two different genes, they share a highly 
conserved DBD (over 95% identity) and moderately conserved LBD (56%). Thus, both 
receptors can recognize the same DNA sequence and several reports demonstrate that 
genes expressed in the adrenal, in adipocytes, and in the ovary previously shown to be 
regulated by SF-1 can also be transactivated by LRH-1.20-24 On the other hand, their 
different biological activities are contributed in part by distinct structural features in 
their LBDs, which recruit specific cofactors to regulate transcription.25 
 
1.2.3. Biological functions of ONRs: Liver Receptor Homolog-1 (LRH-1) and 
Steroidogenic Factor-1 (SF-1) 
LRH-1 plays a critical role in embryonic development of the endoderm.26  In adults it is 
expressed in the intestine, liver, exocrine pancreas and ovary. It is extensively expressed 
in the mouse brain.27 LRH-1 regulates the expression of genes involved in hepatic bile 
acid biosynthesis,28 the bile salt export pump29 and cholesterol homeostasis.13  Thus, the 
receptor may be a target for the treatment of cardiovascular disease30 and cholinostatic 
liver diease.31 It is a key controller in the hepatic acute-phase response.32  
LBD 
AF2 
Hinge DBD 
Ftz-F1 
A box 
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Its regulation of aromatase expression33 also suggests a possible utility in cancer 
therapy, particularly human breast carcinomas.34, 35, 36-39 LRH-1 is expressed in human 
intestinal crypt cells where it controls cell proliferation and differentiation.40 Its 
potential role in gastric cancer has been reviewed.41 Expression of LRH-1 is found to be 
substantially raised in human gastric cancer cells,42 and it influences tumor formation 
through effects on cell cycle and inflammation.43 LRH-1 is a key regulator of Mouse 
Embryonic Stem cell pluripotency and differentiation.44 It has been shown to be a key 
regulator of oct-4 expression,26 and oct-4 is important in the maintenance of adult neural 
stem cell pluripotency,45 so there may be applications in neurodegenerative disorders. 
LRH-1 probably has a key role in ovulation and female fertility, and is a possible target 
for contraception.46  
Nuclear receptor SF-1 (NR5A1) plays multiple roles in endocrine development47,48,49 
including sex determination, for example SF-1 knock-out mice were phenotypically 
female independent of genetic sex,50 and lack adrenals, gonads and the ventromedial 
hypothalamic nucleus.51,50  
SF-1 is an important regulator of mouse ES pluripotence and differentiation.44 In 
particular it promotes steroidogenesis demonstrating that is a dominant regulator of the 
steroidogenic cell phenotype. Forced expression of SF-1 transforms human bone 
marrow mesenchymal cells into steroidogenic cells.52, 53, 54,55 Like LRH-1 SF-1 has been 
shown to regulate oct-4 expression with implications for control of stem cell 
pluripotence.56 
SF-1 has an important role in steroid regulation throughout life, particularly via its 
control of the expression of the steroidogenic cytochrome P450 genes in endocrine 
tissues, such as the adrenal cortex, testes, and ovary.57, 58 Mutation of the gene in 
humans correlates with disorders of testes development.59 It is overexpressed in most 
cases of childhood adrenocortical tumors, and reverse agonists inhibit proliferation.60  
SF-1 is closely involved in the development of endometriosis and endometrial 
cancers.61, 62, 63 It is also expressed in the hypothalamus and has been implicated in the 
regulation of feeding behaviour.64, 65 A CNS selective knockout of SF-1 in mice has 
demonstrated strong effects on anxiety, energy homeostasis and appetite.66, 67 
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1.2.4. Mode of action of LRH-1 and SF-1 with suggested regulation of activity 
Unlike most NRs, LRH-1 and SF-1 bind to DNA as monomers and show constitutive 
activation of transcription when expressed in cells.13,14  Receptor activity can be 
regulated by phosphorylation,68 sumoylation69 or through interaction with the atypical 
orphan receptors SHP (NR0B1)70,71 and DAX-1 (NR0B2)72,73 that lack their own DNA-
binding domains.   
Although originally defined as ONRs X-ray crystallography coupled with mass 
spectroscopy (MS) has recently revealed the presence of E. coli derived phospholipids 
phosphatidylethanolamines 1.1 and phosphatidylglycerides 1.2a in the ligand binding 
pockets of human LRH-1 and SF-1 (Figure 1.3).74,75,76,77 The phospholipids identified in 
the crystals had C16 or 18 acyl groups, some of which were identified as having a cis 
alkene in the ∆9 position, but MS studies showed that a wide range of related 
phospholipids (C12-C18 acyl groups with various unsaturation) were also bound to the 
receptors. The binding of phospholipids in SF-1 was shown to strongly activate 
recruitment of co-activator peptide.76  Mutation experiments on hLRH-1 showed a 
correlation between  binding of  phospholipid and LRH-1 induced activation of gene 
expression.77  Exchange of bacterially derived phosphatidyl glyceride 1.1 (Figure 1.3) 
with inosityl phospholipids (particularly the triphosphate derivative 1.3)75 and  
phosphatidylcholine 1.2b78 has been demonstrated for SF-1. In the latter case the 
exchange had little effect on binding of coactivator peptides.78 Recently Moore has 
reported that diundecanoyl (1.2b, R1 = R2 = n-C9H19) and dilauroyl (1.2b, R1 = R2 = n-
C11H23) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor and has shown 
that administration of these lipids to diabetic mice reduces blood glucose levels.79  
Indirect activation of SF-1 through increased levels of phosphatidylinositol (3,4,5) 
triphosphate 1.3 induced by a tamoxifen analogue has been suggested as relevant in 
endometrial cell proliferation.63 Sphingosine 1.4 has also been reported to bind to SF-1 
and suppresses expression of cytochrome P450 17 (CYP17) gene (which is regulated by 
SF-1) suggesting that it may be an antagonist of SF-1.80,81,82 Derivatives of 1.4 such as 
sphingosylphosphorylcholine and N-Acyl-1.4 (ceramides) may also be natural ligands. 
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Figure 1.3 Agonists and antagonists for LRH–1 and SF–1. 
 
Recently, Whitby et al. reported the first synthetic small molecule, GSK8470 1.5 
(Figure 1.4), as a potent agonist for LRH-1 (EC50 = 430 nM) and SF-1 (EC50 = 54 nM). 
A SAR study on series 1.6 led to the more active analogue 1.7 with EC50 = 34 nM for 
LRH-1 and EC50 = 43 nM for SF-1.83  
Subsequently the herbicide atrazine has also been reported84-86 to bind to SF-1 and 
induce aromatase expression at relatively low concentrations (0.1 µM), but as mutations 
of the LBD of SF-1 have no effect the interaction must be other than with the ligand 
binding pocket. 
Recently p-heptyoxyphenol 1.8 was reported as a potent (IC50 = 7.2 µM) inverse agonist 
for SF-1, but with no activity against LRH-1.87 Expression of several reported SF-1 
target genes was suppressed by 1.8 in cell based assays. Although 1.8 was reported to 
inhibit proliferation of adrenocortial carcinoma cell line H295R, it had the same effect 
with an SF-1 negative cell line (SW-13).60  
Several isoquinoline based inverse agonists of SF-1 were discovered through high 
throughput screening and further SAR studies, of which 1.9 was the most active (IC50 = 
200 nM).88, 89 At high levels (10 µM) 1.9 modestly suppressed doxycycline (Dox) 
induced proliferation of H295R cell line with little effect on the SF-1 negative SW-13 
cell line.  
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Closely related isoquinolines affected both cell lines in a similar way suggesting a non-
SF-1 mechanism. The SAR for these series seems complex, for example replacing the 
methoxy group in 1.9 with ethoxy gave a compound highly active against a range of 
other receptors, and exhibiting strong cell toxicity suggesting transactivation assay 
artefacts (e.g. promiscuous inhibition of the reporter system).  
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Figure 1.4 Discovery of small molecule agonist and inverse agonists for LRH-1 and SF-1. 
 
Although GSK8470 1.5 and related compounds 1.6 have proven to be excellent 
biological probes for LRH-1 and SF-1 they have a number of drawbacks.  
Most important is that they are very unstable to acid making handling difficult and 
raising doubts about stability during biological application. The series also shows little 
discrimination between LRH-1 and SF-1.  
 
1.3. Organozirconium chemistry 
1.3.1. Formation of carbon-zirconium bonds 
The origin of organozirconium chemistry is dated by the preparation of the first  
organozirconium compounds, zirconocene dibromide (ZrCp2Br2) and soon after 
zirconocene dichloride (ZrCp2Cl2) by Wilkinson and Birmingham in 1954.90 The use of 
organozirconium chemistry in organic chemistry originated in the early 1970’s with the 
preparation of HZrCp2Cl,91 and the observation by Wailes et al. of its addition across 
carbon-carbon double bonds.92 Extensive studies including synthetic utility of 
HZrCp2Cl were started by Schwartz in 1974,93 whose name has been given to this 
reagent. Formation of acyclic organozirconium species 1.11 and 1.12 is achieved via 
hydrozirconation of alkanes or alkynes with the Schwartz reagent (Scheme 1.1). 
 26 
Cp2ZrHCl
1.10
ZrCp2Cl
R
H
1.11
ZrCp2Cl
R
H
H1.12
(i) (ii)
Reagents and Conditions: (i) 1.0 eq alkene, RT; (ii) 1.0 eq alkyne, RT.
 
Scheme 1.1 Hydrozirconation of alkenes and alkynes. 
 
Products of hydrozirconation can be efficiently converted into organic compounds by 
reacting with electrophiles (halogens, acid chlorides) as well as with carbenoids (e.g. 
carbon monoxide).93,94 
 
The original method for preparation of zirconacycles from alkenes and alkynes was 
based on formation of the 14-electron species zirconocene (Cp2Zr), generated in situ by 
reducing zirconocene dichloride with Mg/Hg amalgams (Scheme 1.2).95,96 
Reagents and Conditions: (i) 0.25 eq Cp2ZrCl2, 0.25 eq HgCl2, 1.25 eq Mg, THF; (ii) 1.0 eq Cp2ZrCl2, 1.0 eq HgCl2, 10 eq Mg.
R R ZrCp2
R
R
R
R
(i) SiMe3 (ii)
ZrCp2
SiMe3
1.13
1.161.151.14
 
Scheme 1.2 Formation of zirconacycles. 
 
Initially this method was satisfactory for performing co-cyclisations, however, a more 
experimentally convenient process avoiding the toxicity of mercury was developed,97 
which still remains the most versatile and commonly used today (Scheme 1.3). 
Treatment of a cold solution of zirconocene dichloride in THF with 2 equivalents of n-
BuLi  gives dibutyl zirconocene 1.17 also known as the Negishi reagent. Warming to 
room temperature leads to loss of butane through -hydrogen abstraction to form the 
active zirconocene(1-butene) 1.18. Zirconocene(1-butene) 1.18 can either be considered 
as Cp2Zr(IV) 1.18a or a Cp2Zr(II) 1.18b species. The weakly bound butene ligand is 
readily displaced by alkene or alkyne from the co-cyclisation substrate, followed by 
carbometallation type reaction to expand the ring to a zirconacycle, such as 1.20 
(Scheme 1.3). 
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Cp2Zr H
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Cp2R1
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IV II
1.17
1.18a 1.18b
1.19
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Reagents and Conditions: (i) n-BuLi (2.0 eq), THF, −78 οC, 15 min; 
(ii) 1,n-diene,-diyne, -enyne; (iii) −78 οC to RT.
(i), (ii), (iii)
 
Scheme 1.3 Mechanism for co-cyclisation of unsaturated organic molecules with Negishi reagent. 
 
The development of zirconocene(1-butene) and its wide applicability to reductive 
couplings of unsaturated organic molecules such as 1,n-dienes, -diynes and -enynes has 
led to rapid expansion of organozirconium chemistry. This method has also been 
successfully applied in the total synthesis of many natural products.98-100 
 
The methodology for formation of monocyclic zirconacycles has also been developed 
(Scheme 1.4). Synthesis of zirconacyclopentanes 1.22, 1.23, zirconacyclopentenes 1.24 
and zirconacyclopentadienes 1.27 is achieved by trapping zirconocene ethylene 1.21 
with alkenes and alkynes.101 The complex 1.21 is generated by either treating ZrCp2Cl2 
with two equivalents of EtMgBr102 or by synthesising zirconocene(1-butene) 1.18 under 
an atmosphere of ethylene gas.103 One ethene molecule remains bound to the Zr atom 
when reaction with alkenes or alkynes occurs, thus leading to the observed selective 
cross-coupling reactions, so that specific monocycles 1.22, 1.23 or 1.24 can be formed. 
Heating the resulting monocycle in the presence of aldehydes, nitriles or other alkynes 
results in the loss of ethane allowing the formation of unsymmetrical 
zirconamonocycles,104 such as 1.25, 1.26 and 1.27. 
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Cp2Zr Cp2Zr
(iii)(iv)
Reagents and Conditions: (i) 2.0 eq n-BuLi, −78 οC to RT, under an atmosphere of
ethene; (ii) 2.0 eq EtMgBr, −78 οC to RT, 1 h; (iii) H2CCHAr, 0 οC; (iv) H2CCHR,
0 οC; (v) R1CCR1, 0 οC; (vi) R3CN, 25 οC; (vii) R2CHO, 50 οC; (viii) R4CCR4,  50 οC.
ZrCp2
R1
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Scheme 1.4 Access to monocycles by trapping zirconocene ethylene complex. 
 
1.3.2. Carbocycle formation by zirconocene mediated co-cyclisation of enynes 
Both 1,6- and 1,7-enynes 1.28 are excellent substrates for zirconocene(1-butene) 
mediated co-cyclisation to afford the corresponding bicyclic zirconacycles usually in 
high yields.105,106 Although preparation of bicyclic zirconacyclopentenes is limited by 
the ring size, a wide variety of substituents on both the ring and the alkyne are tolerated 
(Scheme 1.5).105,107 Furthermore, substitution on the alkyne is required as terminal 
alkynes fail to cyclise under these conditions. Enynes with an α-substituent to the 
alkene show a high level of diastereoselectivity through control of the ring junction 
formed in the cyclisation step.107-110  
 
Examples carrying ring substitutions such as alkyl, protected alcohol, amine and amide 
are also reported in the literature. Cyclisation of precursors possessing substitution on 
the double bond are known, including unusual examples such as allene 1.34.105 
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Scheme 1.5 Variability of substituents on enynes. 
 
1.4. Elaboration of unsaturated zirconacycles 
Although a broad spectrum of unsaturated organic molecules can be co-cyclised in 
intra- and/or inter-molecular fashion to give a variety of metallacycles, the potential of 
organozirconium chemistry is significantly increased by the ability to functionalise the 
C-Zr bond. Over the past two decades many sophisticated methods for elaboration of 
the C-Zr bond have been developed which allow access to a great deal of useful organic 
products. The selected methods will be concisely overviewed throughout the following 
section. 
 
1.4.1. Protonation and halogenation 
The simplest functionalisation of zirconacycles is protonation to give the corresponding 
hydrocarbon, which can be done under acidic or basic conditions. The widely used 
quenches are: MeOH, aqueous solution of NaHCO3, aq HCl or aq H2SO4. Choice of the 
quenching conditions is dictated by the acid/base stability of the products.  
The analogous reaction with MeOD, D2O, DCl or D2SO4 can be used to perform 
deuterolysis. Incorporation of deuterium atom into products is very often a valuable tool 
for the determination of mechanisms.  
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Methodology for selective monohalogenation of zirconacyclopentenes has been 
explored by Takahashi (Scheme 1.6).111 Depending on the reagent used and the 
substituents present on the double bond, halogenation can be regiospecific to give either 
vinyl halides 1.38, 1.40 or the alkyl halides 1.39, 1.41 in yields ranging from 78 to 
94%.112,113 With aryl substituents present on the double bond, vinyl halide is formed by 
method b. Selective methanolysis of the zirconium-alkyl bond was observed to form the 
alkoxy-zirconocene intermediate 1.37, subsequent treatment of such obtained species 
with iodine resulted in alkenyl iodide 1.38 in excellent yield.114 Direct halogenation of 
the zirconacyclopentene 1.36 with iodine, followed by acidic protonolysis gave the 
alkyl iodide with high selectivity. With alkyl substituents present on the double bond, 
the regioselectivity can be controlled by use of either I2 or CBr4. 
Reagents and Conditions: method a: 1.2 eq I2, then HCl; method b: 1.5 eq MeOH, then 
1.2 eq I2; method c: CBr4 or CCl3Br.
ZrCp2
R1
R2
1.36 H
R1
R2
X
X
R1
R2
H
H
R1
R2
R1 = R2 = Ph
1.39, 80% X
X
R1
R2
H
R1 = R2 = Ph
1.38, 78%
a
b
a or b
c
ZrCp2
R1
R2
1.37 OMe
H
R1 = R2 = Et
1.40, 78% for a
1.40, 81% for b
R1 = R2 = Pr
1.41, 94%
 
Scheme 1.6 Selective halogenation of zirconacyclopentenes. 
 
1.4.2. Carbonylation and isocyanide insertion 
One of the earliest and most widely used methods for elaboration of zirconacycles is 
carbonylation.96,115 The availability of the d-orbital on the zirconium atom and carbene-
like nature of carbon monoxide are essential for the reaction to occur. Carbon monoxide 
donates a lone pair of electrons into the vacant d-orbital of the Zr atom to give the 
complex 1.43 (Scheme 1.7). Subsequent migration of the sp3 carbon-zirconium bond 
gives the zirconocene acyl complex 1.44 and allows the zirconium atom to return to its 
favourable 16-electron state. Rearrangement to the zirconocene 2-ketone complex 1.45 
then follows, which can be converted to cyclopentanol 1.46 or cyclopentanone 1.47 on 
protonolysis, or oxidative work-up with iodine (prolonged exposure to CO is an 
alternative method), respectively.116,117 
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ZrCp2
O+
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Reagents and Conditions: (i) CO, −78 οC; (ii) 3 M HCl; (iii) RT, I2.
 
Scheme 1.7 Carbonylation of zirconacycles. 
 
Insertion of isocyanides into zirconacycles is the analogous reaction to carbonylation, 
since isocyanides are isoelectronic with carbon monoxide (Scheme 1.8). 
ZrCp2
N
ZrCp2 ZrCp2
NPh
-
ZrCp2
N(i)
(ii)
(iii)
1.48 1.49 1.50 1.51
1.52
Reagents and Conditions: (i) PhNC, THF, −35 οC; (ii) Alkyne, reflux; (iii) MeOH; (iv) SiO2 
or spontaneous.
R1 R1
R1 R1
R1
ZrCp2N
R3
R2
Ph
Ph
Ph
1.53
R1
NH
R3
R2
Ph
1.54
R1NH
H
Ph
R2
R3
(iv)
R1                R2                 R3     Yield
SiMe3 Me Me 51
SiMe3 Pr Pr 35
Ph Pr Pr 53
Me Pr Pr 61
Bu            Pr             Pr          68
Scheme 1.8 Isocyanide insertion into zirconacyclopentenes. 
 
Insertion of phenyl isocyanide into zirconacyclopentanes affords iminoacyl complex 
1.50, which slowly rearranges to give 2-imine complex 1.51 (Scheme 1.8).118  
Trapping the complex 1.51 with alkyne gives the expanded α,-unsaturated 2-imine 
complex 1.52. Subsequent methanolysis provides diallylic amine 1.53, which undergoes 
an unusual anti-1,3 allylic shift of amine119 either on silica or spontaneously to give the 
tertiary amine product 1.54.  
Insertion of t-butyl isocyanide occurs specifically into the alkyl-zirconium bond to give 
the iminoacyl intermediate 1.55, which does not rearrange to 2-imine complex 
(Scheme 1.9). Protonolysis with HCl gave aldehyde 1.56. 
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ZrCp2
Nt-Bu
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Reagents and Conditions: (i) 2 M HCl, RT.
 
Scheme 1.9 t-Butyl isocyanide insertion into zirconacyclopentaene complex. 
 
More recently copper-mediated insertion of isocyanides into zirconacyclopentadienes 
has been reported.120 
 
1.4.3. Metathesis to main group elements 
Elaboration of both C-Zr bonds present in zirconacycles via exchange of the zirconium 
atom for a main group element provides a range of highly functionalized, often unusual, 
heterocycles (Scheme 1.10).  
Reagents and Conditions: (i) for P, As: PhECl2, 25 οC; (ii) for Sb, Bi: ECl3, 25 οC;
(iii) PhLi; (iv) a. for Si: SiBr4 (neat), 150 οC, 2 d; b. for Ge: GeCl4, 25 οC, 2 min;
(v) GaCl3, 25 οC, 5 min, then (Et)4N+Cl; (vi) PhBCl2,  25 οC, 1 h; (vii) a. for S, Se: 
Z2X2, 25 οC, 1 h; b. Me2SnBr2, 25 οC, 2 d; (viii) S2Cl2, 25 οC, 1 h.
ZrCp2
EPhEX2
BPh Ga-Cl2 +N(Et)4
E Cl
(i)
(iii)
(ii)
(iv)
(v)
(vi)
1. E = P, 81 %
2. E = As, 78 %
3. E = Sb, 78 %
4. E = Bi, 70 %1. E = Si, X = Br,  28 %2. E = Ge, X = Cl,  83 %
1.57
1.58
1.59
1.60
1.61, 68 % 1.62, 73 %
ZrCp2 Z
N
ZrCp2
N
S
Z = S, 55 %
Z = Se, 53 %
Z = SnMe2, 100%
1.66, 65 %
1.63 1.64
1.65
(vii)
(viii)
 
Scheme 1.10 Heterocycle synthesis via metathesis with main group elements. 
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Nugent, who extensively developed this area, demonstrated the facile preparation of 
main group heterocycles 1.58, 1.60 – 1.62, 1.64, 1.66 from zirconacyclopentanes, -enes 
and -dienes (Scheme 1.10).108,121-123 The group 15 phenyl derivatives 1.58.1-4, can be 
prepared by reaction of a zirconacycle with the element dichloride or trichloride. The 
latter case requires treatment of the cyclic monochloride 1.59 with PhLi. Group 14 and 
16 compounds can also be prepared. For group 13 elements, borole 1.61 and gallole salt 
1.62 can be synthesised, and the latter compounds are stable and do not undergo Diels-
Alder reactions. 
 
1.4.4. Carbenoid insertion 
Organic species which exhibit reaction qualitatively similar to those of carbenes are 
referred to as carbenoids. Lithium carbenoids show the greatest utility in organic 
synthesis, although carbenoids with metals such as potassium, sodium and tin are 
known.124 Insertion of lithium carbenoids into organozirconocenes has been extensively 
explored by Whitby118 and a great deal of this thesis is related to this theme. 
 
1.4.4.1. Synthesis and reactivity of lithium carbenoids 
Lithium halocarbenoids are thermolabile molecules in which a single carbon atom is 
substituted with a halogen and lithium atom. These species are formed at temperatures 
usually below –78 °C by either deprotonation or halogen-lithium exchange.  
X
H
(i) X
Li
R R R
R
R
R
R
= +
X
X'
(ii) X
Li
R R R
R
R
R
R
= + +
H
H
X = F, Cl, Br or I
X or X' = F, Cl, Br or I
1.67 1.68
1.69 1.70
Reagents and Conditions: (i) 1.0 eq R2NLi, < −70 οC; (ii) 1.0 eq RLi, ~ −100 οC.
a)
b)
 
Scheme 1.11 Formation of lithium carbenoids. 
 
Deprotonation of an organohalide with an organolithium or lithium amide base 
generates the carbenoid molecule (equation a, Scheme 1.11)125,126 A limitation of this 
method is the low acidity of the proton, which makes deprotonation at low temperatures 
difficult. Alternatively, halogen-lithium exchange of a gem-dihalo-compound leads to 
the same type of structure (equation b, Scheme 1.11)127 however the main drawback 
related to this method is α-metallation.128 
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Carbenoids are usually unstable at temperatures higher than –70 °C and undergo 
decomposition through various reactions (Scheme 1.12). α-Elimination,  which yields 
the highly reactive carbene species 1.72 is the main decomposition reaction.129 For 
certain carbenoids -elimination is an alternative route for decomposition and can result 
in formation of alkenes 1.74 (Scheme 1.12).129 
X
Li
R1
R2
− LiX R1
R2
α-elimination
X
Li
R1
− LiOSiMe3
O
Me3Si
R2
R1
R2
β-elimination
1.71 1.72 1.73 1.74
R1 = alkyl or H
R2 = alkylX
 
Scheme 1.12 Decomposition routes for carbenoids. 
 
Carbenoids show amphiphilic nature therefore they can react as both nucleophiles and 
as electrophiles.124 Carbenoids generally undergo three main types of reaction:126,130,131  
a. Nucleophilic reactions such as alkylations and acylations with retention of 
the configuration at the carbenoid centre. 
b. Electrophilic behaviour includes reactions with strong nucleophiles with 
inversion of the configuration at the carbenoid centre. 
c. Combined nucleophilic and electrophilic properties allow carbenoids to 
insert into single and double bonds. 
 
1.4.4.2. Allyl and alkyl carbenoid insertion into zirconacycles 
Selective means of elaborating carbon-zirconium bonds through regioselective insertion 
of alkyl and allyl carbenoids into unsymmetrical zirconacycles have been reported.132,133 
Distinct substitution patterns of zirconacycles and different electronic properties of the 
carbenoids account for complete selectivity observed in most of the investigated 
examples where a single product is isolated. 
 
1.4.4.2.1. Allyl carbenoid insertion into zirconacyclopentenes 
The first report on carbon-carbon bond forming reactions via insertion of carbenoids 
into organotransition metal complexes was by Negishi et al.134 The authors describe the 
insertion of - and -haloorganolithiums into acyclic organozirconocene derivates to 
give a good yield of alkenes and allenes on acid quench. 
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Whitby extended this methodology to the insertion of a wide range of carbenoids into 
zirconacycles. Initial nucleophilic attack of allyl carbenoid (lithium chloroallylide) 1.76 
onto the Zr atom in zirconacyclopentene 1.75 generates an 18-electron ‘ate’ complex 
1.77 (Scheme 1.13).135 A 1,2-metallate rearrangement136 with loss of the leaving group 
affords zirconocene 3-complex 1.78. Methanolysis of the allyl zirconium complex 
affords an 85 : 15 mixture of alkene products 1.79a and 1.79b in 71% yield. Further 
elaboration of the allyl zirconium complex by benzaldehyde insertion provides the 
alcohol 1.80 in excellent yield.  
Extensive elaborations of this methodology include insertions of various allyl 
carbenoids into a wide range of saturated and unsaturated zirconacycles and trapping the 
resulting zirconocene 3-complex with different electrophiles such as ketones, iminium 
and thienium ions and through the Lewis acid promoted addition of aldehydes, acetals 
and orthoesters.137-139 
ZrCp2
Bu
ZrCp2
Bu
Cl
Li+
ZrCp2
Bu
Bu
Bu+
OHH
H H H
H
H
1.75
1.77
1.80, 91%
1.78
1.79a
1.79b
Cl
Li
(i)
Bu
(ii)
(iii), (iv)1.76
Reagents and Conditions: (i) 1.1 eq CH2CHCH2Cl, LiTMP, −78 to −60  οC, 1 h; (ii) MeOH, 48 h,
RT; (iii) 1.5 eq PhCHO, 1.5 eq BF3·Et2O, −60  οC to RT, 2 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
a : b, 85 : 15, 71%
Ph
 
Scheme 1.13 Insertion of lithium chloroallylide into unsaturated zirconacycle. 
 
1.4.4.2.2. Allyl and alkyl carbenoid insertion into α-substituted zirconacyclopentenes 
A study of lithium chloroallylide and chloromethylallylide insertion into a wide range 
of unsymmetrical zirconacyclopentenes resulted in a very good regioselectivity. In all 
cases the final product was obtained as a single regioisomer (Scheme 1.14).132,135 
Complete selectivity for the alkyl zirconium bond was observed when the vinyl carbon 
- to the zirconium centre was substituted (R’ = Ph, SiMe3, n-Bu) in both monocyclic 
1.81 and bicyclic zirconacycles 1.83a, b, c to provide the corresponding products 1.82 
and 1.84a,b, c. Zirconacyclopentene 1.85 with substitution at the alkyl carbon - to 
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zirconium showed complete regioselectivity for the alkenyl zirconium bond. Further 
studies however, revealed that the nature of substitution at the alkyl carbon adjacent to 
Zr was also important, and exclusive insertions into the most hindered alkyl zirconium 
bond were observed (zirconacycles 1.88, 1.90). 
Reagents and Conditions: (i) 1.1 eq CH2CHCH2Cl, LiTMP, −78 to −60  οC, 1 h;
(ii) 1.5 eq PhCHO, 1.5 eq BF3·Et2O, −60  οC to RT, 2 h; (iii)  MeOH, aq NaHCO3, 
RT, 16 h; (iv) CH2C(CH3)CH2Cl, LDA, −78  οC to RT, 2 h; (v) AcOH, RT, 24 h;
(vi) 5 eq LiTMP, −78 to −30  οC, 2 h; (vii) 5 eq PhCHO, 5 eq BF3·Et2O, −78  οC
to RT, 5 h; (viii) MeOH, aq NaHCO3, RT, 1 h; (ix) CH2C(CH3)CH2Cl, LDA,
−100  οC to −60  οC, 2 h.
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Scheme 1.14 Regiochemistry of allyl carbenoid insertion into zirconacyclopentenes. 
 
Insertion of alkyl carbenoids: lithiated chloroacetonitrile 1.92 and lithiated chloromethyl 
phenyl sulfone 1.95 into monocyclic zirconacyclopentene 1.81 afforded products 1.93 
and 1.96 in good and very good yield, respectively (Scheme 1.15).140 A double insertion 
was observed for lithiated chloroacetonitrile when used in excess to provide the double 
insertion product 1.94 in low yield.  
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Also elimination of the sulfone group from the zirconacycle 1.100 upon warming to RT 
is observed to give product 1.102 in moderate yield. This process can be explained by a 
novel endocyclic cyclometallation process141 to afford the zirconocene 2-alkene 
complex 1.100, which allows the sulfone group to be eliminated 1.101. 
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Reagents and Conditions: (i) 1.0 eq ClCH2CN, LDA, −85 oC, 10 min; (ii) MeOH,
aq NaHCO3, RT, 16-24 h; (iii) 3.2 eq ClCH2CN, LDA, −78 oC, 2 h, (iv) 2.2 eq
ClCH2SO2Ph, LDA, −78 oC, 2.5 h; (v) 1.0 eq ClCH2SO2Ph, LDA, −78 oC to RT, 16 h.
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Scheme 1.15 Regiochemistry of alkyl carbenoid insertion into monocyclic zirconacyclopentenes. 
 
The insertion of electron rich and electron poor alkyl carbenoids into bicyclic 
zirconacycles 1.83c, 1.103 and 1.110 has been examined (Scheme 1.16).133,140 Insertion 
of lithiated chloroacetonitrile 1.92 and lithiated chloromethyl phenyl sulfone 1.95 
(electron poor carbenoids), into zirconacyclopentenes 1.103 and 1.110 was successful 
and afforded products 1.104, 1.106 and 1.111 in reasonable yields, and observed 
regioselectivity for the alkyl zirconium bond in all examples.  
 38 
Treatment of zirconacycle 1.103 with five equivalents of lithiated chloroacetonitrile 
1.92 resulted in double carbenoid insertion product 1.105, isolated in low yield as a 
separable 2.2 : 1 mixture of diastereoisomers (Scheme 1.16).  
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eq ClCH2SiMe3, LDA, −78 οC for 30 min, then to RT; (vi) 1.3 eq ClCH2SO2Ph,
LDA, −78 οC, 2 h; (vii) 1.5 eq ClCH2SO2Ph, LDA, −78 οC to RT over 16 h.
ZrCp2
(v), (ii)
1.108 1.109ratio 87:131.83c
+
n-Bu
SiMe3
n-Bu n-Bu
SiMe3
Cl SiMe3
1.107
Li
Cl CN
1.92
Li
Cl SO2Ph
1.95Li
1.95 1.95
1.92
Scheme 1.16 Regiochemistry of alkyl carbenoid insertion into bicyclic zirconacyclopentenes. 
 
Different conditions were required for efficient insertion of lithiated chloromethyl 
phenyl sulfone 1.95 into zirconacycles 1.103 and 1.110. In the less constrained system 
1.110 insertion occurred at –78 °C to afford sulfone 1.111, however, for insertion into 
the more constrained system 1.103, warming to 0 °C was required to afford sulfone 
1.106. Additionally when the reaction with zirconacyclopentene 1.110 was warmed to 
room temperature before quenching, the product of sulfone elimination, diene 1.112 
was isolated (Scheme 1.16). 
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The electron rich silicon substituted carbenoid Me3SiCHLiCl 1.107 inserts efficiently 
into 1.83c to give, on aqueous work-up, mostly the expected product 1.108, but also a 
significant amount of the regioisomer 1.109 derived from insertion into the zirconium-
alkenyl bond (Scheme 1.16).133 Although other electron rich carbenoids such as lithiated 
chloromethyl methyl ether, 2-methoxyethoxymethyl chloride and chloromethyl phenyl 
sulfide insert into zirconacyclopentenes, the yields are low and the products too messy 
to properly characterise. 
Different models can be used to explain the regiochemistry of carbenoid insertion into 
zirconacycles.118,132 Favoured direction of lateral attack is used to explain the selectivity 
of carbenoid insertion for zirconacycles 1.81, 1.83, 1.103, 1.110. Considering a 
carbenoid as an electrophilic species provides an explanation for the selectivity of 
carbenoid insertion into the more hindered and electron rich C-Zr bond in zirconacycles 
1.88 and 1.90. In the third model, regioselectivity may be determined by the favoured 
1,2-metallate rearrangement of a fluxional ‘ate’ complex created by initial nucleophilic 
attack of the carbenoid on Zr atom. 
 
1.4.4.2.3. Allyl and alkyl carbenoid insertion into α-unsubstituted 
zirconacyclopentenes 
Cyclisation of terminal alkynes with the zirconocene(1-butene) fails105,142 but reaction 
of hept-1-en-6-yne with zirconocene(ethylene), followed by heating104,143 gives the α-
unsubstituted zirconacyclopentene 1.113 (Scheme 1.17).  
Alternative conditions using a combination of activated magnesium and zirconocene 
dichloride also allowed co-cyclisation of the terminally unsubstituted enyne but was 
found to be unreliable and accounts for the poor yields often observed in the series 
based on zirconacycle 1.113.140 Insertion of one allyl and three alkyl carbenoids into 
zirconacyclopentenes 1.113 and 1.116 gave mixed results (Scheme 1.17). Insertion of 
lithium chloroallylide 1.76 followed by benzaldehyde gave a 2.2 : 1 mixture of 
regioisomeric insertion products 1.114 and 1.115.132 Insertion of lithiated 
chloromethylphosphonate 1.117 and lithiated chloroacetonitrile 1.92 (electron poor 
carbenoids) resulted in insertion with complete regioselectivity for the alkyl zirconium 
bond to give products 1.118 and 1.120, respectively. Whereas, the electron rich lithiated 
chloromethyl trimethylsilane 1.107 displayed moderate 3 : 1 selectivity for the alkenyl 
zirconium bond, affording an inseparable mixture of compounds 1.121 and 1.122 
(Scheme 1.17).140 
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ZrCp2
MeO
MeO
H1.116
MeO
MeO
H
1.118, 36%
MeO
MeO
H
(iv), (v)
(vi), (v)
P(OEt)2
O
1.119, 54%
1.120, 20% + 1.119, 29%
Reagents and Conditions:(i) 1.5 eq CH2CHCH2Cl, LiTMP, −78 οC to −30 οC, 2 h;
(ii) 2.0 eq PhCHO, 2.0 eq BF3·Et2O, −78 οC to RT, 5 h; (iii) MeOH, aq NaHCO3,
RT, 1 h; (iv) 2.0 eq ClCH2PO(OEt)2, LiTMP, −78 οC to RT, 14 hr; (v) MeOH,
aq NaHCO3, RT, 16 h; (vi) 1.1 eq ClCH2CN, LiTMP, −78 οC, 15 min; (vii) 1.39 eq
ClCH2SiMe3, s-BuLi, TMEDA, −78 οC, 30 min; (viii) −78 οC to RT, 16 h.
Cl P(OEt)2
O
Cl CN
Cl SiMe3
Li
1.107
(vii), (viii), (v)
MeO
MeO
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MeO
MeO
H1.122
SiMe3
SiMe3
+
1.121 and 1.122 - inseparable mixture - 29% yield, 
ratio 1.121 : 1.122; 3:1; also recovered 26% of 1.119
MeO
MeO
H
+
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H 1.113
(i), (ii), (iii)
Cl
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OH
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1.114 1.115
1.114 : 1.115; 2.2 : 1; 79%
+
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Li 1.76
Li 1.117
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Scheme 1.17 Allyl and alkyl carbenoid insertion into zirconacyclopentenes. 
 
Results from the phosphonate and nitrile carbenoids appear to indicate initial carbenoid 
insertion occurs on the side of the alkyl zirconium bond. This could be explained by the 
alkenyl proton being positioned in the direction of lateral attack, preventing initial 
attack on the alkenyl side of the zirconacycle 1.113. Thomas also gives the explanation 
for the results from lithiated chloromethyl trimethylsilane insertion. The -silicon atom 
stabilises the ‘ate’ complex, formed from silyl carbenoid and zirconacycle 1.116, 
slowing rearrangement and allowing the more electron rich carbon zirconium bond to 
migrate.140  
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Chapter 2. Three-component coupling of zirconacyclo-
pentenes, dihalocarbenoids and acetylides via 
rearrangement to a novel zirconium-alkenylidene 
complex 
This chapter presents a sophisticated method for elaboration of zirconacyclopentenes. 
Sequential addition of 1,1-dihalo-1-lithioalkanes and lithium acetylides to 
zirconacyclopentenes results in highly convergent, three-component coupling on a 
zirconocene template. This process is thought to proceed through the rearrangement to a 
novel zirconium-alkenylidene complex.  
 
2.1. Introduction to research area 
Addition of lithium 2,2,6,6-tetramethylpiperidide (LiTMP) to a mixture of zirconacycle 
1.103, formed by co-cyclisation of enyne 2.1,105 and dichloromethane (1.5 eq) at –78 °C  
followed by addition of lithium phenyl acetylide (1.1 eq) and quenching with MeOH 
and aq NaHCO3 gave the bicyclic compound 2.2 in 52% yield (Scheme 2.1).140,144 
Work-up with MeOD/D2O gave predominantly the bis-deuterated compound 2.3 (77% 
bis-deuterated, residue mono-deuterated) suggesting a zirconium-alkenylidene or 1-
metallo(Zr or Li)-1-zircono-alkene intermediate. When BuCHBr2 was used as the 
carbenoid precursor compound 2.4 was obtained in 42% yield. An important 
observation, with implications for the mechanism, was that the use of 2.2 equivalents of 
lithium phenyl acetylide substantially increased the yield of 2.4 to 86%. Examination of 
the reaction mixture after 1.1 equivalents of lithium phenyl acetylide had been added, 
showed around 50% conversion into 2.4, with the residue being a product of carbenoid 
insertion (Scheme 2.1). 
ZrCp2
Pr
(ii), (iii), (iv)
Ph Pr
H
2.2 R1 = R2 = H
2.3 R1 = H, R2 = D
2.4 R1 = n-Bu, R2 = H
1.103
R1
Pr
2.1
R2
R2
(i)
Reagents and Conditions:(i) Cp2ZrCl2, 2 eq n-BuLi, −78 οC to RT, 3 h; (ii) CHR1X2,
LDA, −78 οC, 0.5 h; (iii) PhCCLi, −78 οC, 0.5 h; (iv) H2O or D2O, −78 οC to RT, 16 h.
Scheme 2.1 Insertion of alkyl lithium carbenoids in the presence of lithium phenyl acetylide. 
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2.2. Precedent and elucidation of the mechanism 
The first proposed step is insertion of 1,1-dihalo-1-lithio species into 1.103 to form the 
expanded six-membered zirconacycle 2.6 via 1,2-metallate rearrangement (Scheme 2.2). 
After addition of lithiated phenyl acetylide 2.7 to afford the ‘ate’ complex 2.8 ring 
closure occurs via 1,2-bond migration to give intermediate 2.9. It has been found from 
the previous work145 that the 1,2-rearrangement of the neutral intermediate 2.6 to be 
slow at –78 °C hence the requirement for the formation of 2.8 before rearrangement 
(Scheme 2.2).  
R
Pr
ZrCp2
Pr
X
X
- ZrCp2
Pr
X
ZrCp2
Pr
X
Ph
- ZrCp2
Ph
(i) (ii)
2.6
2.8 2.9
Ph Pr
H
2.2 R = H
2.4 R = n-Bu
Li+
(iii)
Li+
−LiX
R
−LiX
R
R
R
2.5
Reagents and Conditions:(i) CHRX2, LDA (or LiTMP), −78 οC, 0.5 h; 
(ii) PhCCLi, 2.7, −78 οC, 0.5 h; (iii) H2O, −78 οC to RT, 16 hr.
ZrCp2
Pr
1.103 PhCCLi, 2.7
 
Scheme 2.2 Initial stages of the three-component coupling on zirconocene. 
 
Initially a 3,3-sigmatropic Cope-type rearrangement of 2.9 to the Zr-alkenylidenate 2.13 
was suspected (Scheme 2.3), but theoretical calculations indicated it to have a very high 
activation energy, inconsistent with the low temperature at which the reaction occurs.140 
Successive 1,3-migration of the zirconium to the ring junction to give 2.10 followed by 
a 1,3-alkyl shift from the metal to the beta-position of the alkyne 2.11 is an alternative 
(Scheme 2.3).  
The failure to trap the supposed alkenylidene intermediate 2.11 with alkynes or 
carbonyl compounds144 indicated that even if formed it must be rapidly trapped by 
lithiated alkyne as the ate complex 2.13. Indeed calculations indicate this to be a very 
favourable process and could account for the need for two equivalents of the acetylide. 
It is not expected for complex 2.13 to show normal metal carbene reactivity as it lacks 
the empty orbital on the metal required for concerted [2+2] additions to be allowed. 
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Surprisingly, attempts to trap the intermediate 2.13 with electrophiles such as methyl 
iodide, NBS and benzaldehyde also failed. 
Pr
ZrCp2
Ph
2.9
R
2.10
Pr
R
Cp2Zr
Ph
2.11
Pr
R
Cp2Zr Ph
PhC≡CLi, 2.7
2.13
Pr
R
Cp2Zr Ph
Ph
[3,3] 
rearrangement
PhC≡CLi, 2.7
2.12
Pr
R
Cp2Zr
Ph Ph
 
Scheme 2.3 Possible 3,3-sigmatropic rearrangement of 2.9 to give 2.13. 
 
There is also precedent for the second migration in the ring contraction of zirconacycle 
2.14 to afford a zirconium alkenylidene complex 2.15 (Scheme 2.4),146 and  similar 
transformations are known for mid-/late-transition-metal complexes.147,148 
BuBu
ZrCp2
ZrCp2
2.14 2.15
 
Scheme 2.4 Zirconocene-alkyne to -alkylidene rearrangement. 
 
We would not expect the ‘ate’ complex 2.12 to make a 1,3-alkyl shift as it lacks the 
empty orbital on the metal which makes this a symmetry allowed process. Therefore it 
is believed that addition of the second equivalent of lithiated alkyne occurs before 
rearrangement to give the intermediate 2.16 (Scheme 2.5).  
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ZrCp2
Ph
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Ph
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Ph
R
Ph
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2.17
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Ph Pr
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2.2 R = H
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Scheme 2.5 Final stages of the three-component coupling on zirconocene. 
 
A new mechanism (Scheme 2.5) was therefore proposed based on a fragmentation of 
the zirconate species 2.16 via elimination of the allylic carbanion 2.17 and its 
subsequent re-addition to the -carbon of the bisphenylethynyl zirconium complex 2.18 
to afford the novel zirconocene-alkenylidenate complex 2.13. There is a driving force 
for the rearrangement in release of strain energy in going from a bicyclo[3.3.0]oct-1-ene 
to bicyclo[3.3.0]oct-2-ene system, as it was previously observed for a 1,3-amine 
rearrangement (Scheme 1.8).119 
It is also possible that the fragments 2.17 and 2.18 are formed from 2.12 (Scheme 2.3). 
Rapid loss/re-addition of anions for zirconate complexes is known.149-151 Although beta-
addition to a metal alkyne is unknown for early transition metals, it is an established 
route for the formation of mid-/late-transition-metal alkenylidene complexes.147,148 
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Further work to elucidate the mechanism of the multi-component coupling on 
zirconocene was done by the author. The normal test for a fragmentation/recombination 
mechanism would be a crossover experiment with a different bisalkynyl zirconocene 
added (Scheme 2.6). 
Pr
H
Bu
Pr
ZrCp2
Pr
2.1 1.103 2.19
ZrCp2
Pr
Br
Bu
Pr
H
Bu
2.20 2.4
Ratio of  2.20 : 2.4
Method
(a)          6.4  : 1
(b)          1     : 9.7
(c)          5.0  : 1
(iii)/(iv)/(v)
+
Reagents and Conditions:(i) n-BuLi, THF, −78 οC to RT, 3 h; (ii) BuCHBr2,
LiTMP, −78 οC, 20 min; (iii) 1. Cp2Zr(CCPh)2 2.18, −78 οC, 5 min; 2. 3.0 eq
p-t-BuPhCCLi 2.7a (added sequentially), −78 οC to RT; 3. MeOH, aq NaHCO3,
RT, 16 h; (iv) 1. Cp2Zr(p-t-BuPhCC)2 2.18a, −78 οC, 5 min; 2. 3.0 eq PhCCLi 2.7,
(added sequentially), −78 οC to RT; 3. MeOH, aq NaHCO3, RT, 16 h; (v) 1.
Cp2Zr(CCPh)2 2.18, −78 οC, 5 min; 2. 3.0 eq p-t-BuPhCCLi 2.7a (added rapidly),
−78 οC, 30 min; 3. MeOH, aq NaHCO3, RT, 16.
(i) (ii)
 
Scheme 2.6 Crossover experiment. 
 
To the intermediate 2.19 (Scheme 2.7) was added at –78 °C previously prepared 
bisphenylethynyl zirconocene 2.18 followed by sequential addition of p-t-BuPhCCLi 
2.7a. The progress of the reaction was monitored by GC which showed no reaction after 
addition of the first equivalent of 2.7a. A second equivalent of p-t-BuPhCCLi caused 
incorporation of both alkynes and the final compounds 2.20 and 2.4 were created, in an 
approximate ratio 1.9 : 1 respectively, with the residue being a product of carbenoid 
insertion. The third equivalent of the acetylide forced the remaining intermediate 2.19 to 
convert quickly into the final products in the ratio of 6.4 : 1. Addition to the reaction 
mixture of bis(p-tert-butylphenylethynyl) zirconocene 2.18a in the first instance, 
followed by sequential addition of PhCCLi 2.7, provided the final compounds 2.20 and 
2.4 in the ratio of 1 : 9.7, respectively. 
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Ar2
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Scheme 2.7 Possible explanation of the results from crossover experiment. 
 
Observation of no reaction during first addition of acetylide 2.7a shows that it is all 
trapped by the bis-alkynyl zirconocene 2.18 to give the tris-alkynyl-zirconate 2.21a 
which might further exchange to give 2.18a and 2.7 species. We would expect trapping 
by bromide 2.19 to be slow as the zirconium is sterically hindered. If the formation of 
2.21a was fast and reversible it would lead to an equilbrium concentration of Ar1CCLi 
and Ar2CCLi in a ratio of 1 : 2. If this concentration was either significant, or the 
equilibrium fast, then we would expect the free acetylide to attack bromide 2.19 in an 
irreversible sequence leading to the cyclised product 2.22/2.22a (and hence final 
rearranged products) – presumably as a 1 : 2 ratio of Ar1 and Ar2 substituted cases. This 
does not happen so the formation of 2.18/2.18a + 2.7/2.7a from 2.21a/2.21b is either 
slow or very strongly in favour of 2.21a/2.21b. 
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If formation of trisacetylide zirconate was a slow equilibrium, or effectively irreversible 
(i.e. minimal back reaction) then we would not expect any crossover product. 
As soon as the second equivalent of acetylide 2.7a starts to be added it can only react 
with bromide 2.19 leading to 2.22, but this is much more reactive towards acetylide 
2.7a leading to the alkynate complex 2.23a which does break down to bis-alkyne 
complex 2.18a and allyl anion 2.24. 
2.22a would be expected to be more reactive towards addition of the acetylide 2.7a than 
complex 2.19 as the zirconium is much less hindered. 
There is now a competition between the allyl anion 2.24 and any acetylide present in 
solution for the bis-alkynyl complex 2.18a. Since the reaction normally works well with 
2 equivalents of acetylide the allyl anion 2.24 must react faster (indeed the reaction may 
take place through rapid recombination in the solvent cage). The prediction would be 
that the crossover products should not be seen and sole product 2.25a should be 
obtained, but this is not in accord with the observations. The crossover product, 
however, could arise in two possible ways:  
1. from the presence of 2.7 in solution competing with 2.7a for 2.22a (or 2.19), or  
2. from the presence of 2.18 (or 2.18b) competing with 2.18a for 2.24.  
If the equilibrium between 2.21a/2.21b and 2.18/2.18a + 2.7/2.7a was strongly in 
favour of 2.21a/2.21b, but fast, then the excess 2.7a might exchange to give 2.7.  
The statistical ratio (i.e. would predict 2 : 1 2.25 : 2.25a initially moving to 2 : 3 at end 
of addition of third equivalent of 2.7a) is not observed which may signify that this 
equilibriation is not occurring at a similar rate to the addition of 2.7a  and/or reaction of 
2.7a  with 2.19 but a slow equilibriation could explain the results. 
The observation of a great amount of the crossover product formed as the first part of 
the second equivalent of 2.7a is added, but much less as the third equivalent is added 
could be a reflection of the greater amount of 2.7a  present, but the ratios are not 
statistical indicating that this is at best a partial answer.  
The two extreme cases can be considered: if formation of trisacetylide zirconates was a 
fast equilibrium, and gave a significant concentration of [acetylide + 
bisalkynylzirconium] we would expect substantial ‘crossover’ product (~2 : 1 in favour 
of crossover at start of addition of the second equivalent of acetylide moving to 3 : 2 in 
favour of non-crossover as last part of third equivalent of acetylide was added).  
If the equilibrium of 2.18 + 2.7a to 2.18a + 2.7 was slow, the prediction would be that if 
the three equivalents of acetylide 2.7a were added rapidly no crossover products should 
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be observed. The experiment was carried out and the results showed that both products 
2.20 and 2.4 were created in the ratio of 5 : 1, respectively. This result is inconsistent 
with the above assumption and may indicate that the fragmentation/recombination 
process occurs not entirely in an intramolecular fashion. Additionally, the crossover 
product may arise either from the attack of acetylide 2.7 onto bromide 2.19 or from 
trapping the bisalkynyl Zr complex 2.18a (or 2.18b) by the allylic anion 2.24. 
 
An indication that the proposed mechanism is reasonable is that addition of t-BuLi to 
bis(phenylethynyl)zirconocene 2.18 (Scheme 2.8) at –78 °C with immediate protic 
quench afforded the alkene 2.27 (88% isolated yield), probably via the alkenylidene-ate 
complex 2.26. Addition of n-BuLi to bis(phenylethynyl)zirconocene gave (Z)-1-
phenylhexene 2.30 (73%) only on warming to room temperature before protonolysis, 
presumably by initial addition to the metal to afford 2.28 followed by the type of 1,2-
migration previously reported by Negishi,152 to afford 2.29. The result indicates that a 
bulky nucleophile is important for successful beta addition to the alkyne to inhibit direct 
attack on the metal.  
Accordingly, attempts were made to add PhLi and s-BuLi to 2.18; however, GC 
analysis of those reactions showed no conversion to such products even after warming 
the reaction mixture to RT.   
(i)
Cp2Zr
Ph
t-Bu
Ph
t-Bu
Ph Li+
(ii)
2.26 2.27
Cp2Zr
Ph
Ph
Cp2Zr
Ph
Ph
(iii)
n-Bu
Cp2Zr
Ph
n-Bu n-Bu
Ph
Li+ Li+
(iv)
2.28 2.29 2.30
Ph
2.18
Reagents and Conditions:(i) t-BuLi, −78 οC; (ii) H2O,
−78 οC, 0.5 h; (iii) n-BuLi, −78 οC to RT; (iv) H2O, RT.
 
 Scheme 2.8 Alternative route to alkenylidene zirconate complexes. 
 
 
 
 49 
2.3. Substrate-scoping studies 
The scope of the three-component coupling was investigated through variation of the 
co-cyclisation, carbenoid and acetylide precursors. It was essential to prepare a 
reasonable number of the bicyclic compounds with a wide range of various substituents 
for biological testing. It was hoped that high-throughput screening would lead to the 
identification of an active and selective agonist/antagonist for the human orphan nuclear 
receptors: LRH-1 and SF-1. 
 
2.3.1. Synthesis of starting materials 
2.3.1.1. Synthesis of substituted acetylenes 
1-Ethynyl-3-methoxybenzene 2.31 (Figure 2.1) was prepared from commercially 
available starting materials using literature methods.153,154 Other acetylenes used in the 
reactions were either purchased from suppliers or prepared by previous members of the 
Whitby group. 
OMe
2.31
 
Figure 2.1 1-Ethynyl-3-methoxybenzene. 
 
2.3.1.2. Synthesis of gem-dibromides 
Dibromides 2.33a,b,c (Scheme 2.9) were synthesised according to literature 
precedent155 from the corresponding aldehydes 2.32. Other 1,1-dihalides used in the 
reactions were either purchased from suppliers or prepared by previous members of the 
group. 
Reagents and Conditions:(i) (PhO)3P, Br2,CH2Cl2, −20 οC to  0 οC over 1 h.
R H
O R
a. n-Hex,   72%
b. c-Hex,   9%
c. n-Oct,    77%
R Br
Br(i)
'(PhO)3PBr2'2.32 2.33
 
Scheme 2.9 Conversion of aldehydes into 1,1–dibromoalkanes. 
 
2.3.1.3. Synthesis of co-cyclisation precursors 
The following 1,6-enynes (Scheme 2.10) were prepared by alkylation of the 
corresponding lithiated alkynes with 5-bromo-1-pentene.  
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R
R
    R
a. Ph,       88%
b. n-Bu,    61%
c. n-Hex,  55%
(i), (ii), (iii)
Reagents and Conditions:(i)  n-BuLi, THF, −78 οC, 0.5 h; (ii) HMPA, −78 οC
to −50 οC; (iii) 5-bromo-1-pentene, −50 οC to RT, 4-12 h, then aq NH4Cl.
2.34 2.35
 
Scheme 2.10 Preparation of enynes. 
 
Enynes carrying hydroxyl group have also been prepared. (7-Phenylhept-1-en-6-yn-3-
yloxy)(tert-butyl)dimethylsilane 2.41 was synthesised as in Scheme 2.11. Ethanol and 
in situ generated Me3SiI converted acrolein 2.36 into 1,1-diethoxy-3-iodopropane 
2.37,156, 157 which after rapid purification by chromatography on basic alumina (grade 
III) was reacted with lithium phenyl acetylide to give (5,5-diethoxypent-1-yn-1-
yl)benzene 2.38. Hydrolysis of the acetal to give an aldehyde 2.39 was followed by 
reaction with vinyl magnesium bromide to afford the alcohol 2.40. Protection of the 
hydroxyl group with t-BuMe2SiOTf gave the desired cyclisation precursor 2.41. 
O
I
OEt
OEt
Ph
OEt
OEt
Ph
O
HO
Ph
(i) (ii) (iii)
(iv) (v)
OH
Ph
O
Ph
O
+
(R)-2.40
(vi)
90% e.e.
Reagents and conditions: (i) 1. NaI, Me3SiCl, MeCN; 2. EtOH, 0 οC to RT, 2 h, 47%;
(ii) 1.5 eq PhCCLi, 1.5 eq HMPA, THF, −78 οC, 1 h then RT, 14 h, 81%;
(iii) THF : H2O (4 :1), HCl (2M), RT, 3 h, 100%; (iv) 1. CH2CHMgBr, −78οC to
−65 οC, 1 h; 2. aq NH4Cl, 65%; (v) Me2t-BuSiOTf, imidazole, DMAP, THF, RT, 18 h, 
99%; (vi) (E)-vinyl crotonate, Novozyme 435, 42 οC, 72 h, 96%; (vii) Me2t-BuSiOTf,
Et3N, DCM, 0 οC to RT, 0.5 h, 67%.
TBDMSO
Ph
2.36 2.37 2.38
2.402.39 2.41
(S)-2.42
(vii)
TBDMSO
Ph
(R)-2.41
Scheme 2.11 Synthesis of (7-phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane. 
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The (R)-enantiomer of the alcohol 2.40 was obtained by crotylation reaction using 
Novozyme 435 as the catalyst, an immobilised Candida antartica lipase which is 
known to be selective for the (S)-enantiomer of alcohols with a similar structure.158 
Reaction was stopped at around 50% conversion and the recovered enantioenriched 
alcohol (R)-2.40 (90% e.e.) converted through to (R)-2.41 by the known procedure 
(Scheme 2.11).159 
 
Synthesis of (1-phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane 2.48 was 
achieved in five steps (Scheme 2.12). Protection of the hydroxyl group in (±)-glycidol 
2.43 as the tetrahydropyranyl ether 2.44160 followed by reaction of the crude product 
with vinylmagnesium bromide catalysed by CuBr gave the THP protected pent-4-ene-
1,2-diol 2.45.161 Removal of the THP protecting group162 gave pent-4-ene-1,2-diol 
2.46.163 A one-pot ring closure/ring opening procedure was used to convert pent-4-ene-
1,2-diol into 7-phenylhept-1-en-6-yn-4-ol 2.47.164,165 Thus selective tosylation of the 
primary alcohol was followed by in situ ring closure to an epoxide, and ring opening 
with lithium phenylacetylide to afford the alcohol 2.47. 
The overall yield was poor despite considerable optimization. TBDMS protection of  
alcohol 2.47 gave the desired compound 2.48. 
O OH OH
OTHP
(ii)
Ph
HO
O OTHP(i)
(iv)
Reagents and conditions: (i) 1. DHP, CH2Cl2, TsOH, 0 οC, 15 min; 2. RT, 1 h, 100%; 
(ii) 1. CH2CHMgBr, cat. CuBr, THF, −10 οC, 4 h; 2. aq NH4Cl, 86%; (iii) MeOH,
Amberlyst-15, 50 οC, 1 h, 60%; (iv) 1. NaH, THF, −10 οC; 2. N-Tosyl imidazole,
−10 οC, 1 h; 3. 2.0 eq PhCCLi, THF, HMPA, −10 to 0 οC 1h. 4. RT, 40 h, then
aq NaHCO3, 28%; (v) Me2t-BuSiOTf, imidazole, DMAP, THF, RT, 15 h, 82%.
Ph
TBDMSO
(v)
2.43
OH
OH
(iii)
2.44 2.462.45
2.482.47
 
Scheme 2.12 Synthesis of (1-phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane. 
 
 
 
 
 
 52 
(1-Phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane 2.52 (Scheme 2.13) was 
synthesised from 4-penten-1-ol 2.49 through Swern oxidation to give the corresponding 
aldehyde 2.50, and subsequent nucleophilic addition of phenyl acetylide to the carbonyl 
group to provide the alcohol 2.51.159 The poor yield over the two steps is explained by 
troublesome volatility of the aldehyde 2.50. TBDMS protection of the hydroxyl group 
gave the co-cyclisation precursor 2.52. 
OH O
(i) (ii) Ph
2.51
HO
Ph
2.52
TBDMSO
(iii)
2.49 2.50
Reagents and conditions: (i) 1. DMSO, (COCl)2, DCM, −78 οC, 1 h; 2. Et3N,
−78 οC to RT; 3. H2O/brine; (ii) 1.5 eq PhCCLi, THF, HMPA, −78 οC to −55 οC, 
1.5 h then aq NH4Cl, 27% (over two steps); (iii) Me2t-BuSiOTf, Et3N, DCM,
0 οC to RT, 0.5 h, 74%.
 
Scheme 2.13 Preparation of (1-phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane. 
 
Reaction of lithiated tert-butyldimethyl(pent-4-ynyloxy)silane 2.53 with 5-bromo-1-
pentene gave an inseparable mixture of two compounds 2.54 and 2.55 in the ratio of 2 : 
1 respectively and 63% combined yield (Scheme 2.14). The undesired product 2.55 
resulted from the nucleophilic attack of the lithiated alkyne onto silyl group. Use of 5-
iodo-1-pentene instead provided the desired compound 2.54166 and the by-product 2.55 
with improved ratio (5.7 : 1) and yield (75%). Subsequent zirconocene mediated co-
cyclisation turned out to be selective for the enyne 2.54 and the by-product 2.55 present 
in the reaction mixture has been shown to have no effect on the reaction.  
(i) or (ii)
Reagents and Conditions: method (i) 1. n-BuLi, THF, −78 οC, 0.5 h; 2. HMPA,
−78 οC to −50 οC; 3. 5-bromo-1-pentene, −50 οC to RT, 24 h, then aq NH4Cl, 63%; 
method (ii) 1. n-BuLi, THF, −78 οC, 0.5 h; 2. HMPA, −78 οC to −50 οC; 3.
5-iodo-1-pentene, −50 οC to RT, 24 h, then aq NH4Cl, 75%.
2.53 2.54
OTBDMS
+
2.55
TBDMSO
Si
OTBDMS
 
Scheme 2.14 Synthesis of 10-(tert-butyldimethylsiloxy)-l-decen-6-yn. 
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Enynes containing a nitrogen atom have been prepared (Scheme 2.15). N-methyl-N-
(phenylprop-2-ynyl)prop-2-en-1-amine 2.57 and N-benzyl-N-(phenylprop-2-ynyl)prop-
2-en-1-amine 2.60 (Scheme 2.15) were prepared from N-allyl-N-methylamine 2.56, and 
N-allyl-N-benzylamine 2.59, which was synthesised from allyl amine 2.58 in 78% 
yield,167 respectively in copper-catalysed Mannich reaction.168 
Reagents and Conditions: (i) PhCCH, CH2O, DMSO, cat. CuI, 30 οC, 
24 h, 41%; (ii) BnBr, 0 οC to RT, 16 h then aq NaHCO3, 78%;
(iii) PhCCH, CH2O, DMSO, cat. CuI, 30 οC, 15 h, 89%.
H2N BnHN
MeHN
BnN
Ph
2.58 2.59
2.56
2.60
MeN
Ph
2.57
(ii) (iii)
(i)
 
Scheme 2.15 Synthesis of nitrogen containing substrates. 
 
2.3.2. Synthesis of cis-bicyclo[3.3.0]oct-2-enes by using stoichiometric zirconium 
chemistry 
Extension of the multi component reaction to the use of a wide range of starting enynes, 
dihalocarbenoids, and lithiated alkynes resulted in synthesis of a number of 
bicyclo[3.3.0]octanes (Scheme 2.16, Table 2.1). 
2.62
R3 R1
H
R2ZrCp2
R1
2.61
2.20, 2.63 a-aa
ZrCp2
R1
R2
X
Reagents and conditions: (i) R2CHX2 [X= Br for R2 = n-Hex, n-Bu, n-Oct.
X = Cl for R2 = H, SiMe2Ph], LDA or LiTMP, −78 οC, 15 min; (ii) 3 eq R3CCLi, 
−78 οC to −60 οC over 0.5 h; (iii) MeOH, aq NaHCO3, RT, 12-16 h.
(i) (ii), (iii)
 
Scheme 2.16 One-pot tandem reaction sequence on zirconocene. 
 
The synthetic route introduced above (Scheme 2.16) provides an efficient method for 
construction and functionalisation at multiple sites rigid core structures containing cis-
bicyclo[3.3.0]oct-2-ene skeleton. Yields range from good to very good (Table 2.1). 
 54 
Use of a wide range of acetylides (2.63a-l) (Table 2.1) provided the final compounds in 
very good yields. Diminished yields were however observed for alkyl-substituted 
acetylides (2.63i,k,l) in comparison with acetylides carrying aromatic substituent. These 
results seem to imply that alkyl-substituted acetylides for some reasons are less reactive 
towards the zirconium-alkenylidene rearrangement than aryl-substituted acetylides.  
 
Compound  R1 R2 R3 Yield / %a 
2.20 n-Pr n-Bu 4-t-BuPh 66 
2.63a Ph n-Hex Ph 86 
2.63b Ph n-Hex 3-MeOPh 78 
2.63c Ph n-Hex 4-MeOPh 72 
2.63d Ph n-Hex 4-MePh 62 
2.63e Ph n-Hex 4-EtPh 70 
2.63f Ph n-Hex 4-n-BuPh 78 
2.63g Ph n-Hex 4-t-BuPh 51 
2.63h Ph n-Hex 4-PhPh 60 
2.63i Ph n-Hex n-Pr 54 
2.63j Ph n-Hex n-Bu 75 
2.63k Ph n-Hex n-Hex 65 
2.63l Ph n-Hex n-Oct 56 
2.63m 3-MeOPh n-Hex Ph 75 
2.63n 4-EtPh n-Hex Ph 70 
2.63o n-Pr n-Hex Ph 82 
2.63p n-Bu n-Hex Ph 88 
2.63q n-Hex n-Hex Ph 86 
2.63r c-Hex n-Hex Ph 80 
2.63s (CH2)3OH n-Hex Ph 61 
2.63t Ph H Ph 58 
2.63u Ph n-Bu Ph 71 
2.63v Ph n-Oct Ph 73 
2.63w Ph SiMe2Ph Ph 45 
2.63x n-Bu SiMe2Ph Ph 69 
2.63y n-Hex c-Hex Ph 10 
2.63z n-Hex n-Hex n-Bu 68 
2.63aa n-Pr n-Hex 4-t-BuPh 86 
Table 2.1 Variation of 1-(2-alkenyl)-bicyclo[3.3.0]oct-2-enes 2.63. 
a
 isolated yield of >95% pure material. 
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The bicyclic compounds 2.63m-r (Table 2.1) were obtained in very good yields for both 
R1 = alkyl and R1 = aryl. A slightly lower yield is observed for compound 2.63s, but the 
yield was given for two steps: the reaction sequence on zirconocene and TBAF 
deprotection step. 
Insertion of lithiated dichloromethane followed by insertion of phenyl acetylide gave 
the product 2.63t in 58% isolated yield. In this particular case the yield is lower due to 
multiple insertion of this carbenoid into the zirconacycle, therefore the purification was 
made difficult. Silyl substituted carbenoids were also examined, and the final 
compounds 2.63w, x with incorporated SiMe2Ph group were obtained in 45% and 69% 
yield respectively. The final yield of product 2.63w is significantly diminished by the 
undesired de-silylation which occurred under the reaction conditions. The same de-
silylation process was observed by Thomas,140 who has also noted that different quench 
conditions may have prevented this de-silylation process from occurring, however these 
were not tried. Incorporation of a carbenoid carrying an alpha-branch occurred very 
poorly and provided the desired compound 2.63y only in 10% isolated yield. The poor 
yield is due to deprotonation of the α-branched 1,1-dihalo species 2.33b being 
immediately followed by 1,2-H shift (even at –78 °C) with loss of LiBr, to give 
relatively unreactive alkenylhalide species 2.66 (Scheme 2.17). This process is thought 
to be occurring due to metal assisted ionisation as in 2.65.124,169-171 
Br Br
(i)
Br LiBr
H
Br
2.33b 2.66
−LiBr
Reagents and conditions: (i) LDA or LiTMP, THF, −78 °C.
2.64 2.65
Br LiBr
H
δ−
δ+
 
Scheme 2.17 Decomposition of α-branched carbenoids. 
 
The tandem reaction sequence also worked well for the formation of pyrrolidine fused 
systems 2.67a, b (Scheme 2.18). 
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RN
Ph Ph
n-Hex
H
RN
Ph (i), (ii)
(iii), (iv)
2.67a, R = Me, 62%
2.67b, R = Bn, 74%
Reagents and conditions: (i) Cp2ZrBu2, THF, −78 °C to RT, 2 h;(ii) n-HexCHBr2, LDA, −78 °C, 15 min; (iii) 3.0 eq PhCCLi, −78 °C 
to −60 °C over 0.5 h; (iv) MeOH, aq NaHCO3, RT, 12-16 h.
2.57, R = Me
2.60, R = Bn
 
Scheme 2.18 Formation of pyrrolidine fused systems. 
 
Co-cyclisation of precursor 2.41, and further carbenoid and acetylide insertion resulted 
in synthesis of compounds with oxygen-substitution on the saturated cyclopentane ring. 
The synthesis of the 6-oxygenated compounds is shown in Scheme 2.19. 
Ph Ph
n-Hex
HTBDMSO
Ph Ph
n-Hex
HTBDMSO
H
H
exo : endo, 1.6:1, 88%
+
2.68-exo
2.68-endo
TBDMSO
Ph
Reagents and conditions: (i) Cp2ZrBu2, THF −78 οC, 0.5 h, then 2 h at RT; (ii)
n-HexCHBr2, LDA, −78 οC, 15 min; (iii) 3.0 eq PhCCLi, −78 οC to −60 οC over
45 min; (iv) MeOH, aq NaHCO3, RT, 5 h; (v) 5.0 eq TBAF, THF, RT, 20 h, then 
H2O; (vi) Pyridine, 73 eq Ac2O, 0.58 eq DMAP, RT, 13 h.
Ph Ph
n-Hex
HHO
Ph Ph
n-Hex
HHO
H
H
+
Ph Ph
n-Hex
HAcO
Ph Ph
n-Hex
HAcO
H
H
+
(i), (ii)
(iii), (iv)
2.41
(v) (vi)2.69-exo
2.69-endo
2.70-exo, 82%
2.70-endo, 95%
exo : endo, 1.6:1, 76%
 
Scheme 2.19 Synthesis of 6-oxygenated series. 
 
Precursor 2.41 underwent the zirconocene induced co-cyclisation, carbenoid insertion 
and phenyl acetylide addition to give a 1.6 : 1 mixture of the exo- and endo-isomers 
2.68 after protonolysis. TBAF cleavage of the silyl group furnished the desired bicyclic 
alcohols 2.69. The exo- and endo- isomers were partly separated by careful 
chromatography, the endo-isomer eluting first. The relative stereochemistries of the exo- 
and endo- isomers were clear from coupling patterns to the proton adjacent to the 
hydroxyl group. In the endo-isomer it appears as a ddd, J = 9.1, 8.5, 5.5 Hz, in the exo-
isomer as a broad singlet, the patterns being in accord with expectations from molecular 
modelling and the Karplus relationship of couplings to dihedral angles.172, 173  
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The separated diastereoisomers of 2.69 were acylated to afford 2.70-exo and 2.70-endo. 
A crystal structure of 2.70-endo (attached in appendix) confirmed the stereochemical 
assignment.174 
It was required to separate enantiomers of 2.69-exo for biological testing (Scheme 
2.20). The most convenient route to the enantiopure compounds proved to be separation 
by chiral HPLC on a Diacel OD-H column, the two enantiomers having remarkably 
different retention times (2.69-exo-ent-1 at 11.7 min, 2.69-exo-ent-2 after 18.5 min – 1 
mL/min 1% isopropanol in hexane on 4.6 x 250 mm column) allowing clean separation.  
Ph Ph
n-Hex
HHO H
Ph Ph
n-Hex
HHO H
2.69-exo-ent-1 2.69-exo-ent-2
+
Ph Ph
n-Hex
HHO H
(i)
2.69-exo
Reagents and conditions: (i) HPLC on Diacel OD-H chiral column.
 
Scheme 2.20 Chiral HPLC seperation of enantiomers of 2.69-exo. 
 
The identity of the enantiomers was proven by conversion of the enantioenriched 
TBDMS protected alcohol (R)-2.41 (90% e.e.) through to 2.69-exo (Scheme 2.21), 
which was found by chiral HPLC to be predominantly (20 : 1) the more slowly eluted 
enantiomer (2.69-exo-ent-2), thus identifying its absolute stereochemistry. 
TBDMSO
Ph
H
n-Hex
PhPh
TBDMSO
H
n-Hex
PhPh
TBDMSO
H
n-Hex
PhPh
HO
H
n-Hex
PhPh
HO
+ +
2.69-exo-ent-2
2.69-endo-ent-2
2.68-exo-ent-2
2.68-endo-ent-2
Reagents and conditions: (i) Cp2ZrBu2, THF −78 οC, 0.5 h then 2 h at RT;
(ii) n-HexCHBr2, LDA, −78 οC, 15 min; (iii) 3.0 eq PhCCLi, −78 οC to −60 οC 
over 45 min; (iv) MeOH, aq NaHCO3, RT, 12 h, 90%; (v) 20 eq TBAF, THF,
RT, 22 h, then H2O, 65%.
(i), (ii)
(iii), (iv)
(v)
(R)-2.41
 
Scheme 2.21 Asymmetric synthesis of alcohol 2.69-exo. 
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The 7-oxygenated series was synthesised as shown in Scheme 2.22. Enyne 2.48 was 
subjected to the zirconocene mediated co-cyclisation, dibromocarbenoid insertion and 
phenyl acetylide driven zirconate rearrangement to obtain a 1 : 1 mixture of the exo- and 
endo-isomers 2.71. After TBAF cleavage of the silyl group, the exo- and endo- isomers 
of 2.72 were partly separated by careful chromatography, the endo-isomer eluting first. 
Acylation of the separated diastereoisomers gave 2.73-exo and 2.73-endo (Scheme 
2.22). 
Ph Ph
n-Hex
H
Ph Ph
n-Hex
H
exo : endo, 1:1, 78%
+
2.71-exo
2.71-endo
Ph
Reagents and conditions: (i) Cp2ZrBu2, THF −78 οC, 0.5 h, then 2 h at RT; (ii) n-HexCHBr2,
LDA, −78 οC, 15 min; (iii) 3.0 eq PhCCLi, −78 οC to −60 οC over 45 min; (iv) MeOH,
aq NaHCO3, RT, 5 h; (v) 2.0 eq TBAF, THF, RT, 20 h, then H2O; (vi) Pyridine, 73 eq
 Ac2O, 0.58 eq DMAP, RT, 17 h.
Ph Ph
n-Hex
H
Ph Ph
n-Hex
H
+
Ph Ph
n-Hex
H
Ph Ph
n-Hex
H
+
(i), (ii)
(iii), (iv)
2.48
(v) (vi)2.72-exo
2.72-endo
2.73-exo, 80%
2.73-endo, 79%
exo : endo, 1:1, 70%
TBDMSO
H
TBDMSO
TBDMSO
H
HO
H H
AcO
HO
H H
AcO
 
Scheme 2.22 Synthesis of 7-oxygenated series. 
 
The relative stereochemistries of 2.72-exo and 2.72-endo (and hence 2.73-exo and 2.73-
endo) were established by NMR studies combined with molecular modelling (Table 
2.2) using the MMFF94 force field as implemented in Spartan 06 (Wavefunction 
Inc.).175 The proton next to the hydroxyl group in one isomer appeared as a tt, J = 8.5, 
5.9 Hz (due to couplings of 8.5, 8.3, 6.3 and 5.5 Hz), consistent with 2.72-exo or the 
equatorial conformer of 2.72-endo (2.72-endo eq. conf.), but as a quintet (J = 5.5 Hz) in 
the other diastereoisomer – not consistent with any minimum energy structure. 
Molecular modelling showed that 2.72-exo had a well defined minimum energy 
conformer, but for 2.72-endo the ‘equatorial’ and ‘axial’ hydroxy conformers (2.72-
endo eq. and 2.72-endo ax.) were <1 kJ/mol different in energy. The expected coupling 
patterns for each conformer of 2.72-endo were calculated using the Altona 
modification173 of the Karplus relationship172 between dihedral angle and 3J as 
implemented in the Mspin program176 from Mestrec. The average showed a good 
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correlation to the observed coupling constants (Table 2.2). Final proof was hoped to 
come from low temperature 1H NMR experiments, however, no splitting of all averaged 
signals for geminal protons into axial and equatorial signals was demonstrated even at 
the lowest temperature (–80 °C). NOE experiments of 2.72-endo also turned out not to 
bring any relevant insights. 
Ph
HO
H
H
HHa
Hb
H
Hb
Ha
hex
Ph
6
5
7
8
Ph
H
H
H
HHa
Hb
OH
Hb
Ha
hex
Ph
6
5
7
8 Ph
H
H
H
HHa
Hb
HO Hb
Ha
hex
Ph
6
5
8
7
44
4
2.72-exo 2.72-endo ax. conf. 2.72-endo eq. conf.
 
3J coupling 
 H7-H8b H7-H8a H7-H6b H7-H6a H6b-H5 H6a-H5 
2.72-exo       
Dihedral 164 47 154 37 14 104 
Calculated 3J 10.2 6.1 8.9 7.6 9.7 1.9 
Observed 3J 8.5 5.5 8.3 6.3 10 3.6 
2.72-endo ax. conf.       
Dihedral 38 80 33 87 18 101 
Calculated 3J 5 1.3 5.9 1.3 9.4 1.6 
2.72-endo eq. conf.       
Dihedral 44 159 46 165 35 155 
Calculated 3J 6.6 9.5 6.3 10.4 7.3 10.5 
Average 2.72-endo 
eq. and -ax. conf. 3J 5.8 5.4 6.1 5.9 8.4 6.1 
Observed 3J 6.2 4.6 5.6 5 9.5 6 
Table 2.2 Correlation between predicted and observed coupling constants for 2.72. 
 
2.3.3. Insertion of alkyl carbenoid and phenyl acetylide into bicyclo[4.3.0]-
zirconacyclopentene and sterically hindered zirconacyclopentenes 
Variation in the ring size fused to the zirconacycles was sought in respect of the multi-
component coupling sequence. Co-cyclisation with Negishi reagent of the homologous 
enyne, 1-(oct-7-en-1-ynyl)benzene 2.74 resulted in six-five fused zirconacycle 2.75 
(Scheme 2.23). Subsequent insertion of lithiated dibromoheptane and lithium phenyl 
acetylide provided a mixture of compounds 2.78 and 2.79 in 52% combined yield and 
initial GC ratio of 4.7 : 1 respectively. Compounds 2.78 and 2.79 were partly separated 
by careful column chromatography to obtain the final products as single compounds in 
26% and 4% yield, respectively. 
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n-Hex
PhPh
2.78
Ph
n-Hex
Ph
n-Hex
Zr
Cp2
PhPh
+
2.79
n-Hex
Ph
Ph
2.77b2.77a
ZrCp2
Ph
2.752.74 2.76
ZrCp2
Ph
n-HexBr
Ph
2.18
2.78 : 2.79, 4.7 : 1, 52%
Reagents and conditions: (i) Cp2ZrBu2, THF −78 οC, 0.5 h, then 2 h at RT; (ii) n-HexCHBr2, LiTMP, −90 οC to −78 οC, 25 min; (iii) 3.0 eq PhCCLi,
 −78 οC to  −55 οC over 45 min; (iv) MeOH, aq NaHCO3, RT, 16 h.
(i) (ii) (iii)
(iv) H
H
 
Scheme 2.23 Extension of the method to six-five fused zirconacyclopentene. 
 
Other unexpected products emerged in the crude reaction mixture. GC and GCMS 
analysis revealed the molecular mass of these products corresponded to the -H 
elimination products 2.82, 2.83 (Scheme 2.24). The presence of a few compounds with 
the same molecular mass strongly suggests the products of both exo- and endocyclic -
H abstraction process, which occurs in the intermediate 2.80. 
Ph
ZrCp2
Ph
C5H11
H
2.80
C5H11
Ph
2.82
n-Hex
Ph
2.83
Ph
n-Hex
ZrCp2
Ph
280 H
+
- Cp2Zr(H)CCPh, 2.81
(+ tautomers for 1,5-H shift)
 
Scheme 2.24 -H Elimination process in six-five fused zirconacycles after alkyl carbenoid insertion. 
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A conclusion can be drawn from these results, that release of strain energy via 1,3-Zr 
rearrangement in the intermediate 2.77 is impeded, thus making the undesired -H 
elimination process more favourable at the stage of the intermediate 2.80 (Scheme 
2.24). Additionally, trapping of the bisalkynyl Zr species 2.18 does not occur 
exclusively in the bridgehead position, which suggests that there is only a small 
difference in release of strain energy between these two resonance structures 2.77a and 
2.77b. Similar results were obtained when enyne 2.84 was subjected to the reaction 
sequence (Scheme 2.25). In the examined reaction coordination of two molecules of 
phenyl acetylide 2.7 to Zr atom to give the corresponding allylic anion 2.85 and 
bis(phenylethynyl) zirconium complex 2.18 does seem to be more favourable process 
than -H abstraction, however the latter process is still competitive and results in 
compounds 2.86 as minor products. Subsequent re-addition of the anion 2.85a to the  
carbon of the Cp2Zr(CCPh)2 complex occurs very slowly, even upon warming the 
reaction mixture to RT. As a result a mixture of compounds 2.87 (major product) and 
2.88 (minor product) is obtained. The final compound 2.87 was isolated in only 25% 
yield since the purification was very difficult due to by-products 2.86 and 2.88, all of 
which have similar polarity. It was assumed, but has not been proven, that the ring 
junction stereochemistry in the product 2.87 is cis. 
n-Hex
n-PrPh
2.87
Pr
n-Hex
2.85b
O
O
O
O
+
n-Hex
n-Pr
2.88
O
O
n-Pr
2.86
O
O C5H11
2.84
O
O
n-Pr
Reagents and conditions: (i) Cp2ZrBu2, THF, −78 οC, 0.5 h then 2 h at RT;
(ii) n-HexCHBr2, LiTMP, −90 οC to −78 οC, 25 min; (iii) 3.0 eq PhCCLi, −78 οC 
to −55 οC over 45 min; (iv) −55 οC  to RT, then MeOH, aq NaHCO3, RT, 16 h.
(i), (ii), (iii) (iv)
Pr
n-Hex
2.85a
O
O
+
+
Cp2Zr(CCPh)2, 2.18
 
Scheme 2.25 Tandem reaction sequence on enyne 2.84. 
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An endocyclic -H elimination was observed in the case of insertion of lithiated 
(dichloromethyl)dimethyl(phenyl)silane into zirconacyclopentene 2.89 (Scheme 2.26). 
SiMe2Ph
3.26b
Li
X
X
SiMe3
SiMe2Ph
ZrCp2
Ph
H
SiMe3
SiMe2Ph
SiMe2Ph
SiMe3
1,5-H and 1,5-Si 
shifts
2.90
2.91 2.92, 52%
ZrCp2
2.89
SiMe3
1.83b
SiMe3 (i) (ii), (iii)
(iv)
Reagents and conditions: (i) Cp2ZrBu2, THF, −78 οC, 0.5 h then 3 h at
RT; (ii) 1.3 eq Cl2CHSiMe2Ph, n-BuLi, −95 οC to −20 οC; (iii) 3.0 eq
PhCCLi, −78 οC to −50 οC over 1 h; (iv)  MeOH, aq NaHCO3, RT, 12 h.
 
Scheme 2.26 Insertion of (dichloromethyl)dimethyl(phenyl)-silane into zirconacycle 2.89. 
 
The steric encumbrance introduced by the silyl carbenoid favours the endocyclic -H 
elimination process in intermediate 2.90, to provide compound 2.91 which after 1,5-H 
and 1,5-Si shifts gives the final diene 2.92 in moderate yield. 
 
2.3.4. Competition between TBDMSO group elimination and 1,3-zirconate 
rearrangement 
Co-cyclisation of TBDMS protected 7-phenylhept-1-en-6-yn-5-ol 2.52 gave a mixture 
of exo : endo unsaturated zirconacycles 2.93 in the ratio of 5 : 1, respectively (ratio 
estimated by taking a sample of the reaction mixture and subsequent GC analysis), 
(Scheme 2.27). Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide resulted in 
partial elimination of the TBDMS protected hydroxyl function in the exo position from 
intermediate 2.95a to give the conjugated diene 2.96 as a major product. Also product 
2.99, which results from protonation of the remaining allylic anion 2.97, was detected in 
the crude reaction mixture. The resulting allylic anion did not react with the 
bisphenylalkynyl complex 2.18 as the bulky TBDMSO group blocks the exo face. The 
compound 2.100 was obtained as a minor product from the Zr-alkenylidene 
rearrangement to give the alkenylidenate species 2.98, as the TBDMSO group is endo 
directed, therefore prevents the elimination process from occurring in intermediate 
2.95b.  
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Products 2.96 and 2.100 were isolated as pure compounds in low yields (21% and 2%, 
respectively) as the purification on silica gel column was difficult; however, the yields 
of compounds 2.96, 2.99 and 2.100 estimated by GC in the crude reaction mixture are 
much higher. 
TBDMSO
Ph
ZrCp2
PhTBDMSO
ZrCp2
PhTBDMSO
PhTBDMSO
ZrCp2
n-Hex
Ph
Ph
n-Hex
2.52 2.93 2.94
2.96
PhTBDMSO
2.98
n-Hex
+
2.95a
partial
elimination
PhTBDMSO
2.97
+
n-Hex
Br
n-Hex
Reagents and conditions: (i) Cp2ZrBu2, THF −78 οC, 0.5 h then 2 h at RT; (ii) n-HexCHBr2, 
LDA, −78 οC, 15 min; (iii) 3.0 eq PhCCLi, −78 οC to −55 οC over 45 min; (iv)  MeOH, 
aq NaHCO3, RT, 16 h.
a
 yield estimated by GC in the crude reaction mixture,
b yield of isolated pure material,
Ph
(PhCC)Cp2Zr
Ph
n-Hex
2.96, 33%a (21%)b
PhTBDMSO
2.100, 12%a (2%)b
n-Hex
PhTBDMSO
2.99, 29%a
+
n-Hex
Ph
(i) (ii) (iii)
(iv)
Ph
PhTBDMSO
ZrCp2
n-Hex
Ph
2.95b
Ph
H
H
H
H
H
H
H
H
H
Scheme 2.27 Competition between elimination of TBDMSO group and 1,3 Zr-alkenylidene 
rearrangement. 
 
2.3.5. Application of the existing method to monocyclic zirconacyclopentenes 
Insertion of lithium 1,1-dibromoheptane into zirconacyclopentene 1.24 (created in situ 
by insertion of the corresponding alkyne into Zr-ethene complex, 1.21) gave the 
expanded six-membered zirconacyle 2.101 (Scheme 2.28). Further Zr-alkenylidene 
rearrangement driven by phenyl acetylide to give intermediate 2.102 followed by endo- 
and exocyclic -H elimination to provide after protonolysis an inseparable mixture of 
products 2.103 and 2.104 in 64% and 45% combined yield for hexyl and phenyl 
substituent, respectively. Although the main limitation of the synthetic route presented 
below is the -H abstraction, this method can be an alternative route for synthesis of 
substituted cyclopentadienes. 
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Cp2ZrCl2
Cp2
ZrR
R
Cp2
ZrR
R
Hex
Br
R
R
ZrCp2
Ph
R
R
R
R
Hex
1.24
2.102
2.101
Cp2Zr
2.104
2.103
1.21
C5H11
HC5H11
R
R
ZrCp2
n-Hex
Ph
H
(i), (ii) (iii)
(iv) (v)
Reagents and conditions: (i) 2 eq EtMgBr, THF −78 οC, 45 min;
(ii) RCCR, −78 οC to +5 οC, 3 h; (iii) 3.0 eq PhCCLi,−78 οC to 0 οC 
over 3 h; (iv)  MeOH, aq NaHCO3,  RT, 12 h.
a. R = n-Hex,  64%
b. R = Ph,       45%, 
(+ tautomers for 1,5-H shift for 2.103b)
+
 
Scheme 2.28 Insertion of alkynes and carbenoids into Zr-ethene complex. 
 
2.4. Synthesis of 1-alkoxy-cis-bicyclo[3.3.0]oct-2-enes 
The results from testing for biological activity against LRH-1 and SF-1 of alkoxy 
analogues 2.107 of 1.7 were required to complete a series for publication (Scheme 
2.29). 
OR Ph
n-Hex
H
Ph
n-Hex
H
OH
Ph
H
O
Ph
2.105 2.106 2.107a-j2.35a
Reagents and conditions: (i) Co2(CO)8, 10 eq DMSO, THF, reflux, 5 h, 80%; 
(ii) n-HexMgBr, CeCl3, −10 οC to RT, 1 h, 90%; (iii) 10 eq ROH, 0.1 eq
camphorsulfonic acid, RT, 3.5 h, then aq NaHCO3.
(i) (ii) (iii)
 
Scheme 2.29 Synthesis of alkoxy analogues of 1.7. 
 
Tertiary alcohol 2.106 was synthesised as previously reported83 from hept-6-en-1-yn-1-
ylbenzene 2.35a via Pauson-Khand cyclisation to give the cyclopentenone 2.105 and 
cerium trichloride assisted 1,2-addition of hexylmagnesium bromide (Scheme 2.29). 
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Exposure of 2.106 to various alcohols in the presence of catalytic amounts of 
camphorsulphonic acid gave a series of analogues 2.107 of 1.7 in which an alkoxy 
group replaced the aniline substituent. Yields for the last step were generally good 
(Table 2.3), the exception being when the alcohol carried an alpha-branch. The products 
2.107 were unstable to silica, so were purified by column chromatography on basic 
grade III alumina. 
Compound R Yield / % 
2.107a OMe 75 
2.107b OEt 69 
2.107c OPr 71 
2.107d O-i-Pr 7 
2.107e O-n-Bu 68 
2.107f OCH2CH(Me)(Et) 64 
2.107g O-n-Pent 62 
2.107h O-n-Hex 65 
2.107i O-c-Hex 12 
2.107j OBn 63 
Table 2.3 Synthesis of 1-alkoxy-3-hexyl-2-phenyl-cis-bicyclo[3.3.0]oct-2-enes. 
 
2.5. SAR for 1-alkoxy-cis-bicyclo[3.3.0]oct-2-enes and ‘all carbon’ 
analogues of GSK8470 
The compounds 2.63a-w, 2.67a-b, 2.69, 2.70, 2.72, 2.73, 2.78 and 2.107a-j were 
screened for activity against both hLRH-1 and hSF-1 using FRET-based peptide 
recruitment assay.177 Purified bacterial expressed ligand binding domains75 of human 
LRH-1 or human SF-1 were labelled with biotin and incubated with APC labelled 
streptavidin (Molecular Probes). Peptides derived from TIF2 amino acids 737-757 (B-
QEPVSPKKKENALLRYLLDKDDTKD-CONH2) for LRH-1, or from DAX-1 amino 
acids 1-23 (B-MAGENHQWQGSILYNMLMSAKQT-CONH2) for SF-1 were labelled 
with biotin and incubated with europium labelled streptavidin (Wallac Inc.). The 
labelled receptor and peptide were incubated in the presence of various concentrations 
of test compound and the associated complexes quantified by time resolved 
fluorescence energy transfer (TR-FRET). The EC50’s of the test compounds, which 
serve as a measure of the binding affinity for the receptor, was estimated from a plot 
using the ratio of fluorescence values collected at 671 nM to fluorescence values 
collected 618 nM versus concentration of test compound added.  
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Typically 11 points over certain concentration range were used to construct each dose-
response curve and the EC50 was calculated using the appropriate software. For LRH-1 
6 repeats were carried out, for SF-1 3. Standard deviation (SD) serves as a measure of 
uncertainty of the results. Test compounds that increased the affinity of the receptors for 
the peptide yielded an increase in fluorescent signal which is reported as the relative 
efficacy (RE) at peptide recruitment, which in the absence of a known standard was 
normalized to racemic 2.69-exo for LRH-1 and 2.69-exo-ent-2 for SF-1. 
The data is presented in several tables. Table 2.4 shows the alkoxy-substituted series 
2.107a-j, Table 2.5, Table 2.6 and Table 2.7 show the series 2.63 compounds with 
emphasis of variation at the 1, 2 and 3 positions of the bicyclo[3.3.0]oct-2-ene skeleton 
respectively. Table 2.8 contains the alternative core structures of 2.67 and 2.78. Finally, 
Table 2.9 provides results from compounds 2.69, 2.70, 2.72 and 2.73 with oxygen 
substitution on the cyclopentane ring.177  
O
H
2.107a-j
PhR
 
LRH-1 SF-1 
Compound R pEC50 
(±SD) 
RE (±SD) 
pEC50 
(±SD) 
RE (±SD) 
1.5 – 6.2 (0.07)  0.89 6.8 (0.008)  0.35 
1.7 – 7.5 (0.003)  0.38 7.4 (0.008)  0.70 
2.107a OMe ia ia ia ia 
2.107b OEt 5.6 (0.05)  0.17 (0.02) 6.3 (0.06)  0.50 (0.02) 
2.107c OPr 5.6 (0.10)  0.21 (0.04) 6.7 (0.04)  0.62 (0.02) 
2.107d O-i-Pr 5.5 (0.04)  0.19 (0.03) 6.4 (0.04)  0.46 (0.04) 
2.107e OBu 5.3 (0.05)  0.39 (0.03) 6.6 (0.07) 0.60 (0.03) 
2.107f OCH2CH(Me)(Et) 5.6 (0.06)  0.18 (0.03) 6.7 (0.06) 0.52 (0.02) 
2.107g OPent ia ia 6.4 (0.08)  0.40 (0.02) 
2.107h O-n-Hex ia ia ia ia 
2.107i O-c-Hex 6.1 (0.03)  0.16 (0.02) 7.1 (0.05) 0.63 (0.006) 
2.107j OBn ia ia ia ia 
Table 2.4 LRH-1 and SF-1 binding and activation of alkoxy substituted series 2.107. 
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Pleasingly, it was found that many of the alkoxy-substituted analogues were active 
against both LRH-1 and SF-1 showing that the nitrogen in the aniline series 1.6 
(exemplified by 1.5 and 1.7) was not necessary. All the compounds bound substantially 
less strongly to LRH-1 (pEC50 are ranging from 5.3 to 6.1), and induce less recruitment 
of peptide (RE from 0.16 to 0.39), than the aniline series (pEC50 = 7.5 and RE = 0.38 for 
1.7) suggesting that an aromatic group is preferred by LRH-1 in this region. 
Unfortunately it was not possible to make the OPh substituted system – it was too 
unstable, both because phenoxide is a much better leaving group than alkoxides, but 
also because phenol will act as an acid catalyst for decomposition. The compounds 
showed reasonable selectivity for SF-1, with binding approaching (pEC50 = 6.3 ÷ 7.1), 
and efficacy exceeding (RE = 0.40 ÷ 0.63) that of the currently most used biological 
tool 1.5 (pEC50 = 6.8 and RE = 0.35). For both LRH-1 and SF-1 was found a clear SAR 
relating to the size of the R group with both small groups (Me) and large groups giving 
compounds which bound weakly (pEC50 < 5.0). The cut-off for large chains is sharp 
indicating a defined pocket being filled. For LRH-1 this is above four carbons long 
(cyclohexyl, CH2CH(Me)(Et), and n-butyl all fit, n-pentyl does not. For SF-1 the pocket 
appears slightly larger with n-pentyl fitting, but n-hexyl not. Similar trend was observed 
with aniline series 1.6, where compounds with NPh bound strongly (pEC50 > 6.0) and 
were active (RE = 0.50 ÷ 1.0), whereas compounds with 3- or 4-substitution on the NAr 
ring gave reduced binding (pEC50 < 5.0) or inactive compounds.83  
Although the alkoxy-substituted series provided a candidate for one of the key-aims – 
the SF-1 selective compound 2.107g, the compounds proved as acid sensitive as the 
aniline series. For example they decomposed on attempted chromatography on silica, or 
if stored in glassware which had not been base washed.  
Due to acid instability of series 2.107, compound 2.63a was examined as it has similar 
cis-bicyclo[3.3.0]oct-2-ene structure but lacking the cause of acid instability – the 
bridgehead leaving group. Delightfully it was found to exhibit good binding and 
activation of both LRH-1 and SF-1 (Table 2.5). 
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R Ph
H
2.63a-l
 
LRH1 (RE) SF1 (RE) Compound R pEC50 (±SD) RE (±SD) pEC50 (±SD) RE (±SD) 
2.63a Ph 6.6 (0.06) 0.24 (0.05) 7.2 (0.02) 0.82 (0.06) 
2.63b 3-MeOPh 6.5 (0.05) 0.25 (0.04) 7.2 (0.1) 0.27 (0.008) 
2.63c 4-MeOPh ia ia ia ia 
2.63d 4-MePh 5.7 (0.12) 0.25 (0.02) 6.8 (0.05) 0.28 (0.004) 
2.63e 4-EtPh ia ia ia ia 
2.63f 4-n-BuPh ia ia ia ia 
2.63g 4-t-BuPh ia ia ia ia 
2.63h 4-PhPh ia ia ia ia 
2.63i n-Pr 5.5 (0.17) 0.23 (0.04) 6.8 (0.02) 0.63 (0.02) 
2.63j n-Bu ia ia 6.7 (0.07) 0.70 (0.03) 
2.63k n-Hex ia ia ia ia 
2.63l n-Oct ia ia ia ia 
Table 2.5 Variation of bridgehead substituent in series 2.63 compounds. 
 
Variation of the lithiated alkyne used in the multi-component synthesis of 2.63 allowed 
variation of the bridgehead substituent (Table 2.5). As with the series 2.107 compounds, 
a strict cut-off in the size of group R which can be accommodated is observed. Even 
addition of a para-methyl group to the preferred phenyl substituent decreased binding 
2.63d, and anything larger 2.63e-h gave inactive compounds. Interestingly a 3-MeO 
group was well tolerated perhaps indicating some stabilisation via dipolar interactions 
or weak H-bonding, whereas a 4-OMe substitution gave an inactive compound (2.63c). 
When R is an alkyl group 2.63i-l LRH-1 binds only the shortest tried 2.63i (R = n-Pr), 
and then with low pEC50 and efficacy. Even compound 2.63j with R = n-Bu is inactive, 
and since this is little longer that R = Ph indicates a strong preference for an aryl group. 
SF-1 bound the R= n-Bu compound 2.63j strongly and with good efficacy confirming 
the larger pocket noted in the SAR of series 2.107, and providing an excellent SF-1 
selective analogue. Compounds with the longer chain R = n-Hex, n-Oct; 2.63k,l 
respectively, were inactive. 
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Ph R
H
2.63a, m-s
 
LRH1 (RE) SF1 (RE) 
Compound R 
pEC50 (±SD) RE (±SD) pEC50 (±SD) RE (±SD) 
2.63a Ph 6.6 (0.06) 0.24 (0.05) 7.2 (0.02) 0.82 (0.06) 
2.63m 3-MeOPh 6.6 (0.02) 0.23 6.9 (0.02) 0.40 
2.63n 4-EtPh ia ia ia ia 
2.63o n-Pr ia ia 6.4 (0.02) 0.52 (0.11) 
2.63p n-Bu ia ia 6.6 (0.08) 0.57 (0.03) 
2.63q n-Hex ia ia ia ia 
2.63r c-Hex ia ia 6.7 (0.05) 0.56 (0.04) 
2.63s (CH2)3OH 6.0 (0.04) 0.38 (0.05) ia ia 
Table 2.6 Variation of 2-substituent in series 2.63 compounds. 
 
Changing the 1,6-enyne starting material allowed the structure activity relationship due 
to variation of the substituent on position 2 of the bicyclo[3.3.0]oct-2-ene to be probed 
(Table 2.6). The tight constraints, and apparent preference for aryl groups of the LRH-1 
binding site are again apparent. Although a 3-methoxy-phenyl group 2.63m is tolerated, 
4-ethylphenyl 2.63n is not, and surprisingly none of R = n-Pr, n-Bu, or c-Hex 2.63o,p,r, 
all similar sizes to a phenyl group, gave active compounds. SF-1 proved much more 
accommodating, consistent with the larger ligand binding pocket, although compounds 
with 4-ethyl-phenyl 2.63n or n-Hex, 2.63q, substituents were not active. n-Pr, n-Bu and 
c-Hex substituted compounds 2.63o,p,r all gave similar binding and efficacy with SF-1, 
but distinctly poorer than compound 2.63a (R = Ph). Remarkably, the 3-hydroxypropyl 
subsistent in 2.63s gave good binding and activation of LRH-1, but is inactive against 
SF-1 providing the only example of a highly LRH-1 selective compound. It is believed 
that the hydroxyl group may be picking up binding to the polar area at the entrance to 
the ligand binding pocket where the phosphate portion of phospholipids is found in 
crystal structures of LRH-1. The inactivity of 2.63s indicates this to be a very non-polar 
area in SF-1.  
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Ph Ph
R
H
2.63a, t-w
 
LRH1 (RE) SF1 (RE) 
Compound R 
pEC50 (±SD) RE (±SD) pEC50 (±SD) RE (±SD) 
2.63a Ph 6.6 (0.06) 0.24 (0.05) 7.2 (0.02) 0.82 (0.06) 
2.63t H ia ia ia ia 
2.63u n-Bu 6.7 (0.02) 0.54 (0.05) 7.4 (0.03) 0.85 (0.01) 
2.63v n-Oct 5.8 (0.16) 0.15 (0.02) 6.8 (0.07) 0.65 (0.04) 
2.63w SiMe2Ph 6.8 (0.05) 0.54 (0.05) 7.2 (0.04) 0.33 (0.002) 
Table 2.7 Variation of 3-substituent in series 2.63 compounds. 
 
Using alternative dihalocarbenoids in the formation of 2.63 allowed the biological effect 
of some variation in the 3-substituent (Table 2.7). Reducing it to a hydrogen, gave an 
inactive compound against both receptors indicating that the ligand binding pocket does 
need to be filled for binding/activity. Shortening the n-hexyl 2.63a substituent to n-butyl 
2.63u gave a substantial increase in efficacy for LRH-1 without affecting SF-1.  
The bulky SiMe2Ph substituent gave a substantial increase in efficacy for LRH-1, and a 
significant decrease in efficacy for SF-1. An n-octyl chain gave some reduction in 
binding and efficacy, particularly for LRH-1. 
RN
Ph Ph
H
Ph Ph
H
2.67a, R = Me
2.67b, R = Bn
2.78
 
LRH1 (RE) SF1 (RE) 
Compound 
pEC50 (±SD) RE (±SD) pEC50 (±SD) RE (±SD) 
2.63a 6.6 (0.06) 0.24 (0.05) 7.2 (0.02) 0.82 (0.06) 
2.78 6.6 (0.05) 0.24 (0.04) 7.2 (0.05) 0.40 (0.004) 
2.67a 5.9 (0.03) 0.20 (0.03) 6.5 (0.11) 0.49 (0.02) 
2.67b ia ia ia ia 
Table 2.8 Effect of variations in skeleton on biological activity. 
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Variation in the core skeleton was also considered (Table 2.8). The only effect of 
changing the fused saturated ring from cyclopentane (in 2.63a) to cyclohexane (in 2.78) 
was reduced efficacy against SF-1. The pyrrolidine fused systems 2.67a,b offered the 
potential of improved solubility. The N-methyl compound 2.67a was active against both 
receptors, although with reduced binding and efficacy, particularly against LRH-1. 
Given the improved solubility characteristic of 2.67a c.f. the hydrocarbons 2.63 it is a 
useful SF-1 selective compound. 
Ph Ph
H
RO
2.72, R = H
2.73, R = OAc
Ph Ph
HRO
2.69, R = H
2.70, R = OAc
 
Table 2.9 Effect of oxygen substitution on the cyclopentane ring. 
 
Finally some analogues with oxygen substitution of the cyclopentane ring were 
examined (Table 2.9). The choice was driven by the crystal structure of LRH-175 which 
indicated a polar patch (Arg-393 and His-390) in the generally hydrophobic ligand 
binding site. 
Pleasingly it was found that the compound with a 6-exo-hydroxy substituent (2.69-exo) 
was the most active of all the compounds tested – both in binding and efficacy against 
both LRH-1 and SF-1.  
LRH1 (RE) SF1 (RE) 
Compound 
pEC50 (±SD) RE (±SD) pEC50 (±SD) RE (±SD) 
2.63a 6.6 (0.06) 0.24 (0.05) 7.2 (0.02) 0.82 (0.06) 
2.69-exo (racemic) 6.6 (0.05) 1.0 (0.05) 7.5 (0.10) 0.94 (0.05) 
2.69-exo-ent-1 6.6 (0.02) 0.29 (0.04) 7.6 (0.04) 0.99 (0.03) 
2.69-exo-ent-2 6.7 (0.19) 0.88 (0.06) 7.5 (0.21) 1.0 (0.10) 
2.69-endo 6.4 (0.08) 0.68 (0.03) 7.2 (0.06) 0.74 (0.005) 
2.70-exo 6.4 (0.09) 0.18 (0.03) 6.4 (0.01) 0.18 (0.007) 
2.70-endo 6.6 (0.06) 0.18 (0.04) 7.0 (0.03) 0.25 (0.008) 
2.72-exo 6.0 (0.07) 0.53 (0.06) 6.6 (0.07) 0.45 (0.02) 
2.72-endo 5.8 (0.04) 0.32 (0.03) 6.5 (0.05) 0.87 (0.007) 
2.73-exo ia ia ia ia 
2.73-endo 6.3 (0.09) 0.13 (0.01) 6.7 (0.04) 0.32 (0.02) 
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The strong activity provided an incentive to separately test the two enantiomers of 2.69-
exo, and surprisingly it turned out that both enantiomers have equal binding to both 
LRH-1 and SF-1. Indeed the only difference between them was the substantially greater 
efficacy of ent-2 c.f. ent-1 with LRH-1. It is usual for only one enantiomer of a 
compound to be active against a particular receptor, and particularly surprising in this 
case when such strong SAR effects against small changes in structure has been 
observed. The endo-epimer of 2.69 showed very similar binding and efficacy against 
both receptors as compound 2.63a lacking the oxygen substitution. Acylation of the 
alcohol had little effect on binding (Table 2.9, entries 6 vs 2 and 7 vs 5), but 
substantially reduced efficacy, with the exception of 2.70-exo where binding to SF-1 
was reduced, incidentally providing one of the most ‘LRH-1 selective’ compounds 
produced.  
The 7-hydroxyl substituted systems 2.72-exo and 2.72-endo showed reduced binding 
compared to the unsubstituted analogue 2.63a, though efficacies were reasonable. 
Acylation of the exo-alcohol gave inactive compound 2.73-exo against both LRH-1 and 
SF-1 (entry 10) indicating a size limitation of this part of the binding pocket. Acylation 
of the endo alcohol to give 2.73-endo (entry 11) was well tolerated. 
 
Agonist/antagonist crossover 
For most compounds the biological results were clear – excellent agreement between 
the repeats, with nicely sigmoidal curves for active compounds (at least when EC50 >6) 
and inactive compounds showing no response. However, in a few cases variable results 
were obtained which might be attributed to agonist/antagonist crossover. For LRH-1 
this is best illustrated by the curves for the N-benzyl pyrrolidine 2.67b (Figure 2.2). In 
this case three runs showed agonist activity with a pEC50 of 6.5, but another three 
showed what may be interpreted as antagonist activity, with around the same binding 
constant. Similar behaviour, but with 4 agonist and 2 antagonist lines were observed for 
2.63m and 2.72-endo (pEC50 6.6 and 5.8 respectively). Since the protein used for assay 
is known to contain phospholipids, and some of these are known agonists for LRH-1 it 
is possible that 2.67b has stronger binding, but lower efficacy than the natural ligand. If 
the amount or type of phospholipids varied between experiments it is possible to get the 
apparent agonist/antagonist crossover behaviour observed. Against SF-1 the 
agonist/antagonist behaviour was observed in two compounds – the exo-acetates 2.70-
exo and 2.73-exo. In the former case 2/3 curves showed agonist activity (as in Table 
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2.9), the other antagonist (~same pEC50 and RE of –0.2); in the later 1/3 curves was 
agonist (pEC50 6.8, RE 0.2) and 2/3 antagonist (pEC50 6.8, RE –0.2). In addition two 
compounds (2.63n and 2.63s) showed quite convincing antagonist activity (sigmoidal 
curves showing negative response) with pEC50’s of ~6.5.    
 
Figure 2.2 Agonist/antagonist crossover for 2.67b. 
 
Comparison of efficacy and binding 
It is notable that with both receptors examined the maximum activation (RE) varied 
widely. Ploting the RE against the pEC50 for all the ‘all carbon’ systems for LRH-1 and 
SF-1 (Figure 2.3) demonstrates the modest correlation between the two, particularly for 
LRH-1. In particular there are groups of compounds with strong binding, but poor 
efficacy, providing indications of how agonists can be developed. 
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Figure 2.3 Comparison of efficacy and binding. 
 74 
Choice of compounds recommend as biological probes 
Compound 2.69-exo provides an excellent replacement for compound 1.5 as a 
biological tool. It has excellent stability, reasonable solubility in polar solvents and 
improved binding and efficacy against both LRH-1 and SF-1. Little is lost by using the 
1.6 : 1 mixture of 2.69-exo and 2.69-endo produced directly from the zirconium 
mediated reaction thus avoiding a tricky separation. Compound 2.63j provides the best 
tool for selective activation of SF-1 (with 2.63o,p,r also being good). Its main 
disadvantage is its non-polar nature which may cause solubility problems in polar 
solvents, in which case pyrrolidine 2.67a provides reasonable selectivity and may be 
preferred.  
 
2.6. Conclusions for chapter 2 
Substrate scoping studies for the one-pot tandem reaction sequence on zirconocene 
template resulted in synthesis of a wide range of bicyclic compounds containing rigid 
cis-bicyclo[3.3.0]oct-2-ene skeleton. The final compounds were obtained in yields 
ranging from good to very good. For sterically encumbered zirconacycles (or 
carbenoids), the undesired -hydride elimination process was observed. Nonetheless, 
the one-pot tandem reaction sequence provides an excellent method for construction of 
bicyclic compounds and potential for functionalisation at multiple sites. Such obtained 
compounds were tested for biological activity in search for active and selective agonists 
and antagonists for orphan nuclear receptors: hLRH-1 and hSF-1. Pleasantly, 
improvement in binding, efficacy, selectivity and acid stability in the case of certain 
compounds was observed in comparison with the previously reported 1-aryl amino cis-
bicyclo[3.3.0]oct-2-enes.  
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Chapter 3. Dihalocarbenoid and acetylide insertion into 
saturated zirconacyclopentanes 
3.1. Introduction to research area 
3.1.1. Zirconocene mediated co-cyclisation of dienes 
A wide range of 1,n-dienes can be cyclised with the Negishi reagent to afford saturated 
zirconacycles. Extensive research in this area is well described in literature122,116,178,179 
The great range of dienes containing heteroatoms, available for co-cyclisation has led to 
a number of heterocycles being synthesised by this method.180 Also zirconocene 
mediated co-cyclisation of dienes has been applied to the total synthesis of natural 
products.181 
 
3.1.2. Elaboration of zirconacyclopentanes 
There are several well established methods in which zirconacyclopentanes can be 
further elaborated to give useful organic products. Similarly to unsaturated 
zirconacycles, zirconacyclopentanes can be protonated, halogenated,111 transmetallated 
to Cu182 and Mg.102,183 They also undergo metathesis with main group elements,121,123 
carbon monoxide,116,117 isonitrile184 and carbenoid118 insertion. The latter method is 
more relevant to research described in this section and therefore will be reviewed in 
more detail. 
 
3.1.2.1. Allyl and methylallyl carbenoid insertion into saturated zirconacycles 
Insertion of lithium chloroallylide and chloromethylallylide into zirconacyclopentanes 
has been extensively investigated by Whitby and co-workers. (Scheme 3.1).138,185 
Insertion of lithiated allyl chloride 1.76 into saturated zirconacycle 3.0 affords the 18-
electron allyl-zirconocene complex 3.1. Protonolysis of this complex with acetic acid 
gives excellent control of the double bond geometry in product 3.2.  
The one-pot tandem reaction sequence on zirconocene allows a great deal of diversity in 
terms of diene, carbenoid and electrophile variability. The allyl-Zr complex 3.1 was 
found to react with a broad spectrum of electrophiles yielding the products shown in 
Scheme 3.1.139 Lewis acid promoted insertion of aldehydes, acetals, and additional 
iminium ions provides the corresponding alcohols 3.3, ethers 3.4 and amines 3.5, 
though without significant diastereoselectivity. For insertion of ketones longer reaction 
times and higher temperatures were required to obtain tertiary alcohols 3.7. 
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ZrCp2
OHH
H
H
3.3
3.1
3.2
(ii) (iii), (iv)
Reagents and Conditions: (i) CH2CHCH2Cl, LDA or LiTMP, −78 οC, 0.5 h; (ii) MeOH
or AcOH, 16 h; (iii) 1.1 eq RCHO, 1.1 eq BF3·Et2O, −40 οC to RT, 3 h; (iv)  MeOH, aq 
NaHCO3, RT, 12 h; (v) RCH(OEt)2, BF3·Et2O, −78 οC to RT, 2 h; (vi) for a: 1.3 eq
(CH2NR2)I, −78 οC to RT, 1.5 h; for b, c: 1.5 eq RCH(NR12)(OBu), 1.5 eq BF3·Et2O,
−78 οC to RT, 2 h; (vii) 2.0 eq 1,3-dithenium-tetrafluoroborate, −78 οC to RT, 1.5 h;
(viii) for a: Me2CO, benzene, 80 οC, 48 h; for b, c: Ph2CO, cyclohexanone, toluene,
110 οC, 48 h.
MeOH, E:Z, 70:30, 94%
AcOH, E:Z, >98:2, 75%
R
H
H H
NR12
H
3.5
H
OEtH3.4
H
OHH3.7
H
R
R
R1
R
3.3      R                      Yield, %   d.r.
a.       Ph                       90           2.9:1 
b.      2,4-(MeO)C6H3    60           3.1:1    
c.      CHMe2                 90           1.3:1
d.      (CH2)2Me             95           1.5:1
a. R = H, R1 = Me, 89%
b. R = Ph, R1 = -(CH2)5-, 95%
c. R = 4-Cl-C6H4, R1 = Me, 92%
a. R = Me, 73%
b. R = Et, 61%
c. R = CH=CH2, 64%
d. R = CH=CHPr, 76%
e. R = CH=CHCH=CHMe, 84%
f.  R = OEt, 71%
H
3.6, 70%
H
S
S
a. R = R1 = Me, 54%
b. R = R1 = Ph, 57%
c. R = R1 = -(CH2)5-, 56%
(v), (iv)
(vii), (iv)
(vi), (iv)
(viii), (iv)
H 3.0
H
ZrCp2
(i)
 
Scheme 3.1 Diversity of allyl zirconocene complexes elaboration. 
 
Variations of allyl carbenoid in terms of leaving group and substitution have also been 
investigated.137 
 
3.1.2.2. Insertion of 1-halo-1-lithioalkanes into zirconacyclopentanes 
Alkyl carbenoid insertion into a wide range of zirconacyclopentanes has also been 
investigated.133,186 
Carbenoids with electron-donating and electron-withdrawing groups were found to 
insert into bicyclic and monocyclic unsubstituted zirconacyclopentanes (Scheme 3.2). 
 77 
Reagents and Conditions: (i) LiTMP or LDA, −78 οC; 
(ii)  MeOH, aq NaHCO3, RT, 12 h.
ZrCp2
R
R
H
H
R
R
H
H
ZrCp2
R1 R
R
H
H
R1
(i)
(ii)
3.8 3.9 3.10
Cl R1
ZrCp2 ZrCp2
R1
(i)
(ii)
3.11 3.12
Cl R1 R1
3.13
 
Scheme 3.2 Insertion of  alkyl carbenoids into zirconacyclopentanes. 
 
Entry Zirconacycle/ R, R Carbenoid/ R1 Yields of 3.10, 3.13/ % 
a 3.8a/ -CH2OCMe2OCH2- 1.107/ SiMe3,  78 
b 3.8a/ -CH2OCMe2OCH2- 3.14/ SiMe2Ph 77 
c 3.8b/ -CH2OMe, -CH2OMe 3.14/ SiMe2Ph 70 
d 3.8b/ -CH2OMe, -CH2OMe 3.15/ SnBu3 11 
e 3.8a/ -CH2OCMe2OCH2- 3.16/ SPh 77 
f 3.8a/ -CH2OCMe2OCH2- 3.17/ OEt 45 
g 3.8b/ -CH2OMe, -CH2OMe 1.117/ P(O)(OEt)2 74 
h 3.8b/ -CH2OMe, -CH2OMe 1.92/ CN 24 
i 3.8b/ -CH2OMe, -CH2OMe 1.95/ SO2Ph 67 
j 3.11 1.117/ P(O)(OEt)2 56 
Table 3.1 Yields of 3.10 and 3.13 from insertion o various carbenoids into zirconacycles 3.8a, b and  
3.11. 
 
Insertion of alkyl carbenoids into zirconacycles 3.8a,b and 3.11 occurred successfully in 
many cases to provide the corresponding products, apart from a few cases, in very good 
yields (Table 3.1). In all but one case products of monoinsertion were obtained. The low 
yields of products 3.10d,f and h are related to the peculiar reactivity of the carbenoids 
used in these reactions. The α-stannyl carbenoid 3.15 is suspected to undergo 
tin/lithium exchange very quickly, the α-ethoxy carbenoid 3.17 is thermally unstable 
and the complex 3.9f decomposes above –20 οC, whereas insertion of lithiated 
chloroacetonitrile 1.92 resulted in bisinsertion product to be the major (45%) and 
monoinsertion product 3.10h to be the minor (24%).133  
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3.1.2.3. Insertion of 1,1-dihalo-1-lithioalkanes into zirconacyclopentanes 
A special case of insertion of a dihalocarbenoid into an organozirconium system 3.8a 
was reported in 1999,145 where the zirconacycle ring expansion was followed by a ring 
closure with loss of a second halide (Scheme 3.3). In this example, the 1,2-metallate 
rearrangement134,136 to afford zirconacyclohexane 3.19 is followed by dyotropic 
rearrangement187-189 to form the bicyclo-Zr complex 3.20, which after protonolysis 
provides the bicyclo[3.3.0]octane system 3.21. If the intermediate 3.20 with R = n-Pr 
was warmed to RT before quench, dehydrozirconation process occurred to give solely 
product 3.22 (Scheme 3.3).145 Very poor yields were obtained for insertion of 
dichloromethane, but reasonable in other cases. 
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2 h; (ii) 1.5 eq
RCHX2, 1.7 eq LDA, −78  οC to −55  οC over 2 h; (iii)  MeOH, aq NaHCO3, −78  οC 
to RT, 16 h; (iv) −78  οC to RT, then MeOH, aq NaHCO3, 16 h.
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O
O
O ZrCp2
X
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R
X
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O
R
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O
R
O
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3.8a 3.193.18
3.22, 86%
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b.     n-Pr        
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d.     SiMe2Ph 
e.     CN
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Li+
-LiCl
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66
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48
X    
Cl      
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Scheme 3.3 Carbocycles synthesis via insertion of dihalocarbenoids into zirconacyclopentane. 
 
3.2. Construction of bicyclo[3.3.0]octanes via insertion of 1,1-dihalo-
1-lithio species and lithium acetylides into zirconacyclopentanes 
The following section discusses further work in the area of dihalocarbenoid insertion 
into zirconacyclopentanes. Alkyl carbenoid and acetylide insertion into a range of 
zirconacyclopentanes has been investigated. The reaction sequence worked well in the 
case of unsubstituted dienes to provide the corresponding products of three-component 
coupling on a zirconocene template in reasonable yields. The main limitation of this 
method has arisen from the -hydride elimination process observed in the case of 
sterically encumbered zirconacycles.  
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3.2.1. Preparation of cyclisation precursors 
4,4-Bis(methoxymethyl)hepta-1,6-diene 3.23, (Z)-4,4-bis(methoxymethyl)nona-1,6-
diene 3.24 and N-allyl-N-benzyl-2-methylprop-2-en-1-amine 3.25 (Figure 3.1) were 
prepared from commercially available starting materials using literature methods and 
had spectral properties consistent with those included in the thesis of former group 
members or literature.132 
O
O
3.23
O
O
3.24
BnN
3.25
 
Figure 3.1 Dienes for Zr-mediated cyclisation and further elaboration. 
 
3.2.2. Elaboration of zirconacyclopentanes via dihalocarbenoid and acetylide 
insertion 
 
3.2.2.1 Insertion of alkyl carbenoids and acetylides into α-unsubstituted 
zirconacyclopentanes 
Extension of the one-pot three-component coupling of saturated zirconacycles, 
dihalocarbenoids and acetylides resulted in synthesis of a series of novel compounds 
containing a bicyclo[3.3.0]octane core (Scheme 3.4).  
Insertion of 1,1-dihalo-1-lithio species 3.26 into zirconacyclopentane 3.8b affords the 
‘ate’ complex 3.27 which undergoes 1,2-metallate rearrangement to provide the 
expanded zirconacyclohexane 3.28. Nucleophilic attack of lithium acetylide onto the Zr 
atom forces the second C-Zr bond to migrate, thus to afford the carbobicyclo-Zr 
complex 3.30. Insertion of a second equivalent of acetylide affords the bisalkynyl-
zirconium species 2.18 (2.18c) through elimination of carbanion 3.32. Subsequent re-
addition of the anion to -carbon of the bisalkynyl-zirconium intermediate 2.18 (2.18c) 
provides the novel zirconium-alkenylidenate complex 3.33 to give the carbobicyclic 
compounds 3.34a-c after quenching (Scheme 3.4). 
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Y = C(CH2OMe)2
3.26/ R1               R2          Yield (%)
3.26a/ n-Hex       Ph           3.34a, 77
3.26a/ n-Hex       n-Hex      3.34b, 47
3.26b/ SiMe2Ph   Ph           3.34c, 35
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X
X R1
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R1 Y
ZrCp2
X
R1
R2
Y
R1
ZrCp2
R2
Y
R1
ZrCp2
R2
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Y
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Cp2Zr
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R2 Y
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H
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H H H
H H H
H
H
H H H
H HH
H
3.27
Li+
Li+
Li+
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2 h;
(ii) 1.3 eq R1CHX2, X = Br for R1 = n-Hex, X = Cl for R1 = SiMe2Ph, 1.5 eq
LDA or LiTMP, −78  οC, 15 min; (iii) 3.0 eq (4.0 for b) R2CCLi, −78  οC to
−55  οC (−25 οC for b and −15 οC for c); (iv)  MeOH, aq NaHCO3, RT, 12-16 h.
(iii)
(i) (ii)
(iv)
2.18, R2 = Ph
2.18b, R2 = n-Hex
R1
3.26
Li
X
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Scheme 3.4 Insertion of dihalocarbenoids and acetylides into zirconacyclopentanes. 
 
Insertion of lithiated 1,1-dibromoheptane 3.26a and acetylide 2.7 into zirconacycle 3.8b 
provided the bicyclic compound 3.34a in good yield. The much lower yield for 3.34b is 
related to use of the acetylide with an aliphatic substituent 2.18b (R2 = n-Hex) which 
turned out to be less reactive than the acetylide with an aromatic substituent 
(observation consistent with insertion of acetylides in zirconacyclopentenes), therefore 
four equivalents of this reagent were required to obtain the desired product 3.34b in an 
acceptable yield of 47%. Insertion of lithiated (dichloromethyl)dimethyl(phenyl)silane 
3.26b into zirconacycle 3.8b occurred efficiently, however, the following phenyl 
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acetylide insertion turned out to be sluggish and gave the desired compound  3.34c in 
only 35% yield, provided that the reaction mixture was warmed to –20 °C before 
quench. In this case a higher temperature was required to make the zirconium-
alkenylidene rearrangement occur (3.32c  3.33c) since the resulting anion 3.32c is 
stabilized by the adjacent silyl group, therefore the intermediate is less reactive towards 
the rearrangement. Additionally, the protonated compounds 3.35a,b (96 : 4 
respectively) were detected by GC in the crude reaction mixture in nearly equimolar 
amount.  
H
H
O
O SiMe2Ph
3.35a
H
H
O
O SiMe2Ph
3.35b
 
Figure 3.2 Product of protonation 3.32c. 
 
When the procedure was modified by addition of phenylacetylide previously pre-mixed 
with HMPA to 3.28, and the whole reaction mixture was allowed to warm to –15 °C 
before quenching, the major product obtained in the reaction was compound 3.35a. 
 
Zirconocene mediated co-cyclisation of 1-allyl-2-vinylbenzene 3.36 provided a mixture 
of trans : cis ring junction zirconacycles 3.37a,b in GC ratio of protonated products 82 : 
18, respectively (Scheme 3.5). The stereochemistries of the ring junction of these 
compounds were assigned by correlation of 1H NMR shifts of the methyl groups in 
products 3.38a and b with the reported spectra190 of trans- and cis-1,2-dimethylindans. 
The proton NMR shifts of the methyl groups in cis-isomer were shifted upfield: 1.19 
and 1.03 ppm (lit. 1.14, 0.98 ppm) in comparison with the shifts of the methyl groups 
being in trans relationship: 1.36 and 1.26 ppm (lit. 1.28, 1.19 ppm). 
Further insertion of lithiated 1,1-dibromoheptane 3.26a and phenyl acetylide 2.7, 
however, occurred exclusively into the trans ring junction zirconacycle 3.37a to give 
compounds 3.39a,b as an inseparable mixture of two diastereoisomers in the ratio of 1.4 
: 1. The stereochemistry at the quaternary carbon centre has not been assigned. 
It is postulated that steric reasons of the cis ring junction zirconacycle 3.37b inhibited 
the carbenoid and acetylide insertion, therefore the yield of the final products 3.39 is 
diminished (48%). 
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Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2 h;
(ii) 2M HCl, RT, 20 h; (iii) 1.05 eq n-HexCHBr2, 1.1 eq LDA, −78  οC, 15 min;
(iv) 3.0 eq PhCCLi, −78  οC to −30  οC, 1.5 h; (v)  MeOH, aq NaHCO3, RT, 12 h.
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Scheme 3.5 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into zirconacycle 3.37a. 
 
Dienes containing a nitrogen atom were examined next (Scheme 3.6). Co-cyclisation of 
N-allyl-N-benzylprop-2-en-1-amine 3.40a provided a mixture of 3.2 : 1 trans : cis ring 
junction zirconacycles 3.41a (ratio and stereochemistry determined by GC analysis of 
the quenched zirconacycles and comparison with the literature precedent). Literature 
precedent reports a zirconocene mediated co-cyclisation of this diene under similar 
conditions to give an 4 : 1 mixture of trans : cis ring junction zirconacycles.116 Further 
insertion of lithiated 1,1-dibromoheptane followed by acetylide addition gave the final 
compound 3.42a in 59% yield and the same ratio of 3.2 : 1, trans : cis ring junction 
diastereoisomers, which were separable by silica gel column chromatography.  
In turn, zirconocene mediated co-cyclisation of N,N-diallylbenzenamine 3.40b provided 
the final compounds 3.42b as a mixture of cis : trans ring junction isomers in the ratio 
of 1.27 : 1 and 70% yield (Scheme 3.6). Nugent and Taber obtained the cis : trans ring 
junction zirconacycles 3.41b in the ratio of 2 : 1.122 Noteworthy is the fact that both cis 
diastereoisomers of the final product 3.42b were created in GC ratio of 13.75 : 1 with 
respect to the newly formed quarternary carbon centre. The cis, trans stereochemistry of 
the final compounds was determined on the basis of 13C NMR analysis.  
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For the cis isomer 13C NMR symmetry was observed therefore the number of signals of 
the core carbons was twofold reduced whereas for the trans isomer all core carbon 
signals were observed. 
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 3 h;
(ii) 1.05 eq n-HexCHBr2, 1.5 eq LiTMP, −78  οC, 20 min; (iii) 3.0 eq PhCCLi, 
−78  οC to −45  οC, 1 h; (iv)  MeOH, aq NaHCO3, RT, 12 h.
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3.41b, cis:trans
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3.40b, Y = NPh
Y
H
H
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3.42b, Y = NPh, cis+trans, 70%
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Y
H
H
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Y
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3.42a, cis (major d.r.)
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Scheme 3.6 Construction of pyrrolidine-fused carbocycles 3.42. 
 
3.2.2.2 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into α-
substituted zirconacyclopentanes 
In the case of terminally substituted dienes 3.24 and 3.43 the sole products obtained in 
the one-pot tandem reaction sequence on a zirconocene template were compounds 
resulting from the -hydride elimination (dehydrozirconation) process 3.45a and 3.45b 
(Scheme 3.7). Product 3.45a was obtained as a single (E)-isomer from (Z)-Et substituted 
diene 3.24, whereas product 3.45b was obtained from (E)-Ph substituted diene 3.43 and 
consisted of two (E)- and (Z)-isomers in the ratio of  9 : 1, respectively (Figure 3.3).  
ZrCp2
H
H
O
O
O
O
RR
3.24, R = Z-Et
3.43, R = E-Ph 3.44a3.44b
H
H
O
O
R
n-C5H11
3.45a. R = Et, 75%
3.45b. R = Ph, 85%
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 14-15 h; 
(ii) 1.3 eq n-HexCHBr2, 1.5 eq LiTMP, −78  οC, 0.5 h; (iii) 3.0 eq PhCCLi,
−78  οC to −35  οC, (to −15  οC for b); (iv)  MeOH, aq NaHCO3, RT, 16 h.
(i) (ii), (iii), (iv)
 
Scheme 3.7 Insertion of carbenoid and acetylide into α-substituted zirconacyclopentanes 3.44a, b. 
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The (E)- and (Z)-isomers of 3.45b were identified by means of 13C NMR shifts of the 
crucial carbon 10 (Figure 3.3) which was shifted upfield in the (E)-isomer by steric 
compression (‘γ-gauche effect’),191 and this isomer appeared to be the major. 
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Figure 3.3 Difference in 13C NMR shifts between E and Z isomers of 3.45b. 
 
The -hydride elimination was revealed to be a very fast process even at low 
temperature (–78 °C and lower) when carbenoid insertion was followed by phenyl 
acetylide addition to give the the intermediate 3.46 (Scheme 3.8). 
Y
R
3.45
a. R = n-Et
b. R = Ph
Y = C(CH2OMe)2
Y
R
3.48a, b
Cp2Zr(H)Br, 3.49
RT
n-C5H11
ZrCp2
Br
Y ZrCp2
Br
n-Hex
3.47a, b
R
Y
R
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ZrCp2
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H H
Cp2Zr(H)CCPh, 2.81
-78  oC
 
Scheme 3.8 Dehydrozirconation process in complexes 3.46 and 3.48. 
 
The availability of an empty orbital on Zr atom and the steric encumbrance in complex 
3.46 (Figure 3.4) favour the undesired dehydrozirconation process before insertion of 
the second equivalent of phenyl acetylide and subsequent 1,3-Zr rearrangement. 
Therefore quick addition or increase in equivalents of the phenyl acetylide did not result 
in its incorporation into the final molecule. 
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Figure 3.4 Steric clash in complex 3.46 favours -H elimination. 
 
The same process, however, was observed when the zirconacyclohexane complex 3.47 
was allowed to warm above 0 °C (Scheme 3.8). In this case the dyotropic 
rearrangement187-189 to give carbocycle-Zr complex 3.48 is a temperature driven process 
and the resulting species 3.49 is postulated to be expelled from intermediate 3.48 
through -hydride elimination process. 
 
3.2.2.3. Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into -
substituted zirconacyclopentanes 
Zirconocene mediated co-cyclisation of dienes with internally substituted double bonds,  
3.25 and 3.50 gave exclusively cis-fused zirconacycles 3.51a and 3.51b respectively 
(Scheme 3.9).132 Subsequent addition of carbenoid 3.26a and phenyl acetylide 2.7 
resulted in obtaining a mixture of final compounds 3.53a,b and both exo- and 
endocyclic -H elimination products 3.54a,b and 3.55a,b. Product 3.53a was obtained 
in 35% yield and contained 3% by 13C NMR of the other isomer (at the carbenoid C 
centre). It was assumed, but has not been proven, that the major isomer is the shown exo 
addition product. Simultaneously in this reaction were obtained other products, which 
are deemed to be 3.54a and 3.55a in 44% combined yield, as an inseparable mixture of 
four compounds. 
Product 3.53b was obtained in only 14% overall yield and contained 6% (by 13C NMR) 
of the other isomer (at the carbenoid C centre). Simultaneously in this reaction were 
obtained products 3.54b and 3.55b in 23% combined yield, as an inseparable mixture of 
four compounds. The residue consisted of product 3.56, derived from protonation of 
zirconacycle 3.51b (Scheme 3.9). These results suggest that the -substituent in 
zirconacycles 3.51a and 3.51b clearly has an effect on the reaction by facilitating the -
H abstraction process as well as direction of the nucleophilic attack of the acetylide onto 
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Zr atom in intermediate 3.52. It is believed that the acetylide attacks the 
zirconacyclohexane 3.52 from its exo face, however, the bulky bridgehead substituent 
introduces a steric clash therefore the nucleophilic attack also occurs in small amounts 
from the endo face, to provide an inseparable mixture of diastereoisomers of the final 
products 3.53a,b. The size of the substituent is considered to play a role as for R = Me, 
there was found only 3% of the minor isomer, whereas for R = Ph, the amount was 
increased to 6%. 
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3.25, R = Me
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3.53a, R = Me, 35%
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Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 3 h;
(ii) 1.1 eq n-HexCHBr2, 1.15 eq  LiTMP, −90 οC  to −78  οC, 0.5 h; (iii) 3.0 eq 
PhCCLi, −78  οC to −20  οC, 3 h; (iv)  MeOH, aq NaHCO3, RT, 12-16 h.
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Scheme 3.9 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into -substituted 
zirconacyclopentanes 3.51a and b. 
 
3.2.2.4 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into  
zirconacyclopentanes fused to a six-membered ring 
Variation in the ring size of zirconacycles was sought in respect of the multi-component 
coupling sequence. Zirconocene mediated co-cyclisation of 1,7-heptadiene 3.57 
provided  six-five fused zirconacycles as a mixture of cis : trans ring junction isomers, 
3.58 in the ratio of 82 : 18 respectively. These zirconacycles were subjected to insertion 
of lithiated 1,1-dibromoheptane 3.26a and further phenyl acetylide 2.7 to provide 
compounds 3.59 as an inseparable mixture of  cis : trans ring junction isomers in the 
ratio of 2 : 1 and 53% combined yield (Scheme 3.10).  
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The cis, trans stereochemistry of the final compounds was determined on the basis of 
13C NMR analysis. For the cis isomer 13C NMR symmetry was observed therefore the 
number of signals of the core carbons was twofold reduced whereas for the trans isomer 
splitting of the core carbon signals was observed. Also only one cis isomer was created 
in this reaction.  
An exocyclic -H elimination was observed for this system and alkene 3.60 was 
obtained as a single cis ring junction isomer in 40% yield. 
ZrCp2
H
H
H
H
n-Hex
Ph
+
H
H
C5H11
3.57
3.58
3.60, 40%
3.59 cis
(i) (ii), (iii), (iv)
H
H
n-Hex
Ph
+
3.59 cis:trans, 
           2:1, 53%
3.59 trans
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2 h; (ii) 1.3 eq
n-HexCHBr2, 1.5 eq  LDA, −78  οC, 15 min; (iii) 3.0 eq PhCCLi, −78  οC to −50  οC, 
0.5 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
Scheme 3.10 Coupling of zirconacycle 3.58, carbenoid and phenyl acetylide on zirconocene. 
  
Three component coupling of zirconacycle 3.62, derived from co-cyclisation of 1,2-
diallylbenzene 3.61, lithiated 1,1-dibromoheptane 3.26a and phenyl acetylide 2.7 gave a 
single cis ring-fused product 3.64 in 40% yield (Scheme 3.11). The stereochemistry of 
the product 3.64 was assigned by 13C NMR analysis which showed 13C NMR symmetry 
for the core carbons. However, during the co-cyclisation step cis : trans zirconacycles 
3.62 were formed in the ratio of 57 : 43 respectively. According to the literature 
precedent the zirconocene mediated co-cyclisation of 3.61 provided a mixture of cis : 
trans zirconacycles in the ratio of  92 : 8.133  
An endocyclic and exocyclic -hydride elimination as well as protonation of the 
intermediate 3.63b occurred to provide the corresponding compounds 3.65, 3.66 and 
3.67 as an inseparable mixture in 33% combined yield and following GC ratio 65 : 31 : 
4%, respectively. It is postulated that the cis ring junction intermediate 3.63a favours 
the carbenoid and phenyl acetylide insertion to give the final products 3.64, whereas the 
trans ring junction intermediate 3.63b favours -hydride elimination. 
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Results obtained from insertion of lithiated 1,1-dibromoheptane 3.26a and phenyl 
acetylide 2.7 into zirconacycles 3.58 and 3.62 are consistent with those obtained from 
insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into unsaturated 
zirconacycle 2.75, and strongly indicate that the cyclohexane ring fused to zirconacycles 
introduces conformation constraints which somehow favours the -hydride elimination 
process.  
ZrCp2
n-Hex
Ph
n-Hex
H
H
H
H
3.61
3.64, 40%
3.62
cis : trans
57 : 43
3.65
H
H
C5H11
H
H3.66
n-Hex
H
H3.67
+
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2.5 h; 
(ii) 1.3 eq n-HexCHBr2, 1.5 eq LDA, −78 οC, 15 min; (iii) 3.0 eq PhCCLi,
−78  οC to −55  οC, 1 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
(ii), (iii)
(i)
3.63a
H
H
ZrCp2
Ph
C5H11
(iv)
Cp2Zr(H)CCPh, 2.81
+
3.63b
H
H
ZrCp2
Ph
C5H11
Scheme 3.11 Cuopling of zirconacycle 3.62, alkyl carbenoid and phenyl acetylide on zirconocene. 
 
3.2.2.5 Insertion of lithiated 1,1-dibromoheptane and phenyl acetylide into tricyclic 
zirconacycles 
Insertion of alkyl carbenoid and phenyl acetylide into tricyclic zirconacycle 3.69 has 
also been probed (Scheme 3.12). The insertion of lithiated 1,1-dibromoheptane occurred 
very poorly and was followed by -hydride elimination to provide an inseparable 
mixture of 3 : 1 (by 13C NMR), E : Z isomers of 3.70 and 9% combined yield, the 
residue being the product of cyclisation 3.71. It remains unclear why the insertion of the 
carbenoid did not work well; however, steric hindrance in the zirconacycle 3.69 is 
postulated to greatly inhibit the carbenoid insertion. 
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O
O
O
O ZrCp2
+
3.68 3.70, 9%3.69
HH
H
O
O
HH
H
C5H11
H
3.71, 91%
O
O
HH
H
H
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 2 h; (ii) 1.1 eq 
n-HexCHBr2, 1.15 eq LiTMP, −90 οC to −78  οC, 20 min; (iii) 3.0 eq PhCCLi,
−78  οC to RT, 2 h; (iv)  MeOH, aq NaHCO3, RT, 16 h.
H
(i) (ii), (iii), (iv)
Scheme 3.12 Insertion of lithiated 1,1-dibromoheptane and acetylide 2.7 into tricyclic zirconacycle. 
 
3.2.2.6 Insertion of lithiated 1,1-dichloromethane and phenyl acetylide into 
zirconacyclopentane 
The unusual reactivity of lithiated dichloromethane 3.26c towards insertion into 
zirconacycle 3.8b was observed (Scheme 3.13).  
ZrCp2
Cl
ZrCp2
Ph
ZrCp2 ZrCp2
ZrCp2ZrCp2
Cl3.73
-
3.74 3.75
-
3.76 3.77
3.8b
-
3.23
O
O
MeO
MeO
MeO
MeO
ClCl Cl
Cl Cl
ClMeO
MeO
MeO
MeO
MeO
MeO
Cl
MeO
MeO
MeO
MeO
Cl
ZrCp2
Cl
Ph 3.78
MeO
MeO ZrCp2
Cl
Ph
Ph
3.79
MeO
MeO ZrCp2
Ph
Ph
MeO
MeO ZrCp2
Ph
Ph
MeO
MeO ZrCp2
Ph
Ph
3.80b
MeO
MeO
3.81
MeO
MeO Ph
3.72H
H
H
H
Cl
Cl
Li
-
H
O
H
O
H H
H H H
H H H
HH
HH
HHH
HHH
HHH
H
Reagents and Conditions: (i) Cp2ZrCl2, n-BuLi, THF, −78  οC to RT, 12 h; 
(ii) 1.0 eq CH2Cl2, 1.2 eq LiTMP, −78 οC to −60  οC, 1 h; (iii) 3.0 eq
PhCCLi, −78  οC to −35  οC, 3 h; (iv)  MeOH, aq NaHCO3, RT, 18 h.
(i) (ii)
(iii)
(iv)
+
+
3.80a
MeO
MeO
H
H
+
Ph
Ph
3.26c
Scheme 3.13 Insertion of lithiated dichloromethane and phenyl acetylide into zirconacycle 3.8b. 
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The initial ‘ate’ complex 3.72, created by insertion of lithiated dichloromethane 3.26c 
into saturated zirconacycle 3.8b, and subsequent 1,2-metallate rearrangement provides 
the ring expanded zirconacyclohexane 3.73, which undergoes second insertion of the 
lithium carbenoid and ring closure to provide the carbobicyclo-Zr complex 3.75. 
Addition of phenyl acetylide causes a second 1,2-metallate rearrangement to occur, 
therefore the second molecule of the carbenoid is incorporated into the bicycle to give 
the intermediate 3.77. Further acetylide insertion allows for incorporation of the alkynyl 
moiety into the molecule to provide intermediate 3.79, which after protonolysis gives 
three products: 3.80a,b and 3.81 as an inseparable mixture of compounds in 10% 
combined yield and following ratio: 3.80a/b : 3.80b/a, 1.8 : 1 and 3.80 : 3.81, 1 : 2 by 
NMR. Despite considerable optimization undertaken, the reaction proved to be low 
yielding and the purification of the final product difficult due to many unidentifiable 
products.  
 
3.3. Conclusions for chapter 3 
The one-pot three component coupling on zirconocene template was probed for 
construction of bicyclo[3.3.0]- and bicyclo[4.3.0]nonanes as well as tricyclic structures. 
Various saturated zirconacycles were examined for carbenoid insertion and subsequent 
1,3-Zr rearrangement. The examined method was successful for unsubstituted 
zirconacycles and the expected carbobicycles were obtained in reasonable yields. 
However, -H elimination was the main limitation of the method and occurred 
exclusively in the case of α-substituted zirconacycles to provide the corresponding 
alkenes. The undesired dehydrozirconation process was also competitive with the 
acetylide driven 1,3-Zr rearrangement in -substituted zirconacycles. Insertion of 
dihalocarbenoid into tricyclic zirconacycle was very low yielding, and such obtained 
expanded zirconacycle was subjected to immediate -H elimination process. Lithiated 
dichloromethane performed multiple insertion into saturated zirconacycle to provide 
interesting bicyclic compounds, albeit in low yield. 
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Chapter 4. Insertion of allenyl and propargyl carbenoids into 
acyclic organozirconium bonds 
4.1. Introduction to research area 
Acyclic organochlorozirconocenes can be prepared via hydrozirconation of alkenes and 
alkynes with the Schwartz reagent 1.10 and are very useful class of transition metal 
derivatives for use in organic synthesis.192 Hydrozirconation of unsaturated organic 
molecules is very easy to perform with no need for any special glove-box techniques. 
The insertion of C,C-double and -triple bonds into Zr-H bond (hydrozirconation) occurs 
via a four-atom, concerted transition state 4.4 (Scheme 4.1) which is formally 
symmetry-allowed due to the vacant d-orbitals on Zr atom.193,194 The final outcome of 
this process is a hydrometallation product 4.3 obtained by cis-addition of zirconium and 
hydrogen across the double or triple bond. 
Cp2Zr CH2
H
CH2
4.4
Cl
R R
ZrCp2
Cl
H
R
ZrCp2Cl
H
4.1 4.2
4.3
Cp2Zr HCl
1.10
 
Scheme 4.1 Hydrozirconation of alkenes/alkynes. 
 
Organochlorozirconocenes react with electrophiles such as halogens, acid chlorides and 
aldehydes to afford the corresponding organic halides, ketones and alcohols.93,195 
Insertion of carbon monoxide affords the acylzirconocene chlorides which can be 
converted into aldehydes, carboxylic acids, esters and acyl bromides by treatment with 
dilute HCl, NaOH/H2O2, Br2/MeOH and NBS, respectively.94 Insertion of isonitriles 
into alkyl- and alkenylzirconocene chlorides and subsequent treatment of the resulting 
iminoacyl complex with dilute acid provides a reliable route of aldehyde synthesis from 
corresponding alkenes and alkynes with one-carbon homologation.196  
 
 
 92 
In spite of the substantial polarization of the zirconium-carbon bond, the organometallic 
chemistry of zirconocenes would be limited as a consequence of the steric shielding 
effect of the cyclopentadienyl ligands; therefore, much of the development of this 
chemistry has focused on indirect carbon-carbon bond forming reactions through 
transmetallation to other metals and further elaborations. This chemistry has been 
reviewed in depth by Wipf.194  
An emerging field in this chemistry is the use of zirconium complexes in asymmetric 
and diastereocontrolled transformations. Hydrozirconation can also be a fundamental 
step in multicomponent reactions allowing to access many useful organic products. 
Representative example from Floreancig’s work197 related to multicomponent synthesis 
of ‘oxidized’ amides through nitrile hydrozirconation is shown in Scheme 4.2. 
Reagents and Conditions: (i) Cp2Zr(H)Cl, CH2Cl2, RT, 10 min; (ii) 0 οC, 1.5 eq 4.7, 
10 min; (iii) 20 eq MeOH.
NC (i) (ii)
(iii)
4.5
4.6
4.7
4.9
4.8OEt
4
OEt
4NCp2Zr
Cl OEt
4N
O
Cl
O
4.10
OEt
4NH
O OMe
4.9 + 4.10, 71%, d.r. 5.7:1
OEt
4NH
O OMe
+
 
Scheme 4.2 Multicomponent approach to amide synthesis through nitrile hydrozirconation. 
 
A particulary interesting method for elaboration of organochlorozirconocenes is the 
insertion of a wide range of carbenoids. The first insertion of carbenoids into an acyclic 
C-Zr bond was reported by Negishi,134 and concerned the insertion of - and -
haloorganolithiums into acyclic organozirconocene derivates to give a good yield of the 
corresponding alkene 4.16 and allene 4.14 on acid quench ( Scheme 4.3). 
ZrCp2Cl
 ii
 ii
i.i.
Li
Br
n-Oct
H
n-Oct
n-Hex
Cp2ZrHCl
4.11
4.12
4.13
4.14, 76%
4.15
4.16, 65%
Cl
Li
n-Oct
Reagents and Conditions: (i)  THF, −78  οC; (ii) HCl.
 Scheme 4.3 First insertion of lithium carbenoids into acyclic zirconocene systems. 
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Kasatkin and Whitby have extended the existing methodology by insertion of a wide 
range of carbenoids into acyclic organozirconium species to give substituted alkenes, 
dienes, trienes and dienynes.  
 
4.1.1. Insertion of alkenyl carbenoids into organochlorozirconocenes 
Alkenyl carbenoid 4.18, created in situ by deprotonation of the corresponding vinyl 
halide 4.17, has been inserted into acyclic zirconium species 4.20 to give the ‘ate’ 
complex 4.21, which rearranges via 1,2-metallate rearrangement to afford the alkenyl 
zirconocene intermediate 4.22. Trapping this intermediate with various electrophiles 
affords a range of useful organic products 4.23 (Scheme 4.4).198,199 
R1
(i)
R1 ZrCp2Cl
4.19 4.20
R
Cl
R
Cl
Li
Li+
ZrCp2Cl
4.21
R1
ClR
R ZrCp2Cl
R1
R
R1
E
E+
4.17 4.18
4.22 4.23a-d
R = (E)-CH=CH(CH2)7CH3
R1 = n-Bu
a. E+ = H+; E = H, 82%
b. E+ = I2; E = I, 81%
c. E+ = NBS; E = Br, 73%
d. E+ = BuNC; E = CHO, 67%
(ii)
-LiCl
(iii)
Reagents and Conditions: (i) 1.2 eq Cp2ZrHCl, 20 οC, 1 h; (ii) carbenoids formed
in-situ, 0.83 eq LiTMP, −90 οC to −80 οC, 15 min; (iii) a: 2M HCl, −78 οC to RT, 0.5 h; 
b: 1.5 eq I2, −60 οC to −40 οC, 1 h; c: 1.5 eq NBS, −60 οC to −40 οC, 1 h; d: 1.3 eq
BuNC, RT, 16 h, then 50% AcOH/H2O, RT, 1 h.
 
Scheme 4.4 Elaboration of alkyl chlorozirconocenes via alkenyl carbenoid insertion. 
 
A broad range of alkenyl carbenoids have been inserted into acyclic zirconium systems 
(Scheme 4.5). Insertion of 2-monosubstituted vinyl carbenoids 4.29, 4.39 and butadiene 
derived carbenoids 4.36, 4.40 provided the corresponding dienes 4.30, enynes 4.33, 
trienes and dienynes 4.37, 4.41 with expected inversion of configuration on carbenoid 
carbon and good level of stereoselectivity. The unsubstituted carbenoid 4.44 generated 
from 1,2-dichloroethane inserted successfully into alkyl- and alkenyl-Zr bond to give 
prducts 4.45 in modest yields (Scheme 4.5).  
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Carbenoids carrying two different -substituents 4.47 also inserted successfully; 
however, poor stereocontrol was observed due to rapid isomerisation of the 
carbenoid.199  
R1
R1 Li
(i)
(ii)
R1 ZrCp2Cl
2ZrCp2ClR1
R1 = n-Bu, n-Hex, n-Oct or -(CH2)2OSiMe2t-Bu
R2 = R3 = Me, n-Hex
R4 = (E)-CHCH(CH)nCH3 or -CC(CH2)5CH3
R5 = n-Hex
H
R4
Cl
Li
R4
Cl
+ 4.20/4.25(iii)
R4
R1
R5 Cl (iii) R5 Cl +  4.20
Li
R5
R1
Cl
Cl (iv)
Cl
Cl
Li
R1
Cl (iv) Cl
Li
Cl R1
Cl
4.28
4.31
4.38
4.29
4.32
4.35
4.39
4.36
4.40
4.30
4.33
                 4.37
a. from 4.20, E:Z = 91:9, 83%
b. from 4.25, 3E,5E : 3Z,5E = 86:14, 48%
c. from 4.27, E:Z = 96:4, 64%
Reagents and Conditions: (i) 1.2 eq Cp2ZrHCl, 20 οC, 1 h; (ii) 2.0 eq Cp2ZrCl2, −20 οC,
then 0 οC, 2 h; (iii) carbenoids formed in-situ, 1.0 eq LiTMP, −90 οC to −80 οC, 15 min; 
(iv) carbenoids formed in-situ, 2.0 eq LiTMP, −90 οC to −80 oC, 15 min; (v) 2M HCl.
(v)
(v)
(v)
(v)
33 - 82%
17%
(iv)
Cl Cl
Li
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4.42
4.43 4.44
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(v)Cl Cl
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4.26 4.27
+ 4.20/4.25/4.27
4.34
+ 4.20/4.25/4.27
                   4.41
a. from 4.20, Z:E = > 5:95, 76%
b. from 4.25, 3Z,5E : 3E,5E = > 95:5, 72%
c. from 4.27, Z:E = 93:7, 72%
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Cl
Li
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(v)R3
11 -86%
R2
Cl
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R2
R3
R2
+ 4.20/4.25
+ 4.20/4.25
(iii)
Scheme 4.5 Insertion of alkenyl carbenoids into acyclic organozirconium species. 
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4.1.2. Insertion of alkyl carbenoids into organochlorozirconocenes 
Insertion of a range of lithium alkyl carbenoids was next examined (Scheme 4.6).200,201 
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A
Li
X
4.50
XHA Li ZrCp2Cl
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Reagents and Conditions: (i) 1.3 eq ACH2X, 1.3 eq LiTMP/LDA, −100  οC to −60/40  οC 
over 1 h; (ii) aq NaHCO3; (iii) 1.3 eq PhCHO, BF3·Et2O, −78 οC to RT, 18 h.
 
Scheme 4.6 Insertion of alkyl carbenoids into organochlorozirconocenes. 
 
The insertion of alkyl carbenoids 4.50 into 1-octenylzirconocene 4.49 results in 
formation of functionalized allylmetallics 4.52. Protonation of these species gives the 
two alkenes, generally with good selectivity (Scheme 4.6). The organometallic products 
4.52 can be further elaborated by reacting with electrophiles such as aldehydes. Lewis 
acid promoted insertion of aldehydes into the resulting allylmetallics 4.52 gave higher 
selectivity for the -hydroxysilane 4.54. 
 
4.1.3. Insertion of lithiated epoxynitriles into organochlorozirconocenes 
Finally, lithiated epoxynitriles 4.57 were successfully inserted into 
alkenylchlorozirconocene 4.49 through 1,2-metallate rearrangement to give 
intermediate 4.59. Elimination of zirconocene oxide in 4.60 followed by acid quench 
provides the corresponding 2-cyano-1,3-dienes 4.61 in good yield (Scheme 4.7).202 
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It is postulated that the lack of stereoselectivity of insertion of the carbenoids 4.57 is 
related to their configurational instabillity and rapid interconversion when formed under 
the reaction conditions.202 
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d.
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Reagents and Conditions: (i) 1.3 eq 4.57, THF, −90 οC to −60 οC, over 1h; (ii) 2 M HCl.
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100:0
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Scheme 4.7 Insertion of metallated epoxynitriles into 1-octenylzirconocene. 
 
4.2. Insertion of allenyl carbenoids into acyclic zirconium species 
Insertion of allenyl and propargyl carbenoids into bisalkyl/alkynyl biscyclopentadienyl 
zirconium complex led to a 1,2-zirconate rearrangement with expulsion of the 
corresponding leaving group. Trapping the resulting allenyl/propargyl Zr species with 
aldehydes gave, after hydrolysis, a series of propargylic alcohols.  
Insertion of chiral carbenoids into alkyl/alkenyl organochlorozirconocenes and further 
asymmetric 1,2-metallate rearrangement provided the final alcohols as enantiomerically 
enriched products. 
 
4.2.1. Insertion of allenyl carbenoid into acyclic bisalkyl-/alkynyl-zirconium 
species 
Insertion of an allenyl carbenoid into an acyclic bisalkyl-/alkenyl-zirconium systems is 
shown in Scheme 4.8. Treatment of zirconocene dichloride with two equivalents of 
organolithium reagent gives the corresponding acyclic organozirconocene species 4.62 
which inserts the γ-organolithium reagent 4.64 to provide the ‘ate’ complex 4.65. 
Subsequent 1,2-metallate rearrangement gives the allenyl Zr intermediate 4.66 which 
can be trapped with electrophiles such as aldehydes and ketones to give secondary and 
tertiary alcohols 4.68, respectively (Scheme 4.8). 
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LDA or LiTMP, −78 οC to −50 οC, 1 h; (iii) a. for R3 = Ph, R4 = H, 1.5 eq
PhCHO, BF3·OEt2, −60 οC to RT over 1 h, then RT, 3 h; b. for R3 = R4 = Me,
3.0 eq Me2CO, BF3·OEt2, −60 οC to RT over 1 h, then RT, 2 h, then reflux 20 h; 
(iv) MeOH, aq NaHCO3, RT, 12-16 h.
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H
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R24.63
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Scheme 4.8 Insertion of allenyl carbenoid into bisalkyl/alkynyl Zr species. 
 
The secondary alcohols 4.68a-f were obtained with modest diastereocontrol and in most 
cases poor yields (Table 4.1). The low yields for the final products can be somewhat 
related to the decreased reactivity of these carbenoids towards insertion into such sort of 
organozirconium complexes. Insertion of the allenyl carbenoid and benzaldehyde into 
the alkynyl Zr species 4.62 (R1 = CCPh) provided compound 4.68d in reasonable yield 
(62%), but worse diastereocontrol was observed in all the other examples. Insertion of 
acetone into the allenyl Zr intermediate 4.76 provided the corresponding tertiary alcohol 
4.68g only in 25% yield. This result is consistent to some extent with the observation 
regarding the low reactivity of allyl zirconocene species towards insertion of ketones.138 
Entry R1 R2 R3 R4 anti : syn Yield of 4.68/ % 
a n-Bu n-Hex Ph H 77 : 23 35 
b Me n-Hex Ph H 79 : 21 40 
c Ph n-Hex Ph H 79 : 21 35 
d PhCC n-Hex Ph H 62 : 38 62 
e Ph Me Ph H 81 : 19 39 
f Me Me Ph H 73 : 27 37 
g Me n-Hex Me Me - 25 
Table 4.1 Yields and anti : syn relationship of the secondary alcohols 4.68a-f. 
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Asymmetric synthesis of the secondary alcohols 4.68e,f was attempted by insertion of 
the chiral carbenoid 4.64 (R2 = Me, prepared by deprotonation with LDA of the 
corresponding tosylate 4.63 (R2 = Me), derived from commercially available (S)-but-3-
yn-2-ol) into acyclic organozirconium systems 4.62 (R1 = Ph, Me). Such obtained 
compounds 4.68e,f were analysed by chiral HPLC (on a Diacel OD-H column) which in 
both cases showed racemic products.  
The anti : syn relationship of the products 4.68a-f was assigned by correlation with 
literature precedent. In 1996 Harada et al. published a synthesis of a wide range of 
homopropargylic alcohols by trapping allenic zinc reagents with aldehydes (Scheme 
4.9).203 
Reagents and Conditions: (i) 1.0 eq (R3)3ZnLi, THF, −85 οC, 15 min; (ii) 3.0 eq
ZnCl2 over 15 min, −85 οC, 1 h; (iii)  1.5 eq R4CHO, −85 οC to 0 οC over 2 h; (iv) HCl.
R2
R1
X R2
R1 R3
Zn(L) R
4
OH
R2R1
R3
4.69 4.70
(i) (ii), (iii)
(iv) 4.71, 18 - 98%anti : syn, from 
56:44 to 99.7:0.3
Scheme 4.9 Harada’s synthesis of homopropargylic alcohols via allenic zinc complex. 
 
There is a very close structural similarity between compound 4.68a and compound 
4.71a synthesised in the Harada group (Table 4.2). The very good chemical correlation 
of compounds 4.68a major and minor isomers with 4.71a anti and syn isomers provided 
strong evidence for the assignment of stereochemistry of compound 4.68a. The crucial 
proton adjacent to the hydroxyl group was shifted upfield in all anti isomers reported by 
Harada, and this trend is well retained for the major isomer of compounds 4.68a-f; 
therefore, they were all assigned as the anti isomers and the minor isomers were 
identified as the syn isomers. 
Compound Ph
OH
Hn-Oct
n-Bu
4.71a anti
 
Ph
OH
Hn-Hex
n-Bu
4.68a major
 
Ph
OH
Hn-Oct
n-Bu
4.71a syn
 
Ph
OH
Hn-Hex
n-Bu
4.68a minor
 
H (CHOH) 
(ppm) 
4.47 4.49 4.69 4.71 
Multiplet dd dd dd app. t 
J (Hz) 6.8, 3.9 6.8, 4.3 5.3, 3.6 4.8 
Table 4.2 Correlation studies. 
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4.2.2. Insertion of propargyl carbenoid into acyclic bisalkylzirconium species 
Insertion of propargyl carbenoid 4.73 (Scheme 4.10), created in situ by deprotonation of 
the propargyl chloride 4.72 with LDA, into bismethylzirconocene 4.62 (R1 = Me) 
provided the ‘ate’ complex 4.74 which led to the propargylic Zr intermediate 4.75 via 
1,2-metallate rearrangement. Trapping this species with benzaldehyde in the presence of 
BF3·OEt2, gave after protonolysis the secondary alcohol in 69% yield as a 77 : 23 
mixture of anti : syn diastereoisomers.  
Cp2Zr
R1
R1
4.62
Reagents and Conditions: (i) 1.0 eq 4.72, LDA, −78 οC to −65 οC, 1.5 h; (ii) 1.5 eq PhCHO, 
BF3·OEt2, −60 οC to RT over 1 h, then RT, 3 h; (iii) MeOH, aq NaHCO3, RT, 12-16 h.
Cl
n-Bu
4.74
Li+
4.75 4.76, 69%
anti:syn =  77:23
n-Bu
Me
OH
Ph
-LiCl (ii), (iii)4.72
(i)
R1 = Me
Cl
n-Bu
4.73
Li
Cp2Zr
Me
n-Bu
Me
Cp2Zr Me
Me
Cl
n-Bu
Scheme 4.10 Insertion of propargyl carbenoid into acyclic Zr systems. 
 
Although compound 4.76 structurally resembles the alcohols 4.68a-f and has been 
obtained with comparable stereoselectivity, it has been synthesised by insertion of a 
different sort of carbenoid into an acyclic Zr system. The significantly better yield is 
thought to be related to the improved general reactivity of the propargyl carbenoid in 
comparison with the allenyl carbenoids 4.64. 
 
4.2.3. Insertion of allenyl carbenoid into organochlorozirconocenes with the 
potential for asymmetric synthesis 
Hydrozirconation with Schwartz reagent of 1-octene 4.77a or 1-octyne 4.77b provides 
the organochlorozirconocene complex 4.78 which undergoes insertion of allenyl 
carbenoid 4.64 to provide the ‘ate’ complex 4.79 (Scheme 4.11). Subsequent 1,2-
metallate rearrangement gives the allenic zirconium intermediate 4.80 which can be 
further elaborated through aldehyde and ketone insertion to provide secondary and 
tertiary alcohols respectively. 
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Cp2Zr
Cl
Li+
−LiOTs
Cp2Zr
Cl
R2
R1
O
R4
BF3·OEt2
R1
R2 OH
Cp2Zr
Cl
R2
R1
OTs
R2
(i)
(ii)
(iii) (iv)
Reagents and Conditions: (i) 1.0 eq Cp2ZrHCl, RT, 1 h; (ii) 1.0 eq 4.63, LDA or 
LiTMP, −78 οC to RT, over 1 h; (iii) a. for R3 = Ph, R4 = H, 1.5 eq PhCHO, 
BF3·OEt2, −78 οC to RT over 1 h, then RT, 2 h; b. for R3 = R4 = Me, 3.0 eq Me2CO, 
−78 οC to RT over 1 h, then reflux 20 h; c. for R3 = n-Hex, R4 = H, 3.0 eq n-HexCHO, 
−78 οC to RT over 1 h, then RT, 3 h; (iv) MeOH, aq NaHCO3, RT, 12-16 h.
4.78a, b
4.64
4.80
4.81
H
4.82
Li
OTs
R24.63
n-Hex
Cp2Zr
Cl
R1
R2TsO
4.79
H
R3 R3 R4
4.77a
n-Hex
n-Hex
4.77b
or
n-HexR1 =
 
Scheme 4.11 Allenyl carbenoid insertion into organochlorozirconocenes. 
 
Insertion of aromatic and aliphatic aldehydes 4.81 into the allenyl zirconocene complex 
4.80 provides the corresponding secondary alcohols in modest yield and stereocontrol in 
favour of the anti isomer (Table 4.3). Insertion of heptanal into 4.80 occurred with the 
highest anti stereoselectivity compared with other examples to give the products 4.82c 
as an inseparable mixture of anti : syn isomers. Surprisingly, insertion of acetone into 
the allenic Zr intermediate provided the tertiary alcohol 4.82d in good 50% yield, which 
was contaminated with 10% of unidentified and inseparable products. 
Entry R1 R2 R3 R4 anti : syn Yield of 4.82/ % 
a n-Oct Me Ph H 74 : 26 60 
b (E)-1-Oct Me Ph H 69 : 31 40 
c n-Oct n-Hex n-Hex H 89 : 11 44 
d n-Oct n-Hex Me Me - 50 
Table 4.3 Yields and anti : syn relationship of the alcohols 4.82a-d. 
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In this system the 1,2-zirconate rearrangement occurred in only 80 % yield (by GC) 
provided that the reaction mixture was warmed to RT. It is postulated that the ‘ate’ 
complex 4.79 loses the chloride anion to give the neutral Zr species 4.83 (Scheme 4.12). 
Reaction with an additional nucleophile (PhCCLi) at this stage was expected to provide 
the new ‘ate’ complex 4.84; however, subsequent protonation gave two products: the 
rearranged product 4.85 and the product of initial hydrozirconation, 4.86 in approximate 
1 : 1 ratio, showing that application of phenyl acetylide was not helpful.  
Li+
Cp2Zr
Cl
R1
R2TsO
4.79
Cp2Zr
R2TsO
4.83
R1
Li+
Cp2Zr R1
R2TsO
4.84
Ph
R2
R1
+ R1
4.85
4.86
(i) (ii)
Reagents and Conditions: (i) 1.0 eq PhCCLi, −78 οC to RT, over 1 h; 
(iv) MeOH, aq NaHCO3, RT.
−LiCl
 
Scheme 4.12 Possible explanation of incomplete 1,2-rearrangement in organochlorozirconocenes. 
 
The concept of ‘dummy ligands’ has also been applied and the intermediate 4.78a was 
treated with different nucleophiles 4.87 before insertion of allenyl carbenoid 4.63 
(Scheme 4.13). The resultant intermediate 4.88 should be still reactive towards 
carbenoid insertion and further rearrangement. However, s-BuLi and Me3SiLi 
completely inhibited the allenyl carbenoid insertion, PhCCLi afforded the desired 
intermediate 4.90 in approximately 25 % GC yield, though the reaction mixture was 
warmed to RT. Use of PhLi caused the R5 group migration to give selectively the 
intermediate 4.91, which after benzaldehyde insertion and protonolysis, provided 
product 4.68e in low yield. 
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n-Hex
ZrCp2
Cl
n-Oct
ZrCp2
Cp2Zr
R5
n-Oct
R2TsO
Cp2Zr
R5
n-Oct
R2TsO
4.89
Cp2Zr
R5
R2
n-Oct
4.90
H
Cp2Zr
n-Oct
R2
R5
4.91
H
4.78a
4.88
(ii)
(iii), (iv)
(iii), (iv)
n-Oct
Me
OH
4.83a
4.68e
Ph
Ph
Me OH
Ph
Reagents and Conditions: (i) 1.0 eq R5Li, −78 οC, 15 min; (ii) 1.0 eq 4.63, LDA or 
LiTMP, −78 οC to RT, over 1 h; (iii) 1.5 eq PhCHO, BF3·OEt2, −78 οC to RT over
1 h, then RT, 2 h; (iv) MeOH, aq NaHCO3, RT, 12-16 h.
R5
R5 Li
4.87
(i)
 
Scheme 4.13 Application of dummy ligands to organochlorozirconocenes. 
 
It remains unknown why the 1,2-metallate rearrangement is retarded for the 
organochlorozirconocene system. Competition studies of the carbenoid insertion 4.63 
(R2 = Me) into bisalkyl Zr species 4.62 (R1 = Bu) and 1-octanylzirconocene 4.78a 
species have shown that this carbenoid inserts selectively into 4.78a in 80% GC yield (+ 
octane detected) (Scheme 4.14). This observation would be consistent with the 
electronic properties of 4.78a, where the Zr atom is more electron poor (because of the 
chlorine atom present), than in 4.62. This information, however, does not explain the 
incomplete 1,2-metallate rearrangement in these systems. Another concern is related to 
the stability of the allenyl carbenoids, which decompose even at –78 οC, immediately 
after deprotonation either with LDA or LiTMP to give unidentified products. 
n-Hex
ZrCp2
Cl4.78a
Cp2Zr
R1
R1
+
4.62
Reagents and Conditions: (i) 1.0 eq 4.63, LDA, −78 οC to 0 οC, over 1 h.
Cp2Zr
Cl
n-Oct
MeTsO
4.92
Cp2Zr
Cl
Me
n-Oct
4.93
H
−LiOTs
Li+
(i)
Cp2ZrBu2 +
4.62
 
Scheme 4.14 Competition studies for allenyl carbenoid insertion. 
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Insertion of carbamate carbenoid 4.95 (Scheme 4.15), prepared by deprotonation with 
LDA of the corresponding carbamate derivative 4.94 (prepared from commercially 
available but-3-yn-2-ol, according to the known procedure204), was unsuccessful. These 
results were unexpected as it is known that lithiated carbamates readily participate in 
1,2-metallate rearrangement.205 
OCb
4.95
Li
Reagents and Conditions: (i) 1.0 eq LDA, THF, −78 οC, 15 min.
OCONi-Pr2
4.94
(i)
 
Scheme 4.15 Preparation of carbamate carbenoid. 
 
Regardless of modest yields, asymmetric synthesis of the secondary alcohols 4.82a, b 
was attempted by insertion of the chiral carbenoid 4.64 (R2 = Me, prepared by 
deprotonation with LDA of the corresponding tosylate 4.63 (R2 = Me), derived from 
commercially available (S)-but-3-yn-2-ol) into organochlorozirconocenes 4.7a, b. 
It could be assumed that the 1,2-metallate rearrangement in intermediate 4.79 will cause 
the elimination of the tosyl group completely in an anti fashion, therefore the chiral 
information from the carbenoid would not be lost and the allenic Zr complex 4.80 
would be a chiral intermediate. Subsequent aldehyde insertion would provide the 
secondary alcohols as chiral products. Analysis by chiral HPLC (on a Diacel OD-H 
column) revealed that the compound 4.82a was obtained in 71% e.e. It was suspected 
that the transfer of chiral information may be affected by the presence of the Lewis acid 
in the reaction mixture, thus the reaction for 4.82b was carried out without using 
BF3·OEt2 in the final step. Analysis by chiral HPLC showed that the compound 4.82b 
was obtained with diminished, 62% e.e. These results imply, that the loss of chiral 
information occurs during the formation of the allenic Zr complex 4.80 (syn elimination 
of the tosyl group may occur partially); however, the loss of chiral information during 
aldehyde insertion into complex 4.80 cannot be ruled out. Nonetheless, insertion of 
allenyl carbenoids derived from chiral precursors 4.63 into organochlorozirconocenes 
4.7a, b showed potential for asymmetric synthesis. 
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4.3. Conclusion for chapter 4 
Allenyl and propargyl carbenoid have been inserted into acyclic zirconium systems. 
Trapping of the corresponding allenic and propargylic Zr intermediates with aldehydes 
and ketones gave after protonolysis secondary and tertiary alcohols respectively, mostly 
in modest yields and low level of diastereocontrol. The insertion of chiral allenyl 
carbenoid into organochlorozirconocenes showed promise for asymmetric synthesis of 
homopropargylic alcohols. More optimization studies in terms of yield and asymmetric 
course of the reaction are required to introduce the three component coupling of acyclic 
zirconocenes, carbenoid and aldehydes/ketones as a synthetically useful method. 
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Chapter 5. Towards the total synthesis of mucosin 
5.1. Introduction to research area 
5.1.1. Mucosin: a new bicyclic eicosanoid 
Isolation of the natural product mucosin from the marine sponge Reniera mucosa, 
which is native to the Mediterranean has been reported in 1997 by Casapullo et al. 
(Figure 5.1).206 
OH
O
H
H
H
H 5.1
 
Figure 5.1 Reported structure of mucosin. 
 
The natural product contains an unsaturated indene type skeleton with four contiguous 
stereocenters, a cis-6,5 ring junction and two side chains, one of which is carrying 
double bond and carboxyl functionality. The C-20, eicosanoid character of this 
molecule suggests its biosynthesis from arachidonic acid via an intramolecular 
cyclisation pathway. For characterisation purposes, the extracted carboxylic acid was 
converted to its methyl ester with diazomethane. The structure of the methyl ester was 
determined by its mass, infrared and high field NMR spectroscopy and the 
stereochemistry was assigned by means of various 2D NMR experiments. The 
compound was also optically active. 
Although the biological activity of mucosin is unknown, the unusual 
bicyclo[4.3.0]nonene core and carboxylic acid side chain containing a trans double 
bond  make the structure attractive to both total synthesis and testing for biological 
activity. The synthesis of mucosin has already been attempted by Owen207 within the 
Whitby group. 
 
5.1.2. Literature precedent and Owen’s approach to mucosin 
Due to the four chiral centres present in the bicycle core of mucosin, stereocontrolled 
synthesis of the desired diastereoisomer would appear difficult, however, Taber and 
Louey208 reported a reliable precedent for a zirconocene-mediated route to synthesise 
the natural product (Scheme 5.1). 
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OBn OBn
ZrCp2
OBn
OH
OHCp2Zr(1-butene)
i. O2
ii. H+
5.2 5.3 5.4
 
Scheme 5.1 Stereocontrolled co-cyclisation of diene 5.2. 
 
The zirconocene mediated co-cyclisation of diene 5.2 followed by oxygen quench122,209 
provided diol 5.4 as a 3 : 1 mixture of diastereoisomers, epimeric at the secondary 
alcohol centre. Thus, complete diastereoselectivity of the ring junction formed during 
cyclisation has been achieved through the presence of the methoxybenzyl substituent 
present in the cyclopentane ring. The anti relationship between the CH2OBn group and 
the newly created hydroxymethyl group can be considered to be analogous to the anti 
relationship between the cyclohexene bridge and carboxylic acid bearing side chain in 
the natural product. The retrosynthetic strategy for the first total synthesis of mucosin 
proposed by Owen is shown in Scheme 5.2. 
OH
O
H
H
H
H
1,4-attack of allyl Zr H
H
ZrCp2
allyl carbenoid 
insertion H
H
ZrCp2 Zr mediated co-cyclisation
Cl
Li
RO
OR
5.1 5.7
5.6 5.5
1.76
 
Scheme 5.2 Owen’s retrosynthetic analysis of mucosin. 
 
Zirconocene(1-butene) mediated co-cyclisation of triene 5.5 provides the zirconacycle 
5.6 which undergoes allyl carbenoid insertion to give the corresponding allyl 
zirconocene complex 5.7. 1,4-Attack of the resulting allyl zirconocene onto an acrolein 
acetal would provide the bicyclic molecule precursors with all carbon atoms in the 
bicycle and the desired stereochemistry and trans geometry of the double bond in 
carboxylic acid side chain. Further strightforward transformations would provide the 
desired product. 
 107 
The precedent for selective insertion of an allyl carbenoid into less hindered C-Zr bond 
in saturated zirconacycles was reported by Gordon et al.132 Therefore the desired allyl 
zirconocene 5.7 would be obtained selectively, and the remaining three carbons carrying 
carboxylic acid functionality would be incorporated into the molecule via a 1,4-attack of 
the resulting allyl zirconocene onto an appropriate Michael acceptor. This area of 
organozirconium chemistry was explored by Luker,139 and the corresponding example is 
shown in Scheme 5.3. 
ZrCp2
H
3.1
H
OEtH
3.4c, 64%
H
H
5.8, 14%
H
OEt
+
OEt
OEt
BF3·OEt2
1,2-attack product 1,4-attack product
Scheme 5.3 1,4-Attack by an allyl zirconocene onto acrolein acetal. 
 
This strategy would provide an excellent method not only for bicyclic core construction 
but also for elaboration of the carboxylic acid side chain in a one-pot tandem reaction 
sequence on zirconocene, starting from the triene 5.5. Further simple transformations 
would provide the desired target. 
The crucial starting material, 5.5a was initially prepared by Owen in a multistep 
reaction sequence as a 77 : 23 mixture of Z : E isomers.207 Co-cyclisation of this 
precursor with Negishi reagent did not provide a single diastereomer but a mixture of 
three products, the major constituting 60%, as shown by 13C NMR and GC analysis 
(Scheme 5.4). 
5.5
a. Z:E, 77:23 
b. Z:E, 91:9
c. Z:E, 73:27
Me
Negishi reagent
5.9
a
b c
d
 
Scheme 5.4 Owen’s cyclisation of triene 5.5. 
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To investigate the stereoselectivity, each of the mixtures of the double bond isomers of 
precursor 5.5, b and c were cyclised separately by Owen. As a result, the same product 
mixture was seen in each case, with three components dominating and roughly in the 
same GC ratio. Owen postulated that the probable reason for the mixture of products 5.9 
is a lack of diastereoselectivity. The anti relationship between the newly created chiral 
centres ‘c’ and ‘d’ (Scheme 5.4) is very likely, as is the propensity for the chiral centre 
‘b’ to induce complete control in ‘c’ in an anti fashion. The net result is a syn 
relationship between centres ‘b’ and ‘d’, and this would be in agreement with Taber’s 
observations.208 Co-cyclisation precursor 5.5, however, contains an additional chiral 
centre ‘a’, and it is very likely that this centre will induce an anti relationship between 
itself and centre ‘d’, therefore contradicting the effects of centre ‘b’. A reasonable proof 
for this hypothesis could be a 1,3-stereoinduction observed in his synthesis of 
cyclopentanol 5.11 via zirconocene-mediated co-cyclisation – -elimination process 
(Scheme 5.5).210  
HO
Ph
OEt HO
Ph
5.10 5.11, 44%, 75% d.e.
(i) Cp2Zr(butene)
(ii) MeOH
 
Scheme 5.5 1,3-Stereoinduction observed by Owen. 
 
The other factors which could affect the stereoselectivity in the co-cyclisation step and 
proposed by Owen are the additional double bond present in the cyclohexene ring and 
the propyl substituent on the double bond. To test this hypothesis Owen prepared the 
appropriate analogues 5.12 and 5.14 of triene 5.5, which were next subjected to the 
zirconocene mediated co-cyclisation (Scheme 5.6).207 
Me
5.13
5.15, 65%
(i) Cp2Zr(butene)
(ii) MeOH
(i) Cp2Zr(butene)
(ii) O2(iii) H2SO4 / Na2SO4
OH
OH
5.16, 46%
O
O
OCOp-PhPh
5.12
5.14
H
H
H
H
NEt3, p-PhC6H4COCl,
DMAP, DCM
H
H
H
H
 
Scheme 5.6 Zirconocene mediated co-cyclisation of precursors 5.12 and 5.14. 
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The co-cyclisation of diene 5.12 again provided a mixture of products 5.13 in combined 
yield 65%, whereas co-cylisation of 5.14 followed by oxygen quench of the C-Zr bonds 
provided the corresponding diol 5.15, as a single diasteroisomer in 65% yield after 
column chromatography. However gas chromatography of the crude reaction mixture of 
5.15 showed the major component making up 80% of the mixture and two minor 
products. The improved diastereoselectivity observed for the triene 5.14 suggests that 
the presence of a propyl chain on the doble bond is detrimental. The bis(p-
phenylbenzoyl)ester of diol 5.15, compound 5.16 proved the correct stereochemistry 
(Scheme 5.6).207 
 
5.1.3. Studies towards the carboxylic acid side chain of mucosin 
Owen also carried out thorough studies on elaboration of the carboxylic acid chain of 
the natural product ( Scheme 5.7).207 
O
O ZrCp2
O
O
OMe
5.17
5.18, 71%
OMe
OMe
BF3OEt2, then
MeOH
2.36a
2.36b
OEt
2.36c
O
O
2.36d
OEt
OEt
OEt
OEt
Br
O
O
5.19, 64%
S
S
O
O
5.20, 56%
SS
OTBDMS O
O
5.21, 47%
OH
S+ S
BF4−
i. n-BuLi
ii. ICH2CH2OTBDMS
i. TBAF, THF
ii. Raney-Ni, EtOH
 Scheme 5.7 Owen’s studies towards the carboxylic acid side chain of mucosin. 
 
Relying on the discovery achieved within the Whitby group and relating to the selective 
insertion of allyl carbenoid into zirconacycles132 and further elaboration of the resulting 
zirconocene 3-complex via addition of different electrophiles,139 Owen prepared the 
model -allyl zirconocene system 5.17 and treated it with various Michael acceptors.  
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Owen repeated Luker’s experiment, in which the allyl zirconocene attacks acrolein 
diethyl acetal, first using the dimethyl acetal 2.36a ( Scheme 5.7). However, the results 
indicated almost exclusively 1,2-attack product 5.18 and very small amount (<5%) of 
the desired 1,4-attack product. In order to induce the required 1,4-attack, three other 
acrolein acetals 2.36b, c and d were prepared by Owen.207 It was hoped that the 
additional steric encumbrance present in these Michael acceptors would induce the 
desired 1,4-attack of allyl Zr complex 5.17. Unfortunately, the extra hindrance proved 
too great, and none of the three acetals reacted with the allyl zirconocene. 
Owen, in his studies on the synthesis of the carboxylic acid side chain, used an 
alternative route, initially inspired by Luker’s work. Trapping of the intermediate 5.17 
with dithienium tetrafluoroborate provided the compound 5.19 in respectable yield and 
the chain was further elongated to obtain product 5.20. De-silylation with TBAF was 
followed by removal of the dithiane with Raney-Ni, which also resulted in clean 
reduction of the double bond, providing alcohol 5.21 in moderate yield. 
Although the synthesis was not completed, Owen had laid down groundwork for the 
second approach to the first total synthesis of mucosin. 
 
5.2. Revised approach to the total synthesis of mucosin 
5.2.1. Revised retrosynthetic analysis of mucosin 
The revised retrosynthetic analysis of mucosin is shown in Scheme 5.8. 
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Scheme 5.8 Modified approach to the synthesis of mucosin. 
 
This approach is very similar to that proposed by Owen; however, in this method the 
allyl zirconocene complex 5.7 is trapped with monomeric formaldehyde to give after 
protonolysis the desired homoallylic alcohol 5.22. Subsequent homologation of the 
chain using malonate chemistry should provide the desired natural product. 
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5.2.2. Preparation of the crucial co–cyclisation precursor 
The cheap and commercially available reagent, tetrahydrophthalic acid anhydride 5.23 
was reduced with sodium borohydride in DMF to the lactone 5.24 in good yield (62% 
on 1.0 mol scale) in a convenient one-pot procedure211 (Scheme 5.9). The lactone was 
converted into the alcohol 5.26 by following the two-step literature precedent.212 Partial 
reduction of the lactone 5.24 with DIBAL-H provided the corresponding lactol 5.25, 
which underwent a Wittig methylation to give the desired alcohol 5.26. The yield of the 
alcohol over these two steps was 74% on 100 mmol scale (86% for each step). The one-
pot procedure213 was also followed in which DIBAL-H is added to the lactone 5.24 to 
form the aluminium salt of the lactol, and the resulting reaction mixture is added to a 
solution of methylene phosphorane. Refluxing the whole mixture for 16 h gave the 
desired alcohol 5.26 in modest 30% yield, on 30 mmol scale. Therefore the two-step 
procedure was applied on a scale-up process. The synthesis continues with one carbon 
homologation of alcohol 5.26. 
Quantitative conversion of the alcohol to its mesylate 5.27, followed by cyanide 
displacement provided nitrile 5.28 in 86%. DIBAL-H reduction of the resultant nitrile 
followed by imine hydrolysis gave aldehyde 5.29 in 86% yield, which was further 
treated with the corresponding Wittig reagent to provide the co-cyclisation substrate 5.5 
as a 4 : 1 mixture of Z : E isomers and 94% yield for the last step (Scheme 5.9). Such 
prepared triene 5.5 had already estabilished stereochemistry at two out of the four 
stereocentres present in the bicycle core of the natural product. Spectral data of all the 
intermediates and the triene 5.5 were consistent with those presented in the cited 
literature or reported by Owen.207 
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OH
OMs CN O5.285.27
5.255.245.23
5.29
Reagents and Conditions: (i) NaBH4, DMF, 0 οC to RT, then 1.0 M H2SO4, 62%;
(ii) DIBAL-H (fast addition), PhMe, −78 οC, 1 h, then 3.0 M HCl, 86%; (iii)
MePh3P+Br−, n-BuLi, THF, 0 οC to RT, 2 h, then 1.0 M HCl, 86%; (iv) MsCl,
Et3N, DMAP, THF, 0 οC, 2 h, 100%; (v) KCN, NaI, 18-crown-6, 90 οC, 66 h, 86%;
(vi) DIBAL-H (dropwise addition), THF, −78 οC to RT, 2 h, then MeOH, aq NaHCO3, 
86%; (vii) BuPh3P+Br−, n-BuLi, THF, 0 οC to RT, 2 h, then 1.0 M HCl, 94%.
(i) (ii) (iii)
(v) (vi) (vii)
5.5
OH5.26
(iv)
Scheme 5.9 Preparation of the co-cyclisation precursor 5.5. 
 
5.2.3. Studies on zirconocene(1-butene) mediated co-cyclisation of triene 5.5 
Screening of different Zr reagents for co-cyclisation of the triene 5.5 revealed that the 
best reagent for this purpose still remains Negishi reagent i and Cp2ZrDMAP2 iii 
(Scheme 5.10). Using the DMAP method214,215 cyclisation of the starting material 
occurred faster in comparison with Cp2ZrBu2. In the latter case, the Z isomer of the 
precursor was co-cyclised in the first instance (after about 1 h upon stirring at RT) to 
give presumably the zirconacycle 5.6a, which is a kinetic product of cyclisation.  
The zirconacycle 5.6a was then observed to be converting into another product, thought 
to be the needed 5.6b, and the E isomer started to undergo the initial co-cyclisation. 
Subsequent heating of the reaction mixture at 60 °C for 0.5 h forced the co-cyclisation 
of the E isomer to completion and at that time gas chromatography showed four 
products to be created in the following ratio 58.5 : 22.5 : 14 : 5%. Also trace amounts of 
by-products were discernible by GC and further heating of the reaction mixture for 
several hours led to decomposition. 
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Scheme 5.10 Zirconocene mediated co-cyclisation of triene 5.5. 
 
Both zirconacycles were prepared separately under kinetic and thermodynamic 
conditions and were further elaborated through allyl carbenoid and benzaldehyde 
insertion to obtain the corresponding alcohols 5.30a, b (Scheme 5.11). 
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H
H
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H
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Reagents and Conditions: (i) 1.2 eq CH2CHCl; LiTMP, −78 οC to −60 οC over 
20 min; (ii) 3.0 eq PhCHO, BF3·OEt2, −60 οC to −5 οC over 4 h; (iii) MeOH,
aq NaHCO3, RT, 12-16 h.
(i) (ii), (iii) 5.30a
5.30b
 
Scheme 5.11 Elaboration of zirconacycles 5.6a, b via allyl carbenoid and benzaldehyde insertion. 
 
Alcohols 5.30 contained all the crucial carbons of the bicycle core and the double bond 
of one of the side chains, and therefore were appropriate for correlation with the 
reported spectral data of the natural product (Table 5.1). 
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Thermodynamic 
product Mucosin Kinetic product 
C (ppm) 
C Experimental data 
major/minor d.r.  
Literature 
data 
of 
mucosin 
 
Experimental data 
major/minor d.r. 
4 42.76 11.06 31.7 11.09 42.79 
5 133.62 3.82 129.8 4.03/3.99 133.83/133.79 
6 127.04 2.94 130.0 3.74/3.77 126.26/126.23 
7 36.49/36.55 0.19/0.25 36.3 1.26 37.56 
8 52.06/52.09 0.04/0.01 52.1 1.28/1.23 50.82/50.87 
9 47.03/47.08 0.07/0.02 47.1 3.1/3.07 44.00/44.03 
14 40.03 0.13 39.9 2.91/2.88 36.99 /37.02 
16 42.21/42.25 0.11/0.15 42.1 1.88/1.93 40.22/40.17 
Table 5.1 Comparison of 13C signals of 5.30a, b with the reported spectral data of mucosin. 
 
Comparison of the shifts of the crucial carbons in both products 5.30a, b with the 
natural product led to the conclusion that the thermodynamic product 5.30b had the 
same relative stereochemistry as the natural product. Strong evidence for this hypothesis 
is the excellent agreement of the carbon signals between the thermodynamic product 
5.30b and mucosin 5.1, whereas product 5.30a showed significant inconsistency with 
the natural product (Table 5.1). Additional support was provided by DFT relative 
energy calculations,216 which indicated the zirconacycle 5.6a to be less stable (≈ 4 
kJ/mol) than zirconacycle 5.6b. Therefore the thermal equilibration of the zirconacycles 
for mucosin synthesis gives the desired zirconacycle as the main product, though only 
in 60% yield. 
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5.2.4. Studies towards synthesis of the carboxylic acid side chain of mucosin 
Following encouraging results from the zirconocene-mediated co-cyclisation of triene 
5.5, the synthesis of the carboxylic acid side chain was addressed. 
Initial ideas for elaboration of the carboxylic acid side chain of mucosin through 
insertion of various carbenoids into zirconacycle were conceived (Scheme 5.12). All 
those experiments were carried out using the model zirconacycle 3.8c. 
Insertion of allyl carbenoid 1.76 into the model zirconacycle 3.8c occurred 
quantitatively to give the 3-Zr complex 5.31 (Scheme 5.12). Efforts were undertaken to 
trap the allyl zirconocene with monomeric formaldehyde (prepared according to the 
procedure reported by Schlosser et al.217), MOM or BOM chloride to obtain the alcohol 
or its Me or Bn ethers 5.32a, b, c, respectively. Unfortunately, all three attempts failed. 
According to the known procedure,218 allenyl carbenoids such as 4.64 insert into 
zirconacycles to give intermediate 5.33, which after aldehyde quench, provides 
secondary alcohols. In the probed example, the insertion of the carbenoid occurred in 
only 75% yield by GC (although 2 equivalents of the carbenoid were used) and upon 
basic quench, a 2 : 1 mixture of compounds 5.34a, b was obtained. The incomplete 
insertion of the carbenoid and difficulty to avoid the allene product makes this route less 
viable.  
The insertion of metallated epoxides 5.35 into zirconacycles202 was explored next and it 
appeared that the insertion of the carbenoid 5.35 occurs in only 30% by gas 
chromatography. Unfortunately, all the examples reported in the literature do not 
include α-substituted saturated zirconacycles as it is in the example below (Scheme 
5.12). The results presented in chapter 3 relating to the carbenoid insertion in α-
substituted saturated zirconacycles suggest, that substituents adjacent to the Zr atom 
may inhibit insertion of different types of carbenoids into such zirconacycles. Insertion 
of non-stabilized metallated epoxides 5.38 into zirconacyle 3.8c failed. 
According to Norton’s work,146,219 insertion of lithiated trans-1,2-dichloroethylene 5.39 
into saturated zirconacycle should proceed via expulsion of the terminal chlorine in the 
intermediate 5.40 to give the terminal alkyne 5.41 (Scheme 5.12). In this case, the 
insertion did not occur at all indicating, that the ethyl substituent indeed has a big effect 
on reactivity of the zirconacycle.  
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Scheme 5.12 Studies towards synthesis of the carboxylic acid side chain of mucosin. 
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Insertion of conjugated vinyl carbenoid 4.36 into zirconacycle133 3.8c occurred in 75% 
(estimated by GC) to give upon acidic quench the compounds 5.43 as a mixture of E 
and Z isomers. Some loss of the stereo information must have happened during either 
deprotonation or the insertion step, as the 1,4-dichloro-trans-2-butene is contaminated 
with its cis isomer up to 10%, and the final compounds were obtained as a 3.7:1 mixture 
of E and Z isomers. If conjugated diene 5.43 had been formed cleanly and in high yield, 
it could have been elaborated via selective hydrometallation of the terminal double 
bond. A more elegant approach entails insertion of the sulfone carbenoid 5.44. 
According to the work published by Dixon et al.,133 the reaction should yield the desired 
one-carbon homologation product with incorporated sulfone group in good yield. The 
homologated product would be an ideal substrate for Julia-Kocieski220,221 olefination 
as the crucial step in the construction of the trans double bond present in the side chain 
of mucosin. In this example insertion of the sulfone carbenoid occurs at temperatures 
above 0 °C and is immediately followed by -H elimination from the ethyl substituent 
at the stage of the intermediate 5.45 to give the alkene products 5.46 in modest 45% 
yield, as a 3.8 : 1 mixture of E : Z isomers (Scheme 5.12). 
Further attempts at selective functionalization of the unsubstituted C-Zr bond in 
zirconacycles 3.8c or 3.71 are given in Scheme 5.13. Activation of the zirconacycle 3.8c 
by addition of 1.1 eq of n-BuLi led to halogen-metal exchange with ICH2Cl or CBr4, 
either directly via the 18-electron Zr complex 5.47a, or via the lithium species 5.47b,133 
to give the corresponding iodide 5.48 or bromides 5.50 and 5.51. Such method for ring 
opening of zirconacyclopentanes with alkyllithium reagents is known in the literature.150 
As the ClCH2¯  anion is not the best leaving group, the desired iodide 5.48 was created 
in 66% GC yield only, and the protonated cyclised starting material 5.49 was also 
recovered (approximately 34% by GC). Choosing carbon tetrabromide as a source of 
halogen, the desired products 5.50 and 5.51 were obtained with 100% GC conversion 
and after column chromatography in 76% and 70% yield respectively. Following this 
idea, efforts were made to halogenate the allyl Zr species 5.52 to obtain the 
corresponding compound containing the allyl bromide motif 5.53. The intermediate 
5.52 which in practice is an 3-Zr complex does seem to be very unreactive and even 
addition of n-BuLi does not force this species to perform nucleophilic attack on CBr4. 
As a net result, the protonated zirconacycle 5.52 was obtained after quenching (Scheme 
5.13). 
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Scheme 5.13 Attempts to functionalise the unsubstituted C-Zr bond in saturated zirconacycles. 
 
It was hoped that treatment of the zirconacycle 3.71 with m-CPBA under various 
conditions might result in oxidation of the C-Zr bond. Unfortunately, none of these 
reactions worked. Addition of orthoacetate to the activated Zr complex 5.47 resulted in 
incorporation of the electrophile into the molecule in good GC yield; however, the dq at 
5.364 ppm (J = 13.0, 6.5 Hz) in the 1H NMR spectra of the crude material strongly 
correlate to the vinylic proton in the -H elimination product 5.55 (Scheme 5.13). 
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5.3. Future work towards mucosin 
An idea for successful elaboration of the carboxylic acid side chain came at the end of 
the project and concerns the insertion of the carbenoid 5.57 (Scheme 5.14). 
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Scheme 5.14 Suggested elaboration of the carboxylic acid side chain of mucosin. 
 
It is known from the previous work that α-alkoxy carbenoids are thermally unstable and 
insert into zirconacycles in poor yields but their silyl analogues insert usually 
selectively into C-Zr bond in good yields.133 The use of the alkyl carbenoid 5.57 
generated from the cheap and commercially available reagent, (chloromethyl)(methoxy) 
-dimethylsilane 5.56 could provide after quenching the product 5.58 which after Tamao 
oxidation222 and further separation of the resulting diastereoisomers would give the 
desired alcohol 5.59. Alcohols 5.59 could be oxidized to give the corresponding 
aldehyde, which in turn would be the substrate for a trans selective Julia-Kocieski 
olefination.220,221 Subsequent modifications could provide the desired natural product. 
Unfortunately, due to time constraints, this idea was not pursued. 
 
5.4. Conclusions for chapter 5 
The synthesis of the natural product mucosin has been attempted. Extensive studies 
have been done on the zirconocene-mediated co-cyclisation of the appropriate triene as 
well as elaboration of the carboxylic acid side chain. This research revealed the Zr-
based total synthesis of mucosin to be significantly limited. Nevertheless, the correct 
stereochemistry of the major product of zirconocene mediated co-cyclisation and the 
latest idea for elaboration of the carboxylic acid side chain seem to be viable and are 
encouraging for further work on the first synthesis of mucosin. 
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Chapter 6. Experimental 
6.1. General experimental 
All reactions involving air or moisture sensitive compounds were carried out under an 
argon atmosphere using standard Schlenk equipment and syringe techniques. All 
glassware was dried in a hot oven (>140 ºC, for at least 12 hours) and cooled in a sealed 
desiccator over silica gel or assembled while hot and cooled under vacuum.  
Reactions were monitored by GC and/or TLC using Merck silica gel 60 F254 plates with 
detection by UV and/or polyphosphomolybdic acid and/or potassium permanganate 
stains. Silica gel 60A (particle size 35-70 microns) supplied by Fisher Scientific was 
used for flash chromatography columns and Merck silica gel 60 (0.040-0.063 mm) or 
basic alumina Brockman I deactivated with 6% of H2O, were used for purification of 
final compounds or acid sensitive products respectively. Columns were packed and run 
under light pressure. Solvent compositions are described as ratios prior to mixing.  
 
Unless otherwise stated, reagents were obtained from commercial suppliers and if 
necessary dried and distilled before use. Solvents for air or moisture sensitive reactions 
were prepared in the following ways. THF and diethyl ether were freshly distilled from 
sodium benzophenone ketal under argon. DCM and MeCN were freshly distilled over 
CaH2 under argon. HMPA was distilled over CaH2 and stored in stock bottles under 
argon. n-Butyllithium was used as a 2.5 M solution in hexanes (Aldrich), stored in stock 
bottles under argon. Lithium diisopropylamide was used as a 1.8 M solution in 
THF/heptane/ethylbenzene (Aldrich), stored in stock bottles under argon. DIBAL-H 
was used as a 1.0 M solution in toluene, stored in stock bottles under argon. Lithium 
2,2,6,6-tetramethylpiperidide was prepared from 2,2,6,6-tetramethylpiperidine (freshly 
distilled, or distilled and stored over 4Å sieves under argon) in THF by addition of 1 
equivalent of n-BuLi at 0 ºC and stirring for 20 minutes. 
 
NMR spectra were recorded on Bruker AV300, AM300 or DPX400 spectrometers. The 
chemical shifts, , were recorded as values in ppm referenced to chloroform residual 
peaks at 7.27 ppm for 1H spectra and 77.00 ppm (centre peak of triplet) for 13C spectra 
and benzene 7.16 ppm for 1H spectra and 128.39 ppm (centre peak of triplet) for 13C 
spectra. The following abbreviations were used to denote multiplicity and may be 
compounded: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, 
 121 
fs = fine splitting. Coupling constants, J, are measured in Hertz (Hz). 13C NMR spectra 
were proton decoupled and are reported as C, CH, CH2, CH3, depending on the number 
of directly attached protons. DEPT, COSY and 1H-13C correlation experiments were 
used to aid assignment of spectra. The lettered assignment for proton and carbon signal 
is for identification purposes only and does not represent the systematic IUPAC 
numbering. Proton chemical shifts, , are reported with three decimal places with the 
exception for compounds in experimental section for chapter 4 (whose chemical shifts, 
, are reported with two decimal places). Carbon-13 chemical shifts, , are reported with 
two decimal places in all cases. 
 
Electron impact ionisation mass spectra (EI) were recorded on a ThermoQuest TraceMS 
GCMS. Electrospray mass spectra (ESI) were recorded using a VG platform quadrupole 
spectrometer. All electrospray were (ESI+) unless otherwise stated. Values of m/z are 
reported in atomic mass units and the peak intensity relative to the base peak is reported 
in parenthesis. Only the most abundant isotope is reported for compounds containing 
chlorine. Accurate mass spectra were recorded on a VG analytical 70-250-SE double 
focusing mass spectrometer using electron impact ionisation (EI) at 70 eV or a Bruker 
Apex III using electrospray ionisation.  
 
Infra-red spectra were run as neat films on a Thermo Mattson FTIR Golden Gate 
spectrometer and a Thermo Nicolet 380 FT-IR spectrometer with a Smart 
Orbit Goldengate attachment. Absorptions are given in wavenumbers (cm–1) and the 
following abbreviations used to denote peak intensities: s = strong, m = medium, w = 
weak, br = broad. 
 
Gas chromatography was performed on a Hewlett Packard HP 6890 series GC system, 
using a HP-5 (cross-linked 5% PH ME siloxane) 30 m column, with a film thickness of 
0.25 m and 0.32 mm internal diameter. The carrier gas was helium and the flow rate 
was 2.7 mL min-1.  
 
The X-ray structure of 2.70-endo was determined by the EPSRC National 
Crystallography Service at the University of Southampton, Department of Chemistry.  
Melting points were recorded on a Reichert 349 360 melting point apparatus and are 
uncorrected. 
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The following compounds were prepared by literature methods (or found in the 
laboratory chemicals collection) and had spectral properties consistent with those 
published or included in the thesis of former group members. These include: 
• (hept-6-en-1-ynyl)trimethylsilane 1.83b,96 
• 1-ethynyl-3-methoxybenzene 2.31,153,154,223 
• 1,1-dibromoalkanes 2.33a, b, c,155,224 
• 1- (hept-6-en-1-ynyl)benzene 2.35a,225  
• undec-1-en-6-yne 2.35b,166  
• tridec-1-en-6-yne 2.35c,226 
• 1,1-diethoxy-3-iodopropane 2.37,156, 157 
• 7-phenylhept-1-en-6-yn-4-ol 2.47,227 
• 2-((oxiran-2-yl)methoxy)-tetrahydro-2H-pyran 2.44,160 
• 1-( tetrahydro-2H-pyran-2-yloxy)pent-4-en-2-ol 2.45,161 
• pent-4-ene-1,2-diol 2.46,163 
• 7-phenylhept-1-en-6-yn-4-ol 2.47,164,165,227 
• 1-phenylhept-6-en-1-yn-3-ol 2.51,228 
• (1-phenylhept-6-en-1-yn-3-yloxy)(tert-butyl)dimethylsilane 2.52,228 
• 10-(tert-butyldimethylsiloxy)-l-decen-6-yn 2.54,166 
• N-allyl-N-benzylamine 2.59,167 
• 1-(oct-7-en-1-ynyl)benzene 2.74,229 
• 4,4-bis(methoxymethyl)-2-methyldec-1-en-6-yne 2.84,141 
• (2S,3aR)-2-hexyl-2,3,3a,4,5,6-hexahydro-1-phenylpentalen-2-ol 2.106,83 
• 4,4-bis(methoxymethyl)hepta-1,6-diene 3.23,230 
• (Z)-4,4-bis(methoxymethyl)nona-1,6-diene 3.24,132 
• N-allyl-N-benzyl-2-methylprop-2-en-1-amine 3.25,132 
• 1-allyl-2-vinylbenzene 3.36,231 
• N-allyl-N-benzylprop-2-en-1-amine 3.40a,232 
• N,N-diallylbenzenamine 3.40b,233 
• 1-((E)-4,4-bis(methoxymethyl)hepta-1,6-dienyl)benzene 3.43,132 
• N-allyl-N-benzyl-2-phenylprop-2-en-1-amine 3.50,234 
• 1,2-diallylbenzene 3.61,235 
• 3-(1-methoxy-2- (methoxymethyl)pent-4-en-2-yl)cyclohex-1-ene 3.68,132 
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6.2. Experimental from chapter 2 
 
6.2.1. (7-Phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane (2.41) 
Procedure: A 1 L Schlenk flask was charged with NaI (36.0 g, 0.24 mol) and dry 
MeCN (0.40 L) was added. After stirring for 0.5 h at RT the reaction mixture was 
cooled to –5 οC and addition of freshly distilled acrolein (12.6 mL, 0.20 mol), Me3SiCl 
(30.5 mL, 0.24 mol) and dry EtOH (24.5 mL, 0.42 mol) followed. After stirring for 15 
min at the same temperature, the reaction mixture was warmed to RT and the stirring 
was continued for 2 h before pouring the whole reaction mixture onto 5% aqueous 
NaHCO3 solution (0.40 L). The products were extracted with pentane (3 × 0.20 L). The 
organic phases were washed with 5% aqueous Na2S2O3 solution (0.30 L) and brine (3 × 
0.20 L). Drying over K2CO3 and concentration in vacuo gave the crude material as a 
yellow oil which was immediately purified by flash column chromatography on Al2O3 
(basic, grade III) with 10% Et2O in pentane to provide the desired material (24.30 g, 
47%). The pure iodide was immediately reacted in the next step. To a stirred solution of 
1-ethynylbenzene (16.5 mL, 0.15 mol) in dry THF (0.30 L) at –78 οC was added 
dropwise n-BuLi (60.0 mL of a 2.5 M solution in hexanes, 0.15 mol). The reaction 
mixture was allowed to warm to –50 οC within 0.5 h. HMPA (26.0 mL, 0.15 mol) was 
added dropwise followed by dropwise addition of solution of the iodide (24.30 g, 0.094 
mol) in dry THF (0.10 L). The reaction mixture was stirred under an Ar atmosphere for 
13 h during which time it was allowed to warm to RT. The reaction was stopped by 
addition of saturated aqueous NH4Cl solution (0.10 L) and the whole mixture was 
poured onto H2O (0.30 L). The products were extracted with Et2O (3 × 0.20 L) and the 
combined organic phases were washed with H2O (3 × 0.20 L) and brine (2 × 0.20 L), 
dried over K2CO3, filtered and concentrated in vacuo to give the crude material as a 
yellow oil which was immediately purified by flash chromatography column on Al2O3 
(basic, grade III) with 5% Et2O in hexanes as the eluent to give the pure material as a 
colourless liquid (17.7 g, 81%).  
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.382 – 7.357 (2H, m, Ho-Ph), 7.260 – 7.242 
(3H, m, Hm-Ph + p-Ph), 4.664 (1H, t, J = 5.7 Hz, H3), 3.673 (2H, dq, J = 9.3, 7.0 Hz, H2), 
3.528 (2H, dq, J = 9.5, 7.0 Hz, H2), 2.476 (2H, t, J = 7.3 Hz, H5), 1.897 (2H, td, J = 7.2, 
5.7 Hz, H4), 1.212 (6H, t, J = 7.0 Hz, H1). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 131.47 (2CHo-Ph), 128.12 (2CHm-Ph), 127.51 
(CHp-Ph), 123.88 (Ci-Ph), 101.81 (CH3), 89.32 (C6/7), 80.76 (C6/7), 61.54 (2CH22), 32.77 
(CH24), 15.30 (2CH31), 15.01 (CH25). 
HRMS (EI): Found: [M]+, 232.1465. [C15H20O2]+ requires: 232.1463. 
LRMS (EI): m/z: 232 ([M]+, 1%), 231 ([M – H]+, 3%), 186 ([M – EtOH]+, 67%), 157 
([M – EtOH – Et]+, 100%), 127 (91%). 
IR (thin film): ν~ = 2975 (m), 2926 (m), 2869 (m), 1599 (w), 1489 (m), 1448 (m), 1368 
(m), 1123 (s), 1058 (s), 760 (s), 688 (s) cm–1. 
 
Such obtained acetal (17.67 g, 0.076 mol) was dissolved in THF : H2O (4 : 1, 0.50 L) 
and after stirring at RT for 5 min, a 2 M solution of HCl (0.114 L, 0.228 mol) was 
slowly added and the stirring was continued for 3 h. The reaction mixture was poured 
onto saturated aqueous NaHCO3 solution (0.20 L) and the products extracted with Et2O 
(3 × 0.20 L), the combined organic phases were washed with H2O (3 × 0.20 L) and 
brine (0.30 L), dried over MgSO4, filtered and concentrated in vacuo to give the crude 
material (12.02 g, 100%) as a pale yellow oil which was immediately reacted in the next 
step without any purification. 
O
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1H NMR (300 MHz, CDCl3):  (ppm) = 9.837 (1H, s), 7.379 – 7.241 (5H, m), 2.768 – 
2.703 (4H, m). 
 
To a stirred solution of the crude aldehyde (12.02 g, 0.076 mol) in dry THF (0.40 L) at 
–78 οC was added dropwise vinylmagnesium bromide (0.114 L of a 1.0 M solution in 
THF, 0.114 mol). The reaction mixture was stirred for a further 5 h during which time it 
was allowed to warm to RT before quenching with saturated aqueous NH4Cl solution 
(0.10 L). The whole mixture was poured onto H2O (0.20 L) and the products extracted 
with  Et2O (3 × 0.20 L) and the combined organic phases were washed with H2O (3 × 
0.15 L) and brine (0.20 L), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude material as a yellow oil. Purification by flash chromatography column on 
silica with EtOAc : hexane (1 : 3) as the eluent gave 7-phenylhept-1-en-6-yn-3-ol 2.40 
as a pale yellow oil (9.21 g, 65%).  
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.431 – 7.381 (2H, m, Ho-Ph), 7.321 – 7.261 
(3H, m, Hm-Ph + p-Ph), 5.925 (1H, ddd, J = 17.1, 10.3, 6.0 Hz, H2), 5.315 (1H, dt, J = 17.3, 
1.4 Hz, H1t), 5.172 (1H, dt, J = 10.5, 1.3 Hz, H1c), 4.353 (1H, m, H3), 2.582 (1H, dt, J = 
17.0, 7.5 Hz, H5), 2.522 (1H, dt, J = 17.0, 6.8 Hz, H5), 1.871 – 1.812 (3H, m, 2H4 + 
OH). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 140.45 (CH2), 131.52 (2CHo-Ph), 128.19 
(2CHm-Ph), 127.65 (CHp-Ph), 123.73 (Ci-Ph), 115.09 (CH21), 89.37 (C6/7), 81.16 (C6/7), 
72.01 (CH3), 35.61 (CH24), 15.64 (CH25). 
HRMS (EI): Found: [M]+, 186.1044. [C13H14O]+ requires: 186.1045. 
LRMS (EI): m/z: 186 ([M]+, 22%), 185 ([M – H]+, 46%), 167 ([M – H2O + H]+, 77%), 
152 (47%), 128 (69%), 115 (100%). 
IR (thin film): ν~ = 3338 (m, br), 2941 (w), 2915 (w), 1599 (w), 1489 (m), 1433 (m), 
1047 (m), 987 (m), 926 (m), 748 (s), 688 (s) cm–1. 
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To a stirred solution of imidazole (1.904 g, 28.00 mmol) and DMAP (1.709 g, 14.00 
mmol) in dry THF (60.0 mL) at RT was added dropwise TBDMSOTf (3.20 mL, 14.00 
mmol). After stirring for 10 min, a solution of the allylic alcohol (1.303 g, 7.00 mmol) 
in dry THF (10 mL) was added and the stirring continued for 18 h at the same 
temperature before quenching with H2O (20 mL). The whole mixture was poured onto 
H2O (100 mL) and the products extracted with Et2O (3 × 100 mL). The combined 
organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude material as a yellow oil. 
Purification by flash chromatography column on silica with 5% Et2O in hexanes as the 
eluent provided the title compound as a yellow oil (2.079 g, 99%).  
OSi
1
3 2
5
4
76
810
9
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.423 – 7.399 (2H, m, Ho-Ph), 7.326 – 7.258 
(3H, m, Hm-Ph + p-Ph), 5.850 (1H, ddd, J = 17.1, 10.5, 6.0 Hz, H2), 5.228 (1H, dt, J = 17.1, 
1.5 Hz, H1t), 5.092 (1H, dt, J = 10.5, 1.7 Hz, H1c), 4.330 (1H, apparent q, J = 6.0 Hz, 
H3), 2.522 (1H, dt, J = 16.8, 7.5 Hz, H5), 2.458 (1H, dt, J = 16.8, 6.5 Hz, H5), 1.823 – 
1.764 (2 H, m, H4), 0.944 (9H, s, H10), 0.129 (3H, s, H8), 0.085 (3H, s, H8). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.16 (CH2), 131.50 (2CHo-Ph), 128.18 
(2CHm-Ph), 127.50 (CHp-Ph), 124.04 (Ci-Ph), 114.20 (CH21), 89.98 (C6/7), 80.83 (C6/7), 
72.39 (CH3), 36.88 (CH24), 25.89 (3CH310), 18.24 (C9), 15.36 (CH25), –4.34 (CH38), –
4.86 (CH38). 
HRMS (EI): Found: [M]+, 300.1908. [C19H28OSi]+ requires: 300.1909. 
LRMS (EI): m/z: 300 ([M]+, 1%), 299 ([M – H]+, 2%), 243 ([M – C(CH3)3]+, 87%), 
225 (15%), 189 (46%), 115 (71%), 75 (100%). 
IR (thin film): ν~ = 2953 (m), 2911 (m), 2854 (m), 1467 (w), 1357 (w), 1247 (m), 1066 
(m), 979 (m), 922 (m), 839 (s), 779 (s), 756 (s), 692 (s) cm–1. 
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6.2.2. (R)-(7-Phenylhept-1-en-6-yn-3-yloxy)(tert-butyl)dimethylsilane ((R)-2.41) 
A solution of the racemic alcohol 2.40 (0.372 g, 2.00 mmol) in vinyl crotonate (0.91 
mL) was placed in Schlenk tube and an immobilized Candida antartica lipase 
(Novozyme 435) was added (0.091 g). The reaction was incubated at 42 °C (without 
stirring) for 72 h. After this time the reaction mixture was filtered through sintered 
funnel and the resins were washed with dry Et2O. The filtrate was concentrated in vacuo 
to give the crude products as a yellow oil. Purification by column chromatography on 
SiO2 with hexane : ethyl acetate (4 : 1) as the eluent gave (R)-7-phenylhept-1-en-6-yn-
3-ol (R)-2.40 as a pale yellow oil (0.179 g, 96%, 90% e.e.) and (E)-(S)-7-phenylhept-1-
en-6-yn-3-ylbut-2-enoate 2.42 as a yellow oil (0.229 g, 90%). 
To a stirred solution of the alcohol (R)-2.40 (0.179 g, 0.96 mmol) in dry DCM (12.0 
mL) was added dropwise Et3N (0.39 mL, 2.82 mmol) at 0 °C. The stirring was 
continued at the same temperature for 5 min before dropwise addition of TBDMSOTf 
(0.33 mL, 1.41 mmol). After stirring for 10 min at 0 °C the ice bath was removed and 
the stirring continued for 30 min at RT before quenching with H2O (20 mL). The whole 
mixture was poured onto H2O (100 mL) and the products extracted with DCM (2 × 75 
mL). The combined organic phases were washed with H2O (2 × 100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to give the crude material as 
a yellow oil. Purification by flash chromatography column on Al2O3 (basic, grade III) 
with hexane as the eluent provided the title compound as a pale yellow oil (0.193 g, 
67%) whose spectral data was consistent with those obtained for racemic product. 
 
6.2.3. (1-Phenylhept-6-en-1-yn-4-yloxy)(tert-butyl)dimethylsilane (2.48) 
To a stirred solution of pent-4-ene-1,2-diol 2.46 (2.05 g, 20.0 mmol) in dry THF (100 
mL) at –10 °C was added sequentially NaH ( 2.40 g of a 60 % dispersion in mineral oil, 
60.0 mmol). After 15 min N-tosyl imidazole (2.45 g, 20.0 mmol) (prepared in 62% 
yield by the known procedure)236 was added and the reaction mixture continued to stir 
at –10 °C for 1 h. Freshly prepared lithium phenyl acetylide was added and the reaction 
mixture was allowed to warm to 0 °C. [Lithium phenyl acetylide was freshly prepared 
from phenylacetylene (4.40 mL, 40.0 mmol) in dry THF (50 mL) and n-BuLi (16.0 mL 
of a 2.5 M solution in hexanes, 40.0 mmol) at –10 °C for 30 min]. Subsequently, HMPA 
(14.0 mL, 40.0 mmol) was added dropwise to the reaction mixture and the stirring was 
continued at 0 °C for 1 h. After this time, the cooling bath was removed and the reaction 
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mixture was left at RT for 40 h. The reaction mixture was poured onto saturated 
aqueous NaHCO3 solution (200 mL), and the products extracted with Et2O (2 × 200 
mL). The combined organic phases were washed with H2O (2 × 200 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product, 7-phenylhept-1-
en-6-yn-4-ol 2.47 as a brown oil that was further purified by column chromatography 
on SiO2 (for flash chromatography) with hexane : ethyl acetate (3 : 1) as the eluent to 
yield the title compound as a yellow oil (1.045 g, 28%). The spectral properties of 2.47 
were consistent with those published.227  
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1H NMR (300 MHz, CDCl3):  (ppm) = 7.316 – 7.257 (2H, m, Ho-Ph), 7.182 – 7.127 
(3H, m, Hm-Ph + p-Ph), 5.744 (1H, ddt, J = 17.2, 10.2, 7.1 Hz, H2), 5.068 (1H, ddt, J = 
17.2, 2.0, 1.5 Hz, H1t), 5.024 (1H, ddt, J = 10.2, 2.1, 1.1 Hz, H1c), 3.778 (1H, tt, J = 7.1, 
5.7 Hz, H4), 2.538 (1H, dd, J = 16.8, 5.7 Hz, H5), 2.462 (1H, dd, J = 16.8, 6.5 Hz, H-5), 
2.383 – 2.171 (2H, m, H3), 1.965 (1H, br s, OH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 134.14 (CH2), 131.66 (2CHo-Ph), 128.26 (2CH 
m-Ph), 127.94 (CHp-Ph), 123.39 (Ci-Ph), 118.38 (CH21), 85.92 (C6/7), 83.13 (C6/7), 69.38 
(CH4), 40.77 (CH23), 27.63 (CH25). 
LRMS (EI): m/z: 186 ([M]+·, 3%), 168 ([M – H2O]+·, 21%), 115 (100%), 91 (12%), 89 
(33 %), 77 (13%). 
IR (thin film): ν~ = 3380 (m, br), 2930 (w), 1637 (w), 1599 (w), 1486 (m), 1436 (w), 
1349 (w), 1066 (m), 756 (s), 696 (s) cm–1. 
 
To a stirred solution of imidazole (2.250 g, 33.08 mmol) and DMAP (2.020 g, 16.54 
mmol) in dry THF (100 mL) at RT was added dropwise TBDMSOTf (3.78 mL, 16.54 
mmol). After stirring for 10 min, a solution of the alcohol 2.47 (1.54 g, 8.27 mmol) in 
dry THF (50 mL) was added and the stirring continued for 15 h at the same temperature 
before quenching with H2O (20 mL). The mixture was poured onto H2O (150 mL) and 
the products extracted with  Et2O (2 × 150 mL), the combined organic phases washed 
with H2O (2 × 100 mL) and brine (2 × 100 mL), dried over MgSO4, filtered and and 
concentrated in vacuo to give the crude material as a yellow oil.  
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Purification by flash chromatography column on silica with 3% Et2O in hexanes 
provided pure title compound 2.48 as a pale yellow oil (2.034 g, 82%).  
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.447 – 7.388 (2H, m, Ho-Ph), 7.338 – 7.258 
(3H, m, Hm-Ph + p-Ph), 5.887 (1H, ddt, J = 17.1, 10.3, 6.0 Hz, H2), 5.174 – 5.086 (2H, m, 
H1), 3.971 (1H, quintet, J = 5.9 Hz, H4), 2.562 (2H, d, J = 6.2 Hz, H5), 2.515 – 2.294 
(2H, m, H3), 0.931 (9H, s, H10), 0.134 (3H, s, H8), 0.115 (3H, s, H8). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 134.61 (CH2), 131.53 (2CHo-Ph), 128.17 
(2CHm-Ph), 127.59 (CHp-Ph), 123.93 (Ci-Ph), 117.44 (CH21), 87.48 (C6/7), 82.09 (C6/7), 
71.03 (CH4), 41.52 (CH23), 27.89 (CH25), 25.84 (3CH310), 18.12 (C9), –4.49 (CH38), –
4.58 (CH38). 
HRMS (EI): Found: [M]+, 300.1898. [C19H28OSi]+ requires: 300.1909. 
LRMS (EI): m/z: 300 ([M]+, 1%), 285 ([M – CH3]+, 3%), 259 (17%), 243 ([M – 
(CH3)3]+, 83%), 225 (26%), 115 (67%), 75 (100%). 
IR (thin film): ν~ = 2945 (m), 2922 (m), 2854 (m), 1489 (w), 1357 (w), 1247 (m), 1058 
(s), 832 (s), 775(s), 756 (s), 684 (s) cm–1. 
 
6.2.4. N-Methyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine (2.57) 
N
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1-Ethynylbenzene (0.33 mL, 3.0 mmol), N-allyl-N-methylamine (0.235 g, 3.3 mmol), 
formaldehyde (1.2 mL of a 35% aqueous solution) and CuI (0.012 g, 0.063 mmol) were 
dissolved in DMSO (6 mL). The reaction mixture was stirred at 30 οC for 15 h before 
quenching with saturated aqueous solution of NH4Cl (50 mL). The products extracted 
with Et2O (3 × 25 mL). The combined organic phases were washed with H2O (3 × 50 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude material which was purified by flash chromatography on silica with 25% Et2O 
in hexanes to give the title compound as a yellow oil (0.23 g, 41%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.463 – 7.430 (2H, m, Ho-Ph), 7.325 – 7.290 
(3H, m, Hm-Ph + p-Ph), 5.896 (1H, ddt, J = 17.0, 10.3, 6.6 Hz, H2), 5.266 (1H, dq, J = 17.1, 
1.5 Hz, H1t), 5.186 (1H, ddt, J = 10.1, 1.9, 1.0 Hz, H1c), 3.554 (2H, s, H5), 3.146 (2H, dt, 
J = 6.8, 1.1 Hz, H3), 2.392 (3H, s, H4). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 135.42 (CH2), 131.69 (2CHo-Ph), 128.22 
(2CHm-Ph), 127.97 (CHp-Ph), 123.28 (Ci-Ph), 118.01 (CH21), 85.34 (C6/7), 84.47 (C6/7), 
59.18 (CH23), 45.98 (CH25), 41.71 (CH34). 
HRMS (ESI+): Found: [M + H]+, 186.1276. [C13H16N]+ requires: 186.1277. 
LRMS (ESI+): m/z: 186 ([M + H]+, 100%). 
IR (thin film): ν~ = 3070 (w), 2933 (w), 2786 (w), 1641 (w), 1599 (w), 1493 (m), 1436 
(m), 1331 (m), 1123 (m), 1002 (m), 926 (m), 748 (s), 692 (s) cm–1. 
 
6.2.5. N-Benzyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine (2.60) 
N
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Benzyl bromide (19.99 g, 117 mmol) was added dropwise to neat allylamine (52.7 mL, 
702 mmol) at 0 °C. After 16 h at room temperature, the reaction was quenched with 
aqueous NaHCO3 solution (200 mL), extracted with Et2O (3 × 100 mL), and dried over 
K2CO3. Purification by flash chromatography on silica with 30  50% Et2O in hexanes 
gave N-allyl-N-benzylamine 2.59 (13.45 g, 78%) as a yellow oil whose spectral data 
was consistent with those published.167 1-Ethynylbenzene (1.10 mL, 10 mmol), N-allyl-
N-benzylamine (1.77 g, 12.0 mmol), formaldehyde (4 mL of a 35% aqueous solution) 
and CuI (0.040 g, 0.21 mmol) were dissolved in DMSO (20 mL). The reaction mixture 
was stirred at 30 °C for 15 h before quenching with a saturated aqueous solution of 
NH4Cl (200 mL). The products extracted with Et2O (3 × 150 mL), the combined 
organic phases were washed with H2O (3 × 150 mL) and brine (200 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude material which was 
purified by flash chromatography on silica with 25% Et2O in hexanes to give the title 
compound as a yellow oil (2.34 g, 89%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.502 – 7.259 (10H, m, HAr), 5.948 (1H, ddt, J 
= 17.0, 10.3, 6.4 Hz, H2), 5.328 (1H, dq, J = 17.2, 1.6 Hz, H1t), 5.212 (1H, ddt, J = 10.1, 
1.9, 1.0 Hz, H1c), 3.738 (2H, s, H4/5), 3.550 (2H, s, H4/5), 3.276 (2H, dt, J = 6.4, 1.3 Hz, 
H3). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 138.71 (Ci-Ph), 135.70 (CH2), 131.74 
(2CHAr), 129.19 (2CHAr), 128.28 (2CHAr), 128.26 (2CHAr), 127.97 (CHp-Ph), 127.11 
(CHp-Ph), 123.41 (Ci-Ph), 117.94 (CH21), 85.66 (C6/7), 84.46 (C6/7), 57.44 (CH23/4), 56.84 
(CH23/4), 42.18 (CH25). 
HRMS (ESI+): Found: [M + H]+, 262.1586. [C19H20N]+ requires: 262.1590. 
LRMS (ESI+): m/z: 262 ([M + H]+, 100%). 
IR (thin film): ν~ = 3024 (w), 2922 (w), 2816 (w), 1644 (w), 1599 (w), 1489 (m), 1315 
(m), 1119 (m), 922 (m), 756 (s), 733 (s), 688 (s) cm–1. 
 
6.2.6. Preparation of compounds 2.20 and 2.63a-aa 
General procedure A: To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 
mL) cooled to –78 °C was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 
mmol) dropwise (usually over 2 minutes). After 25 min, a solution of the appropriate 
enyne (1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and continued to stir for 2 – 
3 h. After re-cooling the reaction mixture to –78 °C, a solution of the appropriate 1,1-
dihalo alkane (1.1 mmol) in dry THF (1 mL) was added followed by dropwise addition 
of LDA (0.64 mL of a 1.8 M solution, 1.15 mmol) or freshly prepared LiTMP, [LiTMP 
prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 mmol) in 
dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C 
over 20 min]. The reaction mixture was stirred at –78 °C for 15 min before dropwise 
addition of the corresponding lithium acetylide, [prepared from alkyne (3.0 mmol) in 
dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for 0.5 – 1 h during which the reaction mixture 
was allowed to warm to –55 °C before addition of MeOH (10 mL) and saturated 
aqueous solution of NaHCO3 (10 mL). The mixture was allowed to warm to room 
temperature and left stirring for 12 – 16 h. The mixture was poured onto H2O (100 mL), 
the products extracted with Et2O (3 × 75 mL). The combined organic phases were 
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washed with H2O (3 × 100 mL) and brine (100 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to give the crude products mostly as yellow oils.  
 
Stability tests 
The following compounds: 2.63a, 2.69-exo, 2.69-endo, 2.72-exo and 2.72-endo were 
stable after being kept in CDCl3 (in NMR tube) at RT in the presence of daylight for 2 
weeks. The compounds also turned out to be stable after being exposed to 1.0 
equivalent of (+)-camphorsulfonic acid in CDCl3 (in NMR tube) at RT in the presence 
of daylight for 1 week. 2.63a was also resistant to 2.0 equivalents of (+)-
camphorsulfonic acid in CDCl3 for 2 weeks regardless of warming the NMR tube to 50 
°C for the last two days. 
 
6.2.6.1. rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-propyl-
bicyclo[3.3.0]oct-2-ene (2.20) 
H Hb
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General procedure A was used with dec-1-en-6-yne, 1,1-dibromopentane and 1-tert-
butyl-4-ethynylbenzene as components except that LiTMP was used instead of LDA. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.242 
g (66%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.237 (2H, m, Ho-Ph), 7.129 (2H, m, Hm-Ph), 
5.114 (1H, d, J = 1.8 Hz, H13), 4.986 (1H, d, J = 1.8 Hz, H13), 2.354 (1H, tt, J = 8.9, 2.1 
Hz, H5), 2.278 (1H, dd, J = 15.7, 8.9 Hz, H4b), 2.082 (2H, t, J = 7.3 Hz, H14/17), 1.966 
(2H, t, J = 8.4 Hz, H14/17), 1.835 – 1.700 (4H, m), 1.586 – 1.273 (9H, m), 1.324 (9H, s, 
H9), 0.931 (3H, t, J = 7.2 Hz, H16/20), 0.923 (3H, t, J = 7.3 Hz, H16/20). 
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13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.93 (C12), 149.00 (C11), 141.49 (Ci-Ph/2/3), 
138.96 (Ci-Ph/2/3), 137.42 (Ci-Ph/2/3), 127.45 (2CHo-Ph), 124.16 (2CHm-Ph), 112.79 (CH213), 
70.37 (C1), 43.96 (CH5), 43.92 (CH24), 36.60 (CH2), 36.09 (CH2), 34.33 (C10), 31.39 
(3CH39), 30.05 (CH2), 29.02 (CH214/17), 28.92 (CH214/17), 25.32 (CH2), 23.73 (CH2), 
22.91 (CH2), 15.09 (CH316/20), 14.11 (CH316/20). 
HRMS (EI): Found: [M]+, 364.3128. C27H40 requires: 364.3130. 
LRMS (EI): m/z: 364 ([M]+, 56 %), 335 ([M – Et]+, 11 %), 307 ([M – p-t-Bu]+, 55 %), 
205 ([M – p- t-Bu-Styrene]+, 100 %). 
IR (thin film): ν~ = 2949 (s), 2862 (s), 1610 (w), 1504 (w), 1467 (m), 1365 (w), 1266 
(w), 1119 (w), 1017 (w), 900 (s), 847 (s), 733 (s), 601 (w) cm–1. 
 
6.2.6.2. rac-(1R,5R)-3-Hexyl-2-phenyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63a) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.318 g (86%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.350 – 7.235 (10H, m, HAr), 5.038 (1H, d, J = 
1.6 Hz, H10), 5.022 (1H, d, J = 1.6 Hz, H10), 2.433 (1H, tdd, J = 8.6, 3.2, 1.4 Hz, H5), 
2.342 (1H, ddd, J = 16.2, 8.4, 1.0 Hz, H4b),  2.148 – 1.968 (3H, m), 1.854 (1H, dtd, J = 
12.2, 9.7, 6.8 Hz), 1.706 – 1.661 (2H, m), 1.622 – 1.521 (3H, m), 1.429 – 1.206 (8H, 
m), 0.881 (3H, t, J = 6.8 Hz, H16). 
13C NMR (75 MHz, CDCl3):  (ppm) = 155.39 (C9), 144.40 (Ci-Ph), 142.48 (Ci-Ph), 
138.95 (C2 or 3), 137.98 (C2 or 3), 129.69 (2CHo-Ph or m-Ph), 127.93 (2CHo-Ph or m-Ph), 127.55 
(2CHm-Ph or o-Ph), 127.52 (2CHm-Ph or o-Ph), 126.47 (CHp-Ph), 126.33 (CHp-Ph), 114.45 
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(CH210), 70.16  (C1), 45.71 (CH5), 43.83 (CH2), 36.33 (CH2), 35.64 (CH2), 31.70 (CH2), 
29.89 (CH2), 29.41 (CH2), 27.87 (CH2), 25.60 (CH2), 22.60 (CH2), 14.06 (CH316). 
HRMS (EI): Found: [M]+, 370.2655. C26H34 requires: 370.2661. 
LRMS (EI): m/z: 370 ([M]+·, 100%), 299 ([M – C5H11]+·, 35%), 267 ([M – Styrene]+·, 
85%). 
IR (thin film): ν~ = 2926 (m), 2851 (m), 1632 (w), 1596 (w), 1491 (m), 1439 (w), 902 
(m), 768 (m), 703 (s) cm–1. 
 
6.2.6.3. rac-(1R,5R)-3-Hexyl-1-(3-methoxyphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]-
oct-2-ene (2.63b) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-3-methoxybenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with 2.5 % Et2O in hexane as the 
eluent gave the title compound as a pale yellow oil in yield of 0.312 g (78%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.355 – 7.251 (5H, m, HAr), 7.199 (1H, t, J = 
8.0 Hz, H13), 6.957 (1H, ddd, J = 8.0, 1.5, 1.0 Hz, H14), 6.916 (1H, dd, J = 2.5, 1.5 Hz, 
H9), 6.833 (1H, ddd, J = 8.0, 2.5, 1.0 Hz, H12), 5.081 (1H, d, J = 1.8 Hz, H16), 5.017 
(1H, d, J = 1.8 Hz, H16), 3.793 (3H, s, H11), 2.508 – 2.414 (2H, m, H5 + 4b), 2.104 (1H, 
dt, J = 21.5, 8.0 Hz, H17), 2.051 (1H, dt, J = 21.5, 8.0 Hz, H17), 2.046 (1H, d, J = 15.3 
Hz, H4a), 1.870 (1H, tdd, J = 11.8, 10.0, 6.5 Hz,  H6), 1.716 – 1.501 (4H, m), 1.444 – 
1.367 (3H, m), 1.332 – 1.240  (6H, m), 0.901 (3H, t, J = 7.0 Hz, H22). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.90 (C10), 155.23 (C15), 145.88 (C2 or 3), 
142.43 (C2 or 3), 139.14 (Ci-Ph), 137.94 (Ci-Ph), 129.72 (2CHm-Ph), 128.45 (CH13), 127.54 
(2CHo-Ph), 126.33 (CHp-Ph), 120.48 (CH14), 114.59 (CH216), 113.68 (CH9), 111.90 
(CH12), 70.13 (C1), 55.10 (CH311), 45.74 (CH5), 43.96 (CH24), 36.38 (CH26), 35.82 
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(CH28), 31.71 (CH2), 29.91 (CH217), 29.41 (CH2), 27.96 (CH2), 25.55 (CH27), 22.58 
(CH2), 14.07 (CH322). 
HRMS (EI): Found: [M]+, 400.2763. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 400 ([M]+, 100%), 267 ([M – m-MeO – Styrene]+, 24%). 
IR (thin film): ν~ = 2934 (m), 2848 (m), 1574 (m), 1455 (m), 1283 (m), 1040 (m), 889 
(m), 764 (m), 700 (s) cm–1. 
 
6.2.6.4. rac-(1R,5R)-3-Hexyl-1-(4-methoxyphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]-
oct-2-ene (2.63c) 
H Hb
Ha
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-methoxybenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.290 g (72%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.343 – 7.241 (7H, m, HAr), 6.838 – 6.801 
(2H, m, H11), 5.018 (1H, d, J = 1.8 Hz, H13), 4.994 (1H, d, J = 1.8 Hz, H13), 3.827 (3H, 
s, H9), 2.430 (1H, td, J = 8.5, 2.4 Hz, H5), 2.375  (1H, dd, J = 16.0, 8.5 Hz, H4b), 2.077 
(1H, dt, J = 21.3, 8.0 Hz, H14), 2.058 (1H, dt, J = 21.3, 7.5 Hz, H14), 2.012 (1H, d, J = 
16.0 Hz, H4a), 1.856 (1H, tdd, J = 12.0, 9.5, 7.0 Hz,  H6), 1.737 – 1.668 (2H, m, H8), 
1.623 – 1.484 (2H, m, H7), 1.423 – 1.341 (3H, m), 1.323 – 1.204 (6H, m), 0.892 (3H, t, 
J = 7.0 Hz, H19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.33 (C10), 154.81 (C12), 142.39 (C2 or 3), 
138.98 (C2 or 3), 137.96 (Ci-Ph), 136.91 (Ci-Ph), 129.64 (2CHo- or m-Ph), 128.91 (2CHo- or m-
Ph), 127.52 (2CHo- or m-Ph), 126.29 (CHp-Ph), 113.98 (CH213), 112.89 (2CH11), 70.23 (C1), 
55.16 (CH39), 45.64 (CH5), 43.90 (CH24), 36.36 (CH26), 35.62 (CH28), 31.71 (CH2), 
29.88 (CH214), 29.41 (CH2), 27.87 (CH2), 25.59 (CH27), 22.60 (CH2), 14.07 (CH319). 
 136 
HRMS (EI): Found: [M]+, 400.2768. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 401 ([M + H]+, 100%), 267 ([M – p-MeO – Styrene]+, 55%). 
IR (thin film): ν~ = 2930 (m), 2854 (m), 1607 (m), 1508 (s), 1244 (s), 1176 (m), 1036 
(m), 903 (w), 832 (s), 767 (m), 699 (s) cm–1. 
 
6.2.6.5. rac-(1R,5R)-3-Hexyl-1-(4-methylphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]oct-
2-ene (2.63d) 
H Hb
Ha
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-methylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexane as the eluent gave the 
title compound as a pale yellow oil in yield of 0.237 g (62%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.344 – 7.234 (7H, m, HAr), 7.099 – 7.080 
(2H, m, H9), 5.035 (1H, d, J = 1.8 Hz, H13), 4.998 (1H, d, J = 1.8 Hz, H13), 2.470 – 
2.346 (2H, m, H5 + 4b), 2.370 (3H, s, H9), 2.096 (1H, dt, J = 21.5, 7.8 Hz, H14), 2.061 
(1H, dt, J = 21.5, 7.5 Hz, H14), 2.016 (1H, d, J = 14.8 Hz, H4a), 1.855 (1H, tdd, J = 12.0, 
9.8, 6.8 Hz, H6), 1.701 – 1.667 (2H, m), 1.601 – 1.535 (2H, m), 1.431 – 1.356 (3H, m), 
1.325 – 1.229 (6H, m), 0.897 (3H, t, J = 7.0 Hz, H19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.21 (C12), 142.33 (C2 or 3), 141.53 (C2 or 
3), 139.09 (Ci-Ph or 10), 137.99  (Ci-Ph or 10), 136.01 (Ci-Ph or 10), 129.71 (2CHo- or m-Ph), 
128.24 (2CHo- or m-Ph), 127.76 (2CHo- or m-Ph), 127.51 (2CHo- or m-Ph), 126.28 (CHp-Ph), 
114.24 (CH213), 70.19 (C1), 45.67 (CH5), 43.91 (CH24), 36.36 (CH26), 35.70 (CH28), 
31.72 (CH2), 29.88 (CH214), 29.40 (CH2), 27.88 (CH2), 25.58 (CH27), 22.60 (CH2), 
21.08 (CH311), 14.07 (CH319). 
HRMS (EI): Found: [M]+, 384.2820. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 384 ([M]+, 100%), 267 ([M – p-Me – Styrene]+, 33%). 
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IR (thin film): ν~ = 2929 (m), 2848 (m), 1596 (w), 1493 (w), 1445 (w), 894 (m), 824 
(m), 759 (m), 694 (s) cm–1. 
 
6.2.6.6. rac-(1R,5R)-1-(4-Ethylphenyl)vinyl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-
ene (2.63e) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethyl-4-ethynylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a pale yellow oil in yield of 0.280 g (70%). 
 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.440 – 7.047 (9H, m, HAr), 5.164 
(1H, d, J = 1.8 Hz, H13), 5.094 (1H, d, J = 1.8 Hz, H13), 2.592 (1H, tdd, J = 8.3, 4.3, 1.5 
Hz, H5), 2.511 (1H, dd, J = 16.3, 8.3 Hz, H4b), 2.500 (2H, q, J = 7.5 Hz, H10), 2.154 – 
2.115 (2H, m, H14), 1.987 (1H, d, J = 16.3 Hz, H4a), 1.881 – 1.730 (3H, m), 1.688 – 
1.530 (2H, m), 1.426 – 1.348 (3H, m), 1.287 – 1.158 (6H, m), 1.131 (3H, t, J = 7.7 Hz, 
H9), 0.863 (3H, t, J = 7.2 Hz, H19). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 156.22 (C12), 143.09 (C2 or 3), 
142.81 (C11), 142.64 (C2 or 3), 140.32 (Ci-Ph), 138.79 (Ci-Ph), 130.51 (2CHo- or m-Ph), 
128.71 (2CHo- or m-Ph), 128.46 (2CHo- or m-Ph), 127.87 (2CHo- or m-Ph), 127.26 (CHp-Ph), 
114.96 (CH210), 71.14 (C1), 46.50 (CH5), 44.68 (CH24), 37.13 (CH2), 36.54 (CH2), 32.41 
(CH2), 30.64 (CH2), 30.15 (CH2), 29.24 (CH2), 28.67 (CH2), 26.39 (CH2), 23.36 (CH2), 
16.22 (CH39), 14.66 (CH319). 
HRMS (EI): Found: [M]+, 398.2974. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]+, 100%), 267 ([M – p-Et – Styrene]+, 45%). 
IR (thin film): ν~ = 2933 (s), 2850 (m), 1493 (w), 1452 (w), 902 (m), 835 (s), 760 (m), 
695 (s) cm–1. 
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6.2.6.7. rac-(1R,5R)-1-(4-Butylphenyl)vinyl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-
ene (2.63f) 
H Hb
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-butyl-4-ethynylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.333 g (78%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.370 – 7.265 (7H, m, HAr), 7.125 – 7.099 
(2H, m, H14), 5.066 (1H, d, J = 1.8 Hz, H16), 5.025 (1H, d, J = 1.8 Hz, H16), 2.650 (2H, 
t, J = 7.6 Hz, H12), 2.466 (1H, td, J = 8.8, 2.8 Hz, H5), 2.399 (1H, dd, J = 16.0, 8.8 Hz, 
H4b), 2.118 (1H, dt, J = 21.0, 7.5 Hz, H17), 2.087 (1H, dt, J = 21.0, 7.3 Hz, H17), 2.027 
(1H, d, J = 16.0 Hz, H4a), 1.880 (1H, tdd, J = 12.3, 9.3, 6.8 Hz, H6), 1.730 – 1.506 (6H, 
m), 1.469 – 1.368  (5H, m), 1.349 – 1.256 (6H, m), 0.991 (3H, t, J = 7.3 Hz, H9 or 22), 
0.920 (3H, t, J = 7.0 Hz, H9 or 22). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.29 (C15), 142.34 (C2 or 3), 141.64 (C13), 
141.05 (C2 or 3), 139.06 (Ci-Ph), 138.02 (Ci-Ph), 129.71 (2CHo- or m-Ph), 127.74 (2CHo- or m-
Ph), 127.51 (4CHo- or m-Ph), 126.27 (CHp-Ph), 114.12  (CH210), 70.19 (C1), 45.69 (CH5), 
43.91 (CH24), 36.35 (CH26), 35.67 (CH2), 35.29 (CH212), 33.63 (CH2), 31.73 (CH2), 
29.90 (CH217), 29.43 (CH2), 27.87 (CH2), 25.60 (CH2), 22.61 (CH2), 22.42 (CH2), 14.08 
(CH39 or 22), 13.97 (CH39 or 22). 
HRMS (EI): Found: [M]+, 426.3293. C32H42 requires: 426.3286. 
LRMS (CI): m/z: 427 ([M + H]+, 100%), 267 ([M – p-Bu – Styrene]+, 47%). 
IR (thin film): ν~ = 2926 (s), 2854 (m), 1512 (w), 1459 (w), 900 (m), 835 (w), 752 (m), 
699 (s) cm–1. 
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6.2.6.8. rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-phenyl-
bicyclo[3.3.0]oct-2-ene (2.63g) 
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-tert-butyl-4-ethynylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a pale yellow oil in yield of 0.221 g (51%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.332 – 7.222 (9H, m, HAr), 5.040 (1H, d, J = 
1.8 Hz, H13), 4.976 (1H, d, J = 1.8 Hz, H13), 2.440 (1H, td, J = 8.5, 2.2 Hz, H5), 2.390 
(1H, dd, J = 15.5, 8.3 Hz, H4b), 2.085 – 2.040 (2H, m, H14), 1.993 (1H, d, J = 15.5 Hz, 
H4a), 1.835 (1H, tdd, J = 12.3, 10.0, 6.9 Hz, H6), 1.692 – 1.658 (2H, m, H8), 1.601 – 
1.489 (2H, m, H7), 1.409 – 1.208 (9H, m), 1.335 (9H, s, H9), 0.877 (3H, t, J = 7.0 Hz, 
H19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.17 (C12), 149.28 (C11), 142.27 (C2 or 3), 
141.37 (C2 or 3), 139.17 (Ci-Ph), 138.00 (Ci-Ph), 129.74 (2CHo- or m-Ph), 127.47 (4CHo- or m-
Ph), 126.26 (CHp-Ph), 124.37 (2CHo- or m-Ph), 114.23 (CH213), 70.17 (C1), 45.66 (CH5), 
43.97 (CH24), 36.38 (CH26), 35.74 (CH28), 34.38 (C10), 31.73 (CH2), 31.40 (3CH311), 
29.90 (CH214), 29.42 (CH2), 27.87 (CH2), 25.56 (CH27), 22.61 (CH2), 14.08 (CH319). 
HRMS (EI): Found: [M]+, 426.3283. C32H42 requires: 426.3286. 
LRMS (CI): m/z: 427 ([M + H]+, 100%), 267 ([M – p- t-Bu – Styrene]+, 51%). 
IR (thin film): ν~ = 2949 (s), 2930 (s), 2862 (m), 1508 (w), 1489 (w), 1467 (w), 1367 
(w), 1270 (w), 903 (m), 843 (s), 763 (m), 699 (s) cm–1. 
 
 
 140 
6.2.6.9. rac-(1R,5R)-3-Hexyl-2-phenyl-1-(4-phenylphenyl)vinyl)-bicyclo[3.3.0]oct-
2-ene (2.63h) 
H Hb
Ha
3
8
7
6 5 4
21
1211
10
9
13 14 15 16
 
General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynyl-4-phenylbenzene as components. Purification of the crude material by 
column chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the 
title compound as a yellow oil in yield of 0.266 g (60%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.478 – 7.089 (14H, m, HAr), 4.943 (1H, d, J = 
1.6 Hz, H10), 4.885 (1H, d, J = 1.6 Hz, H10), 2.324 (1H, td, J = 8.4, 2.3 Hz, H5), 2.272 
(1H, dd, J = 16.6, 8.4 Hz, H4b), 1.937 (1H, dt, J = 21.6, 7.8 Hz, H11), 1.906 (1H, dt, J = 
21.6, 7.3 Hz, H11), 1.868 (1H, d, J = 16.6 Hz, H4a), 1.710 (1H, tdd, J = 12.0, 10.3, 7.0 
Hz, H6), 1.572 – 1.539 (2H, m, H8), 1.477 – 1.382 (2H, m, H7), 1.286 – 1.196 (3H, m), 
1.168 – 1.022 (6H, m), 0.715 (3H, t, J = 6.9 Hz, H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.03 (C9), 143.49 (C2 or 3), 142.52 (C2 or 3), 
140.96 (Ci-Ph), 139.30 (Ci-Ph), 139.07 (Ci-Ph), 137.94 (Ci-Ph), 129.71 (2CHo- or m-Ph), 
128.71 (2CHo- or m-Ph), 128.29 (2CHo- or m-Ph), 127.57 (2CHo- or m-Ph), 127.09 (CHp-Ph), 
126.95 (2CHo- or m-Ph), 126.36 (CHp-Ph), 126.23 (2CHo- or m-Ph), 114.64 (CH210), 70.20 
(C1), 45.69 (CH5), 43.98 (CH24), 36.41 (CH2), 35.78 (CH28), 31.71 (CH2), 29.90 
(CH211), 29.42 (CH2), 27.89 (CH2), 25.56 (CH27), 22.61 (CH2), 14.07 (CH316). 
HRMS (EI): Found: [M]+, 446.2972. C34H38 requires: 446.2974. 
LRMS (CI): m/z: 446 ([M]+, 100%), 267 ([M – p-Ph – Styrene]+, 69%). 
IR (thin film): ν~ = 2933 (m), 2858 (m), 1603 (w), 1482 (s), 1440 (w), 903 (m), 847 
(m), 767 (s), 737 (s), 699 (s) cm–1. 
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6.2.6.10. rac-(1R,5R)-3-Hexyl-1-(pent-1-en-2-yl)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63i) 
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-pentyne as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a colourless oil in yield of 0.183 g (54%). 
 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.248 – 7.187 (4H, m, Ho- + m-Ph), 
7.116 – 7.072 (1H, m, Hp-Ph), 4.988 (1H, d, J = 1.0 Hz, H13), 4.941 (1H, q, J = 1.5 Hz, 
H13), 2.852 (1H, dd, J = 16.8, 8.3 Hz, H4b), 2.440  (1H, tdd, J = 8.3, 3.3, 1.8 Hz, H5), 
2.287 – 2.070 (5H, m, H4a + 4H), 1.918 – 1.741 (2H, m), 11.701 – 1.535 (5H, m), 1.459 
– 1.355 (3H, m), 1.267 – 1.107 (6H, m), 0.981 (3H, t, J = 7.3 Hz, H9 or 19), 0.850 (3H, t, 
J = 7.1 Hz, H9 or 19). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 154.63 (C12), 141.69 (C2 or 3), 
140.80 (C2 or 3), 138.75 (Ci-Ph), 130.16 (2CHo- or m-Ph), 128.39 (2CHo- or m-Ph), 127.12 
(CHp-Ph), 108.43 (CH213), 72.04 (C1), 46.35 (CH5), 44.97 (CH24), 37.39 (CH2), 35.50 
(CH2), 34.60 (CH2), 32.36 (CH2), 30.30 (CH2), 29.84 (CH2), 28.81 (CH2), 26.52 (CH2), 
23.37 (CH2), 22.39 (CH2), 15.03 (CH39 or 19), 14.64 (CH39 or 19). 
HRMS (EI): Found: [M]+, 336.2818. C25H36 requires: 336.2817. 
LRMS (CI): m/z: 337 ([M + H]+, 100%), 293 ([M – C3H7]+, 35%). 
IR (thin film): ν~ = 2956 (s), 2926 (s), 2854 (m), 1633 (w), 1489 (w), 1455 (w), 892 
(m), 877 (m), 760 (m), 699 (s) cm–1. 
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6.2.6.11. rac-(1R,5R)-1-(Hex-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63j) 
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-hexyne as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.263 g (75%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.292 – 7.172 (3H, m, Hm-Ph + p-Ph),  7.055 – 
7.024 (2H, m, Ho-Ph), 4.806 (1H, q, J = 1.4 Hz, H10), 4.792 (1H, q, J = 1.4 Hz, H10),  
2.841 (1H, dd, J = 16.8, 8.4 Hz, H4b), 2.431 (1H, dddd, J = 9.7, 8.4, 3.2, 1.6 Hz, H5), 
2.207 – 2.006 (5H, m), 1.888 (1H, dtd, J = 12.0, 9.4, 7.0 Hz, H6), 1.705 (1H, m), 1.595 
– 1.478 (6H, m), 1.456 – 1.326 (4H, m), 1.297 – 1.211 (6H, m), 0.950 (3H, t, J = 7.2 
Hz, H11 or 20), 0.860 (3H, t, J = 6.9 Hz, H20 or 11). 
13C NMR (75 MHz, CDCl3):  (ppm) = 154.57 (C9), 141.21 (Ci-Ph), 139.63 (C2 or 3), 
138.04 (C2 or 3), 129.40 (2CHo- or m-Ph), 127.42 (2CHm- or o-Ph), 126.11 (CHp-Ph), 107.27 
(CH210), 71.24 (C1), 45.53 (CH5), 44.33 (CH2), 36.67 (CH2), 33.84 (CH2), 32.05 (CH2), 
31.68 (CH2), 30.75 (CH2), 29.59 (CH2), 29.13 (CH2), 28.06 (CH2), 25.70 (CH2), 23.05 
(CH2), 22.61 (CH2), 14.15 (CH311 or 20), 14.04 (CH320 or 11). 
HRMS (EI): Found: [M]+, 350.2979. C26H38 requires: 350.2974. 
LRMS (EI): m/z: 350 ([M]+·, 57%), 307 ([M – C3H7]+·, 26%), 293 ([M – C4H9]+·, 
100%). 
IR (thin film): ν~ = 2925 (m), 2852 (m), 1630 (w), 1487 (w), 1467 (m), 886 (m), 760 
(m), 698 (s) cm–1. 
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6.2.6.12. rac-(1R,5R)-3-Hexyl-1-(oct-1-en-2-yl)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63k) 
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-octyne as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a colourless oil in yield of 0.247 g (65%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.286 – 7.186 (3H, m, Ho- + p-Ph), 7.053 – 7.023 
(2H, m, Hm-Ph), 4.806 (1H, q, J = 1.5 Hz, H16), 4.791 (1H, d, J = 1.0 Hz, H16), 2.844 
(1H, dd, J = 16.7, 8.3 Hz, H4b), 2.430 (1H, tdd, J = 8.3, 3.3, 1.8 Hz, H5), 2.193 – 2.018 
(4H, m), 2.132 (1H, d, J = 16.7 Hz, H4a), 1.888 (1H, tdd, J = 12.3, 9.5, 7.0 Hz, H6), 
1.736 – 1.667 (1H, m), 1.600 – 1.177 (20H, m), 0.916 (3H, t, J = 7.0 Hz, H9 or 22), 0.862 
ppm (3H, t, J = 7.0 Hz, H9 or 22). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 154.61 (C15), 141.21 (Ci-Ph), 139.59 (C2 or 3), 
138.01 (C2 or 3), 129.38  (2CHo- or m-Ph), 127.42 (2CHo- or m-Ph), 126.10 (CHp-Ph), 107.23 
(CH216), 71.22 (C1), 45.50 (CH5), 44.33 (CH24), 36.68 (CH26), 33.82 (CH2), 32.35 
(CH2), 31.95 (CH2), 31.69 (CH2), 29.70 (CH2), 29.59 (CH2), 29.14 (CH2), 28.47 (CH2), 
28.05 (CH2), 25.69 (CH2), 22.71 (CH2), 22.62 (CH2), 14.11 (CH39 or 22), 14.06 (CH39 or 
22). 
HRMS (EI): Found: [M]+, 378.3289. C28H42 requires: 378.3286. 
LRMS (CI): m/z: 378 ([M]+, 100%), 293 ([M – C6H13]+, 63%). 
IR (thin film): ν~ = 2926 (s), 2858 (m), 1633 (w), 1493 (w), 1467 (m), 884 (m), 763 
(m), 699 (s) cm–1. 
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6.2.6.13. rac-(1R,5R)-1-(Dec-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.63l) 
H Hb
Ha
3
8
7
6 5 4
21
2019
13
12 10
21 22 23 24
11 9
14
15
17
18
16
 
General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-decyne as components Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.229 g (56%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.291 – 7.192 (3H, m, Ho- + p-Ph), 7.060 – 7.030 
(2H, m, Hm-Ph), 4.813 (1H, apparent q, J = 1.5 Hz, H18), 4.798 (1H, d, J = 1.0 Hz, H18), 
2.852 (1H, dd, J = 16.6, 8.4 Hz, H4b), 2.430  (1H, tdd, J = 8.4, 3.3, 1.5 Hz, H5), 2.196 – 
2.023 (4H, m), 2.138 (1H, d, J = 16.6 Hz, H4a), 1.895 (1H, tdd, J = 12.3, 9.8, 7.0 Hz,  
H6), 1.744 – 1.674 (1H, m), 1.621 – 1.480 (5H, m), 1.420 – 1.168 (19H, m), 0.914 (3H, 
t, J = 7.0 Hz, H9 or 24), 0.871 (3H, t, J = 7.0 Hz, H9 or 24). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 154.61 (C17), 141.21 (Ci-Ph), 139.60 (C2 or 3), 
138.01 (C2 or 3), 129.38  (2CHo- or m-Ph), 127.41 (2CHo- or m-Ph), 126.10 (CHp-Ph), 107.28 
(CH218), 71.22 (C1), 45.50 (CH5), 44.34  (CH24), 36.68 (CH2), 33.82 (CH2), 32.34 
(CH2), 31.92 (CH2), 31.69 (CH2), 30.03 (CH2), 29.68 (CH2), 29.59 (CH2), 29.37 (CH2), 
29.14 (CH2), 28.49 (CH2), 28.05 (CH2), 25.69 (CH2), 22.70 (CH2), 22.63 (CH2), 14.12 
(CH39 or 24),14.06 (CH39 or 24). 
HRMS (EI): Found: [M]+, 406.3598. C30H46 requires: 406.3600. 
LRMS (CI): m/z: 406 ([M ]+, 100 %), 293 ([M – C8H17]+, 47 %). 
IR (thin film): ν~ = 2930 (s), 2858 (m), 1633 (w), 1493 (w), 1463 (m), 884 (m), 763 
(m), 699 (s) cm–1. 
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6.2.6.14. rac-(1R,5R)-3-Hexyl-2-(3-methoxyphenyl)-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63m) 
H Hb
Ha
3
8
7
6 5 4
21
1413
12
15 16 17 18
10
9
11
O
 
General procedure A was used with 1-(hept-6-en-1-ynyl)-3-methoxybenzene, 1,1-
dibromoheptane and 1-ethynylbenzene as components. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluent gave the title compound as a pale yellow oil in yield of 0.302 g (75%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.346 – 7.219 (6H, m, HAr), 6.889 – 6.815 
(3H, m, HAr), 5.082 (1H, d, J = 1.6 Hz, H10), 5.051 (1H, d, J = 1.6 Hz, H10), 3.793 (3H, 
s, H12), 2.420 (1H, tdd, J = 8.3, 3.0, 1.3 Hz,  H5), 2.294 (1H, dd, J = 16.6, 8.3 Hz,  H4b), 
2.116 (1H, dt, J = 25.5, 7.8 Hz,  H13), 2.082 (1H, dt, J = 25.5, 7.5 Hz,  H13), 1.985 (1H, 
d, J = 16.6 Hz,  H4a), 1.860 (1H, tdd, J = 12.3, 10.0, 6.8 Hz, H6), 1.718 – 1.682 (2H, m, 
H8), 1.612 – 1.466 (2H, m, H7), 1.413 – 1.202 (9H, m), 0.888 (3H, t, J = 7.0 Hz, H18). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.92 (C11), 155.54 (C9), 144.28 (C2 or 3), 
142.72 (C2 or 3), 139.41 (Ci-Ph), 138.55 (Ci-Ph), 128.44 (CHo- or m-Ph), 127.97 (2CHo- or m-Ph), 
127.49 (2CHo- or m-Ph), 126.46 (CHp-Ph), 122.33 (CHo- or m-Ph), 115.19 (CHo- or m-Ph), 114.32 
(CH210), 111.74 (CHo- or m-Ph), 70.09 (C1), 55.07 (CH312), 45.74 (CH5), 43.75 (CH24), 
36.26 (CH6), 35.47 (CH28), 31.74 (CH2), 29.96 (CH213), 29.47 (CH2), 27.89 (CH2), 
25.67 (CH27), 22.61 (CH2), 14.08 (CH318). 
HRMS (EI): Found: [M]+, 400.2763. C29H36O requires: 400.2766. 
LRMS (CI): m/z: 401 ([M + H]+, 100%), 297 ([M – Styrene]+, 30%). 
IR (thin film): ν~ = 2930 (m), 2858 (m), 1595 (m), 1572 (m), 1489 (m), 1455 (m), 1281 
(m), 1051 (m), 903 (m), 779 (s), 703 (s) cm–1. 
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6.2.6.15. rac-(1R,5R)-2-(4-Ethylphenyl)-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-
ene (2.63n) 
H Hb
Ha
3
8
7
6 5 4
21
1514
10
9
16 17 18 19
11
12 13
 
General procedure A was used with 1-ethyl-4-(hept-6-en-1-ynyl)benzene, 1,1-
dibromoheptane and 1-ethynylbenzene as components. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluent gave the title compound as a pale yellow oil in yield of 0.281 g (70%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.380 – 7.163 (9H, m, HAr), 5.080 (1H, d, J = 
1.8 Hz, H10), 5.057 (1H, d, J = 1.8 Hz, H10), 2.701 (2H, q, J = 7.5 Hz,  H12), 2.436 (1H, 
tdd, J = 8.3, 2.8, 1.0 Hz, H5), 2.318 (1H, dd, J = 16.6, 8.3 Hz, H4b), 2.133 (1H, dt, J = 
21.3, 7.8 Hz, H14), 2.080 (1H, dt, J = 21.3, 7.5 Hz, H14), 2.002 (1H, d, J = 16,6 Hz, H4a), 
1.875 (1H, tdd, J = 12.3, 10.3, 7.0 Hz, H6), 1.725 – 1.687 (2H, m, H8), 1.601 – 1.509 
(2H, m, H7), 1.431 – 1.358 (3H, m), 1.339 – 1.211 (6H, m), 1.303 (3H, t, J = 7.5 Hz, 
H13), 0.909 (3H, t, J = 7.0 Hz, H19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.49 (C9), 144.38 (C2 or 3), 142.17 (C11), 
142.06 (C2 or 3), 138.69 (Ci-Ph), 135.14 (Ci-Ph), 129.50 (2CHo- or m-Ph), 128.00 (2CHo- or m-
Ph), 127.46 (2CHo- or m-Ph), 127.03 (2CHo- or m-Ph), 126.42 (CHp-Ph), 114.25 (CH210), 70.05 
(C1), 45.72 (CH5), 43.71 (CH24), 36.30 (CH26), 35.49 (CH28), 31.74 (CH2), 29.96 
(CH214), 29.44 (CH2), 28.52 (CH212), 27.90 (CH2), 25.64 (CH27), 22.61 (CH2), 15.33 
(CH313), 14.08 (CH319). 
HRMS (EI): Found: [M]+, 398.2974. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]+, 100%), 369 ([M – Et]+, 39%). 
IR (thin film): ν~ = 2933 (s), 2854 (m), 1508 (w), 1489 (w), 1452 (w), 903 (m), 824 
(m), 771 (m), 703 (s) cm–1. 
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6.2.6.16. rac-(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-propyl-bicyclo[3.3.0]oct-2-ene 
(2.63o) 
H Hb
Ha
3
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6 5 4
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General procedure A was used with dec-1-en-6-yne, 1,1-dibromoheptane and 1-
ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.277 g (82%). 
 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.306 – 7.270 (2H, m, Ho-Ph), 7.187 – 
7.082 (3H, m, Hm + p-Ph), 5.189 (1H, t, J = 2.1 Hz, H10), 5.071 (1H, t, J = 2.1 Hz, H10), 
2.484 (1H, tq, J = 8.8, 2.4 Hz, H5), 2.333 (1H, dd, J = 16.0, 8.8 Hz, H4b), 2.142 – 2.018 
(4H, m), 1.875 – 1.716 (4H, m), 1.613 – 1.455 (4H, m), 1.384 – 1.242 (9H, m), 0.951 
(3H, t, J = 7.3 Hz, H13 or 19), 0.913 (3H, t, J = 7.5 Hz, H13 or 19). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 156.88 (C9), 145.26 (Ci-Ph), 139.96 
(C2 or 3), 138.03 (C2 or 3), 128.76 (2CHm-Ph), 128.16 (2CHo-Ph), 127.15 (CHp-Ph), 113.77 
(CH210), 71.26 (C1), 44.84 (CH5), 44.51 (CH24), 37.31 (CH2), 36.70 (CH2), 32.58 (CH2), 
30.29 (CH2), 30.06 (CH2), 29.78 (CH2), 28.57 (CH2), 26.17 (CH2), 24.61 (CH2), 23.43 
(CH2), 15.68 (CH313 or 19), 14.71 (CH313 or 19). 
HRMS (EI): Found: [M]+, 336.2820. C25H36 requires: 336.2817. 
LRMS (CI): m/z: 336 ([M]+, 100%), 233 ([M – Styrene]+, 51%). 
IR (thin film): ν~ = 2952 (s), 2926 (s), 2858 (m), 1486 (w), 1444 (m), 900 (m), 775 (m), 
699 (s) cm–1. 
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6.2.6.17. rac-(1R,5R)-2-Butyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63p) 
H Hb
Ha
3
8
7
6 5 4
21
1615
10
9
17 18 19 20
12 1311
14
 
General procedure A was used with undec-1-en-6-yne, 1,1-dibromoheptane and 1-
ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.308 g (88%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.238 – 7.151 (5H, m, HAr), 5.127 (1H, d, J = 
1.8 Hz, H10), 4.954 (1H, d, J = 1.8 Hz, H10), 2.317 (1H, tt, J = 8.8, 2.3 Hz, H5), 2.201 
(1H, dd, J = 15.7, 8.8 Hz, H4b), 2.081 – 1.962 (4H, m), 1.818 – 1.687 (4H, m), 1.564 – 
1.503 (3H, m), 1.404 – 1.271 (12H, m), 0.916 (3H, t, J = 6.8 Hz, H14 or 20), 0.909 (3H, t, 
J = 6.8 Hz, H14 or 20). 
13C NMR (75 MHz, CDCl3):  (ppm) = 156.09 (C9), 144.55 (Ci-Ph), 139.13 (C2), 
137.16 (C3), 127.93 (2CHo- or m-Ph), 127.30 (2CHm- or o-Ph), 126.22 (CHp-Ph), 113.05 
(CH210), 70.44 (C1), 44.01 (CH5), 43.79 (CH2), 36.57 (CH2), 35.93 (CH2), 32.66 (CH2), 
31.83 (CH2), 29.51 (CH2), 29.26 (CH2), 27.74 (CH2), 26.24 (CH2), 25.37 (CH2), 23.68 
(CH2), 22.65 (CH2), 14.10 (CH314 or 20), 13.91 (CH320 or 14). 
HRMS (EI): Found: [M]+, 350.2965. C26H38 requires: 350.2974. 
LRMS (EI): m/z: 351 ([M + H]+·, 48%), 307 ([M – C3H7]+·, 25%), 247 ([M – Styrene]+·, 
100%). 
IR (thin film): ν~ = 2926 (s), 2856 (m), 1614 (w), 1497 (w), 1450 (w), 896 (m), 762 
(m), 692 (s) cm–1. 
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6.2.6.18. rac-(1R,5R)-2-Hexyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63q) 
H Hb
Ha
3
8
7
6 5 4
21
1817
10
9
19 20 21 22
12 1311
15 1614
 
General procedure A was used with tridec-1-en-6-yne, 1,1-dibromoheptane and 1-
ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.325 g (86%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.224 – 7.148 (5H, m, HAr), 5.124 (1H, d, J = 
1.8 Hz, H10), 4.951 (1H, d, J = 1.8 Hz, H10), 2.315 (1H, tt, J = 9.0, 2.0 Hz, H5), 2.196 
(1H, dd, J = 15.9, 9.0 Hz, H4b), 2.056 – 1.953 (4H, m), 1.818 – 1.722 (4H, m), 1.579 – 
1.500 (3H, m), 1.479 – 1.2700 (16H, m), 0.909 (3H, t, J = 6.7 Hz, H16 or 22), 0.897 (3H, 
t, J = 6.7 Hz, H16 or 22). 
13C NMR (75 MHz, CDCl3):  (ppm) = 156.01 (C9), 144.55 (Ci-Ph), 139.13 (C2), 
137.23 (C3), 127.94 (2CHo- or m-Ph), 127.30 (2CHm- or o-Ph), 126.22 (CHp-Ph), 113.03  
(CH210), 70.44 (C1), 44.02 (CH5), 43.80 (CH2), 36.57 (CH2), 35.94 (CH2), 31.84 (CH2), 
31.63 (CH2), 30.39 (CH2), 30.33 (CH2), 29.52 (CH2), 29.28 (CH2), 27.76 (CH2), 26.56 
(CH2), 25.38 (CH2), 22.70 (CH2), 22.66 (CH2), 14.09 (2CH316 + 22).  
HRMS (EI): Found: [M]+, 378.3276. C28H42 requires: 378.3286. 
LRMS (EI): m/z: 379 ([M + H]+·, 56%), 349 ([M – CH3]+·, 13%), 293 ([M – C6H13]+·, 
21%), 276 ([M – Styrene + H]+·, 100%). 
IR (thin film): ν~ = 2926 (s), 1640 (w), 1491 (w), 1456 (w), 884 (w), 768 (w), 698 (m) 
cm–1. 
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6.2.6.19. rac-(1R,5R)-2-Cyclohexyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63r) 
H Hb
Ha
3
8
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6 5 4
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9 11
13 14
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16
 
General procedure A was used with (hept-1-en-6-yne)cyclohexane, 1,1-dibromoheptane 
and 1-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.300 g (80%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.311 – 7.202 (5H, m, HAr), 5.133 (1H, d, J = 
1.8 Hz, H10), 5.012 (1H, d, J = 1.8 Hz, H10), 2.376 (1H, dd, J = 16.3, 9.0 Hz, H4b), 2.272 
– 2.234 (2H, m, H17), 2.195 (1H, tt, J = 9.0, 2.2 Hz, H5), 1.989 (1H, tt, J = 11.9, 3.9 Hz,  
H11), 1.873 – 1.158 (25H, m), 0.926 (3H, t, J = 6.9 Hz, H22). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 156.09 (C9), 145.02 (C2 or 3), 140.67 (C2 or 3), 
138.47 (Ci-Ph), 127.70 (2CHo- or m-Ph), 127.46 (2CHo- or m-Ph), 126.35 (CHp-Ph), 113.48 
(CH210), 71.29 (C1), 45.07 (CH24), 43.70 (CH5), 38.02 (CH11), 37.00 (CH2), 36.73 
(CH2), 33.12 (CH2), 32.25 (CH2), 31.90 (CH2), 30.34 (CH2), 29.75 (CH217), 28.10 
(CH2), 27.55 (CH2), 27.39 (CH2), 26.50 (CH2), 25.25 (CH2), 22.70 (CH2), 14.13 
(CH322). 
HRMS (EI): Found: [M]+, 376.3127. C28H40 requires: 376.3130. 
LRMS (CI): m/z: 377 ([M + H]+, 100 %), 271 (77%). 
IR (thin film): ν~ = 2926 (s), 2850 (s), 1614 (w), 1486 (w), 1440 (m), 900 (m), 771 (m), 
699 (s) cm–1. 
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6.2.6.20. rac-(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-(propan-3-ol)-bicyclo[3.3.0]oct-2-
ene (2.63s) 
H Hb
Ha
3
8
7
6 5 4
21
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9 11 OH
1413
 
General procedure A was used with TBDMS protected dec-9-en-4-yn-1-ol, 1,1-
dibromoheptane and 1-ethynylbenzene as components with the exception that the 
reaction was carried out on 2.0 mmol scale. Crude product from the three component 
coupling was purified by flash column chromatography on silica to give the desired 
material which was put into TBDMS group cleavage with TBAF [2.0 mL of a 1.0 M 
solution in THF, (2.0 mmol) in dry THF (8.0) mL, at RT for 20 h]. Purification of the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluent gave the title compound as a yellow oil in yield of 0.430 g (61% over two 
steps). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.236 – 7.163 (5H, m, HAr), 5.146 (1H, d, J = 
1.8 Hz, H10), 4.983 (1H, d, J = 1.8 Hz, H10), 3.649 (2H, q, J = 6.5 Hz, H13), 2.343 (1H, 
tt, J = 9.0, 2.0 Hz, H5), 2.244 (1H, dd, J = 16.0, 9.0 Hz, H4b), 2.133 – 2.020 (4H, m, H11 
+ 15), 1.870 – 1.611 (6H, m), 1.587 – 1.521 (1H, m), 1.485 – 1.385 (1H, m), 1.370 – 
1.261 (10H, m), 0.909 (3H, t, J = 6.9 Hz, H20). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.95 (C9), 144.36 (Ci-Ph), 139.80 (C2 or 3), 
136.21 (C2 or 3), 127.83 (2CHo- or m-Ph), 127.37 (2CHm- or o-Ph), 126.33 (CHp-Ph), 113.26 
(CH210), 70.38 (C1), 63.62 (CH213), 43.99 (CH5), 43.80 (CH24), 36.55 (CH2), 36.05 
(CH2), 33.45 (CH2), 31.84 (CH2), 29.52 (CH2), 29.27 (CH2), 27.73 (CH2), 25.34 (CH2), 
22.65 (CH2), 22.54 (CH2), 14.10 (CH320). 
HRMS (EI): Found: [M]+, 352.2767. C25H36O requires: 352.2766. 
LRMS (CI): m/z: 353 ([M + H]+, 100%), 249 ([M – Styrene]+, 37%). 
IR (thin film): ν~ = 3312 (w, br), 2930 (s), 2854 (m), 1448 (m), 1062 (m), 900 (m), 771 
(m), 699 (s) cm–1. 
 
 152 
6.2.6.21. rac-(1R,5R)-2-Phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene (2.63t) 
H Hb
Ha
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, dichloromethane and 
1-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexane as the eluent gave the title 
compound as a pale yellow oil in yield of 0.332 g (58%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.609 – 7.579 (2H, m, Ho-Ph), 7.350 – 7.249 
(8H, m, HAr), 6.149 (1H, t, J = 2.7 Hz, H3), 5.296 (1H, d, J = 1.8 Hz, H10), 5.032 (1H, d, 
J = 1.8 Hz, H16), 2.693 (1H, J = 8.3, 6.0, 1.5 Hz, H5), 2.396 (1H, ddd, J = 17.6, 8.0, 2.2 
Hz, H4b), 2.117 (1H, dt, J = 12.8, 7.3 Hz, H8a or 8b), 2.084 (1H, ddd, J = 17.6, 3.0, 1.5 Hz, 
H4a), 1.968 (1H, ddt, J = 12.3, 8.8, 6.8 Hz, H6b), 1.792 (1H, dt, J = 12.8, 6.0 Hz, H8a or 
8b), 1.540 (2H, apparent quintet, J = 7.0 Hz, H7) 1.366 (1H, dq, J = 12.3, 6.2 Hz, H6a). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.03 (C9), 145.92 (C2), 143.34 (Ci-Ph), 
136.41 (Ci-Ph), 128.45 (3CHp- + o- or m-Ph), 127.99 (2CHo- or m-Ph), 127.40 (2CHo- or m-Ph), 
127.25 (2CHo or m-Ph), 126.68 (CH3 or p-Ph), 126.53 (CH3 or p-Ph), 113.51 (CH210), 67.12 
(C1), 50.12 (CH5), 38.84 (CH24), 35.73 (CH26), 35.04 (CH28), 26.65 (CH27). 
HRMS (EI): Found: [M]+, 286.1721. C22H22 requires: 286.1722. 
LRMS (CI): m/z: 287 ([M + H]+, 100%), 208 ([M – Ph]+, 14%), 169 (20%). 
IR (thin film): ν~ = 2949 (m), 2858 (w), 1493 (m), 1440 (m), 907 (m), 748 (s), 695 (s) 
cm–1. 
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6.2.6.22. rac-(1R,5R)-3-Butyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63u) 
H Hb
Ha
3
8
7
6 5 4
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromopentane 
and 1-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.244 g (71%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.348 – 7.237 (10H, m, HAr), 5.037 (1H, d, J = 
1.6 Hz, H10), 5.024 (1H, d, J = 1.6 Hz, H10), 2.430 (1H, tdd, J = 8.3, 3.0, 1.5 Hz, H5), 
2.338 (1H, dd, J = 16.3, 8.3 Hz, H4b), 2.090 (1H, dt, J = 24.5, 7.8 Hz, H11), 2.055 (1H, 
dt, J = 24.5, 7.3 Hz, H11), 1.995 (1H, d, J = 16.3 Hz, H4a), 1.851 (1H, tdd, J = 12.0, 10.0, 
6.8 Hz, H6), 1.697 – 1.663 (2H, m, H8), 1.607 – 1.473 (2H, m, H7), 1.419 – 1.214  (5H, 
m), 0.861 (3H, t, J = 7.2 Hz, H14). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.37 (C9), 144.38 (C2 or 3), 142.46 (C2 or 3), 
138.92 (Ci-Ph), 137.96 (Ci-Ph), 129.67 (2CHo- or m-Ph), 127.92 (2CHo- or m-Ph), 129.55 
(2CHo- or m-Ph), 127.51 (2CHo- or m-Ph), 126.46 (CHp-Ph), 126.33 (CHp-Ph), 114.44 (CH210), 
70.14 (C1), 45.69 (CH5), 43.83 (CH24), 36.33 (CH6), 35.61 (CH28), 30.17 (CH2), 29.65 
(CH211), 25.60 (CH27), 22.84 (CH2), 14.13 (CH314). 
HRMS (EI): Found: [M]+, 342.2351. C26H30 requires: 342.2348. 
LRMS (CI): m/z: 343 ([M + H]+, 100%) 239 ([M – Styrene]+, 24%). 
IR (thin film): ν~ = 2941 (m), 2850 (m), 2835 (w), 1595 (w), 1489 (m), 1436 (w), 907 
(m), 763 (m), 695 (s) cm–1. 
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6.2.6.23. rac-(1R,5R)-3-Octyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene 
(2.63v) 
H Hb
Ha
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8
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6 5 4
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General procedure A was used with 1-(hept-6-en-1-ynyl)benzene, 1,1-dibromononane 
and 1-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.291 g (73%). 
 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.457 – 7.393 (4H, m, Hm- + p-Ph), 
7.257 – 7.111 (6H, m, Ho- + m- + p-Ph), 5.117 (1H, d, J = 1.8 Hz, H10), 5.084 (1H, d, J = 1.8 
Hz, H10), 2.536 (1H, tdd, J = 8.5, 2.8, 1.3 Hz, H5), 2.436 (1H, dd, J = 16.4, 8.5 Hz, H4b), 
2.147 – 2.108 (2H, m, H11), 1.967 (1H, d, J = 16.4 Hz, H4a), 1.856 – 1.513 (5H, m), 
1.419 – 1.348 (3H, m), 1.302 – 1.192 (10H, m), 0.899 (3H, t, J = 6.9 Hz, H18). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 156.27 (C9), 145.21 (C2 or 3), 142.99 
(C2 or 3), 140.08 (Ci-Ph), 138.73 (Ci-Ph), 130.46 (2CHo- or m-Ph), 128.72 (2CHo- or m-Ph), 
128.48 (2CHo- or m-Ph), 128.35 (2CHo- or m-Ph), 127.31 (CHp-Ph), 127.29 (CHp-Ph), 115.17 
(CH210), 71.05 (C1), 46.48 (CH5), 44.59 (CH24), 37.10 (CH2), 36.43 (CH2), 32.63 (CH2), 
30.64 (CH2), 30.49 (CH2), 30.19 (CH2), 30.04 (CH2), 28.70 (CH2), 26.38 (CH2), 23.43 
(CH2), 14.70 (CH318). 
HRMS (EI): Found: [M]+, 398.2978. C30H38 requires: 398.2974. 
LRMS (CI): m/z: 399 ([M + H]+, 100%), 295 ([M – Styrene]+, 29%). 
IR (thin film): ν~ = 2926 (s), 2858 (m), 1599 (w), 1493 (m), 1440 (w), 900 (m), 763 
(m), 695 (s) cm–1. 
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6.2.6.24. rac-(1R,5R)-3-Dimethyl(phenyl)silane-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63w) 
H
Si
5
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General procedure B was used with 1-(hept-6-en-1-ynyl)benzene, 
(dichloromethyl)dimethyl(phenyl)silane and 1-ethynylbenzene as components. The 
carbenoid was generated in situ from (dichloromethyl)dimethyl(phenyl)silane (1.3 
mmol) and LDA (0.83 mL of a 1.8 M solution, 1.50 mmol) at –85 °C for 15 min before 
dropwise addition of phenylacetylide. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.191 g (45%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.501 – 7.201 (15H, m, HAr), 5.097 (1H, d, J = 
1.6 Hz, H10), 4.970 (1H, d, J = 1.6 Hz, H10), 2.533 – 2.448 (2H, m, H5 + 4b), 2.186 (1H, 
d, J = 15.1 Hz, H4a), 1.902 (1H, m, H6), 1.818 (1H, m, H7), 1.733 (1H, dd, J = 11.3, 5.5 
Hz, H8), 1.674 (1H, m, H7), 1.614 (1H, dd, J = 11.3, 5.6 Hz, H8), 1.474 (1H, m, H6), 
0.115 (3H, s, H11or 12), 0.096 (3H, s, H11 or 12). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 157.10 (C2 or 9), 154.13 (C2 or 9), 144.39 (Ci-
Ph), 140.63 (Ci-Ph), 139.36 (C3), 138.87 (CSi-i-Ph), 133.62 (2CHSi-o-Ph), 129.75 (2CHSi-m-
Ph), 128.62 (CHSi-p-Ph), 127.72 (2CHo- or m-Ph), 127.64 (2CHo- or m-Ph), 127.56 (2CHo- or m-
Ph), 127.12 (2CHo- or m-Ph), 126.88 (CHp-Ph), 126.53 (CHp-Ph), 115.04 (CH210), 73.06 (C1), 
46.99 (CH24), 46.65 (CH5), 36.71 (CH26), 36.02 (CH27), 25.57 (CH28), –2.36 (CH311or 
12), –2.72 (CH311or 12). 
HRMS (EI): Found: [M]+, 420.2288. C30H32Si requires: 420.2273. 
LRMS (CI): m/z: 420 ([M]+·, 6%), 342 ([M – Ph]+·, 17%), 284 ([M – HSiMe2Ph]+·, 
18%), 135 ([SiMe2Ph]+·, 100%). 
IR (thin film): ν~ = 2964 (m), 2896 (w), 1610 (w), 1580 (m), 1486 (m), 1421 (m), 1251 
(m), 1051 (m), 779 (s), 733 (s), 695 (s) cm–1. 
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6.2.6.25. rac-(1R,5R)-2-Butyl-3-dimethyl(phenyl)silane-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.63x) 
H
Si
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General procedure A was used with undec-1-en-6-yne, 
(dichloromethyl)dimethyl(phenyl)silane and 1-ethynylbenzene as components. The 
carbenoid was generated in situ from (dichloromethyl)dimethyl(phenyl)silane (1.3 
mmol) and LDA (0.83 mL of a 1.8 M solution, 1.50 mmol) at –85 °C for 15 min before 
dropwise addition of phenylacetylide. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.275 g (69%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.428 – 7.074 (10H, m, HAr), 5.074 (1H, d, J = 
1.8 Hz, H10), 4.892 (1H, d, J = 1.8 Hz, H10), 2.291 (1H, J = 8.8, 2.2 Hz, H5), 2.186 (1H, 
dd, J = 15.2, 8.5 Hz, H4b), 1.985 – 1.852 (2H, m, H13), 1.886 (1H, d, J = 16.2, Hz, H4a), 
1.762 (1H, dd, J = 10.5, 5.9 Hz, H8), 1.731 (1H, dd, J = 10.5, 5.5 Hz, H8), 1.681 (1H, m, 
H6), 1.484 (1H, quintet t, J = 6.0, 3.0 Hz, H7), 1.361 (1H, m, H7), 1.266 – 1.182 (3H, m, 
H6 + 14), 1.104 – 0.969 (2H, m, H15),  0.698 (3H, t, J = 7.3 Hz, H16), 0.300 (3H, s, H11/12), 
0.278 (3H, s, H11/12). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 157.46 (C2 or 9), 155.29 (C2 or 9), 144.25 (Ci-
Ph), 139.33 (C3), 144.25 (CSi-i-Ph), 133.79 (2CHSi-o-Ph), 128.71 (CHSi-p-Ph), 127.95 (2CHSi-
m-Ph), 127.66 (2CHo or m-Ph), 127.32 (2CHo or m-Ph), 126.36 (CHp-Ph), 113.35 (CH210), 73.31 
(C1), 46.58 (CH24), 45.68 (CH5), 36.62 (CH26), 36.14 (CH28), 34.05 (CH214), 28.87 
(CH213), 25.53 (CH27), 23.57 (CH215), 13.80 (CH316), –1.95 (CH311/12), –2.03 (CH311/12). 
HRMS (EI): Found: [M]+, 400.2587. C28H36Si requires: 400.2586. 
LRMS (CI): m/z: 400 ([M]+·, 11%), 297 ([M – Styrene]+·, 13%), 264 ([M – 
HSiMe2Ph]+·, 15%), 135 (100%). 
IR (thin film): ν~ = 2945 (m), 2854 (w), 1603 (w), 1251 (m), 1100 (m), 816 (m), 771 
(s), 699 (s) cm–1. 
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6.2.6.26. rac-(1R,5R)-2-Hexyl-3-cyclohexyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oct-2-
ene (2.63y) 
H Hb
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General procedure A was used with tridec-1-en-6-yne, (dibromomethyl)cyclohexane 
(1.0 mmol) and 1-ethynylbenzene (2.2 mmol) as components. The carbenoid was 
generated in situ by using LiTMP [freshly prepared from distilled 2,2,6,6-
tetramethylpiperidine (0.17 mL, 1.0 mmol) in dry THF (2 mL) and n-BuLi (0.40 mL of 
a 2.5 M solution in hexanes, 1.0 mmol) at 0 °C over 20 min] at –85 °C for 30 min 
before dropwise addition of phenylacetylide (2.2 mmol). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.038 
g (10%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.232 – 7.161 (5H, m, HAr), 5.119 (1H, d, J = 
1.8 Hz, H10), 4.938 (1H, d, J = 1.8 Hz, H10), 2.362 – 2.243 (2H, m, H5 + H), 2.114 (1H, 
dd, J = 16.0, 8.7 Hz, H4b), 1.989 – 1.937 (2H, m), 1.816 – 1.682 (5H, m), 1.592 – 1.392 
(10H, m), 1.370 – 1.268 (10H, m), 0.904 (3H, t, J = 6.8 Hz, H16). 
13C NMR (75 MHz, CDCl3):  (ppm) = 156.01 (C9), 143.81 (Ci-Ph), 135.70 (C2), 
128.00 (2CHo- or m-Ph), 127.21 (2CHo- or m-Ph), 126.20 (CHp-Ph), 124.44 (C3), 112.86 
(CH210), 70.16 (C1), 43.64 (CH5), 40.11 (CH2), 38.64 (CH17), 36.64 (CH2), 35.73 (CH2), 
31.91 (CH2), 31.57 (CH2), 30.63 (CH2), 30.30 (CH2), 29.70 (CH2), 26.63 (CH2), 26.41 
(CH2), 26.30 (CH2), 25.28 (CH2), 22.68 (CH2), 14.09 (CH316). 
HRMS (EI): Found: [M]+, 376.3125. C28H40 requires: 376.3130. 
LRMS (EI): m/z: 376 ([M]+·, 54%), 293 ([M – C6H11]+·, 33%), 273 ([M – Styrene]+·, 
100%). 
IR (thin film): ν~ = 2909 (s), 2845 (s), 1573 (w), 1439 (m), 686 (m) cm–1. 
 
 158 
6.2.6.27. rac-(1R,5R)-2-Hexyl-3-hexyl-1-(hex-1-en-2-yl)bicyclo[3.3.0]oct-2-ene 
(2.63z) 
H Hb
Ha
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General procedure A was used with tridec-1-en-6-yne, 1,1-dibromoheptane and 1-
hexyne as components. Purification of the crude material by column chromatography on 
SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title compound as a pale 
yellow oil in yield of 0.243 g (68%). 
 
1H NMR (300 MHz, CDCl3):  (ppm) = 4.851 (1H, d, J = 1.4 Hz, H10), 4.731 (1H, q, J 
= 1.4 Hz, H10), 2.643 (1H, dd, J = 16.2, 8.8 Hz, H4b), 2.306 (1H, tt, J = 8.8, 2.1 Hz, H5), 
2.059 (2H, td, J = 7.3, 0.5 Hz, H26), 1.949 – 1.843 (3H, m), 1.818 – 1.703 (4H, m), 
1.667 – 1.518 (4H, m), 1.389 – 1.258 (20H, m), 0.925 – 0.867 (9H, m, H16 + 22 + 23). 
13C NMR (75 MHz, CDCl3):  (ppm) = 155.49 (C9), 137. 99 (C2 or 3), 137.88 (C2 or 3), 
106.24 (CH210), 71.15 (C1), 44.28 (CH2), 43.95 (CH–5), 36.91 (CH2), 34.16 (CH2), 
31.92 (CH2), 31.86 (CH2), 31.68 (CH2), 30.97  (CH2), 30.25 (CH2), 30.19 (CH2), 29.70 
(CH2), 29.36 (CH2), 29.06 (CH2), 28.03 (CH2), 26.36 (CH2), 25.40 (CH2), 22.95 (CH2), 
22.66 (CH2), 14.09 (3CH316 + 22 + 23). 
HRMS (EI): Found: [M]+, 358.3601. C26H46 requires: 358.3600. 
LRMS (EI): m/z: 358 ([M]+·, 52%), 315 ([M – C3H7]+·, 55%), 301 ([M – C4H9]+·, 74%), 
287 ([M – C5H11]+·, 48%), 273 ([M – C6H13]+·, 100%). 
IR (thin film): ν~ = 2921 (s), 2862 (s), 1637 (w), 1450 (w), 884 (m) cm–1. 
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6.2.6.28. rac-(1R,5R)-1-(4-tert-Butylphenyl)vinyl)-3-hexyl-2-propyl-
bicyclo[3.3.0]oct-2-ene (2.63aa) 
H Hb
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General procedure A was used with dec-1-en-6-yne, 1,1-dibromoheptane and 1-tert-
butyl-4-ethynylbenzene as components. Purification of the crude material by column 
chromatography on SiO2 (230 – 400 mesh) with hexanes as the eluent gave the title 
compound as a pale yellow oil in yield of 0.341 g (86%). 
 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.348 – 7.273 (4H, m, Ho- + m-Ph), 
5.222 (1H, d, J = 1.9 Hz, H13), 5.154 (1H, d, J = 1.9 Hz, H13), 2.560 (1H, tt, J = 8.9, 2.2 
Hz, H5), 2.438 (1H, dd, J = 16.2, 8.9 Hz, H4b), 2.186 – 2.051 (4H, m), 1.906 – 1.849 
(3H, m), 1.777 (1H, dddd, J = 12.0, 10.8, 8.9, 6.5 Hz, H6), 1.654 – 1.475 (4H, m), 1.421 
– 1.291 (9H, m), 1.257 (9H, s, H9), 0.959 (3H, t, J = 7.3 Hz, H16 or 22), 0.919 (3H, t, J = 
6.9 Hz, H16 or 22). 
13C NMR (100 MHz, BENZENE-D6):  (ppm) = 156.83 (C12), 149.74 (C11), 142.44 
(Ci-Ph), 139.68 (C2 or 3), 138.41 (C2 or 3), 128.47 (2CHo-Ph), 125.09 (2CHm-Ph), 113.65 
(CH213), 71.26 (C1), 44.94 (CH5), 44.64 (CH24), 37.31 (CH2), 36.98 (CH2), 34.80 (C10), 
32.60 (CH2), 31.89 (3CH39), 30.32 (CH2), 30.11 (CH2), 29.85 (CH2), 28.61 (CH2), 26.17 
(CH2), 24.60 (CH2), 23.44 (CH2), 15.69 (CH316 or 22), 14.71 ppm (CH316 or 22). 
HRMS (EI): Found: [M]+, 392.3448. C29H44 requires: 392.3443. 
LRMS (CI): m/z: 392 ([M]+, 100%), 335 ([M – t-Bu]+, 24%), 233 ([M – p-t-Bu –
Styrene]+, 57%). 
IR (thin film): ν~ = 2952 (s), 2926 (s), 2862 (m), 1614 (w), 1504 (w), 1463 (m), 1361 
(w), 1270 (w), 1119 (w), 1017 (w), 896 (s), 835 (s), 601 (w) cm–1. 
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6.2.6.29. rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-methylaza-
bicyclo[3.3.0]oct-2-ene (2.67a) 
N
H
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General procedure A was used with N-methyl-N-(phenylprop-2-ynyl)prop-2-en-1-
amine, 1,1-dibromoheptane and 1-ethynylbenzene as components. Purification of the 
crude material by column chromatography on Al2O3 (basic, gr. III) with 2.5% of Et2O in 
hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.240 g 
(62%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.385 – 7.251 (10H, m, HAr), 5.101 (1H, d, J = 
1.1 Hz, H10), 4.929 (1H, d, J = 1.1 Hz, H10), 2.691 (1H, d, J = 9.4 Hz, H8a or 8b), 2.679 
(1H, dd, J = 8.4, 4.0 Hz, H6a or 6b), 2.632 (1H, d, J = 9.4 Hz, H8a or 8b), 2.626 (1H, tdd, J = 
7.9, 4.0, 2.0 Hz, H5), 2.496 (1H, fs ddd, J = 16.8, 8.8, Hz, H4b), 2.446 (1H, dd, J = 8.4, 
4.0 Hz, H6a or 6b), 2.311 (3H, s, H7), 2.152 (1H, dd, J = 16.8, 1.7 Hz, H4a), 2.120 – 2.082 
(2H, m, H11), 1.454 – 1.345 (2H, m), 1.319 – 1.218 (6H, m), 0.892 (3H, t, J = 7.0 Hz, 
H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 153.64 (C2 or 9), 143.66 (C2 or 9), 141.53 (Ci-
Ph), 139.52 (Ci-Ph), 137.54 (C3), 129.89 (2CHo- or m-Ph), 127.73 (2CHo- or m-Ph), 127.65 
(2CHo- or m-Ph), 127.57 (2CHo- or m-Ph), 126.71 (CHp-Ph), 126.46 (CHp-Ph), 114.98 (CH210), 
70.11 (C1), 65.77 (2CH26 + 8), 46.35 (CH5), 42.73 (CH37), 41.98 (CH24), 31.67 (CH2), 
29.81 (CH2), 29.39 (CH211), 27.72 (CH2), 22.58 (CH2), 14.06 (CH316). 
HRMS (ESI+): Found: [M + H]+, 386.2832. [C28H36N]+ requires: 386.2842. 
LRMS (ESI+): m/z: 386 ([M + H]+, 100%). 
IR (thin film): ν~ = 2933 (m), 2858 (m), 2775 (m), 1595 (w), 1497 (m), 1436 (m), 1157 
(m), 900 (m), 771 (m), 699 (s) cm–1. 
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6.2.6.30. rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-benzylaza-
bicyclo[3.3.0]oct-2-ene (2.67b) 
N
H
Ha
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General procedure A was used with N-benzyl-N-(phenylprop-2-ynyl)prop-2-en-1-
amine, 1,1-dibromoheptane and 1-ethynylbenzene as components. The carbenoid was 
generated in situ from 1,1-dibromoheptane (1.3 mmol) and LDA (0.83 mL of a 1.8 M 
solution, 1.50 mmol) at –85 °C for 15 min before dropwise addition of phenyl acetylide. 
Purification of the crude material by column chromatography on Al2O3 (basic, grade III) 
with 1% of Et2O in hexanes as the eluent gave the title compound as a colourless oil in 
yield of 0.341 g (74%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.404 – 7.185 (15H, m, HAr), 5.071 (1H, d, J = 
1.4 Hz, H10), 4.856 (1H, d, J = 1.4 Hz, H10), 3.583 (1H, d, J = 13.4 Hz, H11), 3.538 (1H, 
d, J = 13.4 Hz, H11), 2.725 (1H, dd, J = 8.5, 7.5 Hz, H6b), 2.672 (1H, d, J = 9.4 Hz, H8), 
2.622 (1H, dddd, J = 8.6, 7.5, 3.8, 1.8 Hz, H5), 2.542 (1H, d, J = 9.4 Hz, H8), 2.512 (1H, 
dd, J = 16.8, 9.2 Hz, H4b), 2.476 (1H, d, J = 8.5 Hz, H6a), 2.184 (1H, dd, J = 16.8, 1.8 
Hz, H4a), 2.131 – 2.087 (2H, m, H12), 2.106 (1H, dd, J = 6.6, 2.5 Hz), 1.465 – 1.392 
(2H, m), 1.343 – 1.238 (6H, m), 0.906 (3H, t, J = 7.0 Hz, H17). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 153.64 (C9), 143.67 (C2 or 3), 141.50 (C2 or 3), 
139.84 (Ci-Ph), 139.63 (Ci-Ph), 137.59 (Ci-Ph), 129.90 (2CHo- or m-Ph), 128.30 (2CHo- or m-
Ph), 128.01 (2CHo- or m-Ph), 127.73 (2CHo- or m-Ph), 127.66 (2CHo- or m-Ph), 127.48 (2CHo- or 
m-Ph), 126.69 (CHp-Ph), 126.59 (CHp-Ph), 126.37 (CHp-Ph), 115.02 (CH210), 69.41 (C1), 
63.44 (CH26), 62.77 (CH28), 59.93 (CH211), 45.98 (CH1), 42.03 (CH24), 31.75 (CH2), 
29.71 (CH212), 29.26 (CH2), 27.83 (CH2), 22.62 (CH2), 14.11 (CH317). 
HRMS (ESI+): Found: [M + H]+, 462.3149. [C34H40N]+ requires: 462.3155. 
LRMS (ESI+): m/z: 462 ([M + H]+, 100 %).  
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IR (thin film): ν~ = 2924 (m), 2848 (w), 2783 (w), 1498 (m), 1428 (w), 1142 (w), 1018 
(w), 899 (m), 775 (m), 694 (s) cm–1. 
 
6.2.7. Preparation of compounds 2.69 and 2.70 
General procedure B: To a solution of Cp2ZrCl2 (1.465 g, 5.0 mmol) in dry THF (25 
mL) cooled to –78 °C was added n-BuLi (4.0 mL of a 2.5 M solution in hexanes, 10.0 
mmol) dropwise. After 20 min, a solution of TBDMS protected 7-phenylhept-1-en-6-
yn-3-ol 2.41 (1.50 g, 5.0 mmol) in dry THF (15 mL) was added dropwise. After 30 min 
at –78 °C the reaction mixture was allowed to warm to room temperature and continued 
to stir for 3 h. After re-cooling the reaction mixture to –78 °C, a solution of 1,1-
dibromoheptane (1.42 g, 5.5 mmol) in dry THF (5 mL) was added followed by 
dropwise addition of LDA (3.06 mL of a 1.8 M solution, 5.5 mmol). The reaction 
mixture was stirred at –78 °C for 15 min before dropwise addition of phenyl acetylide. 
[Lithium phenyl acetylide was freshly prepared from phenylacetylene (1.65 mL, 15.0 
mmol) in dry THF (15 mL) and n-BuLi (6.0 mL of a 2.5 M solution in hexanes, 15.0 
mmol) at –10 °C over 15 min].  
The stirring was continued for 45 min during which the reaction mixture was allowed to 
warm to –55 °C before addition of MeOH (30 mL) and a saturated aqueous solution of 
NaHCO3 (30 mL). The whole mixture was allowed to warm to room temperature and 
was left stirring for 5 h. The mixture was then poured onto H2O (200 mL) and the 
products were extracted with Et2O (3 × 200 mL). The combined organic phases were 
washed with H2O (3 × 300 mL) and brine (300 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to give the crude products as yellow oils. Purification 
of the crude material by flash chromatography column with 2.5% of Et2O in hexanes as 
the eluent provided the TBDMS protected alcohols 2.68 as a yellow oil (2.20 g, 88%). 
 
The TBDMS protected alcohols 2.68 (2.20 g, 4.40 mmol) were dissolved in dry THF 
(44 and 38 mL respectively) followed by addition of TBAF (17.60 mL of 1.0 M 
solution in THF), and the reaction mixture was stirred at RT for 20 h. Then the mixture 
was poured onto H2O (200 mL), the products extracted with Et2O (2 × 150 mL). The 
organic phases were washed with H2O (3 × 200 mL), brine (1 × 200 mL), and dried 
over MgSO4. Concentration in vacuo, followed by separation by column 
chromatography on Al2O3 (basic, grade III) and 2.5% EtOAc in hexanes as the eluent 
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gave the partially separated isomers: 0.277 g of pure 2.69-endo (14%), 0.650 g of mixed 
fractions (33%) and 0.556 of pure 2.69-exo (29%), combined yield of 1.483 g (76%). 
Further chromatography of the mixed fractions allowed additional pure 2.69-exo and 
2.69-endo to be isolated. 
 
6.2.7.1. rac-(1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-exo) 
HH
OH HaHb
7 3
5
21
6
8
4
9 10
11
12 13
14
1615
 
Yellow oil. 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.372 – 7.192 (10H, m, HAr), 5.078 (1H, d, J = 
1.5 Hz, H10), 5.001 (1H, d, J = 1.5 Hz, H10), 3.958 (1H, br s, H6), 2.388 (1H, dd, J = 
16.2, 9.6 Hz, H4b), 2.303 (1H, fs dd, J = 9.6 Hz, H5), 2.152 – 2.004 (4H, m), 1.792 – 
1.670 (3H, m), 1.376 – 1.222 (9H, m, 8Haliphatic + OH), 0.869 (3H, t, J = 6.8 Hz, H16). 
13C NMR (75 MHz, CDCl3):  (ppm) = 154.69 (C9), 144.21 (C2 or 3), 141.19 (C2 or 3), 
139.17 (Ci-Ph), 137.43 (Ci-Ph), 129.73 (2CHo- or m-Ph), 127.78 (2CHo- or m-Ph), 127.72 
(2CHo- or m-Ph), 127.62 (2CHo- or m-Ph), 126.66 (CHp-Ph), 126.59 (CHp-Ph), 114.99 (CH210), 
82.10 (CH6), 69.40 (C1), 55.92 (CH5), 40.29 (CH2), 34.04 (CH2), 32.13 (CH2), 31.66 
(CH2), 29.73 (CH2), 29.37 (CH2), 27.83 (CH2), 22.58 (CH2), 14.06 (CH316). 
HRMS (EI): Found: [M]+, 386.2611. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]+·, 36%), 283 ([M – H2O]+·, 21%), 283 ([M – Styrene]+·, 
100%). 
IR (thin film): ν~ = 3327 (m, br), 2918 (m), 1599 (w), 1493 (m), 1338 (w), 771 (m), 699 
(s) cm–1. 
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6.2.7.2. (1S,5S,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-
2-ene (2.69-exo-ent-1) 
Rt 11.7 min on chiral HPLC on a Diacel OD-H, (1 mL/min 1% isopropanol in hexane on 
4.6 x 250 mm column). 
[α]D25 –46.7 (c = 0.48, CHCl3, 100% e.e.). 
 
6.2.7.3. (1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-exo-ent-2) 
Rt 18.5 min on chiral HPLC on a Diacel OD-H, (1 mL/min 1% isopropanol in hexane on 
4.6 x 250 mm column). 
[α]D25 +45.1 (c = 0.49, CHCl3, 100% e.e.). 
 
6.2.7.4. rac-(1R,5R,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.69-endo) 
HHO
H HaHb
Hb
Ha
7 3
5
21
6
8
4
9 10
11
12 13
14
1615
 
Yellow oil. 
1H NMR (300 MHz, CDCl3):  (ppm) = 7.350 – 7.207 (10H, m, HAr), 5.074 (1H, d, J = 
1.5 Hz, H10), 4.955 (1H, d, J = 1.5 Hz, H10), 4.178 (1H, ddd, J = 9.1, 8.5, 5.5 Hz, H6), 
2.633 (1H, dd, J = 17.2, 2.1 Hz, H4a), 2.500 (1H, td, J = 8.5, 2.1 Hz, H5), 2.166 – 2.006 
(3H, m), 1.855 (1H, ddt, J = 10.4, 5.5, 4.4 Hz, H7b), 1.742 – 1.699 (2H, m), 1.573 (1H, 
ddd, J = 10.4, 9.1, 8.1 Hz, H7a), 1.496 – 1.346 (2H, m), 1.287 – 1.239 (7H, m, 6Haliphatic 
+ OH), 0.872 (3H, t, J = 6.8 Hz, H16). 
13C NMR (75 MHz, CDCl3):  (ppm) = 154.86 (C9), 144.00 (C2 or 3), 143.28 (C2 or 3), 
139.37 (Ci-Ph), 137.06 (Ci-Ph), 129.82 (2CHo- or m-Ph), 127.78 (2CHo- or m-Ph), 127.70 
(2CHo- or m-Ph), 127.61 (2CHo- or m-Ph), 126.70 (CHp-Ph), 126.56 (CHp-Ph), 114.88 (CH210), 
74.55 (CH6), 68.83 (C1), 49.19 (CH5), 33.77 (CH2), 33.49 (CH2), 31.83 (CH2), 31.66 
(CH2), 29.89 (CH2), 29.47 (CH2), 27.93 (CH2), 22.60 (CH2), 14.06 (CH316). 
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HRMS (EI): Found: [M]+, 386.2600. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]+·, 12%), 368 ([M – H2O]+·, 17%), 283 ([M – Styrene]+·, 
69%). 
IR (thin film): ν~ = 3323 (m, br), 2922 (m), 1595 (w), 1489 (m), 1289 (w), 1073 (m), 
900 (m), 775 (m), 692 (s) cm–1. 
 
6.2.7.5. rac-(1R,5R,6R)-6-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.70-exo) 
HH
O HaHb
7 3
5
21
6
8
4
O
9 10
11
12 13
14
1615
1718
 
Alcohol 2.69-exo (0.028 g, 0.072 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.15 mL, 1.85 mmol) and freshly distilled acetic anhydride (0.50 mL, 5.25 
mmol). After stirring for 10 min at RT, DMAP (0.005 g, 0.041 mmol) was added and 
the stirring was continued at RT for 13 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated and washed with HCl (15 mL of a 1.0 M solution), a saturated aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with 3% of EtOAc in 
hexanes as the eluent gave the title compound (exo diastereoisomer) as a colourless oil 
in yield of 0.0254 g (82%). 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.350 – 7.220 (10H, m, HAr), 5.076 (1H, d, J = 
1.5 Hz, H10), 5.035 (1H, d, J = 1.5 Hz, H10), 4.828 (1H, t, J = 2.9 Hz,  H6), 2.391 (1H, d, 
J = 9.4 Hz, H5), 2.348 (1H, dd, J = 15.5, 9.4 Hz, H4b), 2.182 (1H, d, J = 15.5 Hz, H4a), 
2.085 – 1.963 (3H, m), 2.010 (3H, s, H18), 1.783 – 1.686 (3H, m), 1.365 – 1.193 (8H, 
m), 0.872 (3H, t, J = 7.0 Hz, H16). 
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13C NMR (100.5 MHz, CDCl3):  (ppm) = 170.77 (C17), 154.41 (C9), 143.85 (C2 or 3), 
141.87 (C2 or 3), 138.59 (Ci-Ph), 137.28 (Ci-Ph), 129.58 (2CHo- or m-Ph), 127.76 (2CHo- or m-
Ph), 127.69 (4CHo- or m-Ph), 126.71 (CHp-Ph), 126.65 (CHp-Ph), 115.03 (CH210), 84.83 
(CH6), 69.35 (C1), 53.23 (CH5), 40.29 (CH2), 32.38 (CH2), 31.62 (CH2), 31.44 (CH2), 
29.72 (CH2), 29.37 (CH2), 27.79 (CH2), 22.57 (CH2), 21.41 (CH318), 14.06 (CH316). 
HRMS (ESI+): Found: [M + Na]+, 451.2604. [C30H36O2Na]+ requires: 451.2608. 
LRMS (EI): m/z: 428 ([M]+·, 6%), 368 ([M – AcOH]+·, 86%), 283 ([M – AcOH – 
Hex]+·, 43%), 265 ([M – Ph – C2H5]+·, 100%). 
IR (thin film): ν~ = 2922 (m), 1731 (s), 1603 (w), 1493 (m), 1239 (s), 1021 (m), 907 
(m), 767 (m), 703 (s) cm–1. 
 
6.2.7.6. rac-(1R,5R,6S)-6-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.70-endo) 
HO
H HaHb
7 3
5
21
6
8
4
O
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1615
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18
 
Alcohol 2.69-endo (0.028 g, 0.072 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.150 mL, 1.85 mmol) and freshly distilled acetic anhydride (0.50 mL, 5.25 
mmol). After stirring for 10 min at RT, DMAP (0.005 g, 0.041 mmol) was added and 
the stirring was continued at RT for 13 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated and washed with HCl (15 mL of a 1.0 M solution), saturated aqueous solution 
of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a pale yellow oil. Purification of the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with 3% of 
EtOAc in hexanes as the eluent gave the title compound (endo diastereoisomer) as a 
colourless oil (0.021 g, 95%). Crystallization from hexanes gave white crystals. 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.342 – 7.214 (10H, m, HAr), 5.078 (1H, d, J = 
1.5 Hz, H10), 5.012 (1H, td, J = 9.1, 7.0 Hz, H6), 4.973 (1H, d, J = 1.5 Hz, H10), 2.682 
(1H, dd, J = 8.8, 1.8 Hz, H5), 2.283 (1H, dd, J = 17.4, 1.8 Hz, H4a), 2.120 – 2.024 (2H, 
m), 2.062 (3H, s, H18), 1.998 (1H, dd, J = 17.4, 8.8 Hz, H4b), 1.913 (1H, m), 1.754 – 
1.626 (3H, m), 1.429 – 1.357 (2H, m), 1.310 – 1.205 (6H, m), 0.877 (3H, t, J = 6.9 Hz, 
H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 170.64 (C17), 154.35 (C9), 143.67 (C2 or 3), 
143.22 (C2 or 3), 138.58 (Ci-Ph), 136.95 (Ci-Ph), 129.72 (2CHo- or m-Ph), 127.81 (2CHo- or m-
Ph), 127.71 (2CHo- or m-Ph), 127.66 (2CHo- or m-Ph), 126.75 (CHp-Ph), 126.63 (CHp-Ph), 
115.16 (CH210), 76.37 (CH6),  68.59 (C1), 46.94 (CH5), 34.61 (CH2), 31.73 (CH2), 31.16 
(CH2), 30.12 (CH2), 29.77 (CH2), 29.39 (CH2), 27.85 (CH2), 22.61 (CH2), 21.08 
(CH318), 14.08 (CH316). 
HRMS (EI): Found: [M]+, 428.2721. C30H36O2 requires: 428.2715. 
LRMS (EI): m/z: 428 ([M]+·, 14%), 368 ([M – AcOH]+·, 94%), 325 ([M – Styrene]+·, 
22%), 283 ([M – AcOH – Hex]+·, 42%), 265 ([M – Ph – C2H5]+·, 61%). 
IR (thin film): ν~ = 2924 (m), 1741 (s), 1599 (w), 1493 (m), 1239 (s), 1055 (m), 907 
(m), 770 (m), 703 (s) cm–1. 
m.p. 42 – 44 oC. 
 
6.2.8. Preparation of compounds 2.72 and 2.73 
Following general procedure B and using TBDMS protected 7-phenylhept-1-en-6-yn-4-
ol 2.48. Purification of the product by flash chromatography column with 2.5% of Et2O 
in hexanes provided the TBDMS protected alcohols 2.71 as a yellow oil, in yield of 
1.94 g (78%). The TBDMS protected alcohols (1.94 g, 3.88 mmol) were dissolved in 
dry THF (38 mL) followed by addition of TBAF (7.76 mL of 1.0 M), and the reaction 
mixture was stirred at RT for 20 h. Then the mixture was poured onto H2O (200 mL), 
the products extracted with Et2O (2 × 150 mL). The organic phases were washed with 
H2O (3 × 200 mL), brine (1 × 200 mL), and dried over MgSO4. Concentration in vacuo, 
followed by separation by column chromatography on Al2O3 (basic, grade III) and 2.5% 
EtOAc in hexanes as the eluent gave the partially separated isomers: 0.632 g of pure 
2.72-endo (33%), 0.349 g of mixed fractions (18%) and 0.361 of pure 2.72-exo (19%), 
combined yield of 1.342 g (70%). Further chromatography of the mixed fractions 
allowed additional pure 2.72-exo and 2.72-endo to be isolated. 
 168 
6.2.8.1. rac-(1R,5R,7R)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.72-exo) 
HH
a
Hb HaHb
7 3
5
21
6
8
4
PhHa
HO
Hb
H
9
10
11
12 13
14
1615
 Pale yellow oil. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.291 – 7.191 (10H, m, HAr), 4.992 (1H, d, J = 
1.5 Hz, H10), 4.980 (1H, d, J = 1.5 Hz, H10), 4.197 (1H, tt, J = 8.0, 5.9 Hz, H7), 2.554 
(1H, dddd, J = 10.0, 8.4, 3.6, 1.5 Hz, H5), 2.186 (1H, dd, J = 16.8, 8.3 Hz, H4b), 2.064 – 
1.890 (3H, m, 2H11 + H4a), 1.927 (1H, ddd, J = 12.4, 5.5, 1.5 Hz, H8a), 1.823 (1H, ddd, J 
= 12.7, 10.0, 8.3 Hz, H6b), 1.718 (1H, dd, J = 12.4, 8.5 Hz, H8b), 1.642 (1H, dddd, J = 
12.7, 6.3, 3.6, 1.5 Hz, H6a), 1.498 (1H, br s, OH) 1.301 – 1.152 (9H, m), 0.812 (3H, t, J 
= 7.0 Hz, H16). 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.406 – 7.366 (4H, m, Ho-Ph), 7.252 – 
7.095 (6H, m, Hm + p-Ph), 5.056 (2H, br s, H10), 4.163 (1H, tt, J = 8.0, 5.9 Hz, H7), 2.626 
(1H, dddd, J = 10.0, 8.4, 3.6, 1.5 Hz, H5), 2.225 (1H, dd, J = 16.6, 8.3 Hz, H4b), 2.068 
(2H, apparent t, J = 7.8 Hz, H11), 2.035 (1H, ddd, J = 12.4, 5.5, 1.5 Hz, H8a), 1.841 (1H, 
dd, J = 16.6, 1.5 Hz, H4a),  1.804 (1H, ddd, J = 12.6, 10.0, 8.3 Hz, H6b), 1.752 (1H, dd, J 
= 12.4, 8.8 Hz, H8b), 1.582 (1H, dddd, J = 12.6, 6.3, 3.6, 1.5 Hz, H6a), 1.321 – 1.098 
(9H, m, 8Haliphatic + OH), 0.863 (3H, t, J = 7.0 Hz, H16). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 155.97 (C9), 144.35 (C2 or 3), 142.36 
(C2 or 3), 140.17 (Ci-Ph), 138.41 (Ci-Ph), 130.35 (2CHo- or m-Ph), 128.91 (2CHo- or m-Ph), 
128.69 (2CHo- or m-Ph), 128.59 (2CHo- or m-Ph), 127.44 (CHp-Ph), 127.41 (CHp-Ph), 115.14 
(CH210), 73.34 (CH7),  68.49 (C1), 45.09 (CH26), 44.77 (CH5), 44.30 (CH24 or 8), 43.96 
(CH24 or 8), 32.37 (CH2), 30.59 (CH2), 30.17 (CH2), 28.55 (CH2), 23.34 (CH215), 14.66 
(CH316). 
HRMS (EI): Found: [M]+, 386.2597. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]+·, 25%), 368 ([M – H2O]+·, 22%), 283 ([M – Styrene]+·, 
100%). 
IR (thin film): ν~ = 3330 (m, br), 2930 (m), 1603 (w), 1504 (m), 1349 (w), 1073 (m), 
907 (m), 775 (m), 692 (s) cm–1. 
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6.2.8.2. rac-(1R,5R,7S)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.72-endo) 
HH
a
Hb HaHb
7 3
5
21
6
8
4
PhHa
H
Hb
HO
9
10
11
12 13
14
1615
 Yellow oil. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.283 – 7.155 (10H, m, HAr), 4.990 (1H, d, J = 
1.3 Hz, H10), 4.939 (1H, d, J = 1.3 Hz, H10), 4.107 (1H, quintet, J = 5.4 Hz, H7), 2.472 
(1H, tdd, J = 8.8, 6.2, 1.4 Hz, H5), 2.311 (1H, dd, J = 16.8, 8.5 Hz, H4b), 2.210 (1H, 
dddd, J = 13.3, 9.3, 5.6, 1.0 Hz, H6b), 2.103 (1H, dd, J = 16.8, 1.4 Hz, H4a), 2.070 – 
1.966 (2H, m, H11), 2.028 (1H, ddd, J = 13.5, 6.2, 1.1 Hz, H8b), 1.791 (1H, ddd, J = 
13.5, 4.6, 1.1 Hz, H8a), 1.459 (1H, dddd, J = 13.3, 6.0, 5.0, 1.3 Hz, H6a), 1.332 – 1.261 
(2H, m), 1.221 – 1.135 (7H, m, 6Haliphatic + OH), 0.792 (3H, t, J = 7.0 Hz, H16). 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.498 (2H, dd, J = 8.1, 1.3 Hz, Ho-Ph), 
7.322 (2H, dd, J = 8.1, 1.3 Hz, Ho-Ph), 7.257 – 7.109 (6H, m, Hm + p-Ph), 5.054 (1H, d, J = 
1.5 Hz, H10), 5.036 (1H, d, J = 1.5 Hz, H10), 4.031 (1H, br s, H7), 2.519 (1H, tdd, J = 
8.8, 6.2, 1.4 Hz, H5), 2.388 (1H, dd, J = 16.6, 8.5 Hz, H4b), 2.115 – 2.011 (5H, m, 2H11 
+ 3H), 1.912 (1H, ddd, J = 13.6, 5.3, 1.3 Hz, H8a), 1.485 (1H, dddd, J = 12.8, 6.5, 3.9, 
1.3 Hz, H6a), 1.382 – 1.307 (2H, m) 1.244 – 1.097 (7H, m, 6Haliphatic + OH), 0.855 (3H, 
t, J = 7.0 Hz, H16). 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 156.04 (C9), 144.57 (C2 or 3), 142.39 
(C2 or 3), 141.00 (Ci-Ph), 138.59 (Ci-Ph), 130.66 (2CHo- or m-Ph), 128.84 (2CHo- or m-Ph), 
128.68 (2CHo- or m-Ph), 128.58 (2CHo- or m-Ph), 127.41 (CHp-Ph), 127.38 (CHp-Ph), 114.85 
(CH210), 74.60 (CH7),  69.51 (C1), 46.09 (CH5), 45.05 (CH26), 44.79 (CH28), 43.39 
(CH24), 32.35 (CH2), 30.65 (CH2), 30.15 (CH2), 28.53 (CH2), 23.33 (CH2), 14.66 
(CH316). 
HRMS (EI): Found: [M]+, 386.2597. C28H34O requires: 386.2610. 
LRMS (EI): m/z: 386 ([M]+·, 2%), 368 ([M – H2O]+·, 16%), 283 ([M – Styrene]+·, 
100%). 
IR (thin film): ν~ = 3328 (m, br), 2932 (m), 1603 (w), 1504 (m), 1349 (w), 1070 (m), 
907 (m), 775 (m), 692 (s) cm–1. 
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6.2.8.3. rac-(1R,5R,7R)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.73-exo) 
HH
a
Hb HaHb
7 3
5
21
6
8
4
PhHa
O
Hb
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14
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18
 
Alcohol 2.72-exo (0.026 g, 0.067 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.14 mL, 1.72 mmol) and freshly distilled acetic anhydride (0.48 mL, 5.06 
mmol). After stirring for 10 min at RT, DMAP (0.0048 g, 0.038 mmol) was added and 
the stirring was continued at RT for 17 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated and washed with HCl (15 mL of a 1.0 M solution), a saturated aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with 3% of EtOAc in 
hexanes as the eluent gave the title compound (exo diastereoisomer) as a colourless oil 
in yield of 0.023 g (80%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.359 – 7.253 (10H, m, HAr), 5.056 (1H, tt, J = 
8.0, 6.1 Hz, H7), 5.027 (1H, d, J = 1.5 Hz, H10), 5.019 (1H, d, J = 1.5 Hz, H10), 2.622 
(1H, dddd, J = 9.8, 7.8, 4.2, 1.0 Hz, H5), 2.285 (1H, dd, J = 16.8, 8.0 Hz, H4b), 2.121 – 
1.907 (4H, m, 2H11 + H6b + H8b), 1.996 (1H, dd, J = 16.8, 1.0 Hz, H4a), 1.961 (3H, s, 
H18), 1.893 (1H, dd, J = 12.8, 8.3 Hz, H8a), 1.807 (1H, dddd, J = 12.8, 6.6, 4.4, 1.5 Hz, 
H6a), 1.378 – 1.180 (8H, m), 0.867 (3H, t, J = 7.0 Hz, H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 170.87 (C17), 154.32 (C9), 143.29 (C2 or 3), 
142.04 (C2 or 3), 138.86 (Ci-Ph), 137.16 (Ci-Ph), 129.61 (2CHo- or m-Ph), 128.14 (2CHo- or m-
Ph), 127.80 (2CHo- or m-Ph), 127.57 (2CHo- or m-Ph), 126.70 (CHp-Ph), 126.65 (CHp-Ph), 
114.73 (CH210), 75.56 (CH7),  67.21 (C1), 43.95 (CH5), 42.80 (CH2), 40.67 (CH2), 39.79 
(CH2), 31.65 (CH2), 29.88 (CH2), 29.42 (CH2), 27.75 (CH2), 22.56 (CH2), 21.21 
(CH318), 14.06 (CH316). 
HRMS (ESI+): Found: [M + Na]+, 451.2605. [30H36O2Na]+ requires: 451.2608. 
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LRMS (EI): m/z: 428 ([M]+·, 9%), 368 ([M – AcOH]+·, 30%), 283 ([M – AcOH – 
Hex]+·, 16%), 265 ([M – Ph – C2H5]+·, 100%). 
IR (thin film): ν~ = 2926 (m), 1741 (s), 1603 (w), 1493 (m), 1245 (s), 1051 (m), 907 
(m), 767 (m), 703 (s) cm–1. 
 
6.2.8.4. rac-(1R,5R,7S)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-
bicyclo[3.3.0]oct-2-ene (2.73-endo) 
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Alcohol 2.72-endo (0.018 g, 0.046 mmol) was dissolved in the mixture of anhydrous 
pyridine (0.10 mL, 1.23 mmol) and freshly distilled acetic anhydride (0.33 mL, 3.46 
mmol). After stirring for 10 min at RT, DMAP (0.0033 g, 0.027 mmol) was added and 
the stirring was continued at RT for 17 h. Then H2O (5 mL) was added to the reaction 
mixture and the whole mixture was poured onto Et2O (15 mL). The organic phase was 
separated and washed with HCl (15 mL of a 1.0 M solution), a saturated aqueous 
solution of NaHCO3 (15 mL) and brine (2 × 15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a pale yellow oil. Purification of the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with 5% of 
EtOAc in hexanes as the eluent gave the title compound (endo diastereoisomer) as a 
colourless oil in yield of 0.016 g (79%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.340 – 7.248 (10H, m, HAr), 5.102 (1H, d, J = 
1.4 Hz, H10), 5.083 (1H, tt, J = 6.2, 5.1 Hz, H7),  5.045 (1H, d, J = 1.4 Hz, H10), 2.550 
(1H, tdd, J = 8.5, 6.5, 1.9 Hz, H5), 2.363 (1H, ddd, J = 13.5, 9.3, 6.2 Hz, H6b), 2.314 
(1H, dd, J = 16.8, 8.3 Hz, H4b), 2.261 (1H, ddd, J = 13.9, 6.2, 0.5 Hz, H8b), 2.171 – 
2.048 (3H, m, 2H11 + H4a), 1.998 (3H, s, H18), 1.904 (1H, ddd, J = 13.9, 5.0, 1.1 Hz, 
H8a), 1.568 (1H, dddd, J = 13.5, 6.5, 5.3, 1.2 Hz, H6a), 1.423 – 1.339 (2H, m), 1.312 – 
1.199 (6H, m), 0.883 (3H, t, J = 7.0 Hz, H16). 
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13C NMR (100.5 MHz, CDCl3):  (ppm) = 170.78 (C17), 154.60 (C9), 143.33 (C2 or 3), 
140.49 (C2 or 3), 139.62 (Ci-Ph), 137.68 (Ci-Ph), 129.70 (2CHo- or m-Ph), 128.10 (2CHo- or m-
Ph), 127.67 (2CHo- or m-Ph), 127.60 (2CHo- or m-Ph), 126.72 (CHp-Ph), 126.47 (CHp-Ph), 
114.49 (CH210), 76.37 (CH7),  68.29 (C1), 45.15 (CH5), 42.42 (CH2), 40.75 (CH2), 40.65 
(CH2), 31.70 (CH2), 30.02 (CH2), 29.49 (CH2), 27.84 (CH2), 22.58 (CH2), 21.36 
(CH318), 14.07 (CH316). 
HRMS (ESI+): Found: [M + Na]+, 451.2606. [C30H36O2Na]+ requires: 451.2608. 
LRMS (EI): m/z: 428 ([M]+·, 8%), 368 ([M – AcOH]+·, 59%), 283 ([M – AcOH –
Hex]+·, 30%), 265 ([M – Ph – C2H5]+·, 100%). 
IR (thin film): ν~ = 2926 (m), 1735 (s), 1599 (w), 1501 (m), 1236 (s), 1017 (m), 907 
(m), 775 (m), 703 (s) cm–1.  
 
6.2.9. Preparation of other bicyclic compounds 
 
6.2.9.1. rac-(1R,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-bicyclo[4.3.0]oct-2-ene 
(2.78) 
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General procedure A was used with 1-(oct-7-en-1-ynyl)benzene, 1,1-dibromoheptane 
and 1-ethynylbenzene as components, except that LiTMP [which was freshly prepared 
from 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.1 mmol) in dry THF (1 mL) and n-BuLi 
(0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 15 min] was used 
instead of LDA. The carbenoid was generated in situ from 1,1-dibromoheptane (1.05 
mmol) and LiTMP at –90 °C for 25 min (during which the reaction mixture was 
warmed to –80 °C), before dropwise addition of phenyl acetylide. Purification of the 
crude material by careful column chromatography on SiO2 (230 – 400 mesh) with 
hexanes as the eluent gave the title compound as a pale yellow oil in yield of 0.101 g 
(26%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.352 – 7.224 (10H, m, HAr), 5.250 (1H, d, J = 
1.6 Hz, H7), 5.130 (1H, d, J = 1.6 Hz, H7), 2.376 (1H, dt, J = 12.0, 6.3 Hz,  H2), 2.725 
(1H, dd, J = 15.5, 7.0 Hz,  H11a or b), 2.207 – 2.169 (2H, m,  H12), 2.129 (1H, dd, J = 
15.5, 6.1 Hz, H11a or b), 2.010 (1H, ddd, J = 13.8, 7.8, 3.3 Hz, H6a or b), 1.610 (1H, ddd, J 
= 13.8, 8.5, 3.5 Hz, H6a or b), 1.525 – 1.236 (13H, m), 0.899 (3H, t, J = 7.0 Hz, H17). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 152.84 (C8), 143.92 (C9 or 10 or i-Ph), 142.08 
(C9 or 10 or i-Ph), 141.87 (C9 or 10 or i-Ph), 137.84 (C9 or 10 or i-Ph),  129.40 (2CHo- or m-Ph), 128.84 
(2CHo- or m-Ph), 127.55 (2CHo- or m-Ph), 127.36 (2CHo- or m-Ph), 126.29 (CHp-Ph), 126.13 
(CHp-Ph), 116.43 (CH27), 58.89 (C1), 40.84 (CH2), 38.97 (CH211), 31.70 (CH2), 30.96  
(CH26), 29.96 (CH212), 29.38 (CH2), 28.11 (CH2), 27.64 (CH2), 22.63 (CH2), 22.34 
(CH2), 21.43 (CH2), 14.07 (CH317). 
HRMS (EI): Found: [M]+, 384.2806. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 384 ([M]+·, 3%), 281 ([M – Styrene]+·, 100%), 197 ([M – Styrene – 
Hex]+·, 9%). 
IR (thin film): ν~ = 2918 (s), 2853 (m), 1639 (m), 1527 (m), 1179 (w), 694 (s), 500 (s) 
cm–1. 
 
6.2.9.2. rac-(3aR)-2-Hexyl-2,3,3a,4,5,6,7-heptahydro-1-phenyl-2-(1-phenylvinyl)-
2H-indene (2.79) 
Ph
HaHb
11
8
9
7
16
1514
13
12
10
17
Ph
H
3
6
5
4 2
1
 
The product was obtained simultaneously with product 2.78. Purification of the crude 
material by careful column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluent gave a pure fraction of the title compound as a pale yellow oil in yield of 
0.016 g (4%). 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.392 – 7.326 (4H, m, HAr), 7.294 – 7.246 
(6H, m, HAr), 5.114 (1H, d, J = 1.6 Hz, H10), 5.001 (1H, d, J = 1.6 Hz, H10), 2.641 (1H, 
d, J = 14.3 Hz, H9a), 2.074 (1H, dd, J = 13.1, 7.8 Hz, H6), 1.881 – 1.783 (2H, m), 1.751 
– 1.710 (1H, m), 1.661 – 1.571 (3H, m), 1.552 – 1.438 (2H, m), 1.365 – 1.083 (10H, m), 
1.047 – 0.947 (1H, m), 0.845 (3H, t, J = 7.0 Hz, H17). 
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13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.83 (C11), 144.83 (C1 or 7), 143.90 (C7 or 
1), 137.85 (Ci-Ph), 136.24 (Ci-Ph),  129.31 (2CHo- or m-Ph), 128.82 (2CHo- or m-Ph), 127.69 
(2CHo- or m-Ph), 127.14 (2CHo- or m-Ph), 126.34 (CHp-Ph), 126.21 (CHp-Ph), 113.33 (CH210), 
59.11 (C8), 44.77 (CH2), 41.19 (CH26), 36.27 (CH2), 35.99 (CH2), 31.73 (CH2), 29.97 
(CH2), 27.32 (CH212), 26.96 (CH2), 25.99 (CH2), 24.33 (CH2), 22.56 (CH2), 14.04  
(CH317). 
HRMS (EI): Found: [M]+, 384.2818. C29H36 requires: 384.2817. 
LRMS (CI): m/z: 385 ([M + H]+·, 100 %), 281 ([M – Styrene]+·, 83 %). 
IR (thin film): ν~ = 2930 (s), 2843 (m), 1482 (w), 1440 (w), 907 (w), 771 (w), 695 (s) 
cm
–1
. 
 
6.2.9.3. rac-(3aR,6aR)-5-Hexyl-1,2,3,3a,4,6a-hexahydro-2,2-bis(methoxymethyl)-
3a-methyl-6a-(1-phenylvinyl)-6-propylpentalene (2.87) 
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General procedure A was used with 4,4-bis(methoxymethyl)-2-methyldec-1-en-6-yne, 
1,1-dibromoheptane and 1-ethynylbenzene as components, except that LiTMP [freshly 
prepared from 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.1 mmol) in dry THF (1 mL) 
and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 15 min] 
was used instead of LDA. The carbenoid was generated in situ from 1,1-
dibromoheptane (1.05 mmol) and LiTMP at –90 °C for 25 min (during which the 
reaction mixture was warmed to –80 °C), before dropwise addition of phenyl acetylide. 
Subsequently the reaction mixture was allowed to warm to RT over 2 h before quench.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.110 g (25%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.343 – 7.320 (2H, m, Ho-Ph), 7.192 – 7.176 
(2H, m, Hm-Ph), 7.112 (1H, tt, J = 7.3, 1.3 Hz, Hp-Ph), 5.252 (1H, d, J = 2.0 Hz, H10), 
5.124 (1H, d, J = 2.0 Hz, H10), 3.353 (2H, s, H12), 3.308 (1H, d, J = 8.3 Hz, H12), 3.241 
(3H, s, H13), 3.163 (1H, d, J = 8.3 Hz, H12), 3.120 (3H, s, H13), 2.402 (1H, d, J = 14.3 
Hz, H6), 2.329 – 2.081 (6H, m), 1.978 (1H, d, J = 14.1 Hz, H8), 1.956 (1H, d, J = 14.3 
Hz, H6), 1.859 – 1.688 (2H, m), 1.654 (1H, d, J = 14.1 Hz, H8), 1.523 – 1.432 (2H, m), 
1.413 – 1.339 (6H, m), 1.255 (3H, s, H11), 1.020 (3H, t, J = 7.3 Hz, H16 or 22), 0.956 (3H, 
t, J = 6.8 Hz, H16 or 22). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 154.43 (C9), 145.33 (C2), 142.02 (Ci-Ph), 
138.60 (C3), 129.60 (2CHo-Ph), 128.08 (2CHm-Ph), 126.98 (CHp-Ph), 118.14 (CH210), 
79.21 (CH212), 77.02 (CH212), 54.20 (C1), 59.20 (CH313), 59.09 (CH313), 53.03 (C5), 
51.49 (CH26), 50.58 (CH24), 46.24 (C7), 40.12 (CH28), 32.56 (CH2), 30.89 (CH2), 30.48 
(CH2), 30.17 (CH2), 28.40 (CH2), 25.51 (CH311), 24.27 (CH2), 23.44 (CH2), 15.90 
(CH316 or 22), 14.71 (CH316 or 22). 
HRMS (EI): Found: [M]+, 438.3490. C30H46O2 requires: 438.3498. 
LRMS (CI): m/z: 438 ([M]+, 15%), 406 ([M – MeOH]+, 17%), 335 ([M – Styrene]+, 
77%), 303 ([M – MeOH – Styrene]+, 100%). 
IR (thin film): ν~ = 2949 (m), 2930 (s), 2862 (m), 1455 (m), 1376 (w), 1194 (m) 1104 
(s), 964 (m), 911 (m), 771 (m), 703 (s) cm–1. 
 
6.2.9.4. rac-(1,2,3,5-Tetrahydro-5-(dimethyl(phenyl)silyl)-5-
(trimethylsilyl)pentalene (2.92) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min, a solution of (hept-6-en-1-ynyl)trimethylsilane (0.166 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the reaction 
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mixture was allowed to warm to room temperature and stirred for 3 h.  After this time, 
the reaction mixture (previously cooled to –94 °C) was transferred via cannula to 
freshly prepared carbenoid. The carbenoid was prepared from 
(dichloromethyl)dimethyl-(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (2 mL) and n-
BuLi (0.52 mL of a 2.5 M solution in hexanes, 2.0 mmol) for 5 min at –94 °C. The 
reaction mixture was stirred for further 7 h within which time was allowed to warm to -
20 °C. After re-cooling to –78 °C, a dropwise addition of lithium phenylacetylide 
followed. [Lithium phenyl acetylide was freshly prepared from phenylacetylene (0.33 
mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 
3.0 mmol) at –5 οC over 15 min]. The stirring was continued for 1 h during which the 
reaction mixture was allowed to warm to –50 °C before addition of MeOH (5 mL) and 
saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and was left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over anhydrous 
MgSO4, filtrated and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as a colourless oil in yield of 0.165 g 
(53% of material in 91% GC purity). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.463 – 7.206 (5H, m, HAr), 5.947 (2H, s, H4, 
4’), 2.432 – 2.276 (4H, m, H2, 2’), 2.173 – 2.009 (2H, m, H1), 0.180 (6H, s, H7), –0.281 
(9H, s, H6). 
13C NMR (100 MHz, CDCl3):  (ppm) = 153.58 (2C3, 3’), 138.76 (Ci-Ph), 134.10 (2CHo-
Ph), 128.69 (CHp-Ph), 127.12 (2CHm-Ph), 122.84 (2CH4, 4’), 60.66 (C5), 31.70 (CH21), 
25.71 (2CH22, 2’), –0.97 (3CH36), –2.62 (2CH37). 
HRMS (EI): Found: [M]+, 312.1731. C19H28Si2 requires: 312.1730. 
LRMS (CI): m/z: 312 ([M + H]+·, 30%), 135 ([SiMe2Ph]+·, 100%). 
IR (thin film): ν~ = 2949 (w), 1429 (w), 1247 (s), 1111 (w), 968 (s), 869 (m), 828 (s), 
775 (s), 733 (s), 699 (s) cm–1. 
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6.2.9.5. rac-2-Hexyl-3,3a,4,5-tetrahydro-1-phenylpentalene (2.96) 
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General procedure A was used with TBDMS protected 7-phenylhept-1-en-6-yn-5-ol, 
1,1-dibromoheptane and 1-ethynyl-4-methoxybenzene as components. Purification of 
the crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes 
as the eluent gave a mixture of three compounds: 2.96, and rac-((3aR,4S,6aR)-2-hexyl-
1,3a,4,5,6,6a-hexahydro-3-phenylpentalen-4-yloxy)(tert-butyl)dimethylsilane 2.99 and 
rac-((3aS,4S,6aR)-2-hexyl-1,3a,4,5,6,6a-hexahydro-3-phenyl-3a-(1-phenylvinyl)-
pentalen-4-yloxy)(tert-butyl)dimethylsilane 2.100 as a pale yellow oil, 0.264 g. Further 
careful purification of the material by column chromatography gave the title compound 
as a colourless oil in yield of 0.056 (21%); however, the yield of this compound 
estimated by GC in the crude reaction mixture was 33%. 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.324 – 7.178 (5H, m, HAr), 5.183 (1H, q, J = 
3.0 Hz, H1), 3.094 (1H, tddd, J = 12.9, 6.6, 3.0, 1.5 Hz, H3), 2.631 (1H, m, H5), 2.518 
(1H, m, H5), 2.486 (1H, dd, J = 15.8, 8.0 Hz, H8), 2.249 (2H, t, J = 8.0 Hz, H11), 2.135 – 
2.062 (2H, m, H4 + 8), 1.499 – 1.382 (3H, m, H4 + 12), 1.268 – 1.135 (6H, m), 0.812 (3H, 
t, J = 7.0 Hz, H16). 
13C NMR (100 MHz, CDCl3):  (ppm) = 158.99 (C7), 152.74 (C2), 136.40 (Ci-Ph), 
133.73 (C6), 128.52 (2CHo-Ph), 128.08 (2CHm-Ph), 126.60 (CHp-Ph), 111.90 (CH1), 49.73 
(CH3), 39.63 (CH28), 37.56 (CH25), 32.84 (CH24), 31.67 (CH2), 30.33 (CH211), 29.35 
(CH2), 28.22 (CH2), 22.59 (CH2), 14.06 (CH316). 
HRMS (EI): Found: [M]+, 266.2033. C20H26 requires: 266.2034. 
LRMS (CI): m/z: 267 ([M + H]+·, 100%), 181 ([M – Hex]+·, 30%). 
IR (thin film): ν~ = 2926 (s), 2854 (m), 2831 (m), 1603 (w), 1489 (m), 1463 (m), 1433 
(m), 797 (m), 767 (m), 699 (s) cm–1. 
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6.2.9.6. rac-((3aS,4S,6aR)-2-Hexyl-1,3a,4,5,6,6a-hexahydro-3-phenyl-3a-(1-
phenylvinyl)pentalen-4-yloxy)(tert-butyl)dimethylsilane (2.100) 
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The title compound was obtained simultaneously with compounds 2.96 and 2.99. 
Careful purification of the material by column chromatography allowed for partial 
separation to give a pure fraction of the title compound as a pale yellow oil in yield of 
0.011 g (2%); however, the yield of this compound estimated by GC in the crude 
reaction mixture was 12%. 
1H NMR (400 MHz, BENZENE-D6):  (ppm) = 5.522 (2H, dd, J = 8.5, 1.5 Hz, Ho-Ph), 
5.460 (2H, dd, J = 8.5, 2.0 Hz, Ho-Ph), 7.254 – 7.083 (10H, m, Hm- + p-Ph), 5.586 (1H, d, J 
= 1.9 Hz, H13), 5.270  (1H, d, J = 1.9 Hz, H13), 4.581 (1H, dd, J = 8.9, 5.4 Hz, H8), 
2.476 (1H, tt, J = 8.8, 2.8 Hz, H5), 2.320 (1H, dd, J = 16.6, 8.5 Hz, H4b), 2.192 (1H, dt, J 
= 22.0, 7.8 Hz, H14), 2.138 (1H, dt, J = 22.0, 8.0 Hz, H14), 1.974 (1H, dd, J = 16.6, 2.0 
Hz, H4a), 1.879 – 1.755 (2H, m, H7), 1.696 (1H, tdd, J = 12.7, 10.3, 7.0 Hz, H6), 1.434 – 
1.360 (2H, m, H15), 1.300 (1H, ddt, J = 12.7, 6.5, 3.0 Hz, H6), 1.245 – 1.167 (6H, m), 
0.866 (3H, t, J = 7.3 Hz, H19), 0.772 (9H, s, H9), –0.072 (3H, s, H11), –0.076 (3H, s, H11) 
13C NMR (100.5 MHz, BENZENE-D6):  (ppm) = 155.43 (C12), 145.95 (C2), 145.00 
(Ci-Ph), 140.72 (Ci-Ph), 137.48 (C3), 130.56 (2CHo- or m-Ph), 129.00 (2CHo- or m-Ph), 128.68 
(CHo- or m-Ph), 128.36 (2CHo- or m-Ph), 128.06 (CHo- or m-Ph), 127.39 (CHp-Ph), 126.44 (CHp-
Ph), 116.12 (CH213), 80.65 (CH8), 72.83 (C1),  45.40 (CH24), 45.05 (CH5), 35.27 (CH27), 
32.42 (CH2), 30.69 (CH2), 30.60 (CH2), 30.31 (CH2), 28.84 (CH2), 26.64 (3CH39), 23.37 
(CH2), 18.61 (C10), 14.67 (CH319), –3.62 (CH311), –4.21 (CH311). 
HRMS (EI): Found: [M]+, 500.3465. C34H48OSi requires: 500.3474. 
LRMS (CI): m/z: 369 ([M – TBDMSO]+, 100%). 
LRMS (ESI+): m/z: 539 ([M + K]+, 2%), 168 (100%). 
IR (thin film): ν~ = 2949 (m), 2930 (m), 2850 (m), 1599 (w), 1467 (w), 1255 (m), 1115 
(m), 828 (s), 775 (s), 703 (s) cm–1. 
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6.2.10. Preparation of monocyclic compounds 
 
6.2.10.1. 1,2,3-Trihexylcyclopenta-1,3-diene (2.103a) and 1,2-dihexyl-3-hexylidene-
cyclopent-1-ene (2.104a) 
n-Hex
n-Hex
H
n-Hex
n-Hex
n-Hex
H
H
H
7
10
9
8
4
3
2
1
5
GC ratio, 64 : 36
n-Bu
6
12
11
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added EtMgBr (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) dropwise over 3 
minutes. After 45 min, a solution of tetradec-7-yne (0.194 g, 1.0 mmol) in dry THF (3 
mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to +5 °C over a period of 3 h.  
After cooling the reaction mixture to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 
1.05 mmol) in dry THF (1 mL) was added, followed by dropwise addition of LDA (0.61 
mL of a 1.8 M solution, 1.1 mmol). The reaction mixture was stirred at –78 °C for 15 
min before dropwise addition of the lithium phenylacetylide, [prepared from 
phenylacetylene (0.33 ml, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M 
solution in hexanes, 3.0 mmol) at –5 °C over 15 min]. The stirring was continued for 2 
h during which the reaction mixture was allowed to warm to 0 °C before addition of 
MeOH (10 mL) and a saturated aqueous solution of NaHCO3 (10 mL). The whole 
mixture was allowed to warm to room temperature and left stirring overnight. The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to give the crude 
products as yellow oils.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title products as an inseparable mixture of two 
compounds 2.103a and 2.104a in GC ratio 64 : 36, respectively in combined yield of 
0.204 g (64%, colourless oil). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 5.849 (1H, t, J = 1.5 Hz, H4), 5.134 (1H, tt, J 
= 7.3, 2.3 Hz, H7), 2.804 (2H, d, J = 1.5 Hz, H5), 2.458 – 2.427 (2H, m, H12), 2.380 – 
2.360 (2H, m, H11), 2.444 – 2.117 (10H, m), 2.380 – 2.360 (2H, q, J = 7.3 Hz, H6),1.616 
– 1.314 (46H, m), 0.913 – 0.899 (18H, m, 6CH3). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 148.62 (C3), 147.51 (C10), 144.95 (C8), 
142.04 (C1), 140.12 (C2), 137.56 (C9), 122.28 (CH4), 114.84 (CH7), 41.42 (CH25), 32.83 
(CH211), 31.87 (CH2major), 31.84 (2CH2major + minor), 31.78 (CH2major), 31.72 (CH2minor), 
30.59 (CH2major), 30.31 (CH2major), 29.74 (CH2minor), 29.66 (CH2minor), 29.63 (CH2major), 
29.51 (3CH2major + minor), 29.45 (CH26), 29.25 (CH2minor), 28.92 (CH2minor), 28.57 
(CH2major), 28.47 (3CH2major + minor), 28.16 (CH2minor), 26.18 (CH212), 25.64 (CH2major), 
24.86 (CH2 minor), 22.68 (6CH2major + minor), 14.10 (6Memajor + minor). 
HRMS (EI): Found: [M]+, 318.3286. C23H42 requires: 318.3286. 
LRMS (CI): m/z: 322 ([M + 4H]+, 100%), 289 ([M – Et]+, 100%). 
IR (thin film): ν~ = 2952 (m), 2926 (s), 2847 (s), 1463 (m), 1377 (m), 722 (m) cm–1. 
 
6.2.10.2. 1-(3-Hexyl-2-phenylcyclopenta-1,3-dienyl)benzene (2.103b), 1-(4-hexyl-5-
phenylcyclopenta-1,4-dienyl)benzene (2.103b’)  and 1-((3E)-3-hexylidene-
2-phenylcyclopent-1-enyl)benzene (2.104b) 
Ph
Ph
H
Ph
n-Hex
Ph
H
H
H
12
15
14
134
3
2
1
5
2.104b2.103b
n-Bu
11
17
16
Ph
n-Hex
Ph
H9
8
7
6
10
2.103b'
H
H
54              :                    16                        :                     30
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added EtMgBr (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) dropwise over 3 
minutes. After 45 min, a solution of 1,2-diphenylethyne (0.178 g, 1.0 mmol) in dry THF 
(3 mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to +6 °C over a period of 8 h. After cooling the reaction mixture to –78 °C, a 
solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) in dry THF (1 mL) was added, 
followed by dropwise addition of LDA (0.58 mL of a 1.8 M solution, 1.05 mmol). The 
reaction mixture was stirred at –78 °C for 15 min before dropwise addition of the 
lithium phenylacetylide, [prepared from phenylacetylene (0.33 ml, 3.0 mmol) in dry 
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THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 °C 
over 15 min]. The reaction mixture was allowed to warm to –15 °C before addition of 
MeOH (10 mL) and a saturated aqueous solution of NaHCO3 (10 mL). The whole 
mixture was allowed to warm to room temperature and left stirring overnight. The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to give the crude 
products as yellow oils.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title products as an inseparable mixture of three 
compounds in GC ratio 54 : 30 : 16 in combined yield of 0.136 g (45%, pale yellow oil). 
NMR characterysation does not contain complete data for compound 2.103b’. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.550 – 7.205 (30H, m, HAr), 6.534 (1H, t, J = 
1.8 Hz, H10), 6.298 (1H, quintet, J = 1.8 Hz, H4), 5.233 (1H, tt, J = 7.4, 2.6 Hz, H12), 
3.608 (1H, d, J = 1.8 Hz, H5), 3.598 (1H, d, J = 1.8 Hz, H5), 3.241 (2H, d, J = 1.8 Hz, 
H9), 3.164 – 3.131 (2H, m, H16), 2.916 – 2.883 (2H, m, H17), 2.860 – 2.783 (2H, m), 
2.678 – 2.219 (10H, m), 2.013 – 1.938 (2H, m), 1.851 – 1.814 (1H, m), 1.724 – 1.336 
(13H, m), 1.057 – 0.985 (9H, m, 6CH3). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 149.47 (C), 149.27 (C), 146.24 (C), 146.08 
(C), 143.82 (C), 142.24 (C), 142.05 (C), 141.56 (C), 141.19 (C), 138.39 (C), 138.04 (C), 
137.68 (C), 137.32 (C), 137.10 (C), 136.90 (C), 129.73 (CH), 129.62 (CH), 128.66 
(CH), 128.47 (CH), 128.39 (CH), 128.32 (CH), 128.20 (CH), 127.98 (CH), 127.81 
(CH), 127.74 (2CH), 127.61 (CH), 127.51 (CH), 127.36 (CH), 126.86 (CH), 126.79 
(CH), 126.60 (CH), 126.48 (CH), 126.25 (CH), 125.94 (CH), 125.72 (CH), 125.63 
(CH), 124.99 (CH), 121.17 (CH), 42.54 (CH2), 42.29 (CH2), 35.32 (CH2), 34.02 (CH2), 
33.67 (CH2), 31.72 (CH2), 31.65 (CH2), 30.62 (CH2), 30.33 (CH2), 29.57 (CH2), 29.41 
(CH2), 29.34 (CH2), 29.28 (CH2), 29.13 (CH2), 28.94 (CH2), 28.78 (CH2), 28.41 (CH2), 
28.28 (CH2), 26.52 (CH2), 22.65 (CH2), 22.59 (CH2), 22.54 (CH2), 14.08 (3CH3). 
HRMS (EI): Found: [M]+, 302.2040. C23H26 requires: 302.2035. 
LRMS (CI): m/z: 304 ([M + 2H]+, 68%), 289 ([M – C6H13 + 2H]+, 100%). 
IR (thin film): ν~ = 2952 (m), 2922 (m), 2858 (m), 1486 (w), 1436 (w), 752 (s), 699 (s)  
cm
–1
. 
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6.2.11. Procedure for crossover experiment 
Method a: To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to 
–78 °C was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) 
dropwise. After 20 min, a solution of dec-1-en-6-yne (0.136 g, 1.0 mmol) in dry THF (3 
mL) was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to 
warm to RT and continued to stir for 2 h. After re-cooling the reaction mixture to –78 
°C, a solution of the appropriate 1,1-dibromopentane (0.242 g, 1.05 mmol) in dry THF 
(1 mL) was added followed by dropwise addition of freshly prepared LiTMP [prepared 
from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 mmol) in dry THF (2 
mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) at 0 °C over 20 
min]. The reaction mixture was stirred at –78 °C for 20 min before addition of 
previously prepared and cooled to –78 °C bis(phenylethynyl)zirconocene 2.18.  
Complex 2.18 was prepared by dropwise addition of lithium phenyl acetylide 
[generated from phenyl acetylene (0.22 mL, 2.0 mmol) and n-BuLi (0.80 mL of a 2.5 M 
solution in hexanes, 2.0 mmol) at 0 °C over 15 min], to a stirred solution of Cp2ZrCl2 
(0.293 g, 1.0 mmol) in dry THF (5 mL) at –78 °C, and the stirring was continued for 30 
min at the same temperature before warming to RT and stirring for 5 h. 
The whole reaction mixture was stirred at –78 °C for 5 min before first equivalent of 
lithium p-tert-butylphenyl acetylide 2.7a [freshly prepared from p-tert-butylphenyl-
ethynylbenzene (0.54 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 
M solution in hexanes, 3.0 mmol) at –5 °C over 15 min] was added and the reaction 
mixture was stirred at the same temperature for 15 min. In the meantime, the reaction 
was sampled for GC analysis. After this time, the second equivalent of lithium p-tert-
butylphenyl acetylide was added and the reaction mixture was stirred at –78 °C for 15 
min. In the meantime, the reaction was sampled for GC analysis. The addition of the 
third equivalent of lithium p-tert-butylphenyl acetylide followed and the reaction 
mixture was stirred at the same temperature for 15 min. In the meantime, the reaction 
was sampled for GC analysis. The reaction mixture was then allowed to warm gradually 
to RT before addition of MeOH (10 mL) and a saturated aqueous solution of NaHCO3 
(10 mL). The whole mixture was allowed to warm to room temperature and left stirring 
for 16 h. The mixture was poured onto H2O (100 mL), the products extracted with Et2O 
(3 × 75 mL). The combined organic phases were washed with H2O (3 × 100 mL) and 
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brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
give the crude product as a yellow oil. 
 
Method b: Exactly as method a but bis(p-tert-butylphenylethynyl) zirconocene 2.18a 
was used instead of 2.18 and PhCCLi 2.7 instead of p-t-BuPhCCLi 2.7a. 
 
Method c: Exactly as method a but the p-tert-butylphenyl acetylide 2.7a (3.0 eq) was 
added all at once at –78 °C to the reaction mixture. The stirring was continued for 30 
min at the dame temperature before quenching. 
 
6.2.12. Preparation of compounds 2.107a-j 
General procedure C: To a stirred solution of (2S,3aR)-2-hexyl-2,3,3a,4,5,6-
hexahydro-1-phenylpentalen-2-ol 2.106 (prepared as shown in Scheme 2.12) (142 mg, 
0.50 mmol) in dry THF (4 ml) at RT was added ROH (5.0 mmol) followed by addition 
of a solution of (+)-camphorsulfonic acid (11.6 mg, 0.050 mmol) in dry THF (1 ml). 
The stirring was continued at the same temperature for 3.5 h after which the reaction 
mixture was poured onto a saturated aqueous solution of NaHCO3 (100 mL), the 
products extracted with Et2O (3 × 75 mL).  
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to give the crude 
products as yellow oils.  
 
6.2.12.1. rac-(1S,5R)-3-Hexyl-1-methoxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107a) 
O
H Hb
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General procedure C was used with ROH = MeOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 2.5% Et2O in petroleum 
ether as the eluent gave the title compound as a yellow oil in yield of 0.112 g (75%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.277 – 7.148 (5H, m, HAr), 3.160 (3H, s, H9), 
2.672 (1H, dd, J = 17.3, 8.5 Hz, H4b), 2.416 (1H, tdd, J = 8.3, 6.0, 1.8 Hz, H5), 2.186 – 
2.070 (2H, m, H10), 2.019 (1H, ddd, J = 12.3, 6.0, 2.5 Hz, H6), 1.978 (1H, dd, J = 17.3, 
1.8 Hz, H4a), 1.644 – 1.504 (3H, m), 1.467 – 1.314 (3H, m), 1.243 – 1.097 (7H, m), 
0.776 (3H, t, J = 6.9 Hz, H15). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 145.38 (Ci-Ph), 136.92 (C2 or 3), 135.15 (C2 or 
3), 128.98 (2CHo- or m-Ph), 127.93 (2CHo- or m-Ph), 126.45 (CHp-Ph), 103.77 (C1), 50.82 
(CH39), 42.40 (CH5), 41.80 (CH24), 37.63 (CH2), 35.63 (CH2), 31.61 (CH2), 29.69 
(CH2), 29.22 (CH2), 28.06 (CH2), 25.36 (CH2), 22.58 (CH2), 14.03 (CH315). 
HRMS (EI): Found: [M]+, 298.2284. C21H30O requires: 298.2297. 
LRMS (CI): m/z: 266 ([M – MeOH]+, 74%), 195 ([M – MeOH – C5H12]+, 100%). 
IR (thin film): ν~ = 2940 (s), 2864 (m), 1493 (w), 1461 (w), 1061 (s), 770 (s), 700 (s) 
cm
–1
. 
 
6.2.12.2. rac-(1S,5R)-1-Ethoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107b) 
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General procedure C was used with ROH = EtOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 2.5% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.108 g (69%). 
Spectral data were consistent with those reported previously.237 
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6.2.12.3. rac-(1S,5R)-3-Hexyl-2-phenyl-1-propoxy-bicyclo[3.3.0]oct-2-ene (2.107c) 
O
H Hb
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General procedure C was used with ROH = PrOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 2% Et2O in petroleum ether as 
the eluent gave the title compound as a yellow oil in yield of 0.115 g (71%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.356 – 7.225 (5H, m, HAr), 3.394 (1H, dt, J = 
9.0, 7.0 Hz, H9), 3.202 (1H, dt, J = 9.0, 7.0 Hz, H9), 2.755 (1H, dd, J = 17.3, 8.3 Hz, 
H4b), 2.490 (1H, tdd, J = 8.3, 5.8, 2.0 Hz, H5), 2.239 – 2.199 (2H, m, H12), 2.346 (1H, 
m, H6), 2.060 (1H, dd, J = 17.3, 2.0 Hz, H4a), 1.762 – 1.580 (5H, m), 1.532 – 1.405 (3H, 
m), 1.326 – 1.207 (7H, m), 0.944 (3H, t, J = 7.4 Hz, H11 or 17), 0.868 (3H, t, J = 7.0 Hz, 
H11 or 17). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.73 (Ci-Ph), 137.06 (C2 or 3), 135.92 (C2 or 
3), 129.00 (2CHo- or m-Ph), 127.86 (2CHo- or m-Ph), 126.35 (CHp-Ph), 103.08 (C1), 64.84 
(CH39), 42.89 (CH5), 41.93 (CH24), 37.64 (CH2), 35.60 (CH2), 31.63 (CH2), 29.72 
(CH2), 29.22 (CH2), 28.02 (CH2), 25.26 (CH2), 23.54 (CH2), 22.61 (CH2), 14.04 (CH311 
or  17), 10.87 (CH311 or  17). 
HRMS (EI): Found: [M]+, 326.2600. C23H34O requires: 326.2610. 
LRMS (CI): m/z: 267 ([M – OPr]+, 100%), 195 ([M – PrOH – C5H12]+, 81%). 
IR (thin film): ν~ = 2918 (s), 2859 (m), 1450 (w), 1083 (s), 770 (m), 694 (s) cm–1. 
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6.2.12.4. rac-(1S,5R)-3-Hexyl-1-isopropoxy-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107d) 
O
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General procedure C was used with ROH = i-PrOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.011 g (7%). 
Spectral data were consistent with those reported previously.237 
 
6.2.12.5. rac-(1S,5R)-1-Butoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107e) 
O
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General procedure C was used with ROH = BuOH. Purification of the crude material by 
column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether as 
the eluaent gave the title compound as a yellow oil in yield of 0.116 g (68%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.327 – 7.195 (5H, m, HAr), 3.401 (1H, ddd, J 
= 9.0, 7.2, 6.2 Hz, H9), 3.216 (1H, dt, J = 9.0, 7.0 Hz, H9), 2.724 (1H, dd, J = 17.3, 8.3 
Hz, H4b), 2.454 (1H, tdd, J = 8.3, 5.8, 2.0 Hz, H5), 2.211 – 2.168 (2H, m, H13), 2.066 
(1H, m, H6), 2.028 (1H, dd, J = 17.3, 1.3 Hz, H4a), 1.726 – 1.532 (5H, m), 1.479 – 1.317 
(5H, m), 1.293 – 1.170 (7H, m), 0.907 (3H, t, J = 7.3 Hz, H12 or 18), 0.837 (3H, t, J = 6.9 
Hz, H12 or 18). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.70 (Ci-Ph), 137.07 (C2 or 3), 135.93 (C2 or 
3), 128.99 (2CHo- or m-Ph), 127.86 (2CHo- or m-Ph), 126.34 (CHp-Ph), 103.08 (C1), 62.91 
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(CH39), 42.91 (CH5), 41.94 (CH24), 37.64 (CH2), 35.60 (CH2), 32.53 (CH2), 31.63 
(CH2), 29.72 (CH2), 29.21 (CH2), 28.02 (CH2), 25.26 (CH2), 22.60 (CH2), 19.64 (CH2), 
14.08 (CH312  or  18), 14.04 (CH312  or  18). 
HRMS (EI): Found: [M]+, 340.2767. C24H36O requires: 340.2766. 
LRMS (CI): m/z: 266 ([M – BuOH]+, 75%), 195 ([M – BuOH – C5H12]+, 100%). 
IR (thin film): ν~ = 2934 (s), 2853 (s), 1471 (m), 1083 (s), 764 (m), 710 (s) cm–1. 
 
6.2.12.6. rac-(1S,5R)-3-Hexyl-1-(2-methylbutoxy)-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107f) 
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General procedure C was used with ROH = 2-Me-BuOH. Purification of the crude 
material by column chromatography on Al2O3 (basic, grade III) with 0.5% Et2O in 
petroleum ether as the eluent gave the title compound as a pale yellow oil in yield of 
0.114 g (64%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.352 – 7.298 (4H, m, Ho- + m-Ph), 7.262 – 
7.219 (1H, m, Hp-Ph), 3.327 (0.5H, dd, J = 8.9, 5.4 Hz, H9), 3.215 (0.5H, dd, J = 8.8, 6.3 
Hz, H9), 3.058 (0.5H, dd, J = 9.0, 6.8 Hz, H9), 2.958 (0.5H, dd, J = 8.9, 7.4 Hz, H9), 
2.748 (1H, dd, J = 17.2, 8.4 Hz, H4b), 2.455 (1H, tdd, J = 8.6, 6.3, 1.8 Hz, H5), 2.286 – 
2.172 (2H, m, H14), 2.086 (1H, m), 2.051 (1H, dd, J = 17.2, 1.3 Hz, H4a), 1.734 (1H, m),  
1.671 – 1.403 (7H, m), 1.312 – 1.205 (7H, m), 1.137 (1H, m), 0.945 (1.5H, d, J = 6.5 
Hz, H11), 0.906 (1.5H, t, J = 7.4 Hz, H13), 0.904 (1.5H, d, J = 6.5 Hz, H11), 0.900 (1.5H, 
7, J = 7.4 Hz, H13), 0.864 (3H, t, J = 7.0 Hz, H19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.46 (Ci-Ph), 137.12 (C2 or 3), 136.14 (C2 or 
3), 129.03 (2CHo- or m-Ph), 127.82 (2CHo- or m-Ph), 126.30 (CHp-Ph), 102.97 (C1), 102.94 
(C1), 68.49 (CH39), 68.47 (CH39), 43.09 (CH5), 43.06 (CH5), 41.92 (CH24), 37.61 (CH2), 
37.59 (CH2), 35.57 (CH10), 35.55 (CH2), 35.37 (CH10), 31.65 (CH2), 29.73 (CH2), 29.18 
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(CH2), 27.98 (CH214), 26.61 (CH2), 26.57 (CH2), 25.34 (CH2), 22.61 (CH2), 17.16 
(CH311), 16.74 (CH311), 14.04 (CH319), 11.55 (CH313), 11.34 (CH313). 
HRMS (ESI+): Found: [M + Na]+, 377.2808. [C25H38NaO]+ requires: 377.2815. 
LRMS (CI): m/z: 267 ([M – 2-Me-BuOH + H]+, 75%), 195 ([M – 2-Me-BuOH – 
C5H12]+, 100%). 
IR (thin film): ν~ = 2961 (s), 2924 (s), 2853 (s), 1455 (w), 1077 (s), 764 (m), 700 (s) 
cm–1. 
 
6.2.12.7. rac-(1S,5R)-3-Hexyl-1-pentyloxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107g) 
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General procedure C was used with ROH = PentOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 0.5% Et2O in petroleum 
ether as the eluent gave the title compound as a yellow oil in yield of 0.110 g (62%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.328 – 7.196 (5H, m, HAr), 3.395 (1H, ddd, J 
= 8.9, 7.3, 6.3 Hz, H9), 3.208 (1H, dt, J = 8.9, 7.1 Hz, H9), 2.723 (1H, dd, J = 17.1, 8.3 
Hz, H4b), 2.455 (1H, tdd, J = 8.3, 5.8, 1.8 Hz, H5), 2.212 – 2.169 (2H, m, H14), 2.068 
(1H, m, H6), 2.027 (1H, dd, J = 17.1, 1.5 Hz, H4a), 1.727 – 1.562 (5H, m), 1.492 – 1.373 
(3H, m), 1.354 – 1.179 (11H, m), 0.887 (3H, t, J = 6.8 Hz, H13 or 19), 0.839 (3H, t, J = 
6.8 Hz, H13 or 19). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.71 (Ci-Ph), 137.07 (C2 or 3), 135.93 (C2 or 
3), 129.00 (2CHo- or m-Ph), 127.86 (2CHo- or m-Ph), 126.34 (CHp-Ph), 103.09 (C1), 63.21 
(CH39), 42.89 (CH5), 41.94 (CH24), 37.65 (CH2), 35.60 (CH2), 31.64 (CH2), 30.10 
(CH2), 29.72 (CH2), 29.21 (CH2), 28.63 (CH2), 28.02 (CH2), 25.26 (CH2), 22.67 (CH2), 
22.60 (CH2), 14.07 (CH313  or  19), 14.04 (CH313 or  19). 
HRMS (ESI+): Found: [M + Na]+, 377.2809. [C25H38NaO]+ requires: 377.2815. 
LRMS (CI): m/z: 266 ([M – PentOH]+, 75%), 195 ([M – PentOH – C5H12]+, 100%). 
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IR (thin film): ν~ = 2930 (s), 2853 (s), 1466 (m), 1083 (s), 759 (m), 707 (s) cm–1. 
 
6.2.12.8. rac-(1S,5R)-3-Hexyl-1-hexyloxy-2-phenyl-bicyclo[3.3.0]oct-2-ene (2.107h) 
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General procedure C was used with ROH = HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 0.5% Et2O in petroleum 
ether as the eluent gave the title compound as a pale yellow oil in yield of 0.119 g 
(65%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.353 – 7.223 (5H, m, HAr), 3.418 (1H, ddd, J 
= 8.9, 7.3, 6.5 Hz, H9), 3.233 (1H, dt, J = 8.9, 7.3 Hz, H9), 2.750 (1H, dd, J = 17.2, 8.5 
Hz, H4b), 2.482 (1H, tdd, J = 8.3, 5.8, 1.8 Hz, H5), 2.237 – 2.193 (2H, m, H15), 2.093 
(1H, m, H6), 2.052 (1H, dd, J = 17.2, 1.3 Hz, H4a), 1.752 – 1.577 (5H, m), 1.513 – 1.399 
(3H, m), 1.387 – 1.205 (13H, m), 0.899 (3H, t, J = 6.5 Hz, H14 or 20), 0.864 (3H, t, J = 
6.8 Hz, H14 or 20). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.71 (Ci-Ph), 137.07 (C2 or 3), 135.93 (C2 or 
3), 129.00 (2CHo- or m-Ph), 127.86 (2CHo- or m-Ph), 126.34 (CHp-Ph), 103.09 (C1), 63.24 
(CH39), 42.89 (CH5), 41.94 (CH24), 37.65 (CH2), 35.59 (CH2), 31.83 (CH2), 31.63 
(CH2), 30.38 (CH2), 29.72 (CH2), 29.21 (CH2), 28.02 (CH2), 26.13 (CH2), 25.26 (CH2), 
22.67 (CH2), 22.60 (CH2), 14.05 (2CH314 + 20). 
HRMS (EI): Found: [M]+, 368.3064. C26H40O requires: 368.3079. 
LRMS (CI): m/z: 266 ([M – HexOH]+, 60%), 195 ([M – HexOH – C5H12]+, 100%). 
IR (thin film): ν~ = 2930 (s), 2854 (s), 1463 (w), 1092 (s), 767 (m), 699 (s) cm–1. 
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6.2.12.9. rac-(1S,5R)-1-Cyclohexyloxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107i) 
O
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General procedure C was used with ROH = c-HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.022 g (12%). 
Spectral data were consistent with those reported previously.237 
 
6.2.12.10. rac-(1S,5R)-1-Benzyloxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene 
(2.107j) 
O
H Hb
Ha
3
8
7
6 5 4
21
 
General procedure C was used with ROH = c-HexOH. Purification of the crude material 
by column chromatography on Al2O3 (basic, grade III) with 1% Et2O in petroleum ether 
as the eluent gave the title compound as a yellow oil in yield of 0.118 g (63%). 
Spectral data were consistent with those reported previously.237 
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6.3. Experimental from chapter 3 
 
6.3.1. rac-(3aS,6aS)-2-Hexyl-octahydro-5,5-bis(methoxymethyl)-2-(1-
phenylvinyl)pentalene (3.34a) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 3 
h.  
After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.255 mL, 1.5 
mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 15 min 
before dropwise addition of lithium phenylacetylide [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at –5 οC over 15 min]. The stirring was continued for 1 h during 
which the reaction mixture was allowed to warm to –55 °C before addition of MeOH (5 
mL) and saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was 
allowed to warm to room temperature and left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
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Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluent gave the title compound as a pale yellow oil 
in yield of 0.295 g (77%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.330 – 7.240 (5H, m, HAr), 5.200 (1H, d, J = 
1.2 Hz, H14), 5.000 (1H, d, J = 1.2 Hz, H14), 3.390 (3H, s, H1 or 2), 3.380 (3H, s, H1 or 2), 
3.321 (1H, d, J = 8.8 Hz, H3 or 4), 3.303 (1H, d, J = 8.8 Hz, H3 or 4), 3.297 (1H, d, J = 8.8 
Hz, H3 or 4), 3.276 (1H, d, J = 8.8 Hz, H3 or 4), 2.186 (1H, dd, J = 12.4, 5.9 Hz, H10a or 11b), 
1.900 (1H, tt, J = 11.8, 5.9 Hz, H8 or 9), 1.808 (1H, tt, J = 11.8, 5.9 Hz, H8 or 9), 1.749 
(1H, dd, J = 11.5, 5.8 Hz, H10a or 11b), 1.632 (1H, d, J = 12.0 Hz, H6a or 7b), 1.618 (1H, d, J 
= 12.2 Hz, H6a or 7b), 1.610 (1H, t, J = 6.0 Hz), 1.566 (1H, d, J = 11.5 Hz, H10b or 11a), 
1.498 (1H, m), 1.357 – 1.172 (6H, m), 1.256 (1H, t, J = 6.9 Hz, H15), 1.117 (1H, t, J = 
12.0 Hz, H10b or 11a), 1.012 (2H, t, J = 11.6 Hz, H6b + 7a), 0.936 (1H, t, J = 6.9 Hz, H15), 
0.891 (3H, t, J = 7.0 Hz, H20). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.04 (C13), 144.03 (Ci-Ph), 128.20 (2CHo-
Ph), 127.52 (2CHm-Ph), 126.36 (CHp-Ph), 113.05 (CH214), 78.08 (2CH23 + 4), 59.20 (CH31 or 
2), 59.18 (CH31 or 2), 58.42 (C12), 54.20 (C5), 51.10 (CH8 or 9), 50.82 (CH8 or 9), 42.84 
(CH2), 42.67 (CH210 or 11), 39.70 (CH210 or 11), 34.74 (CH26 or 7), 34.70 (CH26 or 7), 31.75 
(CH2), 29.75 (CH2), 24.86 (CH2), 22.60 (CH2), 14.04 (CH320). 
HRMS (EI): Found: [M]+, 384.3021. C26H40O2 requires: 384.3028. 
LRMS (CI): m/z: 385 ([M + H]+·, 32%), 353 ([M – MeOH + H]+·, 32%), 339 ([M – 
Et2O + H]+·, 13%), 321 ([M – 2MeOH + H]+·, 49%), 300 ([M – Hex + H]+·, 75%), 45 
(100%). 
IR (thin film): ν~ = 2929 (m), 2870 (m), 1461 (m), 1196 (m) 1104 (s), 894 (m), 775 
(m), 700 (s) cm–1. 
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6.3.2. rac-(3aS,6aS)-2-Hexyl-octahydro-5,5-bis(methoxymethyl)-2-(oct-1-en-2-
yl)pentalene (3.34b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 
12 h. After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 
1.3 mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly 
prepared LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.255 
mL, 1.5 mmol) in  THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 15 min 
before dropwise addition of lithium 1-octyne, [prepared from 1-octyne (0.59 mL, 4.0 
mmol) in dry THF (4 mL) and n-BuLi (1.6 mL of a 2.5 M solution in hexanes, 4.0 
mmol) at –5 οC over 15 min]. 
The stirring was continued for 2.5 h during which time the reaction mixture was 
allowed to warm to –25 °C before addition of MeOH (5 mL) and saturated aqueous 
solution of NaHCO3 (6 mL). The whole mixture was allowed to warm to room 
temperature and left stirring overnight. The mixture then was poured onto H2O (100 
mL), the products extracted with Et2O (3 × 50 mL). The combined organic phases were 
washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluent gave the title compound as a pale yellow oil 
in yield of 0.185 g (47%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 4.830 (1H, br s, H14), 4.742 (1H, q, J = 1.3 Hz, 
H14), 3.352 (3H, s, H1 or 2), 3.331 (3H, s, H1 or 2), 3.276 (1H, d, J = 8.8 Hz,  H3 or 4), 3.250 
(1H, d, J = 8.8 Hz, H3 or 4), 3.250 (1H, d, J = 8.8 Hz, H3 or 4), 3.220 (1H, d, J = 8.8 Hz,  
H3 or 4), 2.066 (1H, dd, J = 12.3, 5.8 Hz), 1.951 – 1.912 (2H, m, H21), 1.783 (1H, qt, J = 
11.7, 5.9 Hz, H8 or 9), 1.684 (1H, qt, J = 11.9, 6.1 Hz, H8 or 9), 1.601 – 1.519 (4H, m), 
1.487 – 1.367 (3H, m), 1.349 – 1.217 (13H, m), 1.110 – 1.013 (2H, m), 0.987 – 0.907 
(3H, m), 0.903 (3H, t, J = 7.0 Hz, H20 or 26), 0.879 ppm (3H, t, J = 7.0 Hz, H20 or 26). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 155.95 (C13), 105.73 (CH214), 78.10 (CH23 or 
4), 78.08 (CH23 or 4), 59.23 (CH31 or 2), 59.19 (CH31 or 2), 59.14 (C12), 54.10 (C5), 50.77 
(CH8 or 9), 50.24 (CH8 or 9), 42.40 (CH2), 40.92 (CH2), 38.34 (CH2), 34.84 (CH2), 34.73 
(CH2), 32.19 (CH2), 31.92 (CH2), 31.88 (CH2), 29.97 (CH2), 29.58 (CH2), 28.92 (CH2), 
24.92 (CH2), 22.70 (CH2), 22.68 (CH2), 14.08 (2CH320 + 26). 
HRMS (EI): Found: [M ]+, 392.9761. C26H48O2 requires: 392.3654. 
LRMS (CI): m/z: 393 ([M + H]+·, 13%), 361 ([M – MeOH + H]+·, 58%), 330 ([M – 
2MeOH + H]+·, 28%), 243 ([M – 2MeOH – Hex + H]+·, 70%), 45 (100%). 
IR (thin film): ν~ = 2929 (m), 2853 (m), 1461 (m), 1202 (m) 1110 (s), 883 (m) cm–1. 
 
6.3.3. rac-((3aR,6aR)-Octahydro-2,2-bis(methoxymethyl)-5-(1-phenylvinyl)-
pentalen-5-yl)dimethyl(phenyl)silane (3.34c) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at -
78 °C the reaction mixture was allowed to warm to room temperature and stirred for 2 
h. After cooling the reaction mixture to –78 °C, a solution of 
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(dichloromethyl)dimethyl(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (1 mL) was 
added followed by dropwise addition of LDA (0.85 mL of a 1.8 M solution, 1.5 mmol). 
The reaction mixture was stirred for 0.5 h during which time was allowed to warm to –
60 °C before re-cooling to –78 °C and dropwise addition of lithium phenyl acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi 
(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 οC over 15 min]. The stirring 
was continued for 3 h during which the reaction mixture was allowed to warm to –15 °C 
before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). 
The whole mixture was allowed to warm to room temperature and left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (3 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a red oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of EtOAc in hexanes as the eluent gave the title compound as a yellow oil in 
yield of 0.152 g (35%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.600 – 7.565 (2H, m, HAr), 7.421 – 7.334 
(3H, m, HAr), 7.177 – 7.125 (3H, m, HAr), 6.873 – 6.835 (2H, m, HAr), 4.976 (1H, d, J = 
1.3 Hz, H14), 4.850 (1H, d, J = 1.3 Hz, H14), 3.327 (3H, s, H1 or 2), 3.321 (3H, s, H1 or 2), 
3.228 (1H, d, J = 8.8 Hz, H3 or 4), 3.202 (1H, d, J = 8.8 Hz, H3 or 4), 3.129 (2H, s, H3 or 4), 
2.166 (1H, dd, J = 11.5, 5.5 Hz, H10b or 11a), 2.004 (1H, dd, J = 12.0, 5.5 Hz, H10b or 11a), 
1.712 (1H, qt, J = 11.5, 5.9 Hz, H8 or 9), 1.525 (1H, t, J = 12.0 Hz, H10a or 11b), 1.494 (1H, 
dd, J = 12.4, 6.2 Hz, H6b or 7a), 1.448 (1H, dd, J = 12.0, 6.0 Hz, H6b or 7a), 1.426 (1H, d, J 
= 11.5 Hz, H10a or 11b), 1.379 (1H, tt, J = 11.8, 5.5 Hz, H8 or 9), 0.862 (1H, t, J = 11.2 Hz, 
H6a or 7b), 0.810 (1H, t, J = 12.0 Hz, H6a or 7b), 0.397 (3H, s, H15 or 16), 0.392 (3H, s, H15 or 
16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 159.63 (C13), 144.41 (CSi-i-Ph), 138.21 (Ci-
Ph), 134.79 (2CHSi-o-Ph), 129.01 (CHSi-p-Ph), 128.58 (2CHSi-m-Ph), 127.53 (2CHo- or m-Ph), 
127.26 (2CHo- or m-Ph), 126.10 (CHp-Ph), 114.19 (CH214), 77.84 (2CH23 + 4), 59.15 (2CH31 
+ 2), 54.63 (C12), 52.10 (CH8 or 9), 51.13 (CH8 or 9), 47.74 (C5), 39.22 (CH210 or 11), 37.73 
(CH210 or 11), 34.58 (CH26 or  7), 34.06 (CH26 or  7), –4.09 (CH315 or 16), –4.18 (CH315 or 16). 
HRMS (EI): Found: [M]+, 434.2643. C28H38O2Si requires: 434.2641. 
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LRMS (CI): m/z: 434 ([M]+·, 10%), 300 ([M – HSiMe2Ph]+·, 35%), 269 ([M – MeOH – 
HSiMe2Ph]+·, 22%), 237 ([M – 2MeOH – HSiMe2Ph]+·, 100%). 
IR (thin film): ν~ = 2933 (m), 2873 (m), 1595 (w), 1448 (m), 1251 (m), 1202 (m), 1107 
(s), 813 (s), 771 (s), 733 (s), 703 (s) cm–1. 
 
6.3.4. rac-((3aS,6aS)-Octahydro-2,2-bis(methoxymethyl)pentalen-5-yl)-
dimethyl(phenyl)silane (major d.r.) (3.35a) and rac-((3aS,6aR)-octahydro-
2,2-bis(methoxymethyl)pentalen-5-yl)-dimethyl(phenyl)silane (minor d.r.) 
(3.35b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 2 
h. After cooling the reaction mixture to –78 °C, a solution of 
(dichloromethyl)dimethyl(phenyl)silane (0.285 g, 1.3 mmol) in dry THF (1 mL) was 
added followed by dropwise addition of LDA (0.85 mL of a 1.8 M solution, 1.5 mmol). 
The reaction mixture was stirred for 0.5 h during which was allowed to warm to –60 °C 
before dropwise addition of lithium phenyl acetylide pre-mixed with HMPA. [Lithium 
phenyl acetylide was freshly prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry 
THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at 0 οC over 
10 min, then HMPA (0.52 mL, 3.0 mmol) was added and the stirring was continued at 
the same temperature for further 15 min]. The stirring was continued for 3 h during 
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which time the reaction mixture was allowed to warm to –15 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture then 
was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a red 
oil.  
Purification of the crude material by column chromatography on Al2O3 (basic, grade III) 
with 5% of Et2O in hexanes as the eluent gave the title compounds as a yellow oil in 
yield of 0.072 g (22%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.547 – 7.496 (4H, m, Ho-Ph major + minor), 7.368 
– 7.336 (6H, m, Hm- + p-Ph major + minor), 3.360 (3H, s, H1/2 minor), 3.357 (3H, s, H1/2 minor), 
3.352 (3H, s, H1/2 major), 3.344 (3H, s, H1/2 major), 3.280 (1H, d, J = 8.8 Hz, H3/4 major), 
3.276 (1H, d, J = 8.8 Hz, H3/4 major), 3.244 (1H, d, J = 8.8 Hz, H3/4 major), 3.218 (1H, d, J 
= 8.8 Hz, H3/4 major), 3.291 – 3.208 (4H, m, H3 + 4 minor), 1.936 (1H, dddd, J = 12.0, 10.5, 
8.3, 3.8 Hz, Hmajor), 1.790 (1H, m, Hmajor), 1.696 (1H, ddd, J = 11.3, 8.0, 5.5 Hz, Hmajor), 
1.605 – 1.479 (12H, m, Hmajor + minor), 1.387 – 1.290 (2H, m, Hmajor + minor), 1.049 – 0.867 
(5H, m, Hmajor + minor), 0.342 (3H, s, H13/13’ minor), 0.340 (3H, s, H13/13’ minor), 0.260 (3H, s, 
H13/13’ major), 0.250 (3H, s, H13/13’ major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 139.27 (2CSi-i-Ph major + minor), 133.82 (4CHSi-
p-Ph major + minor), 128.69 (2CHSi-p-Ph major + minor), 127.60 (4CHSi-m-Ph major + minor), 78.02 
(CH23/4 minor), 78.02 (2CH23/4 major + minor), 77.99 (CH23/4 major), 59.20 (CH31/2 major), 59.17 
(CH31/2 major), 58.06 (2CH31 + 2 minor), 54.95 (C5 major), 54.24 (C5 minor), 53.49 (CH8/9 major), 
52.96 (CH8/9 major), 52.53 (2CH8 + 9 minor), 34.28 (CH26/7 major), 33.97 (CH26/7 major), 31.57 
(2CH26 + 7 minor), 29.35 (CH210/11 major), 29.11 (2CH212 major + minor), 27.27 (CH210/11 major), 
26.32 (2CH210 + 11 minor), –3.12 (CH313/13’ minor), –3.20 (CH313/13’ minor), –4.56 (CH313/13’ 
major),  –4.71 (CH313/13’ major). 
HRMS (ESI+): Found: [M + Na]+, 355.2604. [C20H32NaO2Si]+ requires: 355.2604. 
LRMS (CI): m/z: 254 ([M – Ph]+·, 1%), 222 ([M – MeOH]+·, 2%), 190 ([M – 
2MeOH]+·, 2%), 135 ([M – 2MeOH – SiMe2Ph]+·, 100 %). 
IR (thin film): ν~ = 2952 (m), 2922 (m), 2869 (m), 2820 (m), 1452 (w), 1421 (w), 1251 
(m), 1202 (m), 1107 (s), 813 (s), 775 (s), 722 (s), 695 (s) cm–1. 
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6.3.5. rac-(3aS,8aR)-2-Hexyl-1,2,3,3a,8,8a-hexahydro-2-(1-phenylvinyl)-
cyclopenta[a]indene and rac-(3aR,8aR)-2-hexyl-1,2,3,3a,8,8a-hexahydro-2-
(1-phenylvinyl)-cyclopenta[a]indene (3.39a, b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1-allyl-2-vinyllbenzene 
(0.144 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and stirred for 2 h. After 
cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) 
in dry THF (1 mL) was added followed by dropwise addition of LDA (0.61 mL of a 1.8 
M solution, 1.1 mmol). After stirring the reaction mixture for 15 min at –78 °C, lithium 
phenylacetylide was added dropwise, [prepared from phenylacetylene (0.33 mL, 3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at –5 οC over 15 min]. The stirring was continued for 1.5 h during which the 
reaction mixture was allowed to warm to –30 °C before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and left stirring overnight. The mixture then was poured 
onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined 
organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluent gave the title compound as an inseparable mixture of isomers 
in NMR ratio of 1.4 : 1 and combined yield of 0.165g (48%, pale yellow oil). 
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1H NMR (400 MHz, BENZENE-D6):  (ppm) = 7.311 – 7.249 (4H, m, Ho-Ph), 7.194 – 
7.070 (14H, m, HAr), 5.211 (1H, d, J = 1.3 Hz, H10 major), 5.146 (1H, d, J = 1.3 Hz, H10 
minor), 5.068 (1H, d, J = 1.3 Hz, H10 major), 5.029 (1H, d, J = 1.3 Hz, H10 minor), 2.952 (1H, 
td, J = 12.3, 5.8 Hz, H5b major), 2.891 (1H, td, J = 11.8, 6.3 Hz, H5b minor), 2.665 (1H, dd, J 
= 13.8, 5.8 Hz, H3a major), 2.635 (1H, dd, J = 13.8, 5.8 Hz, H3a minor), 2.550 (1H, dd, J = 
12.3, 6.0 Hz, H7a major), 2.329 (1H, ddt, J = 13.8, 11.5, 1.3 Hz, H3b major), 2.316 (1H, t, J = 
13.8 Hz, H3b minor), 2.252 (1H, dd, J = 12.2, 5.7 Hz, H7a minor), 2.157 – 1.940 (3H, m, 2H4 
+ H6 minor), 1.885 (1H, t, J = 11.3 Hz, H6b major), 1.753 – 1.622 (2H, m, H6 minor + H), 
1.740 (1H, dd, J = 11.3, 5.8 Hz, H6a major), 1.538 – 1.129 (19H, m), 1.412 (1H, t, J = 12.3 
Hz, H7b major), 1.324 (1H, t, J = 12.2 Hz, H7b minor), 0.897 (3H, t, J = 7.0 Hz, H16 minor), 
0.875 (3H, t, J = 7.0 Hz, H16 major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.49 (C9 major ), 158.40 (C9 minor ), 149.66 
(Ci-Ph major), 149.63 (Ci-Ph minor), 145.60 (C1/2 major), 145.56 (C1/2 minor), 144.68 (C1/2 minor), 
144.63 (C1/2 major), 128.99 (4CHAr), 128.68 (2CHAr), 128.40 (2CHAr), 127.30 (CHAr), 
127.27 (CHAr), 126.73 (CHAr), 126.70 (CHAr), 126.44  (2CHAr), 125.65 (CHAr), 125.61 
(CHAr), 122.93 (CHAr), 122.88 (CHAr), 114.10 (CH210 minor), 113.99 (CH210 major), 58.10 
(C8 major), 58.05 (C8 minor), 56.97 (CH4/5 major), 56.61 (CH4/5 minor), 55.40 (CH4/5 minor), 
55.04  (CH4/5 major), 43.40 (CH2major), 43.28 (CH2minor), 42.67 (CH2major), 41.24 
(CH2minor), 39.54 (CH2minor),  38.09 (CH2major), 35.00 (2CH2major + minor), 32.54 (CH2minor), 
32.49 (CH2major), 30.58 (CH2minor), 30.53 (CH2major),  25.74 (CH2minor), 25.63 (CH2major), 
23.40 (2CH2major + minor), 14.67 (2CH316 major + minor). 
HRMS (EI): Found: [M]+, 344.2505. C26H32 requires: 344.2504. 
LRMS (CI): m/z: 345 ([M + H]+·, 61%), 260 ([M – Hex + H]+·, 14%), 130 (100%). 
IR (thin film): ν~ = 2933 (m), 2858 (m), 1622 (w), 1489 (w), 1459 (m), 900 (m), 775 
(m), 741 (s), 699 (s) cm–1. 
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6.3.6. rac-(3aR,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a trans) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of N-allyl-N-benzylprop-2-en-
1-amine (0.187 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –
78 °C the reaction mixture was allowed to warm to room temperature and stirred for 3 
h. After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 
mmol) in dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 
mmol) at 0 °C over 20 min]. The reaction mixture was stirred at –78 °C for 20 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 οC over 15 min]. The stirring was continued for 1 h during 
which time the reaction mixture was allowed to warm to –45 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as an 
orange oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10  50% of Et2O in hexanes as the eluant gave the title compound as a yellow oil 
in yield of 0.175 g (45%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.295 – 7.148 (10H, m, HAr), 5.124 (1H, d, J = 
1.2 Hz, H10), 4.936 (1H, d, J = 1.2 Hz, H10), 3.813 (1H, d, J = 13.3 Hz, H1), 3.754 (1H, 
d, J = 13.3 Hz, H1), 2.771 (1H, dd, J = 8.8, 6.3 Hz, H2b or 3a), 2.744 (1H, dd, J = 8.8, 6.3 
Hz, H2b or 3a), 2.404 (1H, dd, J = 10.0, 8.8 Hz, H2a or 3b), 2.398 (1H, dd, J = 10.0, 8.8 Hz, 
H2a or 3b), 2.124 (1H, dd, J = 12.0, 6.0 Hz, H6b or 8a), 2.106 (1H, m, H4 or 5), 2.017 (1H, tt, 
J = 12.0, 6.0 Hz, H4 or 5), 1.696 (1H, dd, J = 11.8, 6.0 Hz, H6b or 8a), 1.614 (1H, t, J = 11.8 
Hz, H6a or 8b), 1.572 (1H, m), 1.442 (1H, m), 1.272 – 1.104 (6H, m), 1.169 (1H, t, J = 7.0 
Hz, H11), 1.147 (1H, t, J = 12.0 Hz, H6a or 8b), 0.851 (1H, t, J = 7.0 Hz, H11), 0.809 (3H, 
t, J = 7.0 Hz, H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 157.67 (C9), 143.79 (Ci-Ph), 140.25 (Ci-Ph), 
128.53 (2CHo- or m-Ph), 128.18 (2CHo- or m-Ph), 128.16 (2CHo- or m-Ph), 127.58 (2CHo- or m-
Ph), 126.62 (CHp-Ph), 126.45 (CHp-Ph), 113.29 (CH210), 61.80 (CH21), 58.69 (C7), 55.05 
(2CH22 + 3), 50.92 (CH4 or 5), 50.59 (CH4 or 5), 42.71 (CH2), 40.94 (CH26 or 8), 38.09 (CH26 
or 8), 31.71 (CH2), 29.71 (CH2), 24.86 (CH211), 22.58 (CH2), 14.04 (CH316). 
HRMS (ESI+): Found: [M + H]+, 388.2994. [C28H38N]+ requires: 388.2999. 
LRMS (ESI+): m/z: 388 ([M + H]+, 100%). 
IR (thin film): ν~ = 2924 (m), 2853 (m), 2783 (m), 1498 (m), 1450 (m), 1029 (m) 894 
(s), 770 (m), 737 (m), 700 (s) cm–1. 
 
6.3.7. rac-(3aS,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a cis) 
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This compound was obtained simultaneously with isomer 3.42a trans. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10  50% of Et2O in hexanes as the eluant gave the title compound as a pale 
yellow oil in yield of 0.055 g (14%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.357 – 7.212 (8H, m, HAr), 7.134 (2H, 
apparent dd, J = 7.7, 1.7 Hz, HN-o-Ph), 5.170 (1H, d, J = 1.5 Hz, H10), 5.009 (1H, d, J = 
1.5 Hz, H10), 3.584 (2H, br s, H1), 2.627 – 2.560 (2H, m, H4 + 5), 2.512 (2H, d, J = 9.0 
Hz, H2 + 3), 2.242 – 2.170 (4H, m, H2 + 3 + 6 + 8), 1.556 – 1.516 (2H, m, H11), 1.392 – 
1.310 (8H, m), 1.269 – 1.216 (2H, m, H6 +  8), 0.920 (3H, t, J = 6.8 Hz, H16). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 153.33 (C9), 143.52 (Ci-Ph), 139.83 (Ci-Ph), 
128.50 (2CHo- or m-Ph), 128.42 (2CHo- or m-Ph), 128.06 (2CHo- or m-Ph), 127.45 (2CHo- or m-
Ph), 126.58 (CHp-Ph), 126.37 (CHp-Ph), 115.34 (CH210), 60.43 (2CH22 + 3), 59.76 (CH21), 
54.98 (C7), 44.05 (2CH26 + 8), 41.36 (2CH4 + 5), 39.66 (CH211), 31.94 (CH2), 29.93 
(CH2), 25.93 (CH2), 22.73 (CH2), 14.12 (CH316). 
HRMS (ESI+): Found: [M + H]+, 388.2997. [C28H38N]+ requires: 388.2999. 
LRMS (ESI+): m/z: 388 ([M + H]+, 100%). 
IR (thin film): ν~ = 2933 (m), 2850 (m), 2778 (m), 1489 (m), 1452 (m), 1334 (m) 896 
(m), 775 (m), 737 (m), 699 (s) cm–1. 
 
6.3.8. rac-(3aR,6aR)-2-Benzyl-5-hexyl-octahydro-5-(1-phenylvinyl)cyclopenta[c]-
pyrrole (3.42a, b cis + trans) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of N,N-diallylbenzenamine 
(0.173 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
reaction mixture was allowed to warm to room temperature and stirred for 3 h. After 
cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.271 g, 1.05 mmol) 
in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.187 mL, 1.1 
mmol) in dry THF (2 mL) and n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 
mmol) at 0 °C over 20 min]. The reaction mixture was stirred at –78 °C for 20 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi i (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 οC over 15 min]. The stirring was continued for 1 h during 
which time the reaction mixture was allowed to warm to –45 °C before addition of 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture 
was allowed to warm to room temperature and left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh)  
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.263 g (70%) as inseparable mixture of 3.8 : 52.3 : 43.9 cis : cis : trans ring 
junction isomers. Re-crystallization from cold hexane provided the 2.2 : 1 cis (major 
isomer) :  trans mixture of final compounds. 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.356 – 7.178 (14H, m, HAr), 6.747 (1H, t, J = 
7.3 Hz, HN-p-Ph major), 6.699 (2H, dd, J = 7.8, 1.0 Hz, HN-o-Ph major), 6.647 (1H, t, J = 7.3 
Hz, HN-p-Ph minor), 6.520 (2H, d, J = 7.8 Hz, HN-o-Ph minor), 3.748 (1H, d, J = 1.3 Hz, H9 
major), 5.236 (1H, br s, H9 minor), 5.086 (1H, d, J = 1.3 Hz, H9 major), 5.046 (1H, br s, H9 
minor), 3.422 – 3.361 (2H, ddd, J = 9.5, 8.4, 6.5 Hz, H(1 + 2) a/b minor), 3.290 – 3.266 (2H, d, 
J = 9.5 Hz, H(1 + 2) a/b major), 3.159 – 3.118 (2H, apparent dd, J = 9.5, 7.3 Hz, H(1 + 2) a/b 
major), 2.984 – 2.928 (2H, td, J = 8.4, 4.5 Hz, H(1 + 2) a/b minor), 2.901 – 2.803 (2H, septet, J 
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= 8.4 Hz, H(3 + 4) major), 2.412 – 2.361 (2H, dd, J = 12.8, 7.4  Hz, H(5 + 6) a/b major), 2.351 – 
2.306 (1H, dd, J = 12.5, 5.7 Hz, H(5 + 6) a/b minor), 2.272 – 2.082 (2H, m, H(3 + 4) minor), 
1.904 (1H, dd, J = 11.8, 5.8 Hz, H(5/6) a/b minor), 1.824 (1H, t, J = 11.8 Hz, H(5/6) a/b minor), 
1.742 – 1.670 (1H, m, Hminor), 1.609 – 1.52 (4H, m), 1.385 – 1.238 (18H, m), 0.911 (3H, 
t, J = 7.0 Hz, H15 major), 0.888 (3H, t, J = 7.0 Hz, H15 minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 157.37 (C8 minor), 153.27 (C8 major), 149.46 
(CN-i-Ph major), 148.30 (CN-i-Ph minor), 143.64 (Ci-Ph minor), 143.27 (Ci-Ph major), 129.13 (2CHo- 
or m-Ph minor), 129.05 (2CHo- or m-Ph major), 128.40 (2CHo- or m-Ph major), 128.22 (2CHo- or m-Ph 
minor), 127.68 (2CHo- or m-Ph minor), 127.59 (2CHo- or m-Ph major), 126.59 (CHp-Ph minor), 126.55 
(CHp-Ph major), 116.91 (CHN-p-Ph major), 115.47 (CH29 major), 114.94 (CHN-p-Ph minor), 113.75 
(2CHN-o-Ph major), 113.54 (CH29 minor), 110.81 (2CHN-o-Ph minor), 58.23 (C7 minor), 55.07 (C7 
major), 55.00 (2CH21 + 2 major), 50.31 (CH23/4 minor), 50.01 (CH24/3 minor), 49.77 (2CH21 + 2 
minor), 44.73 (2CH25 + 6 major), 42.76 (CH2minor), 41.08 (2CH3 + 4 major), 40.71 (CH5/6 minor), 
39.84 (CH2major), 37.94 (CH6/5 minor), 31.84 (CH2major), 31.74 (CH2minor), 29.81 (CH2major), 
29.71 (CH2minor), 25.84 (CH2major), 24.91 (CH2minor), 22.67 (CH2major), 22.61 (CH2minor), 
14.09 (CH316 major), 14.07 (CH316 minor). 
HRMS (ESI+): Found: [M + H]+, 374.2838. [C27H36N]+ requires: 374.2842. 
LRMS (ESI+): m/z: 374 ([M + H]+, 100%). 
IR (thin film): ν~ = 2922 (m), 2922 (m), 2854 (m), 2812 (m), 1595 (s), 1504 (s), 1467 
(s), 1357 (m), 1327 (m), 892 (m), 741 (s), 692 (s) cm–1. 
 
6.3.9. rac-(E,3aR,6aR)-1-Ethyl-2-hexylidene-octahydro-5,5-bis(methoxymethyl)-
pentalene (3.45a) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to  –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added 
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dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 14 h.  
After cooling the reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 
mmol) in dry THF (1 mL) was added followed by dropwise addition of freshly prepared 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.255 mL, 1.5 
mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of a 2.5 M solution in hexanes, 1.5 
mmol) at –5 °C over 20 min]. The reaction mixture was stirred at –78 °C for 30 min 
before dropwise addition of lithium phenyl acetylide, [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at –5 οC over 15 min]. The stirring was continued for 3 h during 
which the reaction mixture was allowed to warm to –35 °C before addition of MeOH (5 
mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was 
allowed to warm to room temperature and left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as colorless oil in 
yield of 0.231 g (75%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 5.126 (1H, tq, J = 7.0, 2.3 Hz, H15), 3.355 
(3H, s, H1 or 2), 3.353 (3H, s, H1 or 2), 3.296 (1H, d, J = 8.8 Hz, H3 or 4), 3.288 (1H, d, J = 
8.8 Hz, H3 or 4), 3.257 (1H, d, J = 8.8 Hz, H3 or 4), 3.253 (1H, d, J = 8.8 Hz, H3 or 4), 2.386 
(1H, dd, J = 20.3, 12.3 Hz, H10), 1.993 – 1.867 (3H, m, 2H16 + H9), 1.805 – 1.660 (2H, 
m, H10 + H8), 1.684 (1H, dd, J = 12.0, 6.3 Hz, H7a), 1.611 (1H, dd, J = 11.8, 5.9 Hz, 
H6b), 1.394 – 1.229 (8H, m), 1.182 (1H, ddd, J = 13.8, 7.3, 2.0 Hz, H11), 1.076 (1H, t, J 
= 12.0 Hz, H7b), 0.958  (1H, t, J = 11.8 Hz, H6a), 0.918 (3H, t, J = 7.4 Hz, H14), 0.890 
(3H, t, J = 7.0 Hz, H20). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 150.27 (C12), 121.42 (CH15), 78.50 (CH23/4), 
78.41 (CH24/3), 59.24 (2CH31 + 2), 56.84 (CH11), 53.57 (C5), 48.84 (CH8), 48.32 (CH9), 
35.15 (CH27), 34.31 (CH26), 31.96 (CH210), 31.57 (CH213), 29.35 (CH2), 29.12 (CH216), 
26.28 (CH2), 22.62 (CH2), 14.09 (CH320), 12.18 (CH314). 
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HRMS (EI): Found: [M - MeOH]+, 276.2458. [C19H32O]+ requires: 276.2453. 
LRMS (CI): m/z: 309 ([M + H]+·, 100%), 277 ([M – MeOH + H]+·, 57%), 245 ([M – 
2MeOH + H]+·, 43%). 
IR (thin film): ν~ = 2952 (m), 2918 (m), 2858 (m), 1448 (w), 1198 (w), 1107 (s), 960 
(w) cm–1. 
 
6.3.10. rac-(E,3aR,6aR)-2-Hexylidene-octahydro-5,5-bis(methoxymethyl)-1-
phenylpentalene (major d.r.) and  rac-(Z,3aR,6aR)-2-hexylidene-octahydro-
5,5-bis(methoxymethyl)-1-phenylpentalene (minor d.r.) (3.45b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1-((E)-4,4-
bis(methoxymethyl)hepta-1,6-dienyl)benzene (0.260 g, 1.0 mmol) in dry THF (3 mL) 
was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm 
to room temperature and stirred for 15 h. After cooling the reaction to –78 °C, a solution 
of 1,1-dibromoheptane (0.335 g, 1.3 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.255 mL, 1.5 mmol) in dry THF (2 mL) and n-BuLi (0.6 mL of 
a 2.5 M solution in hexanes, 1.5 mmol) at –5 °C over 20 min]. The reaction mixture was 
stirred at –78 °C for 30 min before dropwise addition of lithium phenyl acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi 
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(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 οC over 15 min]. The stirring 
was continued for 4.5 h during which time the reaction mixture was allowed to warm to 
–15 °C before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 
(6 mL). The whole mixture was allowed to warm to room temperature and left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes as the eluant gave the title compound as a pale yellow oil in 
yield of 0.303 g (85%) as an inseparable mixture of isomers (9 : 1). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.304 – 7.155 (10H, m, HAr major + minor), 5.371 
(1H, fs tq, J = 6.9 Hz, H13 minor), 4.869 (1H, tq, J = 6.7, 2.5Hz, H13 major), 3.366 – 3.125 
(16H, m, H-1 + H-2 + H-3 + H-4 + H-11 (major + minor)), 3.331 (3H, s, H1/2 major), 
3.303 (3H, s, H2/1 major), 2.564 (1H, fs dd, J = 11.0 Hz,  H10a major), 2.426 (1H, dd, J = 
13.8, 5.0 Hz, H10b minor), 2.288 – 2.113 (1H, m, H10a minor), 1.959 – 1.770 (9H, m, H-10b 
major + 2H-8 + 2H-9 + 2H-14 (major + minor)), 1.725 (1H, dd, J = 12.3, 5.6 Hz, H6/7 
major), 1.666 (1H, dd, J = 12.3, 6.0 Hz, H6/7 minor), 1.546 (1H, dd, J = 12.0, 6.0 Hz, H7/6 
minor), 1.489 (1H, dd, J = 12.3, 6.0 Hz, H7/6 major), 1.323 – 1.181 (10H, m), 1.158 – 0.953 
(6H, m), 0.876 (3H, t, J = 7.0 Hz, H18 major), 0.790 (3H, t, J = 7.0 Hz, H18 minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 150.57 (C12 major), 148.97 (C12 minor), 146.01 
(Ci-Ph minor), 144.68 (Ci-Ph major), 128.47 (2CHo- or m-Ph major), 128.20 (2CHo- or m-Ph minor), 
128.09 (2CHo- or m-Ph major), 127.45 (2CHo- or m-Ph minor), 125.77 (CHp-Ph major), 125.40 (CHp-
Ph minor), 125.22 (CH13 minor), 125.12 (CH13 major), 78.02 (CH23/4 major), 77.97 (CH24/3 major), 
77.76 (CH23/4 minor), 77.21 (CH24/3 minor), 62.89 (CH31/2 minor), 59.48 (CH3/CH1/2/8/9 major), 
59.24 (CH3/CH1/2/8/9 major), 59.15 (CH3/CH1/2/8/9 major), 59.08 (CH3/CH1/2/8/9 minor), 54.16 
(2CH11 major + minor), 53.12 (C5 major), 52.96 (C5 minor), 50.90 (CH8/9 minor), 48.95 (CH8/9 
major), 38.53 (CH210 minor), 34.60 (CH26/7 major), 34.29 (CH2minor), 33.40 (CH2minor), 33.20 
(CH27/6 major), 32.25 (CH210 major), 31.54 (CH2major), 31.43 (CH2minor), 29.18 (CH2major), 
29.04 (CH2major), 28.74 (CH2minor), 28.59 (CH2minor), 22.54 (CH2major), 22.41 (CH2minor), 
14.07 (CH318 major), 13.99 (CH318 major). 
HRMS (ESI+): Found: [M + Na]+, 379.2607. [C24H36NaO2]+ requires: 379.2608. 
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LRMS (CI): m/z: 357 ([M + H]+·, 74%), 353 ([M – MeOH]+·, 65%), 293 ([M – 2MeOH 
+ H]+·, 72%), 279 ([M – Ph]+·, 59%), 181 (72%), 91 (96%), 45 (100%). 
IR (thin film): ν~ = 2929 (m), 2864 (m), 1450 (m), 1191 (m) 1099 (s), 964 (w), 700 (s) 
cm–1. 
 
6.3.11. rac-(2S,3aR,6aS)-5-Benzyl-2-hexyl-octahydro-3a-methyl-2-(1-phenylvinyl)-
cyclopenta[c]pyrrole (major d.r.) and rac-(2R,3aR,6aS)-5-benzyl-2-hexyl-
octahydro-3a-methyl-2-(1-phenylvinyl)cyclopenta[c]pyrrole (minor d.r.) 
(3.53a) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution N-allyl-N-benzyl-2-
methylprop-2-en-1-amine (0.201 g, 1.0 mmol) in in dry THF (3 mL) was added 
dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 3 h. After cooling the reaction mixture to –90 °C, a solution 
of 1,1-dibromoheptane (0.284 g, 1.1 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-BuLi (0.46 mL 
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of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The reaction mixture 
was stirred for 30 min during which was allowed to warm to –78 °C before dropwise 
addition of lithium phenyl acetylide, [prepared from phenylacetylene (0.33 mL, 3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at 0 οC over 15 min]. The stirring was continued for 3 h during which time the 
reaction mixture was allowed to warm to –20 °C before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 2.5% of Et2O in hexanes as the eluant gave the title compounds as an inseparable 
mixture (97 : 3) of both diastereomers in yield of 0.142 g (35%, pale yellow oil). 
 
NMR characterysation does not contain complete data for the minor isomer. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.383 – 7.220 (10H, m, HAr), 5.270 (1H, d, J = 
1.6 Hz, H11), 5.110 (1H, d, J = 1.6 Hz, H11), 5.071 (1H, d, J = 1.8 Hz, H11 minor), 4.958 
(1H, d, J = 1.8 Hz, H11 minor), 3.587 (2H, br s, H1), 2.701 (1H, d, J = 8.8 Hz, H2), 2.568 
(1H, d, J = 8.8 Hz, H3b), 2.342 (1H, ddd, J = 13.0, 7.8, 2.5 Hz, H9b), 2.295 (1H, dd, J = 
8.8, 6.5 Hz, H3a), 2.208 (1H, dd, J = 13.0, 2.3 Hz, H7b), 2.112 (1H, dddd, J = 9.5, 7.8, 
6.5, 1.3 Hz, H6), 1.884 (1H, d, J = 8.8 Hz, H2), 1.654 (1H, m), 1.610 (1H, d, J = 13.0 
Hz, H7a), 1.480 (1H, dd, J = 13.0, 9.5 Hz, H9a), 1.470 (1H, m), 1.395 – 1.312 (7H, m), 
1.241 (3H, s, H4), 0.939 (3H, t, J = 6.9 Hz, H17), 0.932 (1H, t, J = 6.9 Hz, H12). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 154.09 (C10), 143.94 (Ci-Ph minor), 143.73 (Ci-
Ph), 139.94 (Ci-Ph), 128.61 (2CHo- or m-Ph), 128.38 (2CHo- or m-Ph), 128.06 (2CHo- or m-Ph), 
127.48 (2CHo- or m-Ph), 126.56 (CHp-Ph), 126.38 (CHp-Ph), 125.83 (CHp-Ph minor), 115.97 
(CH211), 113.63 (CH211 minor), 70.67 (CH22 minor), 70.34 (CH22), 60.51 (CH23), 60.03 
(CH21/3 minor), 59.81 (CH23/1 minor), 59.69 (CH21), 53.98 (C8), 53.26 (C8), 51.67 (CH27), 
50.54 (CH2minor), 49.64 (CH6), 49.31 (C5), 49.24 (C5 minor), 48.10 (CH2minor), 45.15 
(CH2minor), 45.04 (CH29), 41.82 (CH2minor), 41.52 (CH2), 31.96 (CH2), 30.34 (CH2minor), 
29.87 (CH2), 29.69 (CH2minor), 28.82 (CH34 minor), 28.36 (CH34), 27.39 (CH2minor), 25.72 
(CH2), 24.62 (CH2minor), 22.73 (CH2), 14.13 (CH317). 
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HRMS (ESI+): Found: [M + H]+, 402.3148. [C29H40N]+ requires: 402.3155. 
LRMS (ESI+): m/z: 402 ([M + H]+, 100%). 
IR (thin film): ν~ = 2924 (m), 2843 (m), 2767 (m), 1488 (m), 1455 (m), 1029 (m) 905 
(s), 775 (m), 737 (m), 700 (s) cm–1. 
 
6.3.12. rac-(3aR,5S,6aS)-2-Benzyl-5-hexyl-octahydro-3a-phenyl-5-(1-phenylvinyl)- 
cyclopenta[c]pyrrole (major d.r.) and rac-(3aR,5R,6aS)-2-benzyl-5-hexyl-
octahydro-3a-phenyl-5-(1-phenylvinyl)-cyclopenta[c]pyrrole (minor d.r.) 
(3.53b) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution N-benzyl-N-(2-
phenylallyl)prop-2-en-1-amine (0.263 g, 1.0 mmol) in dry THF (3 mL) was added 
dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm to room 
temperature and stirred for 3 h. After cooling the reaction mixture to –90 °C, a solution 
of 1,1-dibromoheptane (0.264 g, 1.1 mmol) in dry THF (1 mL) was added followed by 
dropwise addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-BuLi (0.46 mL 
 211 
of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The reaction mixture 
was stirred for 30 min during which was allowed to warm to –78 °C before dropwise 
addition of lithium phenyl acetylide, [prepared from phenylacetylene (0.33 mL, 3.0 
mmol) in dry THF (3 mL) and n–BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
mmol) at 0 οC over 15 min]. The stirring was continued for 3 h during which time the 
reaction mixture was allowed to warm to –20 °C before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230-400 mesh) 
with 5  10% of Et2O in hexanes as the eluant gave the title compounds as an 
inseparable mixture (94 : 6) of both diastereomers in yield of 0.066 g (14%, pale yellow 
oil). 
 
NMR characterysation does not contain complete data for the minor isomer. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.331 – 6.938 (13H, m, HAr), 6.506 (2H, d, J = 
6.8 Hz, HC1-o-Ph), 5.054 (1H, d, J = 1.3 Hz, H10 minor), 4.916 (1H, d, J = 1.0 Hz, H10), 
4.002 (1H, d, J = 1.3 Hz, H10 minor), 4.710 (1H, d, J = 1.0 Hz, H10), 3.604 (1H, d, J = 
13.3 Hz, H1 minor), 3.542 (1H, d, J = 13.2 Hz, H1), 3.464 (1H, d, J = 13.2 Hz, H1), 3.071 
(1H, q, J = 7.7 Hz, H5), 3.011 (1H, d, J = 8.8 Hz, H2), 2.711 (1H, d, J = 8.7 Hz, H3b), 
2.579 (1H, d, J = 13.0 Hz, H6), 2.428 (1H, apparent t, J = 11.4 Hz, H8a), 2.269 (1H, t, J 
= 7.7 Hz, H3a), 1.943 (1H, d, J = 8.8 Hz, H2), 1.862 (1H, d, J = 12.8 Hz, H6), 1.642 (1H, 
m), 1.592 (1H, d, J = 11.4 Hz, H8b), 1.432 (1H, m), 1.267 – 1.204 (8H, m), 0.864 (3H, t, 
J = 6.8 Hz, H16 major), 0.713 (1H, t, J = 7.3 Hz, H16 minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 156.05 (C9 major), 152.19 (C9 minor), 149.78 
(Ci-Ph minor), 149.29 (Ci-Ph major), 143.79 (Ci-Ph minor), 143.16 (Ci-Ph major), 139.76 (Ci-Ph major), 
139.71 (Ci-Ph minor), 128.49 (2CHo- or m-Ph major), 128.44 (2CHo- or m-Ph minor), 128.43 (2CHo- 
or m-Ph minor), 128.37 (2CHo- or m-Ph major), 128.19 (2CHo- or m-Ph minor), 128.12  (2CHo- or m-Ph 
major), 128.09 (2CHo- or m-Ph minor), 128.01 (2CHo- or m-Ph major), 127.49 (2CHo- or m-Ph minor), 
127.14 (2CHo- or m-Ph major), 126.66 (CHp-Ph major), 126.46 (2CHo- or m-Ph major), 126.41 (CHp-
Ph minor), 126.26 (2CHo- or m-Ph minor), 126.05 (CHp-Ph major), 125.80 (CHp-Ph minor), 125.42 
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(CHp-Ph minor), 125.27 (CHp-Ph major), 116.56 (CH210 major), 113.76 (CH210 minor), 71.38 
(CH22 major), 68.09 (CH22 minor), 61.86 (CH23 minor), 60.93 (CH23 major), 59.65 (CH21 minor), 
59.44 (CH21 major), 58.02 (C7 minor), 57.75 (C7 major), 53.55 (C4 major), 53.13 (CH26 major), 
52.80 (C4 minor), 49.03 (CH2minor), 48.68 (CH2minor), 48.45 (CH5 minor), 44.67 (CH5 major), 
44.54 (CH28 major), 40.68 (CH2major), 40.31 (CH2minor), 31.98 (CH2major), 31.88 (CH2minor), 
29.88 (CH2major), 29.69 (CH2minor), 25.77 (CH2major), 24.23 (CH2minor), 22.74 (CH2major), 
22.63 (CH2minor), 14.13 (CH316 major), 14.10 (CH316 minor). 
HRMS (ESI+): Found: [M + H]+, 464.3303. [C34H42N]+ requires: 464.3312. 
LRMS (ESI+): m/z: 464 ([M + H]+, 100%). 
IR (thin film): ν~ = 2956 (m), 2933 (m), 2847 (m), 2775 (m), 1607 (w), 1493 (m), 1452 
(m), 1024 (m) 907 (s), 733 (s), 699 (s) cm–1. 
 
6.3.13. rac-(3aR,7aS)-2-Hexyl-octahydro-2-(1-phenylvinyl)-1-H-indene (major d.r.) 
and rac-(3aR,7aR)-2-hexyl-octahydro-2-(1-phenylvinyl)-1-H-indene (minor 
d.r.) (3.59) 
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Major d.r.                           68 : 32                            Minor d.r.
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1,7-octadiene (0.110 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the reaction 
mixture was allowed to warm to room temperature and stirred for 2 h. After cooling the 
reaction to –78 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.30 mmol) in dry THF 
(1 mL) was added followed by dropwise addition of LDA (0.83 mL of a 1.8 M solution, 
1.50 mmol). The reaction mixture was stirred at –78 °C for 15 min before dropwise 
addition of lithium phenyl acetylide, [prepared from phenylacetylene (0.33 mL, 3.0 
mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 
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mmol) at –5 οC over 15 min]. The stirring was continued for 30 min during which time 
the reaction mixture was allowed to warm to –50 °C before addition of MeOH (5 mL) 
and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to room temperature and left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The combined organic 
phases were washed with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as an orange oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title compounds as a pale yellow oil in combined 
yield of 0.165 g (53%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.315 – 7.214 (10H, m, HAr major + minor), 5.189 
(1H, d, J = 1.4 Hz, H11 major), 5.172 (1H, d, J = 1.5 Hz, H11 minor), 5.008 (1H, d, J = 1.4 Hz, 
H11 major), 4.982 (1H, d, J = 1.5 Hz, H11 minor), 2.220 (1H, dd, J = 12.3, 5.5 Hz, Hminor), 
2.158 – 2.041 (4H, m), 1.862 – 1.735 (3H, m), 1.612 – 1.394 (16H, m), 1.372 – 1.076 
(22H, m), 1.024 – 0.916 (2H, m), 0.878 (3H, t, J = 7.0 Hz, H17 major), 0.870 (3H, t, J = 7.0 
Hz, H17 minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 158.24 (C10 minor), 156.95 (C10 major), 144.14 
(Ci-Ph minor), 143.90 (Ci-Ph major), 128.40 (2CHo- or m-Ph major), 128.20 (2CHo- or m-Ph minor), 
127.50 (2CHo- or m-Ph minor), 127.44 (2CHo- or m-Ph major), 126.31 (2CHp-Ph major + minor), 
113.82 (CH11 major), 113.05 (CH11 minor), 50.71 (C8 major), 49.31 (C8 minor), 46.88 (CH2 
minor), 45.91 (CH1/2 minor), 45.64 (CH2/1 minor), 44.32 (CH2minor), 43.35 (2CH2 minor), 43.07 
(2CH2 major), 42.78 (CH2 minor), 37.84 (2CH1 + 2 major), 31.87 (CH2minor), 31.77 (2CH2major), 
29.80 (2CH2major + minor), 28.34 (2CH2major), 26.43 (CH2minor), 26.35 (CH2minor), 25.81 
(CH2major), 25.03 (CH2minor), 23.17 (2CH2major), 22.63 (2CH2major + minor), 14.08 (2CH317 
major + minor). 
HRMS (EI): Found: [M]+, 310.2661. C23H34 requires: 310.2661. 
LRMS (CI): m/z: 311 ([M + H]+·, 4%), 310 ([M]+·, 3%), 226 ([M – Hex + H]+·, 100%). 
IR (thin film): ν~ = 2922 (s), 2847 (s), 1444 (m), 896 (s), 771 (s), 695 (s) cm–1. 
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6.3.14. rac-(3aS,7aR)-2-Hexylidene-octahydro-1-H-indene (3.60) 
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The product was obtained simultaneously with products 3.59. Purification of the crude 
material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as the 
eluant gave the title compound as a pale yellow oil in yield of 0.084 g (40%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 5.258 (1H, tdd, J = 9.3, 4.5, 2.3 Hz, H10), 
2.305 – 1.929 (8H, m), 1.538 – 1.279 (14H, m), 0.902 (3H, t, J = 7.0 Hz, H15). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.95 (C8),  122.05 (CH10), 38.21 (CH1/2), 
38.18 (CH2/1), 37.91 (CH2), 33.05 (CH2), 31.62 (CH2), 29.51 (CH2), 29.40 (CH2), 27.55 
(CH2), 27.19 (CH2), 23.29 (CH2), 22.76 (CH2), 22.63 (CH2), 14.10 (CH315). 
HRMS (EI): Found: [M]+, 206.2036. C15H26 requires: 206.2034. 
LRMS (CI): m/z: 207 ([M + H]+·, 10%), 206 ([M]+·, 18%), 121 ([M – Hex]+·, 100%). 
IR (thin film): ν~ = 2922 (s), 2850 (m), 1448 (m) cm–1. 
 
6.3.15. rac-(3aS,9aR)-2-Hexyl-2,3,3a,4,9,9a-hexahydro-2-(1-phenylvinyl)-1H-
cyclopenta[b]napthalene (3.64) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 1,2-diallylbenzene (0.158 
g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at –78 °C the 
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reaction mixture was allowed to warm to room temperature and stirred for 2.5 h. After 
cooling the reaction to –85 °C, a solution of 1,1-dibromoheptane (0.335 g, 1.3 mmol) in 
dry THF (1 mL) was added followed by dropwise addition of LDA (0.85 mL of a 1.8 M 
solution, 1.5 mmol). After 15 min a dropwise addition of lithium phenyl acetylide 
followed, [prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and 
n-BuLi (1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at –5 οC over 15 min]. The 
stirring was continued for 1 h during which time the reaction mixture was allowed to 
warm to –55 °C before addition of MeOH (5 mL) and a saturated aqueous solution of 
NaHCO3 (6 mL). The whole mixture was allowed to warm to room temperature and left 
stirring overnight. The mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexanes as the eluant gave the title compound as a pale yellow oil in yield of 0.142 
g (40%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.447 – 7.373 (3H, m, HAr), 7.291 – 7.222 
(6H, m, HAr), 5.357 (1H, d, J = 1.8 Hz, H9), 5.158 (1H, d, J = 1.8 Hz, H9), 2.888 (2H, 
dd, J = 13.9, 5.5 Hz, H1b + 2b), 2.611 (2H, tdd, J = 16.2, 10.0, 5.7 Hz, H3 + 4), 2.494 (2H, 
dd, J = 13.9, 6.2 Hz, H1a + 2a), 2.305 (2H, ddd, J = 12.2, 5.0, 2.4 Hz, H5b + 7b), 1.588 – 
1.378 (10H, m), 1.074 (2H, dd, J = 12.2, 10.0 Hz, H5a + 7a), 1.029 (3H, t, J = 6.9 Hz, 
H15). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 153.39 (C8), 143.44 (Ci-Ph), 139.54 (2Ci-Ph), 
128.40 (2CHo- or m-Ph), 127.57 (2CHo- or m-Ph), 127.49 (2CHo- or m-Ph), 126.41 (CHp-Ph), 
125.81 (2CHo- or m-Ph), 115.40 (CH29), 51.99 (C6), 44.03 (2CH25 + 7), 40.07 (CH2), 36.02 
(2CH
 
3 + 4), 34.53 (2CH21 + 2), 31.91 (CH2), 29.86 (CH2),  25.78 (CH2), 22.71 (CH2), 
14.10 (CH315). 
HRMS (EI): Found: [M]+, 358.2673. C27H34 requires: 358.2661. 
LRMS (CI): m/z: 359 ([M + H]+·, 30%), 274 ([M – Hex + H]+·, 100%). 
IR (thin film): ν~ = 2929 (s), 2853 (m), 2767 (m), 1488 (m), 1455 (m), 899 (m), 775 
(m), 748 (s), 705 (s) cm–1. 
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6.3.16. rac-(3aR,9aS)-1-Hexyl-3a,4,9,9a-tetrahydro-1H-cyclopenta[b]naphtalene 
(major compound, 3.65), rac-(3aS,9aR)-2-hexylidene-2,3,3a,4,9,9a-
hexahydro-1H-cyclopenta[b]naphtalene (minor compound, 3.66) and rac-
(3aS,9aR)-2-hexyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalene 
(trace, 3.67) 
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These products were obtained simultaneously with product 3.64. Purification of the 
crude material by column chromatography on SiO2 (230 – 400 mesh) with hexanes as 
the eluant gave the title compounds as colourless oil in yield of 0.083 g (33%) as an 
inseparable mixture of compounds with the ratio stated above. 
 
NMR characterysation does not contain data for the compound 3.67. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.277 – 7.120 (8H, m, HAr major + minor), 5.264 
(1H, m, H8 minor), 5.198 (1H, br s, H7 major), 3.084 (1H, m), 2.914 – 2.781 (4H, m), 2.741 
– 2.660 (1H, m), 2.612 – 2.307 (9H, m), 2.098 (1H, dd, J = 15.0, 6.0 Hz, Hminor), 2.015 
– 1.959 (6H, m), 1.415 – 1.184 (14H, m), 0.927 – 0.892 (6H, m, H13 major + minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 153.39 (C6 major), 141.12 (C6 minor), 139.77 
(Ci-Ph major), 139.45 (Ci-Ph major), 137.74 (Ci-Ph minor), 137.52 (Ci-Ph minor), 128.17 (CHAr 
minor), 127.28 (CHAr major), 127.12 (CHAr major), 126.70 (CH7 major), 125.82 (CHAr minor), 
125.69 (2CHAr major), 125.66 (CHAr minor), 125.64 (CHAr minor), 121.62 (CH8 minor), 45.41 
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(CH4 major), 42.22 (CH2major), 39.87 (CH2minor), 36.65 (CH3/4 minor), 36.09 (CH4/3 minor), 
35.89  (CH2major), 35.79 (CH3 major), 34.68 (CH2minor), 34.39 (CH2major), 33.19 (CH2minor), 
32.80 (CH2minor), 31.72 (CH2major), 31.55 (CH2minor), 30.92 (CH2major), 29.47 (CH2minor), 
29.37 (CH2minor), 28.83 (CH2major), 27.49 (CH2major), 22.59 (2CH2major + minor), 14.10 
(2CH313 major + minor). 
HRMS (EI): Found: [M]+, 254.2031. C19H26 requires: 254.2034. 
LRMS (CI): m/z: 256 ([M]+·, 13%), 255 ([M + H]+·, 69%), 254 ([M]+·, 88%), 169 
(67%), 128 (79%), 104 (100%). 
IR (thin film): ν~ = 2922 (s), 2854 (m), 2824 (m), 1463 (m), 733 (s) cm–1. 
 
6.3.17. rac-(2aR,4E,4aR,7aS,7bR)-1,1-Bis(methoxymethyl)-4-hexylidenedecahydro-
1H-cyclopenta[cd]indene (major d.r.) and rac-(2aR,4Z,4aR,7aS,7bR)-1,1-
bis(methoxymethyl)-4-hexylidenedecahydro-1H-cyclopenta[cd]indene 
(minor d.r.) (3.70) 
O
O
H
H
H
1 32 12
13
11
7
6
5
4
1817
1615
14
19
8 10
9
O
O
H
H
H
1 32 12
13
11
7
6
5
4
1817
1615
14
19
8 10
9
H
H
Major d.r.
3 : 1
Minor d.r.
 
To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of 3-(1-methoxy-2-
(methoxymethyl)pent-4-en-2-yl)cyclohex-1-ene (0.224 g, 1.0 mmol) in dry THF (3 mL) 
was added dropwise. After 30 min at –78 °C the reaction mixture was allowed to warm 
to room temperature and stirred for 2 h. After cooling the reaction mixture to –90 °C, a 
solution of 1,1-dibromoheptane (0.284 g, 1.1 mmol) in dry THF (1 mL) was added 
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followed by dropwise addition of freshly prepared LiTMP, [prepared from freshly 
distilled 2,2,6,6-tetramethylpiperidine (0.196 mL, 1.15 mmol) in dry THF (2 mL) and n-
BuLi (0.46 mL of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. The 
reaction mixture was stirred for 20 min during which was allowed to warm to –78 °C 
before dropwise addition of lithium phenyl acetylide. [prepared from phenylacetylene 
(0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi (1.2 mL of a 2.5 M solution in 
hexanes, 3.0 mmol) at 0 οC over 15 min]. The stirring was continued for 2 h during 
which time the reaction mixture was allowed to warm to RT before addition of MeOH 
(5 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was 
allowed to warm to room temperature and left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes and Kugelrohr distillation (200 °C, 1.0 mmHg) gave the 
title compounds as an inseparable mixture 3 : 1 of E : Z isomers as a pale yellow oil in 
yield of 0.029 g (9%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 5.196 – 5.157 (2H, m, H14 major + minor), 3.383 
(2H, d, J = 9.0 Hz, H2 major + minor), 3.345 (6H, s, H1 major + minor), 3.313 (6H, s, H1 major + 
minor), 3.345 – 3.313 (4H, m, H2 major + minor), 3.230 (1H, d, J = 8.8 Hz, H2 major), 3.225 
(1H, d, J = 8.8 Hz, H2 minor), 2.538 (1H, dd, J = 17.3, 7.8 Hz,  H13 minor), 2.421  (1H, dd, 
J = 15.0, 6.0 Hz,  H13 major), 2.363 – 2.190 (4H, m, Hmajor + minor), 2.001 – 1.832 (6H, m, 
Hmajor + minor), 1.800 – 1.502 (14H, m, Hmajor + minor), 1.352 – 1.194 (14H, m, Hmajor + 
minor), 1.152 – 0.918 (4H, m, Hmajor + minor), 0.884 (6H, t, J = 6.8 Hz, H19 major +  minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 152.16 (C12 major), 151.44 (C12 minor), 123.28 
(CH14 minor), 122.41 (CH14 major), 78.50 (2CH22 major + minor), 74.53 (2CH22 major + minor), 
59.18 (2CH31 major + minor), 58.91 (2CH31 major + minor), 55.73 (C3 major), 55.60 (C3 minor), 
53.78 (CHminor), 53.24 (CHmajor), 41.70 (CHmajor), 41.52 (CHminor), 39.21 (CHmajor), 38.83 
(CHminor), 38.67 (CHmajor), 36.56 (CHminor), 36.27 (CH213 minor), 35.06 (CH2major), 34.95 
(CH2minor), 32.12 (CH213 major), 31.66 (CH2minor), 31.52 (CH2major), 29.91 (CH2minor ), 
29.51 (CH2major) 29.35 (2CH2major + minor), 29.13 (CH2major), 27.74 (CH2minor), 24.97 
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(CH2minor), 24.84 (CH2major), 23.22 (CH2minor), 23.19 (CH2major), 22.63 (CH2minor), 22.59 
(CH2major), 14.08 (2CH319 major + minor). 
HRMS (EI): Found: [M]+, 320.2710. C21H36O2 requires: 320.2715. 
LRMS (EI): m/z: 322 ([M + 2H]+·, 5%), 321 ([M + H]+·, 23%), 320 ([M]+·, 28%), 289 
([M – MeOH + H]+·, 46%), 288 ([M – MeOH]+·, 56%), 243 (65%), 203 (100%). 
IR (thin film): ν~ = 2926 (s), 2854 (s), 1452 (m), 1202 (m), 1111 (s), 956 (m) cm–1. 
 
6.3.18. rac-(3aS,6aS)-Octahydro-2,2-bis(methoxymethyl)-5-(3-phenylpropa1,2-
dienyl)pentalene (3.80a, b) and rac-(3aS,6aS)-octahydro-2,2-
bis(methoxymethyl)-5-(3-phenylprop-2-ynyl)pentalene (3.81) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise. After 30 min at 
–78 °C the reaction mixture was allowed to warm to room temperature and stirred for 
12 h. After cooling the reaction to –78 °C, 1,1-dichloromethane (0.064 mL, 1.0 mmol) 
was added followed by dropwise addition of freshly prepared LiTMP, [prepared from 
freshly distilled 2,2,6,6-tetramethylpiperidine (0.20 mL, 1.2 mmol) in dry THF (2 mL) 
and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 1.15 mmol) at 0 °C over 20 min]. 
The reaction mixture was stirred for 1 h during which was allowed to warm to –65 °C 
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before re-cooling to –78 °C and dropwise addition of lithium phenyl acetylide, 
[prepared from phenylacetylene (0.33 mL, 3.0 mmol) in dry THF (3 mL) and n-BuLi 
(1.2 mL of a 2.5 M solution in hexanes, 3.0 mmol) at 0 οC over 15 min]. The stirring 
was continued for 3 h during which time the reaction mixture was allowed to warm to –
35 °C before addition of MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 
mL). The whole mixture was allowed to warm to room temperature and left stirring for 
18 h. The mixture then was poured onto H2O (100 mL), the products were extracted 
with Et2O (3 × 50 mL). The combined organic phases were washed with H2O (3 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 5% of Et2O in hexanes gave the title compounds as an inseparable mixture of 
compounds in the following ratio: 3.80a/b : 3.80b/a, 1 : 1.8 and 3.80 : 3.81, 1 : 2, as a 
pale yellow oil in combined yield of 0.033 g (10%). 
 
Spectral data contain NMR and LRMS analysis only. 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.393 – 7.145 (15H, m, HAr), 6.162 (1H, dd, J 
= 6.3, 3.0 Hz, H17a/b), 6.160 (1H, dd, J = 6.3, 2.9 Hz, H17a/b), 5.685 (2H, td, J = 6.5, 3.5 
Hz, H15), 3.334 – 3.218 (30H, m), 2.723 – 2.650 (2H, m, H14), 2.433 (2H, d, J = 7.0 
Hz, H10), 1.989 – 1.348 (27H, m), 1.319 – 0.841 (14H, m). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 203.46 (C16a/b), 203.40 (C16a/b), 135.18 (2Ci-
Ph B), 131.54 (2CHo-Ph A), 128.53 (4CHm-Ph B), 128.14 (2CHm-Ph A), 127.40 (CHp-Ph A), 
126.59 (2CHo-Ph B), 126.54 (2CHp-Ph B), 126.49 (2CHo-Ph B), 124.15 (Ci-Ph A), 101.81  
(CH17a/b), 101.76 (CH17a/b), 95.73 (2CH15a + b), 89.90 (C12), 80.45 (C13), 78.17 (2CH22), 
78.10 (4CH22), 59.20 (6CH31), 54.42 (2C3), 54.34 (C3), 52.33 (3CH6/7), 50.90 (2CH6/7), 
50.76 (CH6/7), 43.33 (CH 10), 42.92 (2CH 14), 34.72 (2CH2), 34.40 (CH2), 34.33 (2CH2), 
34.25 (2CH2), 34.20 (2CH2), 33.61 (2CH2), 32.51 (CH2), 26.99 (CH2). 
LRMS (CI): m/z: 313 ([M + H]+·, 9%), 268 ([M – MeOH + H]+·, 6%), 267 ([M – Et2O 
+ H]+·, 4%), 249 ([M – 2MeOH + H]+·, 9%), 235 ([M – Ph]+·, 7%), 115 ([C9H7]+·, 34%). 
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6.4. Experimental from chapter 4 
 
6.4.1. rac-(1R,2R)-2-Hexyl-1-phenyloct-3-yn-1-ol (4.68a) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise 
over 3 minutes. After 25 min at the same tempereature, a solution of the non-1-yn-3-yl 
benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed 
by dropwise addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was 
continued for a further 1 h during which time the reaction mixture was allowed to warm 
to –50 °C. The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde 
(0.15 mL, 1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
BF3·OEt2 (0.18 ml, 1.5 mmol). The reaction mixture was warmed gradually to RT and 
stirred at the same temperature for 3 h before quenching with MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL) and the mixture was left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 77 : 23). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction of both isomers in combined yield of 0.10 g (35%). 
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Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.36 – 7.29 (5H, m, HAr), 4.49 (1H, dd, J = 
6.8, 4.3 Hz, H5), 2.67 (1H, ddt, J = 6.8, 4.3, 2.3 Hz, H4), 2.64 (1H, d, J = 4.3 Hz, OH6), 
2.23 (2H, td, J = 7.0, 2.3 Hz, H1), 1.54 – 1.21 (14H, m), 0.92 (3H, t, J = 7.3 Hz, H12/15), 
0.87 (3H, t, J = 6.9 Hz, H12/15). 
13C NMR (100 MHz, CDCl3):  (ppm) = 142.12 (Ci-Ph), 128.18 (2CHm-Ph), 127.68 
(CHp-Ph), 126.61 (2CHo-Ph), 85.29 (C2), 79.35 (C3), 76.37 (CH5), 41.82 (CH4), 31.71 
(2CH2), 31.07 (CH2), 28.97 (CH2), 27.36 (CH2), 22.55 (CH2), 21.92 (CH2), 18.46 
(CH21), 14.04 (CH312/15), 13.58 (CH312/15). 
HRMS (EI): Found: [M – H2O]+, 268.2186. [C20H28]+ requires: 268.2191. 
LRMS (CI): m/z: 287 ([M + H]+, 38%), 286 ([M]+, 42%), 269 ([M – H2O + H, 100%). 
IR (thin film): ν~ = 3457 (m, br), 2958 (m), 2925 (s), 2848 (m), 1454 (m), 1185 (w), 
1054 (w), 698 (s) cm–1. 
 
The following H and C signals of the syn isomer were identified in the spectra of the 
mixed fraction: 
1H NMR (400 MHz, CDCl3):  = 7.40 – 7.28 (5H, m, HAr), 4.71 (1H, apparent t, J = 
4.8 Hz, H5), 2.77 (1H, br s, H4), 2.30 (1H, d, J = 4.3 Hz, OH6), 2.16 (2H, td, J = 6.9, 2.3 
Hz, H1), 1.54 – 1.20 (14H, m), 0.90 (3H, t, J = 7.3 Hz, H12/15), 0.87 ppm (3H, t, J = 6.9 
Hz, H12/15). 
13C NMR (100.5 MHz, CDCl3):  = 141.86 (Ci-Ph), 127.94 (2CHm-Ph), 127.47 (CHp-Ph), 
126.60 (2CHo-Ph), 84.44 (C2), 79.95 (C3), 75.99 (CH5), 40.39 (CH4), 31.75 (CH2), 31.01 
(CH2), 29.97 (CH2),  29.06 (CH2), 27.41 (CH2), 22.58 (CH2), 21.83 (CH2), 18.41 
(CH21), 14.03 (CH312/15), 13.57 ppm (CH312/15). 
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6.4.2. rac-1-Phenyl-2-(prop-1-ynyl)octan-1-ol (4.68b) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –50 °C. 
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol) and the reaction mixture warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 3 h before quenching with MeOH (5 
mL) and saturated aqueous solution of NaHCO3 (6 mL) and the mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as an orange oil (anti : syn diastereoisomers in the ratio of 79 : 21). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.097 g (40%, pale yellow 
oil). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.31 – 7.18 (10H, m, HAr), 4.62 (1H, dd, J = 
5.4, 3.7 Hz, H5 minor), 4.40 (1H, dd, J = 6.8, 3.9 Hz, H5 major), 2.65 (1H, m, H4 minor), 2.58 
(1H, d, J = 3.9 Hz, OH6 major), 2.56 (1H, apparent ddq, J = 14.0, 7.0, 2.3 Hz, H4 major), 
2.30 (1H, d, J = 3.7 Hz, OH6 minor), 1.77 (3H, d, J = 2.3 Hz, H1 major), 1.71 (3H, d, J = 2.5 
Hz, H1 minor), 1.47 – 1.10 (20H, m), 0.96 (3H, overlap t, J = 7.1 Hz, H12 minor), 0.96 (3H, 
t, J = 7.0 Hz, H12 major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 142.08 (Ci-Ph major), 141.80 (Ci-Ph minor), 
128.16 (2CHm-Ph major), 127.90  (2CHm-Ph minor), 127.67 (CHp-Ph major), 127.41 (CHp-Ph 
minor), 126.57 (2CHo-Ph major), 126.53 (2CHo-Ph minor), 80.26 (C2 major), 79.47 (C2 or 3 minor), 
79.19 (C3 or 2 minor), 78.61 (C3 major), 76.38 (CH5 major), 75.87 (CH5 minor), 41.67 (CH4 major), 
40.34 (CH4 minor), 31.73 (CH2minor), 31.66 (CH2major), 31.60 (2CH2major + minor), 29.77 
(CH2minor), 29.06 (CH2minor), 28.97 (CH2major), 27.43 (CH2minor), 27.34 (CH2major), 22.54 
(CH2major), 14.00 (2CH3major + minor), 3.57 (CH31 major), 3.51 (CH31 minor). 
HRMS (EI): Found: [M – H2O]+, 226.1720. [C17H22]+ requires: 226.1722. 
LRMS (CI): m/z: 245 ([M + H]+, 70%), 227 ([M – H2O + H]+, 100%). 
IR (thin film): ν~ = 3436 (m, br), 2917 (m), 2848 (m), 1454 (m), 1197 (w), 1042 (w), 
706 (s) cm–1. 
 
6.4.3. rac-1-Phenyl-2-(2-phenylethynyl)octan-1-ol (4.68c) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added PhLi (1.11 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –65 °C. 
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 3 h before quenching with MeOH (5 
mL) and a saturated aqueous solution of NaHCO3 (6 mL) and the mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 79 : 21). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.106 g (35%, yellow oil). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.48 – 7.28 (20H, m, HAr), 4.82 (1H, dd, J = 
6.0, 4.0 Hz, H4 minor), 4.68  (1H, dd, J = 6.5, 4.3 Hz, H4 major), 3.02 (1H, ddd, J = 9.8, 6.0, 
3.9 Hz, H3 minor), 2.94 (1H, ddd, J = 9.6, 6.5, 4.3 Hz, H3 major), 2.60 (1H, dd, J = 4.3, 1.4 
Hz, OH6 major), 2.30 (1H, dd, J = 3.9. 2.0 Hz, OH6 minor), 1.64 – 1.40 (8H, m), 1.35 – 1.23 
(12H, m), 0.90 (3H, t, J = 7.2 Hz, H11 minor), 0.89 (3H, t, J = 6.8 Hz, H11 major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.92 (Ci-Ph B major), 141.85 (Ci-Ph B minor), 
131.69 (2CHo-Ph A major), 131.55 (2CHo-Ph A minor), 128.27 (2CHm-Ph A major), 128.23 (2CHm-
Ph B major), 128.15 (2CHm-Ph A/B minor), 128.05 (2CHm-Ph B/A minor), 127.97 (CHp-Ph A/B major), 
127.86 (CHp-Ph B/A major), 127.75 (CHp-Ph A/B minor), 127.73 (CHp-Ph B/A minor), 126.68 (2CHo-
Ph B minor), 126.60 (2CHo-Ph B major),  123.53 (Ci-Ph A minor), 123.27 (Ci-Ph A major), 90.02 (C1 
minor), 89.34 (C1 major), 84.86 (C2 major), 84.30 (C2 minor), 76.32 (CH4 major), 76.09 (CH4 
minor), 42.20 (CH3 major), 41.09 (CH3 minor), 31.76 (CH2minor), 31.70 (CH2major), 31.46 
(CH2major), 30.15 (CH2minor), 29.11 (CH2minor), 29.00 (CH2major), 27.44 (2CH2minor + minor), 
22.58 (2CH2major + minor), 14.04 (2CH311 major + minor). 
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HRMS (EI): Found: [M – H2O]+, 288.1885. [C22H24]+ requires: 288.1878. 
LRMS (CI): m/z: 306 ([M]+, 34%), 289 ([M – H2O + H]+, 66%). 
IR (thin film): ν~ = 3363 (m, br), 2933 (m), 2864 (m), 1491 (m), 1446 (m), 1029 (m), 
760 (s), 686 (s) cm–1. 
 
6.4.4. rac-1-Phenyl-2-(4-phenylbuta-1,3-diynyl)octan-1-ol (4.68d) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to -78 °C was 
added PhCCLi (freshly prepared from PhCCH (0.22 ml, 2.0 mmol) and n-BuLi (0.8 ml 
of a 2.5 M solution, 2.0 mmol) at 0 °C over 15 min) dropwise over 5 minutes. After 25 
min the cooling bath was removed and the stirring was continued at RT for 4 h before 
re-cooling the reaction mixture to –78 °C. A solution of the non-1-yn-3-yl 
benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed 
by dropwise addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). After stirring 
the reaction mixture for 30 min at the same temperature, a solution of benzaldehyde 
(0.15 mL, 1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
BF3·OEt2 (0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The 
reaction mixture was stirred at RT for 1 h before quenching with MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL), the mixture left stirring overnight. The 
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mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). 
The combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
yellow oil (anti : syn diastereoisomers in the ratio of 62 : 38). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.208 g (62%, yellow oil). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.39 – 7.14 (20H, m, HAr), 4.66 (1H, dd, J = 
5.9, 3.6 Hz, H6 minor), 4.53 (1H, dd, J = 6.5, 4.3 Hz, H6 major), 2.84 (1H, dddd, J = 10.0, 
6.0, 3.7, 0.5 Hz, H5 minor), 2.76 (1H, dddd, J = 10.8, 6.5, 4.4, 0.8 Hz, H5 major), 2.35 (1H, 
dd, J = 4.4 Hz, OH7 major), 2.15 (1H, dd, J = 3.8 Hz, OH7 minor), 1.49 – 1.14 (20H, m), 
0.77 (3H, t, J = 6.5 Hz, H13 minor), 0.76 (3H, t, J = 6.7 Hz, H13 major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.54 (Ci-Ph B major), 141.48 (Ci-Ph B minor), 
132.50 (2CHo-Ph A major), 132.48 (CHp-Ph A major), 128.97 (2CHo-Ph A minor), 128.89 (CHp-Ph A 
minor), 128.39 (2CHm-Ph A major), 128.34 (2CHm-Ph B major), 128.30 (2CHm-Ph A minor), 128.22 
(CHp-Ph B major), 128.05 (2CHm-Ph B minor), 127.92 (CHp-Ph B minor), 126.55  (2CHo-Ph B minor), 
126.48 (2CHo-Ph B major),  121.88 (Ci-Ph A minor), 121.80 (Ci-Ph A major), 84.44 (C1 major), 84.08 
(C4 major), 76.22 (CH6 major), 75.90 (C4 minor), 75.73 (CH6 minor), 75.65 (C1 minor), 74.16 (C2 
or 3 minor), 74.05 (C3 or 2 minor), 68.84 (C2 or 3 major), 68.49 (C3 or 2 major), 42.22 (CH5 major), 
41.30 (CH5 minor), 31.68 (CH2minor), 31.61 (CH2major), 31.26 (CH2major), 29.82 (CH2minor), 
29.05 (CH2minor), 28.94 (CH2major), 27.36 (CH2minor), 27.34 (CH2major), 22.59 (CH2minor), 
22.56 (CH2major), 14.02 (2CH311 major + minor). 
HRMS (EI): Found: [M]+, 330.1984. C24H26O requires: 330.1984. 
LRMS (CI): m/z: 331 ([M + H]+, 34%), 313 ([M – H2O + H]+, 60%). 
IR (thin film): ν~ = 3371 (m, br), 2925 (m), 2852 (m), 1487 (m), 1458 (m), 1025 (m), 
764 (s), 690 (s) cm–1. 
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6.4.5. rac-(1R,2R)-2-Methyl-1,4-diphenylbut-3-yn-1-ol (4.68e) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added PhLi (1.11 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the but-3-yn-2-yl benzensulfonate 
(0.224 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 1 h during which the reaction mixture was allowed to warm to –65 °C.  
The reaction mixture was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL 
1.5 mmol) in dry THF (1 mL) was added followed by dropwise addition of BF3·OEt2 
(0.18 mL, 1.5 mmol). The reaction mixture was warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 2 h before quenching with MeOH (5 
mL) and a saturated aqueous solution of NaHCO3 (6 mL), the mixture left stirring 
overnight. The whole mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 81 : 19). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.091 
g (39%). 
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Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.44 – 7.30 (10H, m, HAr), 4.62 (1H, dd, J = 
7.0, 3.8 Hz, H4), 3.04 (1H, quintet, J = 7.0 Hz, H3), 2.60 (1H, d, J = 3.8 Hz, OH6), 1.20   
(3H, d, J = 7.0 Hz, H6). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.92 (Ci-Ph B), 131.68 (2CHo-Ph A), 128.28 
(2CHm-Ph A/B), 128.24  (2CHm-Ph B/A), 128.02 (CHp-Ph A/B), 127.97 (CHp-Ph B/A), 126.69 
(2CHo-Ph B),  123.15 (Ci-Ph A), 90.48 (C1), 83.71 (C2), 77.64 (CH4), 36.08 (CH3), 17.44 
(CH36). 
HRMS (EI): Found: [M – H2O]+, 218.1094. [C17H14]+ requires: 218.1096. 
LRMS (CI): m/z: 237 ([M + H]+, 41%), 221 ([M – CH3]+, 100%). 
IR (thin film): ν~ = 3383 (m, br), 3032 (w), 2964 (w), 2877 (w), 1588 (w), 1493 (m), 
1444 (m), 1032 (m), 752 (s), 692 (s) cm–1. 
 
6.4.6. rac-2-Methyl-1-phenylpent-3-yn-1-ol (4.68f) 
3
7
65
4
2
1 Me
Me
OH
 
To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the but-3-yn-2-yl benzensulfonate 
(0.224 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of freshly prepared LiTMP, [prepared from freshly distilled 2,2,6,6-
tetramethylpiperidine (0.17 mL, 1.0 mmol) in dry THF (2 mL) and n-BuLi (0.4 mL of a 
2.5 M solution in hexanes, 1.0 mmol) at –5 °C over 15 min]. The stirring was continued 
for a further 1 h during which time the reaction mixture was allowed to warm to –50 °C.  
The reaction mixture was re-cooled to –60 °C and a solution of benzaldehyde (0.30 mL 
3.0 mmol) in dry THF (1 mL). The reaction mixture was warmed gradually to RT. The 
 230 
reaction mixture was stirred at the same temperature for 3 h before quenching with 
MeOH (5 mL) and a saturated aqueous solution of NaHCO3 (6 mL), the mixture left 
stirring overnight. The mixture was poured onto H2O (100 mL), the products extracted 
with Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 
mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
the crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 73 : 27). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.064 g (37%, yellow oil). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.30 – 7.18 (10H, m, HAr), 4.63 (1H, dd, J = 
4.9, 3.4 Hz, H6 minor), 4.33  (1H, dd, J = 7.3, 3.5 Hz, H6 major), 2.74 (1H, m, H4 minor), 2.64 
(1H, quintet q, J = 7.3, 2.4 Hz, H4 major), 2.58 (1H, dd, J = 3.5, 1.8 Hz, OH7 major), 2.25 
(1H, t, J = 3.4 Hz, OH7 minor), 1.76 (3H, dd, J = 2.4, 0.5 Hz, H1 major), 1.71 (3H, dd, J = 
2.5, 0.5 Hz, H1 minor), 0.96 (3H, overlap d, J = 7.0 Hz, H5 minor), 0.96 (3H, d, J = 7.0 Hz, 
H5 major). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.64 (Ci-Ph major), 141.48 (Ci-Ph minor), 
128.19 (2CHm-Ph major), 127.94 (2CHm-Ph minor), 127.80 (CHp-Ph major), 127.45 (CHp-Ph minor), 
126.66 (2CHo-Ph major), 126.40 (2CHo-Ph minor), 80.53 (C2 minor), 80.00 (C2 major), 79.20 (C3 
major), 78.54 (C3 minor), 77.82 (CH6 major), 76.27 (CH6 minor), 35.55 (CH4 major), 34.25 (CH4 
minor), 17.72 (CH35 major), 15.56 (CH35 minor), 3.55 (CH31 major), 3.50 (2CH31 minor). 
HRMS (EI): Found: [M]+, 174.1045. C12H14O requires: 174.1045. 
LRMS (CI): m/z: 174 ([M]+, 2%), 156 ([M – H2O]+, 4%), 118 (27%), 107 (100%). 
IR (thin film): ν~ = 3424 (br), 1454 (m), 1029 (m), 756 (s), 702 (s) cm–1. 
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6.4.7. rac-2-Methyl-3-(prop-1-ynyl)nonan-2-ol (4.68g) 
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To a stirred solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 
°C was added MeLi (1.25 mL of a 1.6 M solution, 2.0 mmol) dropwise over 3 minutes. 
After 25 min at the same tempereature, a solution of the non-1-yn-3-yl benzensulfonate 
(0.294 g, 1.0 mmol) in dry THF (1 mL) was added dropwise followed by dropwise 
addition of LDA (0.56 mL of a 1.8 M solution, 1.0 mmol). The stirring was continued 
for a further 0.5 h during which time the reaction mixture was allowed to warm to –65 
°C. At the same temperature a solution of acetone (0.22 mL 3.0 mmol) in dry THF (1 
mL) was added to the reaction mixture followed by dropwise addition of BF3·OEt2 (0.36 
mL, 3.0 mmol).  The reaction mixture was warmed gradually to RT. The reaction 
mixture was stirred at the same temperature for 2 h before refluxing for 20 h. After that 
time, the reaction mixture was cooled to RT and quenched with MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL), left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compound as a pale yellow 
oil in yield of 0.048 g (25%). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 2.31 (1H, m, H4), 1.96 (1H, s, OH), 1.96 (3H, 
d, J = 2.3 Hz, H1), 1.62 – 1.45 (2H, m), 1.39 – 1.28 (8H, m), 1.24 (3H, s, H6/7), 1.23 
(3H, s, H6/7), 0.89 (3H, t, J = 6.9 Hz, H13). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 79.46 (C2/3), 79.33 (C2/3), 72.03 (C5), 45.35 
(CH4), 31.80 (CH2), 30.07 (CH2), 29.17 (CH2), 28.38 (CH2), 27.07 (CH36/7), 26.26 
(CH36/7), 22.65 (CH2), 14.06 (CH313), 3.52 (CH31). 
HRMS (ESI+): Found: [M + Na]+, 219.1721. [C13H24NaO]+ requires: 219.1719. 
LRMS (CI): m/z: 196 ([M]+, 42%), 179 ([M – OH]+, 90%), 68 (100%). 
IR (thin film): ν~ = 3375 (m, br), 2954 (s), 2933 (s), 2835 (s), 1438 (m), 1377 (s), 1148 
(s), 760 (s), 894 (s) cm–1. 
 
6.4.8. rac-(1R,2R)-2-Methyl-1-phenyloct-3-yn-1-ol (4.76) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added MeLi (1.25 mL of a 1.8 M solution, 2.0 mmol) dropwise over 3 minutes. After 25 
min at the same tempereature, a solution of 1-chlorohept-2-yne (0.131 g, 1.0 mmol) in 
dry THF (1 mL) was added dropwise followed by dropwise addition of LDA (0.56 mL 
of a 1.8 M solution, 1.0 mmol). The stirring was continued for a further 1.5 h during 
which time the reaction mixture was allowed to warm to –65 °C. The reaction mixture 
was re-cooled to –78 °C and a solution of benzaldehyde (0.15 mL, 1.5 mmol) in dry 
THF (1 mL) was added followed by dropwise addition of BF3·OEt2 (0.18 mL, 1.5 
mmol). The reaction mixture warmed gradually to RT within. The reaction mixture was 
stirred at RT for 3-5 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL), the mixture was left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
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combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
yellow oil (anti : syn diastereoisomers in the ratio of 77 : 23). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a pale 
yellow oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.150 
g (69%). 
 
Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.29 – 7.18 (5H, m, HAr), 4.34 (1H, dd, J = 
7.1, 3.7 Hz, H6), 2.67 (1H, quintet t, J = 7.1, 2.3 Hz, H4), 2.56 (1H, d, J = 3.7 Hz, OH7), 
2.12 (2H, td, J = 7.0, 2.3 Hz, H1), 1.45 – 1.27 (4H, m, H7 + 8), 0.97 (3H, d, J = 7.1 Hz, 
H5), 0.83 (3H, t, J = 7.2 Hz, H9). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.67 (Ci-Ph), 128.16 (2CHm-Ph), 127.77 
(CHp-Ph), 126.67 (2CHo-Ph), 84.10 (C2), 80.71 (C3), 77.76 (CH6), 35.69 (CH4), 31.03 
(CH21), 21.92 (CH27 or 8), 18.42 (CH28 or 7), 17.82 (CH35), 13.58 (CH39). 
HRMS (EI): Found: [M]+, 216.1521. C15H20O requires: 216.1514. 
LRMS (CI): m/z: 216 ([M]+, 64%), 199 ([M – OH]+, 100%). 
IR (thin film): ν~ = 3375 (m, br), 2954 (s), 2933 (s), 2835 (s), 1438 (m), 1377 (s), 1148 
(s), 760 (s), 894 (s) cm–1. 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 mL) 
was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –60 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added. 
The reaction mixture was warmed gradually to RT. The stirring was continued at the 
same temperature for 3 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution of  NaHCO3 (6 mL), the mixture left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
yellow oil (anti : syn diastereoisomers in the ratio of of 74 : 26). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.130 g 
(60%). 
 
Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.29 – 7.17 (5H, m, HAr), 4.34 (1H, dd, J = 
7.2, 3.6 Hz, H6), 2.67 (1H, quintet t, J = 7.1, 2.1 Hz, H4), 2.56 (1H, d, J = 3.5 Hz, OH7), 
2.11 (2H, td, J = 7.2, 2.3 Hz, H1), 1.46 – 1.38 (2H, m), 1.32 – 1.14 (10H, m), 0.98 (3H, 
d, J = 6.8 Hz, H5), 0.81 (3H, t, J = 6.9 Hz, H14). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 141.68 (Ci-Ph), 128.17 (2CHm-Ph), 127.78 
(CHp-Ph), 126.67 (2CHo-Ph), 84.20 (C2), 80.70 (C3), 77.77 (CH6), 35.70 (CH4), 31.83 
(CH21), 29.18 (CH2), 29.09 (CH2), 28.95 (CH2), 28.86 (CH2), 22.64 (CH2), 18.74 (CH2), 
17.83 (CH35), 14.08 (CH314). 
HRMS (EI): Found: [M – H2O]+, 254.2040. [C19H26]+ requires: 254.2034. 
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LRMS (CI): m/z: 273 ([M + H]+, 54%), 255 ([M – OH]+, 72%). 
IR (thin film): ν~ = 3448 (m, br), 2925 (s), 2852 (m), 1454 (m), 1021 (m), 1760 (w), 
706 (s) cm–1. 
 
Preparation of the enantioenriched product: (1R,2R/S)-2-methyl-1-phenyldodec-3-
yn-1-ol (4.82a) 
To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the (S)-but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 
mL) was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added 
followed by dropwise addition of BF3·OEt2 (0.36 mL, 3.0 mmol). The reaction mixture 
was warmed gradually to RT. The stirring was continued at the same temperature for 3 
h before quenching with MeOH (5 mL) and a saturated aqueous solution of  NaHCO3 (6 
mL), the mixture left stirring overnight. The mixture was poured onto H2O (100 mL), 
the products extracted with Et2O (3 × 75 mL). The combined organic phases were 
washed with H2O (2 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as yellow oil (anti : syn 
diastereoisomers in the ratio of of 75 : 25). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.134 g 
(61%). 
 
Rt 11.0 min (minor enantiomer) and 12.9 min (major enantiomer) on chiral HPLC on a 
Diacel OD-H, (1 mL/min 2% isopropanol in hexane on 4.6 x 250 mm column). 
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6.4.10. rac-(E,1R,2R)-2-Methyl-1-phenyldodec-5-en-3-yn-1-ol (4.82b) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1.5 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the but-3-yn-2-yl benzensulfonate (0.202 g, 0.9 mmol) in dry THF (1 mL) 
was added dropwise followed by dropwise addition of LDA (0.50 mL of a 1.8 M 
solution, 0.9 mmol). The stirring was continued for a further 2 h during which the 
reaction mixture was allowed to warm to RT. After re-cooling the reaction mixture to –
78 °C a solution of benzaldehyde (0.12 mL, 1.2 mmol) in dry THF (1 mL) was added 
followed by dropwise addition of BF3·OEt2 (0.15 mL, 1.2 mmol). The reaction mixture 
was warmed gradually to RT and the stirring was continued at the same temperature for 
2 h before quenching with MeOH (5 mL) and a saturated aqueous solution of NaHCO3 
(6 mL). The whole mixture was left stirring overnight. The mixture was poured onto 
H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The combined organic 
phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product as yellow oil (anti : syn 
diastereoisomers in the ratio of 69 : 31). 
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.987 g 
(40%). 
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Spectral data of the anti diastereoisomer: 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.29 – 7.16 (5H, m, HAr), 6.03 (1H, dt, J = 
15.8, 7.0 Hz, H1), 5.39 (1H, dq, J = 15.8, 2.0 Hz, H2), 4.38 (1H, dd, J = 7.2, 3.7 Hz, H6), 
2.79 (1H, quintet d, J = 7.2, 2.0 Hz, H5), 2.47 (1H, dd, J = 3.7, 0.6 Hz, OH7), 2. 2.00 
(2H, qd J = 7.3, 1.5 Hz, H9), 1.31 – 1.16 (8H, m), 0.99 (3H, d, J = 7.0 Hz, H8), 0.80 
(3H, t, J = 6.9 Hz, H14). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 144.75 (CH1), 141.51 (Ci-Ph), 128.25 
(2CHm-Ph), 127.92 (CHp-Ph), 126.71  (2CHo-Ph), 109.14 (CH2), 88.68 (C3), 82.52 (C4), 
77.78 (CH6), 36.11 (CH5), 33.01 (CH29), 31.65 (CH2), 28.78  (CH2), 28.70 (CH2), 22.58 
(CH2), 17.52 (CH38), 14.07 (CH314). 
HRMS (EI): Found: [M]+, 270.1982. C19H26O requires: 270.1984. 
LRMS (CI): m/z: 271 ([M + H]+, 40%), 253 ([M – H2O]+, 28%). 
IR (thin film): ν~ = 3379 (m, br), 2938 (m), 2864 (w), 1450 (m), 1029 (m), 935 (m), 
756 (m), 706 (s) cm–1. 
 
Preparation of the enantioenriched product: (E,1R,2R)-2-methyl-1-phenyldodec-5-
en-3-yn-1-ol (4.82b) 
To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the (S)-but-3-yn-2-yl benzensulfonate (0.224 g, 1.0 mmol) in dry THF (1 
mL) was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –60 
°C and a solution of benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (1 mL) was added. 
The reaction mixture was warmed gradually to RT. The stirring was continued at the 
same temperature for 3 h before quenching with MeOH (5 mL) and a saturated aqueous 
solution of  NaHCO3 (6 mL), the mixture left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The 
combined organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), 
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dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
yellow oil (anti : syn diastereoisomers in the ratio of of 70 : 30). 
Purification of the crude material by careful column chromatography on SiO2 (230-400 
mesh) with hexane : EtOAc (10 : 1) as the eluent to allow partial separation of the 
diasteroisomers to give a pure fraction of the title compound (anti isomer) as a yellow 
oil and a mixed fraction (yellow oil) of both isomers in combined yield of 0.074 g 
(34%). 
 
Rt 11.9 min (minor enantiomer) and 15.4 min (major enantiomer) on chiral HPLC on a 
Diacel OD-H, (1 mL/min 2% isopropanol in hexane on 4.6 x 250 mm column). 
 
6.4.11. rac-8-Hexyloctadec-9-yn-7-ol (4.82c) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the non-1-yn-3-yl benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) 
was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1.5 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of 1-heptanal (0.42 mL, 3.0 mmol) in dry THF (1 mL) was added. The 
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reaction mixture warmed gradually to RT. The reaction mixture was stirred at RT for 3 
h before quenching with MeOH (5 mL) and NaHCO3 (6 mL). The mixture left stirring 
overnight. The mixture was poured onto H2O (100 mL), the products extracted with 
Et2O (3 × 75 mL). The combined organic phases were washed with H2O (2 × 100 mL) 
and brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give the 
crude product as a yellow oil (anti : syn diastereoisomers in the ratio of 89 : 11). 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compounds as an inseparable 
mixture of anti : syn diastereoisomers in combined yield of 0.123 g (44%, yellow oil). 
 
NMR characterysation does not contain complete data of the minor (syn) isomer. 
1H NMR (400 MHz, CDCl3):  (ppm) = 3.42 (1H, m, H5 major), 3.33 (1H, m, H5 minor), 
2.38 – 2.36 (2H, m, H4 major + minor), 2.19 (2H, overlap td, J = 6.9, 2.3 Hz, H1 major), 2.16 
(2H, overlap td, J = 7.0, 2.0 Hz, H1 minor), 1.74 (1H, d, J = 7.8 Hz, OHmajor), 1.70 (1H, d, 
J = 8.3 Hz, OHminor), 1.67 – 1.63 (2H, m, Hminor), 1.56 – 1.24 (62H, m, Hmajor + minor),  
0.91 – 0.87 (18H, m, H11 + 17 + 24 (major + minor)). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 84.53 (C2 major), 83.72 (C2 minor), 79.29 (C3 
major), 78.96 (C3 minor), 73.30 (C5 major), 73.23 (C5 minor), 39.91 (CH4 major), 39.22 (CH4 
minor), 35.75 (CH2major), 35.71 (CH2minor), 32.22 (CH2major), 31.83 (4CH2major + minor), 31.79 
(2CH2major + minor), 31.75 (CH2minor), 29.33 (2CH2major + minor), 29.23 (CH2major), 29.14 
(CH2major), 29.10 (2CH2major + minor), 29.08 (CH2major), 28.85 (2CH2major + minor), 28.75 
(CH2minor), 27.62 (CH2major), 27.57 (CH2minor), 25.82 (2CH2major + minor), 22.65 (CH2major), 
22.62 (4CH2major + minor), 18.73 (CH21 major), 18.69 (CH21 minor), 14.06 (6CH311 + 17 + 24 (major 
+ minor)). 
HRMS (EI): Found: [M – C6H13]+, 265.2536. [C18H33O]+ requires: 265.2531. 
LRMS (CI): m/z: 351 ([M + H]+, 69%), 333 ([M – H2O + H]+, 55%). 
IR (thin film): ν~ = 3387 (w, br), 2960 (m), 2933 (s), 2854 (s), 1467 (m), 1372 (w), 
1043 (w, br), 718 (w) cm–1. 
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6.4.12. rac-3-Hexyl-2-methyltridec-4-yn-2-ol (4.82d) 
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To a stirred suspension of Cp2ZrHCl (0.258 g, 1.0 mmol) in dry THF (10 mL) at RT 
was added neat 1-octene (0.125 mL, 0.8 mmol) dropwise over 3 minutes. After stirring 
the yellow solution for 1 h at RT, the reaction mixture was cooled to –78 °C  and a 
solution of the non-1-yn-3-yl benzensulfonate (0.294 g, 1.0 mmol) in dry THF (1 mL) 
was added dropwise followed by dropwise addition of freshly prepared LiTMP, 
[prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.17 mL, 1.0 mmol) in 
dry THF (2 mL) and n-BuLi (0.4 mL of a 2.5 M solution in hexanes, 1.0 mmol) at –5 °C 
over 15 min]. The stirring was continued for a further 1.5 h during which time the 
reaction mixture was allowed to warm to RT. The reaction mixture was re-cooled to –78 
°C and a solution of acetone (0.22 mL 3.0 mmol) in dry THF (1 mL) was added, the 
reaction mixture warmed gradually to RT. The reaction mixture was then refluxing for 
20 h before cooling to RT and quenching with MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL), the mixture left stirring overnight. The mixture was poured 
onto H2O (100 mL), the products extracted with Et2O (3 × 75 mL). The combined 
organic phases were washed with H2O (2 × 100 mL) and brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product as a yellow oil. 
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with hexane : EtOAc (10 : 1) as the eluent to yield the title compound as a yellow oil in 
yield of 0.118 g (50%, contained 10% of unidentified by-products). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 2.34 (1H, m, H4), 2.20 (2H, td, J = 7.0, 2.0 Hz, 
H1), 1.97 (1H, br s, OH), 1.61 (1H, m), 1.54 – 1.47 (3H, m), 1.41 – 1.26 (18H, m), 1.25 
(3H, s, H6/7), 1.24 (3H, s, H6/7), 0.90 (3H, t, J = 6.8 Hz, H13/20), 0.89 (3H, t, J = 6.8 Hz, 
H13/20). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 84.33 (C2), 80.35 (C3), 71.98 (C5), 45.34 
(CH4), 31.81 (2CH2), 30.07 (CH2), 29.21 (CH2), 29.14 (CH2), 29.07 (2CH2), 28.84 
(CH2), 28.36 (CH2), 27.01 (CH36/7), 26.24 (CH36/7), 22.63 (2CH2), 18.70 (CH21), 14.06  
(2CH313 + 20). 
HRMS (EI): Found: [M – CH3]+, 279.2694. [C19H35O]+ requires: 279.2688. 
LRMS (CI): m/z: 294 ([M]+, 26%), 277 ([M – H2O + H]+, 100 %). 
IR (thin film): ν~ = 3410 (w, br), 2930 (s), 2854 (s), 1478 (m), 1372 (m), 1183 (m), 
1142 (m), 903 (w), 722 (w) cm–1. 
 
6.5. Experimental from chapter 5 
 
6.5.1. rac-(R,3E)-5-((2S,3R,3aS,7aS)-2-Butyl-2,3,3a,4,7,7a-hexahydro-1H-inden-3-
yl)-1-phenylpent-3-en-1-ol and  rac-(S,3E)-5-((2S,3R,3aS,7aS)-2-butyl-
2,3,3a,4,7,7a-hexahydro-1H-inden-3-yl)-1-phenylpent-3-en-1-ol (5.30a) 
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To a solution of Cp2ZrCl2 (0.307 g, 1.05 mmol) in dry THF (5 mL) cooled to –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of triene 5.5 (0.190 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise, the stirring continued for 20 min at –78 
°C before the reaction mixture was allowed to warm to RT gradually and the stirring 
continued for 75 min. The reaction mixture was re-cooled to –78 °C, a solution of allyl 
chloride (0.098 mL, 1.2 mmol) in dry THF (1 mL) was added followed by dropwise 
addition of LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.20 
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mL, 1.2 mmol) in dry THF (2 mL) and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 
1.2 mmol) at 0 °C over 20 min]. The reaction mixture was allowed to warm to –65 °C 
within 20 min before benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (3 mL) and 
BF3·OEt2 (0.36 ml, 3.0 mmol) were added dropwise. The reaction mixture was warmed 
gradually to –1 °C within 4 h before addition of MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL). The mixture left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a pale 
yellow oil. Purification of the crude material by careful column chromatography on 
SiO2 (230 – 400 mesh) with 10% of EtOAc in hexanes as the eluent gave a fraction of 
the title compounds as an inseparable mixture of diastereoisomers, epimeric at the 
secondary alcohol centre in the 13C NMR ratio of 1.5 : 1 (0.20 g, pale yellow oil, 69% 
GC purity). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.270 – 7.163 (10H, m, HAr major + minor), 5.615 
– 5.440 (6H, m, 2H11 + 2H12 + 2H6), 5.345 – 5.264 (2H, m, H5 major + minor), 4.603 (2H, br 
dd, J = 7.3, 5.3 Hz, H3 major + minor), 2.444 – 2.316 (4H, m, H4 major + minor), 2.134 – 1.869 
(12H, m, Hmajor + minor), 1.802 – 1.254 (13H, m, Hmajor + minor), 1.209 – 0.960 (13H, m, 
Hmajor + minor), 0.807 (6H, br t, J = 7.2 Hz, H20 major + minor).  
13C NMR (100.5 MHz, CDCl3):  (ppm) = 143.97 (2Ci-Ph major + minor), 133.83 (CH5 
major), 133.79 (CH5 minor), 128.31 (4CHm-Ph major + minor), 128.31 (2CH11/12), 126.37 
(2CH11/12), 126.26 (CH6 major), 126.23 (CH6 minor), 125.99 (2CHp-Ph major + minor), 125.82 
(2CHo-Ph minor), 125.79 (2CHo-Ph major), 73.54 (CH3 minor), 73.50 (CH3 major), 50.87 (CH8 
minor), 50.82 (CH8 major), 44.03 (CH9 minor), 44.00 (CH9 major), 42.79 (2CH4 major + minor), 
40.22 (CH16 major), 40.17 (CH16 minor), 38.09 (2CH2major + minor), 38.09 (2CH27 major + minor), 
37.02 (CH14 minor), 36.99 (CH14 major), 34.89 (2CH2major + minor), 30.97 (2CH2major + minor), 
27.77 (2CH2major + minor), 27.63 (2CH2major + minor), 22.91 (2CH2major + minor), 14.12 (2CH320 
major + minor). 
LRMS (EI): m/z: 321 ([M – H2O]+, 11%), 232 ([M – BnOH + H]+, 5%), 175 (29%), 
130 (32%), 107 (100%). 
IR (thin film): ν~ = 3353 (w, br), 3028 (w), 2922 (m, br), 1452 (m), 1024 (m), 975 (m), 
745 (m), 688 (s) cm–1. 
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6.5.2. rac-(R,3E)-5-((2R,3S,3aS,7aS)-2-Butyl-2,3,3a,4,7,7a-hexahydro-1H-inden-3-
yl)-1-phenylpent-3-en-1-ol and  rac-(S,3E)-5-((2R,3S,3aS,7aS)-2-butyl-
2,3,3a,4,7,7a-hexahydro-1H-inden-3-yl)-1-phenylpent-3-en-1-ol (5.30b) 
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To a solution of Cp2ZrCl2 (0.307 g, 1.05 mmol) in dry THF (5 mL) cooled to –78 °C 
was added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of triene 5.5 (0.190 g, 1.0 
mmol) in dry THF (3 mL) was added dropwise, the stirring continued for 15 min at –78 
°C before the reaction mixture was allowed to warm to RT gradually and heated at 65 
°C for 30 min. The reaction mixture was re-cooled to –78 °C, a solution of allyl chloride 
(0.098 mL, 1.2 mmol) in dry THF (1 mL) was added followed by dropwise addition of 
LiTMP, [prepared from freshly distilled 2,2,6,6-tetramethylpiperidine (0.20 mL, 1.2 
mmol) in dry THF (2 mL) and n-BuLi (0.48 mL of a 2.5 M solution in hexanes, 1.2 
mmol) at 0 °C over 20 min]. The reaction mixture was allowed to warm to –65 °C 
within 20 min before benzaldehyde (0.30 mL, 3.0 mmol) in dry THF (3 mL) and 
BF3·OEt2 (0.36 ml, 3.0 mmol) were added dropwise. The reaction mixture was warmed 
gradually to –5 °C within 4 h before addition of MeOH (5 mL) and a saturated aqueous 
solution of NaHCO3 (6 mL). The mixture left stirring overnight. The mixture was 
poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). The 
combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a pale 
yellow oil.  
Purification of the crude material by careful column chromatography on SiO2 (230 – 
400 mesh) with 2.5  10% of EtOAc in hexanes as the eluent gave a fraction of the 
title compounds as an inseparable mixture of diastereoisomers, epimeric at the 
secondary alcohol centre in the 13C NMR ratio of 3.1 : 1 (0.026 g, pale yellow oil, 
fraction pure in 89% by GC). 
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1H NMR (400 MHz, CDCl3):  (ppm) = 7.270 – 7.162 (10H, m, HAr major + minor), 5.613 
– 5.476 (6H, m, 2H11 + 2H12 + 2H6), 5.356 – 5.283 (2H, m, H5 major + minor), 4.624 – 4.584 
(2H, m, H3 major + minor), 2.443 – 2.319 (4H, m, H4 major + minor), 2.197 – 1.960 (10H, m, 
Hmajor + minor), 1.695 – 1.587 (4H, m, Hmajor + minor), 1.528 – 1.389 (6H, m, Hmajor + minor), 
1.359 – 0.964 (18H, m, Hmajor + minor), 0.813 (6H, br t, J = 7.0 Hz, H20 major + minor).  
13C NMR (100.5 MHz, CDCl3):  (ppm) = 143.99 (2Ci-Ph major + minor), 133.62 (2CH5 
major + minor), 128.33 (4CHm-Ph major + minor), 127.38 (2CH11/12), 127.28 (2CH11/12), 126.37 
(2CHp-Ph major + minor), 127.04 (2CH6 major + minor), 125.83 (2CHo-Ph minor), 125.79 (2CHo-Ph 
major), 73.58 (CH3 minor), 73.54 (CH3 major), 52.09 (CH8 minor), 52.06 (CH8 major), 47.08 
(CH9 minor), 47.03 (CH9 major), 42.76 (2CH4 major + minor), 42.25 (CH16 minor), 42.21 (CH16 
major), 40.03 (2CH14 major + minor), 36.92 (2CH2major + minor), 36.67 (2CH2major + minor), 36.55 
(CH27 minor), 36.49 (CH27 major), 32.37 (2CH2major + minor), 31.50 (2CH2major + minor), 30.69 
(2CH2major + minor), 22.91 (2CH2major + minor), 14.15 (2CH320 major + minor). 
LRMS (EI): m/z: 321 ([M – H2O + H]+, 6%), 320 ([M – H2O]+, 27%), 192 (5%), 130 
(100%). 
IR (thin film): ν~ = 3380 (w, br), 3024 (w), 2956 (m), 2911 (m, br), 1459 (m), 1433 
(m), 1021 (m), 971 (m), 756 (m), 692 (s), 669 (s) cm–1. 
 
6.5.3. rac-1-(2-((1S,2R)-4,4-Bis(methoxymethyl)-2-((E)-prop-1-
enyl)cyclopentyl)ethylsulfonyl)benzene (major d.r.) and rac-1-(2-((1S,2R)-
4,4-bis(methoxymethyl)-2-((E)-prop-1-enyl)cyclopentyl)ethylsulfonyl)-
benzene (minor d.r.) (5.46) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added 
dropwise, the stirring continued for 30 min at –78 °C before the reaction mixture was 
allowed to warm to RT and stirred for a further 4 h. After cooling the reaction to –78 
°C, a solution of 1-(chloromethylsulfonyl)benzene (0.76 g, 4.0 mmol) in dry THF (3 
mL) was added dropwise followed by dropwise addition of LDA (2.22 mL of a 1.8 M 
solution, 4.0 mmol). The reaction mixture was allowed to warm to RT within 5 h and 
stirred at this temperature for a further 4 h, before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL). The mixture left stirring overnight. The 
mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 mL). 
The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 mL), 
dried over MgSO4, filtered and concentrated in vacuo to give the crude product as a 
dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 20  50% of Et2O in hexanes as the eluent gave the title compounds as an 
inseparable mixture of E : Z isomers in the ratio of 3.8 : 1 (0.232 g, 45%, pale yellow 
oil). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 7.990 – 7.915 (2H, m, Ho-Ph minor), 7.896 – 
7.866 (2H, m, Ho-Ph major),  7.670 – 7.634 (1H, m, Hp-Ph minor), 7.651 (1H, t, J = 7.5 Hz, 
Hp-Ph minor), 7.597 – 7.543 (2H, m, Hm-Ph minor), 7.562 (2H, t, J = 7.5 Hz, Hm-Ph minor), 5.471 
– 5.326 (1H, m, H11 minor), 5.368 (1H, dq, J = 15.1, 6.5 Hz, H11 major), 5.180 – 5.075 (1H, 
m, H11 minor), 5.150 (1H, fs ddq, J = 15.1, 8.0, 1.0 Hz, H10 major), 3.319 (6H, s, H1 minor), 
3.289 (6H, s, H1major), 3.214 – 3.035 (10H, m, H2 major + minor + H9 minor), 3.072 (2H, dd, J 
= 9.0, 7.5 Hz, H9 major), 2.400 (1H, m, H7 minor), 2.033 – 1.816 (2H, m, H7 major + H), 
1.781 – 1.655 (4H, m), 1.609 (3H, dd, J = 6.5, 1.5 Hz, H12 major), 1.558 (3H, dd, J = 7.0, 
1.7 Hz, H12 minor), 1.534 – 1.382 (3H, m), 1.318 – 1.117 (4H, m), 1.033 (1H, dd, J = 
13.1, 11.0 Hz, Hminor), 0.974 (1H, dd, J = 13.1, 11.0 Hz, Hmajor).  
13C NMR (100.5 MHz, CDCl3):  (ppm) = 139.27 (Ci-Ph major), 139.21 (Ci-Ph minor), 
133.54 (CHp-Ph/10 major), 133.54 (CHp-Ph/10 minor), 133.52 (CHp-Ph/10 major), 133.34 (CHp-Ph/10 
minor), 129.16 (4CHm-Ph major + minor), 127.99 (4CHo-Ph major + minor), 125.81 (CH11 major), 
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124.87 (CH11 minor), 77.75 (CH22 minor), 77.71 (CH22 major), 77.67 (2CH22 major + minor), 59.18 
(4CH31 major + minor), 55.32 (CH29 minor), 55.24 (CH29 major), 49.31 (CH7 major), 45.73 (C3 
minor), 45.39 (C3 major), 44.61 (CH7 minor), 43.74 (CH6 major), 43.42 (CH6 minor), 39.84 
(CH24/5 major), 39.75 (CH24/5 minor), 38.59 (CH24/5 minor), 38.43 (CH24/5 major), 26.60 (CH28 
minor), 26.25 (CH28 major), 17.88 (CH312 major), 13.24 (CH312 minor). 
HRMS (EI): Found: [M – MeOH]+, 334.1597. [C19H26O3S]+ requires: 334.1603. 
LRMS (EI): m/z: 334 ([M – MeOH]+, 3%), 289 ([M – Ph]+, 20%), 192 (29%), 160 
(100%). 
IR (thin film): ν~ = 2922 (m), 2865 (m), 2824 (m), 1448 (s), 1308 (s), 1138 (s), 1107 
(s), 1085 (s), 968 (s), 729 (s), 684 (s), 533 (s) cm–1. 
 
6.5.4. rac-(3R,4R)-3-(Bromomethyl)-1,1-bis(methoxymethyl)-4-
propylcyclopentane (5.50) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of (Z)-4,4-
bis(methoxymethyl)nona-1,6-diene (0.212 g, 1.0 mmol) in dry THF (3 mL) was added 
dropwise, the stirring continued for 30 min at –78 °C before the reaction mixture was 
allowed to warm to RT and stirred for a further 2 h. After cooling the reaction to –78 
°C, dropwise addition of n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) 
followed. After stirring the reaction mixture at the same temperature for 5 min, a 
solution of CBr4 (0.497 g, 1.5 mmol) in dry THF (1 mL) was added dropwise and the 
stirring was continued for 15 min at –78 °C, before addition of MeOH (5 mL) and a 
saturated aqueous solution of NaHCO3 (6 mL). The whole mixture was allowed to 
warm to RT, left stirring overnight. The mixture was poured onto H2O (100 mL), the 
products extracted with Et2O (3 × 50 mL). The combined organic phases were washed 
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with H2O (3 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product as a dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10% of Et2O in hexanes as the eluent gave the title compound as a yellow oil in 
yield of 0.223 g (76%). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 3.584 (1H, dd, J = 9.8, 3.3 Hz, H8), 3.344 (3H, 
s, H1), 3.341 (3H, s, H1), 3.318 (1H, dd, J = 10.0, 7.5 Hz, H8), 3.225 (2H, br d, J = 9.0 
Hz, H2), 3.195 (1H, d, J = 9.0 Hz, H2), 3.191 (1H, d, J = 9.0 Hz, H2), 1.881 – 1.823 (3H, 
m), 1.642 (1H, m), 1.501 (1H, m), 1.417 – 1.179 (3H, m), 1.131 (1H, dd, J = 13.0, 11.0 
Hz), 1.072 (1H, m), 0.892 (3H, t, J = 7.3 Hz, H11). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 77.76 (CH22), 77.56 (CH22), 59.25 (2CH31), 
47.05 (CH6), 44.95 (C3), 42.98 (CH7), 39.25 (CH2), 38.46 (CH2), 37.84 (CH2), 36.17 
(CH28), 21.21 (CH2), 14.35 (CH311). 
HRMS (EI): Found: [M + Na]+, 315.0932. [C13H25NaBrO2]+ requires: 315.0930. 
LRMS (EI): m/z: 262 ([M – C2H6]+, 11%), 260 ([M – MeOH]+, 7%), 230 (58%), 228 
(54 %), 148 (90%), 45 (100%). 
IR (thin film): ν~ = 2949 (m), 2922 (m), 2869 (m), 1452 (m), 1198 (m), 1104 (s), 960 
(m), 729 (w), 642 (w) cm–1. 
 
6.5.5. rac-(3R,4R)-3-(Bromomethyl)-1,1-bis(methoxymethyl)-4-
methylcyclopentane (major d.r.) and rac-(3S,4R)-3-(bromomethyl)-1,1-
bis(methoxymethyl)-4-methylcyclopentane (minor d.r.) (5.51) 
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To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol) in dry THF (5 mL) cooled to –78 °C was 
added n-BuLi (0.80 mL of a 2.5 M solution in hexanes, 2.0 mmol) dropwise over 3 
minutes. After 25 min at the same temperature, a solution of bis(methoxymethyl)hepta-
1,6-diene (0.184 g, 1.0 mmol) in dry THF (3 mL) was added dropwise, the stirring 
continued for 30 min at –78 °C before the reaction mixture was allowed to warm to RT 
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and stirred for a further 2 h. After cooling the reaction to –78 °C, dropwise addition of  
n-BuLi (0.44 mL of a 2.5 M solution in hexanes, 1.1 mmol) followed. After stirring the 
reaction mixture at the same temperature for 5 min, a solution of CBr4 (0.497 g, 1.5 
mmol) in dry THF (1 mL) was added dropwise and the stirring was continued for 15 
min at –78 °C, before addition of MeOH (5 mL) and a saturated aqueous solution of 
NaHCO3 (6 mL). The whole mixture was allowed to warm to RT, left stirring overnight. 
The mixture was poured onto H2O (100 mL), the products extracted with Et2O (3 × 50 
mL). The combined organic phases were washed with H2O (3 × 100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated in vacuo to give the crude product as 
a dark brown oil.  
Purification of the crude material by column chromatography on SiO2 (230 – 400 mesh) 
with 10% of Et2O in hexanes as the eluent gave the title compounds as an inseparable 
mixture of trans : cis ring junction isomers in the ratio of 94 : 6 (0.186 g, 70%, yellow 
oil). 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 3.562 (1H, dd, J = 9.8, 3.3 Hz, H8 major), 3.365 
(1H, dd, J = 7.9, 2.1 Hz, H8 minor), 3.332 (6H, s, H1major), 3.326 (6H, s, H1 minor), 3.304 
(1H, dd, J = 9.8, 7.0 Hz, H8 major), 3.241 – 3.155 (4H, m, H2 minor), 3.215 (2H, d, J = 8.8 
Hz, H2 major), 3.186 (2H, d, J = 8.8 Hz, H2 major), 1.855 (1H, dd, J = 12.8, 7.3 Hz, H4 
major), 1.819 (1H, dd, J = 12.8, 7.0 Hz, H5 major), 1.819 – 1.646 (2H, m, H6 + 7 major), 1.306 
(1H, dd, J = 12.8, 9.8 Hz, H4 major), 1.146 (1H, dd, J = 12.8, 10.5 Hz, H5 major), 0.970 
(3H, d, J = 6.3 Hz, H9 major), 0.906 (3H, d, J = 7.3 Hz, H9 minor). 
13C NMR (100.5 MHz, CDCl3):  (ppm) = 78.30 (CH22 minor), 77.86 (CH22 major), 77.55 
(CH22 major), 77.35 (CH22 minor), 59.21 (4CH31 major + minor), 48.43 (CH6 major), 46.60 (C3 
minor), 45.16 (CH6 minor), 44.88 (C3 major), 41.74 (CH5 major), 39.68 (CH5 minor), 38.57 (CH28 
major), 38.05 (CH27 major), 37.41 (CH24 major), 36.40 (CH28 minor), 35.57 (CH7 minor), 35.19 
(CH24 minor), 17.87 (CH39 major), 15.19 (CH39 minor). 
HRMS (EI): Found: [M – MeOH]+, 232.0462. [C10H17OBr(79)]+ requires: 232.0463. 
LRMS (EI): m/z: 265 ([M + H]+, 2%), 234 ([M – 2CH3]+, 15%), 232 ([M – MeOH]+, 
13%), 202 (71%), 200 (59%), 107 (97%), 45 (100%). 
IR (thin film): ν~ = 2949 (m), 2915 (m), 2865 (m), 2824 (m), 1444 (m), 1194 (m), 1100 
(s), 960 (m), 642 (w) cm–1. 
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Table 1. Crystal data and structure refinement. 
 
Identification code  2007sot0730     
Empirical formula  C30H36O2 
Formula weight  428.59 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P−1  
Unit cell dimensions a = 9.5488(6) Å α = 106.772(4)° 
 b = 11.0306(6) Å β = 110.048(3)° 
 c = 13.4198(9) Å γ 
 
= 95.736(4)° 
Volume 1239.89(13) Å3 
Z 2 
Density (calculated) 1.148 Mg / m3 
Absorption coefficient 0.070 mm−1 
F(000) 464 
Crystal Block; Colourless 
Crystal size 0.14 × 0.12 × 0.10 mm3 
θ range for data collection 2.98 − 27.48° 
Index ranges −12 ≤ h ≤ 12, −14 ≤ k ≤ 14, −17 ≤ l ≤ 17 
Reflections collected 20095 
Independent reflections 5646 [Rint = 0.0537] 
Completeness to θ = 27.48° 99.0 %  
Absorption correction Semi−empirical from equivalents 
Max. and min. transmission 0.9931 and 0.9903 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5646 / 0 / 292 
Goodness-of-fit on F2 1.071 
Final R indices [F2 > 2σ(F2)] R1 = 0.0570, wR2 = 0.1296 
R indices (all data) R1 = 0.0752, wR2 = 0.1437 
Extinction coefficient 0.020(4) 
Largest diff. peak and hole 0.345 and −0.235 e Å−3 
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Diffractometer: Nonius KappaCCD area detector (φ scans and ω scans to fill asymmetric unit sphere). Cell determination: DirAx 
(Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 92-96.) Data collection: Collect (Collect: Data collection software, R. Hooft, Nonius 
B.V., 1998). Data reduction and cell refinement: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymology (1997) Vol. 276: 
Macromolecular Crystallography, part A, pp. 307−326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption 
correction: SORTAV (R. H. Blessing, Acta Cryst. A51 (1995) 33−37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 421−426). 
Structure solution: SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A46 467−473). Structure refinement: SHELXL97 (G. M. 
Sheldrick (1997), University of Göttingen, Germany). Graphics: Cameron - A Molecular Graphics Package. (D. M. Watkin, L. 
Pearce and C. K. Prout, Chemical Crystallography Laboratory, University of Oxford, 1993). 
 
Special details:  
Table 2. Atomic coordinates [× 104], equivalent isotropic displacement parameters [Å2 × 103] and site occupancy 
factors. Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Atom  x y z Ueq S.o.f. 
 
C1 4935(2) 4604(2) 1560(1) 24(1) 1 
C2 3793(2) 3981(2) 1921(2) 26(1) 1 
C3 2601(2) 4797(2) 1742(2) 26(1) 1 
C4 3559(2) 6211(2) 2246(1) 22(1) 1 
C5 4125(2) 6672(2) 3547(1) 22(1) 1 
C6 5646(2) 6934(2) 4057(1) 23(1) 1 
C7 6401(2) 6779(2) 3221(1) 25(1) 1 
C8 5084(2) 6091(2) 2054(1) 23(1) 1 
C9 3023(2) 6728(2) 4106(1) 22(1) 1 
C10 3052(2) 6028(2) 4826(1) 26(1) 1 
C11 2020(2) 6070(2) 5353(2) 30(1) 1 
C12 935(2) 6815(2) 5166(2) 31(1) 1 
C13 894(2) 7519(2) 4456(2) 30(1) 1 
C14 1924(2) 7481(2) 3936(2) 26(1) 1 
C15 2715(2) 7133(2) 1735(1) 24(1) 1 
C16 1210(2) 6827(2) 1145(2) 30(1) 1 
C17 3607(2) 8421(2) 1900(1) 24(1) 1 
C18 4638(2) 9276(2) 2955(2) 27(1) 1 
C19 5414(2) 10481(2) 3071(2) 31(1) 1 
C20 5163(2) 10860(2) 2141(2) 35(1) 1 
C21 4148(2) 10025(2) 1091(2) 38(1) 1 
C22 3379(2) 8822(2) 972(2) 32(1) 1 
C23 6604(2) 7400(2) 5306(1) 26(1) 1 
C24 7800(2) 8660(2) 5729(2) 27(1) 1 
C25 8869(2) 9026(2) 6964(2) 29(1) 1 
C26 10212(2) 10153(2) 7335(2) 29(1) 1 
C27 11366(2) 10496(2) 8537(2) 31(1) 1 
C28 12644(2) 11652(2) 8856(2) 35(1) 1 
C29 7389(2) 4428(2) 1533(1) 26(1) 1 
C30 8790(2) 3942(2) 2015(2) 35(1) 1 
O1 6342(1) 4169(1) 1952(1) 26(1) 1 
O2 7215(2) 4996(1) 873(1) 36(1) 1 
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Table 3. Bond lengths [Å] and angles [°]. 
 
 
 
Symmetry transformations used to generate equivalent atoms: 
 
Table 4. Bond lengths [Å] and angles [°]. 
 
C1−O1 1.4507(19) 
C1−C2 1.516(2) 
C1−C8 1.553(2) 
C1−H1 1.0000 
C2−C3 1.519(2) 
C2−H2A 0.9900 
C2−H2B 0.9900 
C3−C4 1.551(2) 
C3−H3A 0.9900 
C3−H3B 0.9900 
C4−C15 1.530(2) 
C4−C5 1.545(2) 
C4−C8 1.575(2) 
C5−C6 1.335(2) 
C5−C9 1.483(2) 
C6−C23 1.506(2) 
C6−C7 1.510(2) 
C7−C8 1.543(2) 
C7−H7A 0.9900 
C7−H7B 0.9900 
C8−H8 1.0000 
C9−C10 1.395(2) 
C9−C14 1.401(2) 
C10−C11 1.393(2) 
C10−H10 0.9500 
C11−C12 1.387(3) 
C11−H11 0.9500 
C12−C13 1.385(3) 
C12−H12 0.9500 
C13−C14 1.384(2) 
C13−H13 0.9500 
C14−H14 0.9500 
C15−C16 1.332(2) 
C15−C17 1.497(2) 
C16−H16A 0.9500 
C16−H16B 0.9500 
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C17−C22 1.396(2) 
C17−C18 1.397(2) 
C18−C19 1.394(2) 
C18−H18 0.9500 
C19−C20 1.380(3) 
C19−H19 0.9500 
C20−C21 1.382(3) 
C20−H20 0.9500 
C21−C22 1.388(3) 
C21−H21 0.9500 
C22−H22 0.9500 
C23−C24 1.530(2) 
C23−H23A 0.9900 
C23−H23B 0.9900 
C24−C25 1.524(2) 
C24−H24A 0.9900 
C24−H24B 0.9900 
C25−C26 1.525(2) 
C25−H25A 0.9900 
C25−H25B 0.9900 
C26−C27 1.518(2) 
C26−H26A 0.9900 
C26−H26B 0.9900 
C27−C28 1.521(2) 
C27−H27A 0.9900 
C27−H27B 0.9900 
C28−H28A 0.9800 
C28−H28B 0.9800 
C28−H28C 0.9800 
C29−O2 1.202(2) 
C29−O1 1.348(2) 
C29−C30 1.498(3) 
C30−H30A 0.9800 
C30−H30B 0.9800 
C30−H30C 0.9800 
 
O1−C1−C2 108.43(13) 
O1−C1−C8 114.91(13) 
C2−C1−C8 105.96(13) 
O1−C1−H1 109.1 
C2−C1−H1 109.1 
C8−C1−H1 109.1 
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C1−C2−C3 101.32(13) 
C1−C2−H2A 111.5 
C3−C2−H2A 111.5 
C1−C2−H2B 111.5 
C3−C2−H2B 111.5 
H2A−C2−H2B 109.3 
C2−C3−C4 103.89(13) 
C2−C3−H3A 111.0 
C4−C3−H3A 111.0 
C2−C3−H3B 111.0 
C4−C3−H3B 111.0 
H3A−C3−H3B 109.0 
C15−C4−C5 113.22(13) 
C15−C4−C3 113.02(13) 
C5−C4−C3 109.01(13) 
C15−C4−C8 113.70(13) 
C5−C4−C8 102.27(13) 
C3−C4−C8 104.77(12) 
C6−C5−C9 126.46(15) 
C6−C5−C4 112.69(14) 
C9−C5−C4 120.79(14) 
C5−C6−C23 127.87(15) 
C5−C6−C7 111.89(15) 
C23−C6−C7 120.17(14) 
C6−C7−C8 104.75(13) 
C6−C7−H7A 110.8 
C8−C7−H7A 110.8 
C6−C7−H7B 110.8 
C8−C7−H7B 110.8 
H7A−C7−H7B 108.9 
C7−C8−C1 114.57(13) 
C7−C8−C4 106.25(13) 
C1−C8−C4 103.88(12) 
C7−C8−H8 110.6 
C1−C8−H8 110.6 
C4−C8−H8 110.6 
C10−C9−C14 117.65(15) 
C10−C9−C5 120.73(15) 
C14−C9−C5 121.62(15) 
C11−C10−C9 121.23(16) 
C11−C10−H10 119.4 
C9−C10−H10 119.4 
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C12−C11−C10 120.14(16) 
C12−C11−H11 119.9 
C10−C11−H11 119.9 
C13−C12−C11 119.34(17) 
C13−C12−H12 120.3 
C11−C12−H12 120.3 
C14−C13−C12 120.51(16) 
C14−C13−H13 119.7 
C12−C13−H13 119.7 
C13−C14−C9 121.12(16) 
C13−C14−H14 119.4 
C9−C14−H14 119.4 
C16−C15−C17 118.79(15) 
C16−C15−C4 122.17(15) 
C17−C15−C4 119.04(14) 
C15−C16−H16A 120.0 
C15−C16−H16B 120.0 
H16A−C16−H16B 120.0 
C22−C17−C18 117.44(16) 
C22−C17−C15 119.33(15) 
C18−C17−C15 123.19(15) 
C19−C18−C17 121.10(17) 
C19−C18−H18 119.4 
C17−C18−H18 119.4 
C20−C19−C18 120.40(17) 
C20−C19−H19 119.8 
C18−C19−H19 119.8 
C19−C20−C21 119.30(17) 
C19−C20−H20 120.4 
C21−C20−H20 120.4 
C20−C21−C22 120.44(18) 
C20−C21−H21 119.8 
C22−C21−H21 119.8 
C21−C22−C17 121.31(17) 
C21−C22−H22 119.3 
C17−C22−H22 119.3 
C6−C23−C24 113.93(14) 
C6−C23−H23A 108.8 
C24−C23−H23A 108.8 
C6−C23−H23B 108.8 
C24−C23−H23B 108.8 
H23A−C23−H23B 107.7 
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C25−C24−C23 112.77(14) 
C25−C24−H24A 109.0 
C23−C24−H24A 109.0 
C25−C24−H24B 109.0 
C23−C24−H24B 109.0 
H24A−C24−H24B 107.8 
C24−C25−C26 112.84(15) 
C24−C25−H25A 109.0 
C26−C25−H25A 109.0 
C24−C25−H25B 109.0 
C26−C25−H25B 109.0 
H25A−C25−H25B 107.8 
C27−C26−C25 114.78(15) 
C27−C26−H26A 108.6 
C25−C26−H26A 108.6 
C27−C26−H26B 108.6 
C25−C26−H26B 108.6 
H26A−C26−H26B 107.5 
C26−C27−C28 111.70(15) 
C26−C27−H27A 109.3 
C28−C27−H27A 109.3 
C26−C27−H27B 109.3 
C28−C27−H27B 109.3 
H27A−C27−H27B 107.9 
C27−C28−H28A 109.5 
C27−C28−H28B 109.5 
H28A−C28−H28B 109.5 
C27−C28−H28C 109.5 
H28A−C28−H28C 109.5 
H28B−C28−H28C 109.5 
O2−C29−O1 123.74(16) 
O2−C29−C30 125.01(17) 
O1−C29−C30 111.24(15) 
C29−C30−H30A 109.5 
C29−C30−H30B 109.5 
H30A−C30−H30B 109.5 
C29−C30−H30C 109.5 
H30A−C30−H30C 109.5 
H30B−C30−H30C 109.5 
C29−O1−C1 116.66(13) 
 
Symmetry transformations used to generate equivalent atoms:  
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Table 5. Anisotropic displacement parameters [Å2× 103]. The anisotropic displacement factor exponent takes the 
form: −2pi 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
 
Atom U11 U22 U33 U23 U13 U12 
 
C1 24(1)  21(1) 26(1)  9(1) 10(1)  9(1) 
C2 26(1)  20(1) 32(1)  7(1) 11(1)  4(1) 
C3 24(1)  21(1) 29(1)  5(1) 10(1)  3(1) 
C4 23(1)  18(1) 23(1)  6(1) 8(1)  4(1) 
C5 24(1)  16(1) 24(1)  7(1) 9(1)  5(1) 
C6 24(1)  17(1) 25(1)  7(1) 8(1)  5(1) 
C7 22(1)  22(1) 27(1)  6(1) 8(1)  4(1) 
C8 24(1)  19(1) 24(1)  7(1) 8(1)  5(1) 
C9 23(1)  19(1) 23(1)  6(1) 7(1)  3(1) 
C10 26(1)  22(1) 29(1)  11(1) 10(1)  7(1) 
C11 34(1)  29(1) 32(1)  15(1) 15(1)  5(1) 
C12 30(1)  35(1) 34(1)  13(1) 18(1)  7(1) 
C13 29(1)  33(1) 30(1)  12(1) 12(1)  12(1) 
C14 27(1)  26(1) 27(1)  11(1) 11(1)  9(1) 
C15 26(1)  22(1) 21(1)  6(1) 9(1)  7(1) 
C16 27(1)  28(1) 31(1)  9(1) 7(1)  7(1) 
C17 26(1)  23(1) 26(1)  9(1) 10(1)  10(1) 
C18 31(1)  23(1) 27(1)  9(1) 10(1)  8(1) 
C19 33(1)  22(1) 32(1)  7(1) 8(1)  6(1) 
C20 38(1)  25(1) 43(1)  16(1) 14(1)  7(1) 
C21 46(1)  37(1) 37(1)  23(1) 15(1)  11(1) 
C22 37(1)  31(1) 26(1)  12(1) 8(1)  8(1) 
C23 24(1)  24(1) 26(1)  8(1) 6(1)  5(1) 
C24 25(1)  23(1) 28(1)  7(1) 7(1)  5(1) 
C25 29(1)  26(1) 27(1)  7(1) 7(1)  5(1) 
C26 29(1)  24(1) 29(1)  9(1) 6(1)  4(1) 
C27 32(1)  24(1) 30(1)  9(1) 6(1)  3(1) 
C28 35(1)  26(1) 33(1)  9(1) 5(1)  1(1) 
C29 28(1)  23(1) 26(1)  5(1) 11(1)  6(1) 
C30 28(1)  36(1) 39(1)  10(1) 13(1)  10(1) 
O1 25(1)  25(1) 30(1)  12(1) 12(1)  10(1) 
O2 40(1)  40(1) 39(1)  21(1) 21(1)  14(1) 
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Table 6. Hydrogen coordinates [× 104] and isotropic displacement parameters [Å2 × 103]. 
 
Atom  x y z Ueq S.o.f. 
 
H1 4516 4321 716 28 1 
H2A 4263 4048 2722 32 1 
H2B 3353 3057 1440 32 1 
H3A 1928 4680 2143 31 1 
H3B 1965 4566 928 31 1 
H7A 7173 6246 3362 30 1 
H7B 6907 7635 3270 30 1 
H8 5164 6515 1504 27 1 
H10 3788 5512 4959 31 1 
H11 2060 5588 5841 36 1 
H12 227 6843 5521 38 1 
H13 154 8031 4325 36 1 
H14 1885 7975 3456 31 1 
H16A 722 7422 839 36 1 
H16B 624 6014 1032 36 1 
H18 4813 9033 3604 33 1 
H19 6119 11045 3795 37 1 
H20 5683 11685 2222 42 1 
H21 3976 10276 446 45 1 
H22 2683 8262 244 38 1 
H23A 7132 6714 5482 31 1 
H23B 5922 7534 5722 31 1 
H24A 8413 8561 5259 32 1 
H24B 7272 9372 5638 32 1 
H25A 9266 8261 7081 34 1 
H25B 8282 9265 7445 34 1 
H26A 10747 9934 6814 35 1 
H26B 9809 10929 7260 35 1 
H27A 11810 9737 8612 37 1 
H27B 10840 10700 9064 37 1 
H28A 13170 11451 8336 52 1 
H28B 13373 11837 9630 52 1 
H28C 12211 12412 8805 52 1 
H30A 9273 3729 1468 52 1 
H30B 8503 3164 2176 52 1 
H30C 9510 4617 2715 52 1 
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